atorvastatin

Research Excerpts

Overview

Atorvastatin (AVA) is a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. It is a potent lipid-lowering drug with poor solubility and high presystemic clearance that limits its therapeutic efficacy.

Excerpt	Reference	Relevance
"Atorvastatin (AVA) is a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. "	( Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria. Almeras, L; Amalvict, R; Baret, E; Briolant, S; Fusaï, T; Henry, M; Parquet, V; Pradines, B; Rogier, C; Torrentino-Madamet, M, 2009)	3.24
"Atorvastatin (AVA) is a pentasubstituted pyrrole, which has been tested as an adjuvant in the treatment of cerebral malaria."	( New pentasubstituted pyrrole hybrid atorvastatin-quinoline derivatives with antiplasmodial activity. Bastos, MM; Boechat, N; Carvalho, RC; Kaiser, CR; Krettli, AU; Martins, WA; Pinheiro, LC; Silva, TP, 2016)	1.43
"Atorvastatin is a potential OA-modifying drug that warrants further clinical investigation."	( Standardized study of atorvastatin possible osteoarthritis disease-modifying effect in a rat model of osteoarthritis. El-Hawwary, AA; Elmasry, A; Gaballah, A; Genedy, D; Ghayaty, E, 2022)	1.76
"Atorvastatin ester (Ate) is a structural trim of atorvastatin that can regulate hyperlipidemia. "	( Atorvastatin Ester Regulates Lipid Metabolism in Hyperlipidemia Rats via the PPAR-signaling Pathway and HMGCR Expression in the Liver. Chen, C; Hu, N; Huang, J; Li, C; Wang, J; Yao, D, 2021)	3.51
"Atorvastatin is a statin known to influence both the cholesterol content and the organization of actin."	( Atorvastatin Modulates the Efficacy of Electroporation and Calcium Electrochemotherapy. Kiełbik, A; Kulbacka, J; Novickij, V; Rembiałkowska, N; Saczko, J; Szewczyk, A; Szlasa, W; Tarek, M; Łapińska, Z, 2021)	2.79
"Atorvastatin is an effective therapeutic drug for patients with ED."	( Impact of atorvastatin on erectile dysfunction: A meta-analysis and systematic review. Li, H; Lu, Y; Ma, C; Su, H; Su, X, 2022)	1.85
"Atorvastatin is a member of statin family, with cholesterol-lowering properties."	( Atorvastatin induces downregulation of matrix metalloproteinase-2/9 in MDA-MB-231 triple negative breast cancer cells. Bakar-Ates, F; Ozkan, E, 2022)	2.89
"Atorvastatin is a potent lipid-lowering drug with poor solubility and high presystemic clearance that limits its therapeutic efficacy. "	( Solid dispersions of atorvastatin with Kolliphor RH40: Enhanced supersaturation and improvement in a hyperlipidemic rat model. de la Torre-Iglesias, PM; Guarnizo-Herrero, V; Peña, MÁ; Torrado, G; Torrado-Salmerón, C; Torrado-Santiago, S, 2023)	2.67
"Atorvastatin calcium (ATV) is a well-known anti-hyperlipidemic drug currently being recognized for possessing an anti-inflammatory effect. "	( Syringeable atorvastatin loaded eugenol enriched PEGylated cubosomes in-situ gel for the intra-pocket treatment of periodontitis: statistical optimization and clinical assessment. Elakkad, YE; Elgendy, HA; Ismail, RM; Makky, AMA; Younes, NF, 2023)	2.73
"Atorvastatin (AVA) is a third-generation statin with several pleiotropic effects, considered the last synthetic pharmaceutical blockbuster. "	( In silico and in vitro assessment of anti-Trypanosoma cruzi efficacy, genotoxicity and pharmacokinetics of pentasubstituted pyrrolic Atorvastatin-aminoquinoline hybrid compounds. Araujo-Lima, CF; Bastos, MM; Boechat, N; Carvalho, RCC; Castelo-Branco, FS; Felzenszwalb, I; Fiuza, LFA; Galvão, BVD; Peres, RB; Soeiro, MNC, 2023)	2.56
"Atorvastatin is a commonly used statin for the treatment of hypercholesterolemia in people at high risk for coronary, cerebrovascular, and peripheral artery disease. "	( Fatal hepatic failure following atorvastatin treatment: A case report. Fu, Y; Liu, S; Wang, H; Zhou, C, 2023)	2.64
"Atorvastatin is a statin commonly applied to treat hypercholesterolemia."	( Simultaneous quantification of atorvastatin, erlotinib and OSI-420 in rat serum and liver microsomes using a novel liquid chromatography-mass spectrometry method. In-Albon, K; Kinzi, J; Meyer Zu Schwabedissen, HE; Ricklin, D; Rysz, MA; Schäfer, AM; Schmidlin, S; Schwardt, O; Seibert, I; Zürcher, S, 2023)	1.92
"Atorvastatin is a substrate of cytochrome P450 3a (CYP3a), organic anion-transporting polypeptides (OATPs), breast cancer-resistance protein (BCRP), and P-glycoprotein (P-gp). "	( Prediction of Atorvastatin Pharmacokinetics in High-Fat Diet and Low-Dose Streptozotocin-Induced Diabetic Rats Using a Semiphysiologically Based Pharmacokinetic Model Involving Both Enzymes and Transporters. Chen, N; Chen, Y; Geng, D; Li, P; Liang, L; Liu, L; Liu, X; Wang, Z; Xu, J; Yang, H; Zhang, X; Zhao, K, 2019)	2.32
"Atorvastatin (ATO) is a 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor widely used to treat hypercholesterolemia. "	( Atorvastatin induces mitochondrial dysfunction and cell apoptosis in HepG2 cells via inhibition of the Nrf2 pathway. Guo, JB; He, J; Li, LZ; Peng, SQ; Yu, L; Yuan, XY; Zhang, L; Zhang, TF; Zhao, J; Zhao, ZM, 2019)	3.4
"Atorvastatin is a commonly prescribed statin drug for the control of lipid synthesis and recent studies have shown the cardiac protection potential of atorvastatin. "	( Suppression of miR-143-3p contributes to the anti-fibrosis effect of atorvastatin on myocardial tissues via the modulation of Smad2 activity. Nie, W; Shi, K; Xie, D; Yu, B; Yu, M; Zhang, H, 2020)	2.24
"Atorvastatin is a lipid-lowering drug in clinical treatment."	( Atorvastatin attenuates obese-induced kidney injury and impaired renal organic anion transporter 3 function through inhibition of oxidative stress and inflammation. Chatsudthipong, V; Cherngwelling, R; Jaikumkao, K; Lungkaphin, A; Pengrattanachot, N; Pongchaidecha, A; Swe, MT; Thongnak, L, 2020)	2.72
"Atorvastatin calcium (AT) is an ocular anti-inflammatory with limited bioavailability when taken orally due to its low solubility in low pH and extensive first-pass effect. "	( Chitosan-Coated PLGA Nanoparticles for Enhanced Ocular Anti-Inflammatory Efficacy of Atorvastatin Calcium. Arafa, MG; El-Dahan, MS; Girgis, GNS, 2020)	2.22
"Atorvastatin calcium is a case in point, where confusing terminology, absence of a proper anhydrate form, and loss of water on heating lead to several doubtful conclusions in the literature."	( Does the trihydrate of atorvastatin calcium possess a melting point? Barrio, M; Clevers, S; Coquerel, G; Couvrat, N; Dupray, V; Galai, H; Rietveld, IB; Tamarit, JL; Tizaoui, C, 2020)	1.59
"Atorvastatin is a widely prescribed lipid-lowering agent metabolized by cytochrome P450 (CYP) 3A4, whose hepatocyte uptake is facilitated by organic anion transporting polypeptide (OATP) 1B1/1B3."	( Influence of Drug-Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV. Alves Saldanha, S; Buclin, T; Cavassini, M; Courlet, P; Csajka, C; Decosterd, LA; Guidi, M; Marzolini, C; Stader, F; Stoeckle, M, 2020)	1.52
"Atorvastatin is a statin with the potential to cross the blood-brain barrier; however, the concentrations necessary for a cytotoxic effect against cancer cells exceed the concentrations achievable via oral administration, which made the development of a novel atorvastatin formulation necessary."	( Appelt-Menzel, A; Cubukova, A; Gohla, A; Haider, MS; Jeanclos, E; Kataoka, K; Kinoh, H; Krafft, M; Lübtow, MM; Luxenhofer, R; Meier, L; Oerter, S; Quader, S; Rist, M; Sampetrean, O; Schulte, C, 2020)	1.28
"Atorvastatin is a pleiotropic agent with proven anti-inflammatory effects."	( Atorvastatin protects against postoperative neurocognitive disorder via a peroxisome proliferator-activated receptor-gamma signaling pathway in mice. Lin, D; Liu, J; Ma, D; Wei, C; Wu, A; Xiong, C; Yang, Y, 2020)	2.72
"Atorvastatin (ATV) is a blood cholesterol-lowering drug used to prevent cardiovascular events, the leading cause of death worldwide. "	( The atorvastatin metabolic phenotype shift is influenced by interaction of drug-transporter polymorphisms in Mexican population: results of a randomized trial. Bamford, AD; Barrera-Saldaña, HA; Bustos, MFG; Gómez-Silva, M; León-Cachón, RBR; Meester, I, 2020)	2.56
"Atorvastatin is a statin drug that presents antifungal activity. "	( Antifungal efficacy of atorvastatin-containing emulgel in the treatment of oral and vulvovaginal candidiasis. Amorim, MES; de Freitas Araújo, MG; de Freitas Souza, T; de Oliveira Neto, AS; do Couto, RO; Fabri, RL; Rocha, VN; Souza, ILA, 2021)	2.37
"Atorvastatin is a member of statins, which has shown positive vascular effects, anti-oxidant, anti-platelet, and anti-apoptotic properties."	( Atorvastatin Prevents the Neuron Loss in the Hippocampal Dentate Gyrus Region through its Anti-Oxidant and Anti-Apoptotic Activities. Arani, HZ; Jangholi, E; Karimi, A; Movassaghi, S; Parsa, Y; Sharifi, ZN; Yadollah-Damavandi, S, 2021)	3.51
"Atorvastatin (ATR) is a 3-hydroxy-3-methylglutaryl coenzyme A inhibitor approved for control of plasma cholesterol levels."	( Pretreatment with atorvastatin ameliorates cobra venom factor-induced acute lung inflammation in mice. Guo, J; Li, M; Sun, QY; Yang, Y; Zhang, L; Zhang, LW, 2020)	1.61
"Atorvastatin (ATR) is a poorly water-soluble drug and it has strong anti-hyperlipidemia activity, and it is usually used in combination with lisinopril (LNP), an anti-hypertension drug."	( Co-amorphization of atorvastatin by lisinopril as a co-former for solubility improvement. Fu, Q; He, Z; Li, J; Li, M; Li, W; Liu, X; Song, J; Tian, B, 2021)	1.67
"Atorvastatin is a strong inhibitor of inflammation-induced osteoclastogenesis in inflammatory joint diseases."	( Atorvastatin inhibits osteoclast differentiation by suppressing NF-κB and MAPK signaling during IL-1β-induced osteoclastogenesis. Choi, YJ; Lee, EG; Lee, WS; Sung, MS; Yoo, WH, 2018)	3.37
"Atorvastatin known to be a potential inhibitor of HMG-CoA reductase involved in the synthesis of cholesterol. "	( Preparation and characterisation of atorvastatin and curcumin-loaded chitosan nanoformulations for oral delivery in atherosclerosis. J B, VK; Madhusudhan, B; Ramakrishna, S, 2017)	2.17
"Atorvastatin is a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor with cholesterol-lowering, anti-inflammatory, and antioxidant properties. "	( Atorvastatin Prevents Early Oxidative Events and Modulates Inflammatory Mediators in the Striatum Following Intranasal 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Administration in Rats. Castro, AA; De Bem, AF; Mancini, G; Marques, NF; Prediger, RD; Rocha, FL; Santos, ARS; Tasca, CI, 2018)	3.37
"Atorvastatin is a member of the statin class of drugs, which competitively inhibit the activity of 5‑hydroxy‑3‑methylglutaryl‑coenzyme A reductase. "	( Atorvastatin protects BV‑2 mouse microglia and hippocampal neurons against oxygen‑glucose deprivation‑induced neuronal inflammatory injury by suppressing the TLR4/TRAF6/NF‑κB pathway. Fang, Y; Guo, FQ; Han, J; Shou, WQ; Yin, QH; Zhang, CC, 2018)	3.37
"Atorvastatin is a synthetic statin commonly used in the treatment of hypercholesterolemia. "	( Atorvastatin-loaded lipid nanoparticles: antitumor activity studies on MCF-7 breast cancer cells. Gambhire, MS; Gambhire, VM; Salunkhe, SM, 2018)	3.37
"Atorvastatin is a lipid lowering agent with poor oral bioavailability (12%) because of poor solubility and extensive first pass hepatic metabolism. "	( Systematic approach for the formulation and optimization of atorvastatin loaded solid lipid NANOAPARTICLES using response surface methodology. Jana, U; Manna, PK; Mohanta, GP; Sahoo, J; Sarangi, B, 2018)	2.17
"Atorvastatin is a lipid-regulating drug that is commonly used in clinical practice and can stabilize plaques. "	( Atorvastatin Improves Doxorubicin-Induced Cardiac Dysfunction by Modulating Hsp70, Akt, and MAPK Signaling Pathways. Chen, W; Gao, G; Ge, L; Jiang, S; Sui, S; Zhai, C; Zhang, S, 2019)	3.4
"Atorvastatin (Lipitor™) is a lipid‑lowering agent that is widely used in the treatment of cardiovascular diseases. "	( Effects of various doses of atorvastatin on vascular endothelial cell apoptosis and autophagy in vitro. Chang, F; Fu, H; Li, F; Liu, J; Wang, J; Zhao, J; Zhao, WB, 2019)	2.25
"Atorvastatin is a cholesterol-lowering statin that possesses pleiotropic effects including neuroprotective and antidepressant actions."	( Atorvastatin prevents lipopolysaccharide-induced depressive-like behaviour in mice. Buss, ZS; Doneda, DL; Ferreira, YS; Fraga-Junior, EB; Lima, E; Lopes, L; Rios-Santos, F; Stupp, IJV; Taniguti, EH; Vandresen-Filho, S; Viola, GG, 2019)	2.68
"Atorvastatin is a carboxylic acid that exists in equilibrium with a lactone form in vivo."	( Physiologically-Based Pharmacokinetic Modeling of Atorvastatin Incorporating Delayed Gastric Emptying and Acid-to-Lactone Conversion. Alberts, JJ; Dickinson, GL; Hall, SD; Hillgren, KM; Kolur, A; Loghin, C; Morse, BL; Posada, MM; Rehmel, J; Tham, LS, 2019)	1.49
"Atorvastatin is a lipid lowering agent that is widely used worldwide. "	( Rhabdomyolysis developing secondary to atorvastatin therapy in a patient with liver cirrhosis. Eshraghian, A; Kamyab, AA, 2013)	2.1
"Atorvastatin is a hypolipidemic drug that may have a role in treatment of cancer."	( Effect of atorvastatin and methotrexate on solid Ehrlich tumor. Abdel-Rahman, MN; El Rashidy, MA; El-Sisi, Ael-D; Ezzat, NM; Haleem, MS; Kabel, AM, 2013)	1.51
"Atorvastatin is a 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitor used in treatment of hypercholesterolemia and prevention of coronary heart disease. "	( Antihyperalgesic and anti-inflammatory effects of atorvastatin in chronic constriction injury-induced neuropathic pain in rats. Balaganur, V; Kant, V; Kumar, D; Lingaraju, MC; More, AS; Pathak, NN; Tandan, SK, 2013)	2.09
"Atorvastatin is a 3 hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitor that lowers blood cholesterol levels."	( The effect of atorvastatin on P wave dispersion in hyperlipidemic patients. Akın, F; Avcı, II; Ayça, B; Can, MM; Çelik, Ö; Dinçkal, MH; Okuyan, E; Şahin, I; Yıldız, SS, 2013)	1.47
"Atorvastatin is a potent immunomodulatory agent that holds promise as a novel and safe agent for acute GVHD prophylaxis."	( Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host disease. Brundage, KM; Bunner, P; Craig, MD; Cumpston, A; Gibson, LF; Hamadani, M; Petros, W; Remick, SC; Tse, W; Vos, JA; Wen, S, 2013)	1.36
"Atorvastatin is a statin group medicine that reduces the level of serum cholesterol; thus it is used to treat hypercholesterolaemia. "	( The effect of atorvastatin on lung histopathology in a murine model of chronic asthma. Bagrıyanık, A; Cilaker-Mıcılı, S; Fırıncı, F; Karaman, M; Karaman, O; Uzuner, N, )	1.93
"Atorvastatin is an HMG-CoA reductase inhibitor used in the treatment of hypercholesterolemia and prevention of coronary heart disease. "	( Atorvastatin attenuates neuropathic pain in rat neuropathy model by down-regulating oxidative damage at peripheral, spinal and supraspinal levels. Balaganur, V; Kant, V; Kumar, D; Latief, N; Lingaraju, MC; More, AS; Pathak, NN; Tandan, SK, 2014)	3.29
"Atorvastatin is a statin largely used in the treatment of hypercholesterolemia and recently revealed as a neuroprotective agent. "	( Atorvastatin evokes a serotonergic system-dependent antidepressant-like effect in mice. Binder, LB; Constantino, LC; Cunha, MP; Dal-Cim, T; Kuminek, G; Ludka, FK; Rodrigues, AL; Tasca, CI; Zomkowski, AD, 2014)	3.29
"Atorvastatin is a common statin with greater LDL-C lowering efficacy than most other statins; its availability in generic form will likely increase its use."	( Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US. Marrett, E; Neff, DR; Ramey, DR; Tershakovec, AM; Tomassini, JE; Zhang, NJ; Zhang, Q; Zhao, C, 2014)	1.39
"Atorvastatin is a promising drug with neuroprotective effects that may be useful for the treatment of stroke."	( Atorvastatin protects GABAergic and dopaminergic neurons in the nigrostriatal system in an experimental rat model of transient focal cerebral ischemia. Arango, CA; Cardona, GP; Céspedes, ÁE; Sabogal, AM, )	2.3
"Atorvastatin is a member of the drug class known as statins, which is used for lowering blood cholesterol."	( Inhibition of neointimal hyperplasia in rats treated with atorvastatin after carotid artery injury may be mainly associated with down-regulation of survivin and Fas expression. Fang, Z; Huang, D; Li, X; Liu, Q; Xu, Y; Zheng, C; Zhou, S, 2014)	2.09
"Atorvastatin is a 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitor used in the treatment of atherosclerosis and dyslipidemia. "	( Topical atorvastatin ameliorates 12-O-tetradecanoylphorbol-13-acetate induced skin inflammation by reducing cutaneous cytokine levels and NF-κB activation. Jaji, MS; Krishnan, UM; Kulkarni, NM; Mookkan, J; Muley, MM; Narayanan, S; Raghul, J; Rajesh, NB; Reddy, NK; Vijaykanth, G; Vishwakarma, SL, 2015)	2.29
"Atorvastatin is a potent inhibitor of the mevalonate pathway and widely used as a hypolipidemic drug. "	( Chemically induced mouse liver tumors are resistant to treatment with atorvastatin. Braeuning, A; Bucher, P; Buchmann, A; Hofmann, U; Schwarz, M, 2014)	2.08
"Atorvastatin is a synthetic and lipophilic statin which has been reported to have a positive role in reducing depression. "	( Antidepressant-like effect of atorvastatin in the forced swimming test in mice: the role of PPAR-gamma receptor and nitric oxide pathway. Dehpour, A; Jahanabadi, S; Javadi, S; Khoshnoodi, M; Mehr, SE; Shafaroodi, H; Shahsavarian, A; Shamsaee, J, 2014)	2.13
"Atorvastatin is a synthetic statin characterized by a high efficacy, in part due to its longer half-life compared to other molecules of the same group."	( Pleiotropic effects of statins in atherosclerotic disease: focus on the antioxidant activity of atorvastatin. Buttari, B; Profumo, E; Rigano, R; Saso, L, 2014)	1.34
"Atorvastatin is a reversible and competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, decreasing the de novo cholesterol synthesis. "	( Use of atorvastatin in lipid disorders and cardiovascular disease in Chinese patients. Ye, YC; Zhang, SY; Zhao, XL, 2015)	2.31
"Atorvastatin is a beneficial pharmacological modulator of impaired antiinflammatory HDL-C levels, endothelial functions, and oxidative status against atherosclerosis indicating pleiotropic effects of statins."	( The effects of atorvastatin on antioxidant/antiinflammatory properties of HDLs in hypercholesterolemics. Akalin Çiftçi, G; Akalin, A; Alataş, İÖ; Ertorun, İ; Musmul, A, 2015)	1.49
"Atorvastatin which functions as a potent antioxidant agent may inhibit this LDL-C oxidation by increasing PON-1 activity in atherogenesis."	( Ameliorative effect of statin therapy on oxidative damage in heart tissue of hypercholesterolemic rabbits. Sozer, V, 2015)	1.14
"Atorvastatin calcium (AC) is a BCS class II drug which shows poor bioavailability due to inadequate dissolution. "	( Dissolution enhancement of atorvastatin calcium by co-grinding technique. Patravale, V; Prabhu, P, 2016)	2.17
"Atorvastatin is a cholesterol-lowering statin that has been shown to exert several pleiotropic effects in the nervous system as a neuroprotective and antidepressant-like agent. "	( Involvement of PI3K/Akt/GSK-3β and mTOR in the antidepressant-like effect of atorvastatin in mice. Binder, LB; Constantino, LC; Dal-Cim, T; Ludka, FK; Rodrigues, AL; Tasca, CI; Zomkowski, A, 2016)	2.11
"Atorvastatin is a 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitor widely used in treatment of hypercholesterolemia and prevention of coronary heart disease and has various pleiotropic effects. "	( Effects of Topical Atorvastatin (2 %) on Posthemorrhoidectomy Pain and Wound Healing: A Randomized Double-Blind Placebo-Controlled Clinical Trial. Ala, S; Alvandipour, M; Faramarzi, F; Hamidian, M; Rahmani, N; Saeedi, M; Shiva, A, 2017)	2.23
"Atorvastatin is a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor that is mainly metabolized by cytochrome P450 (CYP) 3A4. "	( Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin. Bae, SK; Kim, KB; Liu, KH; Moon, BS; Park, JE; Shin, JG, 2008)	2.03
"Atorvastatin, which is a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A, is prescribed to decrease high cholesterol levels, and it has anti-inflammation and anti-oxidization activities."	( Atorvastatin inhibits renal crystal retention in a rat stone forming model. Momohara, C; Nonomura, N; Okuyama, A; Tsujihata, M; Tsujimura, A; Yoshioka, I, 2008)	2.51
"Atorvastatin is a widely-used therapeutic statin given for hypercholesterolaemia and for prevention of cardiovascular events. "	( [Atorvastatin-induced drug reaction with eosinophilia and systemic symptoms (DRESS)]. Dubertret, L; Gressier, L; Pruvost-Balland, C; Viguier, M, 2009)	2.71
"Atorvastatin is a highly effective 3-hydroxy-3 methylglutamyl- coenzyme A reductase (statin) used to lower low-density lipoprotein."	( Severe acute cholestatic hepatitis with prolonged cholestasis and bile-duct injury following atorvastatin therapy: a case report. Geubel, AP; Leclercq, I; Rahier, J; Rahier, JF, )	1.07
"Atorvastatin is a potential candidate for the prevention and therapy of diseases associated with insulin resistance such as type 2 diabetes mellitus and cardiovascular disease. "	( Atorvastatin improves insulin sensitivity in mice with obesity induced by monosodium glutamate. Huan, Y; Huang, H; Shen, ZF; Song, GM; Sun, SJ; Zhang, N, 2010)	3.25
"Atorvastatin calcium is a synthetic HMG-CoA reductase inhibitor that is used as a cholesterol-lowering agent. "	( Development and validation of a reversed-phase high-performance thin-layer chromatography-densitometric method for determination of atorvastatin calcium in bulk drug and tablets. Shirkhedkar, AA; Surana, SJ, )	1.78
"Atorvastatin calcium is a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor indicated for the prevention of cardiovascular disease and for the treatment of dyslipidemia. "	( Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males. Jia, JY; Li, GX; Liu, GY; Liu, YM; Lu, C; Pu, HH; Wang, W; Weng, LP; Xu, RJ; Yu, C; Zhang, MQ, 2010)	2.04
"Atorvastatin proved to be an immunomodulatory agent, significantly decreasing lymphocyte proliferation by 15% (p = 0.001), increasing ATP levels by 16% (p = 0.0004), and showing a trend toward increasing T(reg) cells in hypercholesterolemic patients (p = 0.09). "	( Biomarker assessment of the immunomodulator effect of atorvastatin in stable renal transplant recipients and hypercholesterolemic patients. Brunet, M; Cofán, F; Cofán, M; Guillén, D; Millán, O; Ros, E, 2010)	2.05
"Atorvastatin is a statin used for lowering LDL-C concentrations."	( Efficacy and tolerability of a generic and a branded formulation of atorvastatin 20 mg/d in hypercholesterolemic Korean adults at high risk for cardiovascular disease: a multicenter, prospective, randomized, double-blind, double-dummy clinical trial. Cho, YS; Hong, SJ; Hyon, MS; Kim, DW; Kim, HS; Kim, SH; Lee, MY; Moon, GW; Park, K; Sung, JD; Yoon, MH, 2010)	1.32
"Atorvastatin is a selective HMG-CoA reductase competitive inhibitor, used for the treatment of hyperlipidaemia. "	( Influence of atorvastatin on the pharmacokinetics and pharmacodynamics of glyburide in normal and diabetic rats. Gade, J; Neerati, P, 2011)	2.18
"Atorvastatin is a statin that inhibits the 3-hydroxy-methyl-glutaryl coenzyme A (HMG-CoA) reductase. "	( Antinociception induced by atorvastatin in different pain models. Garcia, GG; Miranda, HF; Noriega, V; Olavarría, L; Prieto, JC; Sierralta, F; Zepeda, RJ, 2011)	2.11
"Atorvastatin is an HMG-CoA reductase inhibitor used to treat hypercholesterolemic conditions associated with hypertension. "	( Neuroprotective and anti-inflammatory activities of atorvastatin in a rat chronic constriction injury model. Chen, JY; Cheng, KI; Chu, LW; Wu, BN; Wu, PC; Yu, KL, )	1.82
"Atorvastatin is a synthetic and lipophilic statin that presents a good effect in decreasing cholesterol levels and is safe and well tolerated. "	( Acute atorvastatin treatment exerts antidepressant-like effect in mice via the L-arginine-nitric oxide-cyclic guanosine monophosphate pathway and increases BDNF levels. Cunha, MP; Dal-Cim, T; Ludka, FK; Rodrigues, AL; Tasca, CI; Zeni, AL; Zomkowski, AD, 2013)	2.31
"Atorvastatin (ATV) is a specific competitive inhibitor of 3-hydroxy-2-methyl-glutaryl coenzyme A reductase. "	( Clinical efficacy of subgingivally delivered 1.2% atorvastatin in chronic periodontitis: a randomized controlled clinical trial. Kumari, M; Martande, SS; Naik, SB; Pradeep, AR; Rao, NS, 2013)	2.09
"Atorvastatin is an antilipemic drug belonging to the statins class, whose reference drug is Pfizer's Lipitor®. "	( Degradation kinetics of atorvastatin under stress conditions and chemical analysis by HPLC. Belinelo, VJ; Oliveira, MA; Valotto, RS; Yoshida, MI, 2013)	2.14
"Atorvastatin is a drug of choice in the treatment of coronary heart disease, because this hepatic 3-hydroxy-3-methylglutaryl coenzyme reductase inhibitor significantly decreases plasma cholesterol and triglyceride levels. "	( Induction of lipoprotein lipase gene expression in 3T3-L1 preadipocytes by atorvastatin, a cholesterol- and triglyceride-lowering drug. Bey, L; Hamilton, MT; Laouenan, H; Maigret, P, 2002)	1.99
"Atorvastatin is a powerful new synthetic 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor currently in clinical use. "	( Atorvastatin reduces plasma levels of factor VII activity and factor VII antigen in patients with hyperlipidemia. Asakura, H; Ishino, C; Kanno, M; Matsuda, T; Minami, S; Morishita, E; Nakao, S; Uotani, C, 2002)	3.2
"Atorvastatin is an HMG-CoA reductase inhibitor which across its dosage range (10-80 mg/day) has shown significantly greater lipid-lowering effects than all previously marketed statins."	( Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia. Alvarez, E; Castaño, G; Fernández, L; Illnait, J; Lezcay, M; Mas, R; Mesa, M, 2003)	1.28
"Atorvastatin is a synthetic inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. "	( Efficacy of alternate-day dosing versus daily dosing of atorvastatin. Ahmadi-Kashani, M; Balian, H; Bashir, M; Ebrahimi, R; Jafari, M, 2003)	2.01
"Atorvastatin (Lipitor) is an HMG-CoA reductase inhibitor with well documented lipid-lowering effects. "	( Atorvastatin: a review of its use in the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus. Croom, KF; Plosker, GL, 2005)	3.21
"Atorvastatin is a statin drug that inhibits 3-hydroxy-3-methyl-glutaryl coenzyme A reductase (the rate-limiting step of cholesterol production) and primarily lowers LDL-C levels."	( Torcetrapib/atorvastatin combination therapy. Bays, H; Davidson, M; McKenney, J, 2005)	1.43
"Atorvastatin is a new 3-hydroxy-3-metylglutaryl coenzyme A reductase inhibitor that reduces lipid serum levels."	( A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients. García-Buey, L; Gisbert, JP; Gómez-Domínguez, E; Moreno-Monteagudo, JA; Moreno-Otero, R, 2006)	1.39
"Atorvastatin is an inhibitor of the enzyme 3-hydroxyl-3-methylglutaryl coenzyme A reductase used to prevent coronary heart disease. "	( Atorvastatin inhibits inflammatory hypernociception. Cunha, FQ; Cunha, TM; Ferreira, SH; Parada, CA; Poole, S; Santodomingo-Garzón, T; Valério, DA; Verri, WA, 2006)	3.22
"Atorvastatin is an effective lipid-lowering agent for dyslipidemic subjects with advanced and endstage renal failure, and was reasonably well tolerated."	( Efficacy, safety and tolerability of atorvastatin in dyslipidemic subjects with advanced (non-nephrotic) and endstage chronic renal failure. Healy, H; Morgan, C; Saltissi, D; Westhuyzen, J, 2006)	2.05
"Atorvastatin is an inhibitor of HMG-CoA reductase, which is a key rate-limiting enzyme in the cholesterol biosynthesis."	( Automated enzyme inhibition assay method for the determination of atorvastatin-derived HMG-CoA reductase inhibitors in human plasma using radioactivity detection. Liu, L; Musson, DG; Valesky, RJ; Zhao, JJ, )	1.09
"Atorvastatin is a lipid-lowering agent that has been evaluated in a number of primary and secondary intervention studies. "	( Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events. Lyseng-Williamson, KA; Plosker, GL, 2007)	3.23
"Atorvastatin calcium (AC) is a second-generation 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor approved for clinical use as a lipid lowering agent. "	( Oral nanoparticulate atorvastatin calcium is more efficient and safe in comparison to Lipicure in treating hyperlipidemia. Ankola, DD; Chandraiah, G; Kumar, MN; Meena, AK; Rao, PR; Ratnam, DV, 2008)	2.11
"Atorvastatin is a hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor demonstrated to be effective in reducing both cholesterol (CHOL) and triglyceride (TG) levels in humans."	( Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia. Avisar, I; Brook, JG; Wolfovitz, E, 2008)	2.51
"Atorvastatin is an adequate monotherapy for many mixed hyperlipidemia patients. "	( Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia. Avisar, I; Brook, JG; Wolfovitz, E, 2008)	3.23
"Atorvastatin is a new 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor under development."	( Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Black, DM; Davidson, MH; Haber, HE; Jones, PH; Lupien, PJ; Nawrocki, JW; Schwartz, SL; Sprecher, DL; Weiss, SR, 1995)	1.23
"Atorvastatin is a new 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor that reduces plasma cholesterol by inhibiting cholesterol synthesis and increasing cellular uptake of low density lipoproteins. "	( Effect of age and gender on pharmacokinetics of atorvastatin in humans. Bron, NJ; Gibson, DM; Hounslow, NJ; Richens, A; Sedman, AJ; Whitfield, LR, 1996)	1.99
"Atorvastatin is a synthetic HMG-CoA reductase inhibitor which lowers plasma cholesterol levels by inhibiting endogenous cholesterol synthesis. "	( Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Lea, AP; McTavish, D, 1997)	3.18
"Atorvastatin is a highly efficacious hydroxymethylglutaryl-coenzyme A reductase inhibitor that has been shown to reduce low-density lipoprotein cholesterol by 40% to 60%. "	( Effectiveness of atorvastatin for reducing low-density lipoprotein cholesterol to National Cholesterol Education Program treatment goals. Black, DM; Davidson, MH; Haber, HE; Jones, PH; Lupien, PJ; Nawrocki, JW; Schwartz, SL; Weiss, SR, 1997)	2.08
"Atorvastatin is a powerful and safe lipid-modifying agent for LDL cholesterol; it also modifies HDL cholesterol and triglyceride concentrations, and may suffice as a single agent for many subjects with heterozygous FH."	( Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia. Bateman, ME; Byrnes, P; Firth, JC; Marais, AD; Martens, C; Mountney, J, 1997)	2.46
"Atorvastatin calcium is an HMG-coenzyme A (CoA) reductase inhibitor that was approved by the Food and Drug Administration on December 17, 1996. "	( Atorvastatin calcium: an addition to HMG-CoA reductase inhibitors. Chong, PH; Seeger, JD, )	3.02
"Atorvastatin is a potent inhibitor of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, which catalyzes the conversion of HMG-CoA to mevalonate and constitutes the rate-limiting step in the biosynthesis of cholesterol. "	( Pre- and postnatal toxicity of the HMG-CoA reductase inhibitor atorvastatin in rats. Anderson, JA; Black, A; Colgin, J; Craft, WR; Henck, JW, 1998)	1.98
"Atorvastatin is a major addition to this class of drugs because of its high efficacy and large spectrum of action."	( Advances in drug treatment of dyslipidemia: focus on atorvastatin. Davignon, J, 1998)	1.27
"Atorvastatin is a new member of the class of drugs which inhibit the enzyme Hydroxy-Methylglutaryl Co-A reductase, the rate limiting step in cholesterol biosynthesis."	( Comparison of atorvastatin alone versus simvastatin +/- cholestyramine in the management of severe primary hypercholesterolaemia (the six cities study). Simons, LA, 1998)	2.1
"Atorvastatin is a recent hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor for the treatment of primary hypercholesterolemia, mixed dyslipidemias, and homozygous familial hypercholesterolemia. "	( Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias. Fong, NT; Yee, HS, 1998)	3.19
"Atorvastatin is a valuable addition to the treatment possibilities of patients with serious hypercholesterolaemia, like FH."	( Effects of atorvastatin on serum lipids of patients with familial hypercholesterolaemia. Hoogerbrugge, N, 1998)	2.13
"Atorvastatin is a new potent HMG-CoA reductase inhibitor. "	( Atorvastatin compared with simvastatin in patients with severe LDL hypercholesterolaemia treated by regular LDL apheresis. Geiss, HC; Parhofer, KG; Schwandt, P, 1999)	3.19
"Atorvastatin is a potent inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase, but its effect on bile acid synthesis is unknown. "	( Effect of inhibiting HMG-CoA reductase on 7 alpha-hydroxy-4-cholesten-3-one, a marker of bile acid synthesis: contrasting findings in patients with and without prior up-regulation of the latter pathway. Axelson, M; Dunn, S; Naoumova, RP; Neuwirth, CK; O'Neill, FH; Taylor, GW; Thompson, GR, 1999)	1.75
"Atorvastatin (AT) is a second-generation potent inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, clinically approved for lowering plasma cholesterol. "	( Metabolism and excretion of atorvastatin in rats and dogs. Black, AE; Hayes, RN; Roth, BD; Woo, P; Woolf, TF, 1999)	2.04
"Atorvastatin is a second generation synthetic statin, introduced in Belgium in May 1998. "	( [Atorvastatin (Lipitor)]. Carpentier, Y; Ducobu, J; Sternon, J, 1999)	2.66
"Atorvastatin is a new hepatic hydroxymethyl glutaryl coenzyme A (HMG-CoA) reductase inhibitor that has been demonstrated to be efficacious in reducing both triglyceride (TG) and cholesterol (CHOL) levels in humans. "	( Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin. Bakker-Arkema, R; Black, D; Brown, WV; Innis-Whitehouse, W; Le, NA; Li, X, 2000)	1.96
"Atorvastatin is an effective and safe lipid-lowering agent for peritoneal dialysis patients with mixed dyslipidaemia."	( Effects of atorvastatin on dyslipidaemia in uraemic patients on peritoneal dialysis. Hufnagel, G; Kossari, N; Michel, C; Mignon, F; Queffeulou, G; Vrtovsnik, F, 2000)	2.14
"Atorvastatin is an established HMG-CoA reductase inhibitor which effectively reduces the plasma low density lipoprotein (LDL)-cholesterol level in hyperlipidemic patients. "	( Effects of atorvastatin treatment on the oxidatively modified low density lipoprotein in hyperlipidemic patients. Choy, PC; Dembinski, T; Hatch, G; Kroeger, EA; McMaster, J; Mymin, D; Zhu, Q, 2000)	2.14
"Atorvastatin is a new HMG-CoA reductase inhibitor that has shown a favourable profile of lipid reduction when compared with other statins."	( Short-term effect of atorvastatin in hypercholesterolaemic renal-transplant patients unresponsive to other statins. Calviño, J; Rodriguez, J; Romero, R; Sánchez-Guisande, D, 2000)	1.35
"Atorvastatin is a potent HMG-CoA reductase inhibitor that decreases low-density lipoprotein (LDL) cholesterol and fasting triglyceride concentrations. "	( Atorvastatin improves postprandial lipoprotein metabolism in normolipidemlic subjects. Barrett, PH; Parhofer, KG; Schwandt, P, 2000)	3.19
"Atorvastatin is a new HMG-CoA reductase inhibitor that strongly lowers plasma cholesterol and triglyceride (TG) levels in humans and animals. "	( Prolonged inhibition of cholesterol synthesis by atorvastatin inhibits apo B-100 and triglyceride secretion from HepG2 cells. Arai, Y; Funatsu, T; Goto, M; Ida, M; Kakuta, H; Miyata, K; Nishijima, S; Suzuki, K; Tanaka, H; Yasuda, S, 2001)	2.01
"Atorvastatin is a potent hydroxy-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitor that decreases low-density lipoprotein (LDL) cholesterol and triglyceride concentrations, but little is known about its effects on LDL subtype distribution in different types of hyperlipoproteinemia. "	( Effect of atorvastatin on low-density lipoprotein subtypes in patients with different forms of hyperlipoproteinemia and control subjects. Geiss, HC; Otto, C; Parhofer, KG; Schwandt, P, 2001)	2.16
"Atorvastatin is a synthetic hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. "	( Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia. Goa, KL; Malhotra, HS, 2001)	3.2
"Atorvastatin is an appropriate first-line lipid-lowering therapy in numerous groups of patients at low to high risk of CHD. "	( Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia. Goa, KL; Malhotra, HS, 2001)	3.2
"Atorvastatin is a recently introduced statin that lowers LDL-cholesterol (LDL-C) and triglycerides more than some of the older statins."	( Effect of atorvastatin treatment on lipoprotein lipase mass in the pre-heparin plasma in Japanese hyperlipidemic subjects. Kobayashi, J; Maruyama, T; Masuda, M; Shinomiya, M, 2001)	2.16
"Atorvastatin is a common option among the HMG-CoA reductase inhibitors for the treatment of lipid disorders because of its excellent lipid-lowering efficacy and overall safety profile. "	( A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers. Amsden, GW; Kuye, O; Wei, GC, 2002)	1.99
"Atorvastatin is a safe and effective drug that enables most patients requiring primary prevention to reach LDL-C goal levels, even with a low dose of 10 mg. "	( Efficacy of atorvastatin in treating high risk patients to reach low density lipoprotein-cholesterol goals: the Treat to Target (TTT-Israel) Study. Gavish, D; Harats, D; Leibovitz, E, 2002)	2.14

Effects

Atorvastatin has a dose-dependent risk of developing new-onset diabetes mellitus. It has a pleiotropic effect as anti-inflammatory through one of the target levels of High Mobility Group Box-1 (HMGB-1)

Atorvastatin monotherapy has a better effect on LDL-C and apoprotein B than statin-fibrate combinations, but a lesser effect on HDL-C, TG and fibrinogen. Atorvstatin has been found to have neuroprotective effects in some nervous system diseases.

Excerpt	Reference	Relevance
"Atorvastatin has a significant effect on P-gp mediated intestinal transport of daclatasvir; however, it did not affect the systemic bioavailability of a single oral dose of daclatasvir."	( Effect of Atorvastatin on Single Oral Pharmacokinetics and Safety of Daclatasvir in Rats: Emphasis on P-glycoprotein and Cytochrome P450. El-Demerdash, E; Elbadawy, HA; Wahdan, SA, 2022)	2.57
"Atorvastatin has a dose-dependent risk of developing new-onset diabetes mellitus. "	( Evaluation of glycemic status among hypercholesterolemic patients on atorvastatin in a tertiary care hospital - A retrospective study. Karthick, R; Nalini, R; Ramya, JE, )	1.81
"Atorvastatin has a pleiotropic effect as anti-inflammatory through one of the target levels of High Mobility Group Box-1 (HMGB-1)."	( Analysis of HMGB-1 level before and after providing atorvastatin standard therapy in coronary artery disease patients with type-2 diabetes mellitus compared to without type-2 diabetes mellitus. Handayani, W; Yogiarto, M, 2021)	1.59
"Atorvastatin has a limited advantage to formulate oral dosage forms."	( Solid self microemulsification of Atorvastatin using hydrophilic carriers: a design. Nanda Kishore, R; Rasheed, A; Sushma, M; Vadlamudi, HC; Vandana, KR; Yalavarthi, PR, 2015)	2.14
"Atorvastatin has a protective effect on the myocardial injury in the myocardial ischemia and reperfusion rats. "	( Effect of atorvastatin on serum oxidative stress and N-terminal brain natriuretic peptide expression in rats. Luo, YQ; Xu, Y; Yang, Y, 2014)	2.25
"Atorvastatin has a beneficial effect on bone metabolism in patients with acute ischemic heart disease (mainly males) by incrementing bone mineral density in which vitamin D levels are required to be higher than 30 nmol/l for the drug to be effective."	( Effect of atorvastatin on bone mineral density in patients with acute coronary syndrome. Abad, L; Dueñas, A; García-Porrero, M; Pérez-Castrillón, JL; Pinacho, F; Sanz-Cantalapiedra, A; Vega, G, )	1.98
"Atorvastatin 20 mg has a dramatic effect on the lipid but moderate effect on CRP. "	( Effect of atorvastatin on LDL & hs-CRP in a selected Thai population. Benjanuwatra, T; Boonbaichaiyapruck, S; Buakhamsri, A; Cheepudomwit, S; Moleelerkpoom, W; Panjavenin, P; Sukanandachai, B; Suthichaiyakul, T, 2008)	2.19
"Atorvastatin has a beneficial effect on oxidative stress in rats fed with high-cholesterol diet. "	( Effect of atorvastatin and ezetimibe treatment on serum lipid profile and oxidative state in rats fed with a high-cholesterol diet. Ciralik, H; Gümüşalan, Y; Kilinc, M; Ozbag, D; Toru, H; Yasim, A, 2010)	2.21
"Atorvastatin has a significant effect on lowering of PRA in sensitized hemodialysis patients waiting for kidney transplantation. "	( Alteration of panel-reactive antibodies following treatment with either atorvastatin or low-dose mycophenolate mofetil in sensitized hemodialysis patients. Aref, A; Ehsanpour, A; Ghorbani, A; Shahbazian, H, 2011)	2.04
"Atorvastatin has a further sympatholytic effect in CKD patients, who are on chronic aliskiren, which is independent of blood pressure and heart rate."	( Atorvastatin reduces sympathetic activity in patients with chronic kidney disease. Blankestijn, PJ; Joles, JA; Oey, PL; Siddiqi, L, 2011)	3.25
"Atorvastatin has an anti-inflammatory action benefiting the alleviation of secondary inflammatory damaged in acute cerebral infarction that is independent of lipid lowering."	( [Effects of atorvastatin on plasma hypersensitive C-reactive protein and interleukin-6 in patients with acute cerebral infarction]. Hu, ZP; Jiang, B; Nie, S; Tan, LM; Wu, J; Xiao, ZJ; Zhao, SP; Zhou, HN, 2005)	2.15
"Atorvastatin has a parallel effect on systemic and local inflammatory process in patients with coronary artery disease."	( Relation between local temperature and C-reactive protein levels in patients with coronary artery disease: effects of atorvastatin treatment. Boudoulas, H; Stefanadi, E; Stefanadis, C; Toutouzas, K; Tsiamis, E; Tsioufis, C; Vavuranakis, M, 2007)	1.27
"Atorvastatin monotherapy has a better effect on LDL-C and apoprotein B than statin-fibrate combinations, but a lesser effect on HDL-C, TG and in the case of ciprofibrate combinations, fibrinogen."	( Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia. Athyros, VG; Athyrou, VV; Demitriadis, DS; Kontopoulos, AG; Papageorgiou, AA; Pehlivanidis, AN, 2002)	2.48
"Atorvastatin has been suggested to reduce hematoma volume and improve neurological outcomes in patients with chronic subdural hematoma (CSDH). "	( Effects of postoperative atorvastatin use in elderly patients with chronic subdural hematoma. Guan, JW; Sun, T; Wu, K; You, C; Yuan, YK, 2021)	2.37
"Atorvastatin has been found to have neuroprotective effects in some nervous system diseases, but its role in regulating the pathogenesis of neonatal HIBD remains elusive."	( Atorvastatin inhibits neuronal apoptosis via activating cAMP/PKA/p-CREB/BDNF pathway in hypoxic-ischemic neonatal rats. Li, S; Liu, Q; Liu, S; Mu, D; Qu, Y; Su, X; Sun, H; Ying, J; Yu, L; Zhao, F; Zhou, R, 2022)	2.89
"Atorvastatin has a significant effect on P-gp mediated intestinal transport of daclatasvir; however, it did not affect the systemic bioavailability of a single oral dose of daclatasvir."	( Effect of Atorvastatin on Single Oral Pharmacokinetics and Safety of Daclatasvir in Rats: Emphasis on P-glycoprotein and Cytochrome P450. El-Demerdash, E; Elbadawy, HA; Wahdan, SA, 2022)	2.57
"Atorvastatin has been shown to inhibit inflammation and may be a suitable drug candidate."	( Atorvastatin for unruptured intracranial vertebrobasilar dissecting aneurysm (ATREAT-VBD): protocol for a randomised, double-blind, blank-controlled trial. Huang, J; Kang, H; Li, M; Liu, J; Turhon, M; Wang, K; Yang, X; Zhang, Y, 2022)	2.89
"Atorvastatin has a dose-dependent risk of developing new-onset diabetes mellitus. "	( Evaluation of glycemic status among hypercholesterolemic patients on atorvastatin in a tertiary care hospital - A retrospective study. Karthick, R; Nalini, R; Ramya, JE, )	1.81
"Atorvastatin (ATV) has attracted considerable attention as a potential therapeutic agent for cancer because it inhibits cancer cell proliferation by suppressing the mevalonate pathway. "	( Enhancement of the anticancer effect of atorvastatin-loaded nanoemulsions by improving oral absorption via multivalent intestinal transporter-targeting lipids. Byun, Y; Cho, SS; Khadka, B; Kim, KT; Kweon, S; Pandey, P; Park, JW; Shim, JH; Subedi, L, 2022)	2.43
"Atorvastatin has been used in the management of dyslipidemia and little is known about the efficacy and safety of high-dose atorvastatin administration for secondary prevention of Major Cardiovascular Events (MACE)."	( [Efficacy and safety of atorvastatin in major cardiovascular events: Meta-analysis]. García-Rivero, AA; González-Tovar, NB; Rivas-Ruíz, R; Rivera-Lara, P; Villegas-Quintero, VE, 2023)	2.66
"Atorvastatin has been on the market for several years with a safety profile that is acceptable even in patients with liver disease."	( Atorvastatin for prevention of disease progression and hospitalisation in liver cirrhosis: protocol for a randomised, double-blind, placebo-controlled trial. Bendtsen, F; Deshmukh, AS; Fred, RG; Grønbæk, H; Hansen, T; Kimer, N; Mann, M, 2020)	2.72
"Atorvastatin has beneficial effects in improving Cadmium chloride-induced antioxidative enzymes disturbance which may be contribute to improving liver function in male rats."	( Hepatoprotective effect of atorvastatin on Cadmium chloride induced hepatotoxicity in rats. Bandegi, AR; Dehdashti, A; Ghanbari, A; Goodarzi, Z; Karami, E; Yousefi, S, 2020)	2.3
"Atorvastatin has certain efficacy in the treatment of heart failure."	( Effectiveness of Atorvastatin in the Treatment of Asymptomatic Heart Failure After Myocardial Infarction: A Clinical Study. Bai, L; Cui, XR; Wang, D; Yang, XH; Zhang, JD, 2020)	1.62
"Atorvastatin (ATV) has been widely used to reduce serum lipids levels, but its synergistic effect with RAPA in CKD remains unclear."	( Combined application of rapamycin and atorvastatin improves lipid metabolism in apolipoprotein E-deficient mice with chronic kidney disease. Ahn, S; Ha, J; Min, SK; Oh, GT; Song, EJ, 2021)	1.61
"Atorvastatin and aspirin have been used in treating different forms of epilepsy. "	( Effects of atorvastatin and aspirin on post-stroke epilepsy and usage of levetiracetam. Ding, Y; Feng, X; Lin, W; Zhao, T; Zhou, C, 2020)	2.39
"Atorvastatin has beneficial effects on vessel remodeling due to its lipid-lowering capacity. "	( Atorvastatin pleiotropically decreases intraplaque angiogenesis and intraplaque haemorrhage by inhibiting ANGPT2 release and VE-Cadherin internalization. Baganha, F; de Jong, RCM; de Vries, MR; Delibegovic, M; Jukema, JW; Peters, EA; Quax, PHA; Voorham, W, 2021)	3.51
"Atorvastatin has no statistically significant effect on the prevention of CSDH recurrence after surgery."	( The effect of atorvastatin on recurrence of chronic subdural hematoma after novel YL-1 puncture needle surgery. Chen, P; He, S; Wang, C; Wang, D; Wang, H; Wen, J; Xu, M; Yu, B; Zeng, W; Zhang, H, 2021)	1.7
"Atorvastatin has been reported to alleviate early brain injury (EBI) following subarachnoid hemorrhage (SAH) via reducing reactive oxygen species, antiapoptosis, regulated autophagy, and neuroinflammation."	( Atorvastatin ameliorates early brain injury after subarachnoid hemorrhage via inhibition of pyroptosis and neuroinflammation. Chen, J; Chen, Q; Li, M; Shi, Z; Wang, Y; Yan, T; Yang, L; Zhang, C, 2021)	2.79
"Atorvastatin (ATV) has been shown to play a protective role on endothelial cells."	( Hsa_circ_0004831 downregulation is partially responsible for atorvastatinalleviated human umbilical vein endothelial cell injuries induced by ox-LDL through targeting the miR-182-5p/CXCL12 axis. Liu, H; Lv, J; Su, G; Su, H; Sun, G; Tang, Y; Zhang, W, 2021)	1.58
"Atorvastatin treatment has been suggested as a therapeutic method for women with polycystic ovary syndrome (PCOS) in many clinical studies. "	( Effects of atorvastatin on the insulin resistance in women of polycystic ovary syndrome: A systematic review and meta-analysis. Chen, LL; Zheng, JH, 2021)	2.45
"Atorvastatin has a pleiotropic effect as anti-inflammatory through one of the target levels of High Mobility Group Box-1 (HMGB-1)."	( Analysis of HMGB-1 level before and after providing atorvastatin standard therapy in coronary artery disease patients with type-2 diabetes mellitus compared to without type-2 diabetes mellitus. Handayani, W; Yogiarto, M, 2021)	1.59
"Atorvastatin, which has proven safe in NAFLD/NASH, reduces SUA levels, ameliorates NAFLD/NASH, prevents liver fibrosis, and above all substantially reduces CVD morbidity and mortality in comparison with those on statins but without NAFLD/NASH."	( Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease? Athyros, VG; Giouleme, O; Grammatikos, N; Katsoula, A; Paschos, P; Tsimperidis, A, 2018)	1.2
"Atorvastatin (ATO) has anti-inflammatory and antioxidant properties."	( Preconditioning with atorvastatin against renal ischemia-reperfusion injury in nondiabetic versus diabetic rats. Abdelfattah, S; Ahmad, Z; Hassan, SS; Motawie, A; Rizk, A; Thomann, C, 2019)	1.55
"Atorvastatin has pleiotropic actions, including increasing nitric oxide (NO) bioavailability and reducing inflammation and oxidative damage."	( Atorvastatin protects against deleterious cardiovascular consequences induced by chronic intermittent hypoxia. Baldazza, M; Cachot, S; Faury, G; Fhayli, W; Joyeux-Faure, M; Korichneva, I; Lévy, P; Pépin, JL; Ribuot, C; Totoson, P, 2013)	2.55
"Atorvastatin (ATV) has bone anabolic properties, and alendronate (ALD) is an important antiresorptive drug. "	( Low-dose combination of alendronate and atorvastatin reduces ligature-induced alveolar bone loss in rats. Alencar, NM; Benevides, NM; Goes, P; Lima, V; Melo, IM; Ribeiro, RA; Silva, LM, 2014)	2.11
"Atorvastatin has been shown to be neuroprotective after transient ischaemia or traumatic injury."	( Atorvastatin is beneficial for muscle reinnervation after complete sciatic nerve section in rats. Beaumont, E; Beaumont, PH; Cloutier, FC; Hébert-Davies, J; Rouleau, DM, 2013)	2.55
"Oral atorvastatin has prevented or reversed paralysis in the multiple sclerosis (MS) model experimental autoimmune encephalomyelitis (EAE), and reduced development of new MS lesions in clinical trials. "	( Neither T-helper type 2 nor Foxp3+ regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity. Dunn, SE; Prod'homme, T; Steinman, L; Weber, MS; Youssef, S; Zamvil, SS, 2014)	1.13
"Atorvastatin has pleiotropic effects on restraining inflammation and promoting angiogenesis besides its cholesterol-lowering function."	( Effects of atorvastatin on the inflammation regulation and elimination of subdural hematoma in rats. Chen, J; Cui, W; Jiang, R; Li, T; Quan, W; Tian, Y; Wang, D; Wang, Y; Yu, H; Zhang, J; Zhou, L, 2014)	1.51
"Atorvastatin (AT) has been alternatively used for managing diabetic complications in clinic. "	( Renoprotective effect of atorvastatin on STZ-diabetic rats through attenuating kidney-associated dysmetabolism. Deng, T; Li, H; Li, Y; Tian, L; Zhao, P; Zhou, S, 2014)	2.15
"Atorvastatin has a limited advantage to formulate oral dosage forms."	( Solid self microemulsification of Atorvastatin using hydrophilic carriers: a design. Nanda Kishore, R; Rasheed, A; Sushma, M; Vadlamudi, HC; Vandana, KR; Yalavarthi, PR, 2015)	2.14
"Atorvastatin has a protective effect on the myocardial injury in the myocardial ischemia and reperfusion rats. "	( Effect of atorvastatin on serum oxidative stress and N-terminal brain natriuretic peptide expression in rats. Luo, YQ; Xu, Y; Yang, Y, 2014)	2.25
"Atorvastatin has been demonstrated to reduce the incidence of postoperative atrial fibrillation (POAF) in patients undergoing cardiac surgery, but its effect on isolated heart valve surgery is unknown."	( Atorvastatin Reduces the Incidence of Postoperative Atrial Fibrillation in Statin-Naive Patients Undergoing Isolated Heart Valve Surgery: A Double-Blind, Placebo-Controlled Randomized Trial. Dehghani, MR; Kasianzadeh, M; Rezaei, Y; Sepehrvand, N, 2015)	3.3
"Atorvastatin has been suggested to exhibit anti-cancer effects."	( Atorvastatin induces autophagic cell death in prostate cancer cells in vitro. He, Z; Qi, P; Wang, Z; Yuan, J; Zhang, L, 2015)	2.58
"Atorvastatin 20 mg has no clinically relevant effect on the pharmacokinetics of raltegravir and vice versa. "	( Pharmacokinetic Drug-Drug Interaction Study Between Raltegravir and Atorvastatin 20 mg in Healthy Volunteers. Blonk, M; Burger, D; Colbers, A; Schouwenberg, B; van Beek, M, 2015)	2.1
"Atorvastatin has antioxidant activity and has been reported to increase blood antioxidant capacity. "	( Paradoxical effects of atorvastatin on renal tubular cells: an experimental investigation. Ahmadi, A; Baradaran, A; Hasanpour, Z; Nasri, H; Nasri, P; Nematbakhsh, M; Rafieian-Kopaei, M, 2015)	2.17
"Atorvastatin has been reported to ameliorate ischemic brain damage after stroke, but the underlying mechanisms are not clear. "	( Neuroprotective effects and dynamic expressions of MMP9 and TIMP1 associated with atorvastatin pretreatment in ischemia-reperfusion rats. Dong, X; Fang, X; Ji, X; Shen, J; Tao, D; Wang, Y, 2015)	2.09
"Atorvastatin has protective effects against myocardial ischemia-reperfusion injuries and ischemia-reperfusion arrhythmia. "	( Atorvastatin protects myocardium against ischemia-reperfusion arrhythmia by increasing Connexin 43 expression: A rat model. Bian, B; Nie, J; Teng, T; Wang, Q; Yu, X, 2015)	3.3
"Atorvastatin has prevented or limited LDL oxidation and has showed constitutively beneficial effects in group 4."	( Ameliorative effect of statin therapy on oxidative damage in heart tissue of hypercholesterolemic rabbits. Sozer, V, 2015)	1.14
"Atorvastatin has been reported to ameliorate ischemic brain damage after ischemia reperfusion (I/R)."	( Atorvastatin attenuates cognitive deficits through Akt1/caspase-3 signaling pathway in ischemic stroke. Li, X; Pan, Y; Wang, X; Yang, J, 2015)	2.58
"Atorvastatin (ATV) has been reported to improve AD, however, it is unclear how the anti-inflammatory mechanism is linked with its protection against the impairment of spatial cognitive function in AD."	( Atorvastatin in improvement of cognitive impairments caused by amyloid β in mice: involvement of inflammatory reaction. Chen, L; Chen, T; Li, G; Wan, Q; Wang, C; Yin, J; Zhao, L; Zhi, W, 2016)	2.6
"Atorvastatin 80 mg/day has significant benefits for the primary and secondary prevention of cardiovascular and cerebrovascular disease. "	( Safety Profile of Atorvastatin 80 mg: A Meta-Analysis of 17 Randomized Controlled Trials in 21,910 Participants. Cheng, G; Li, H; Li, R; Sun, S; Wang, C; Zhang, S; Zou, M, 2016)	2.21
"Atorvastatin has preliminarily been proved to be safe and effective for chronic subdural hematomas in both conservative and surgical patients and can provide a drug treatment strategy for neurosurgeons."	( Effects of Atorvastatin on Conservative and Surgical Treatments of Chronic Subdural Hematoma in Patients. Chen, P; Shi, X; Wang, C; Xu, M; Yu, B; Zhu, X, 2016)	2.27
"Atorvastatin has been shown to exert a neuroprotective action by counteracting glutamatergic toxicity. "	( Atorvastatin and Fluoxetine Prevent Oxidative Stress and Mitochondrial Dysfunction Evoked by Glutamate Toxicity in Hippocampal Slices. Binder, LB; Constantino, LC; Dal-Cim, T; Ludka, FK; Massari, C; Tasca, CI, 2017)	3.34
"Atorvastatin (ATV) has shown pleiotropic effects on bone tissue, and osteoporosis can aggravate periodontitis. "	( Effects of Atorvastatin on Periodontitis of Rats Subjected to Glucocorticoid-Induced Osteoporosis. Alexandre, JT; Brito, GA; Chaves, HV; Freitas, R; Furlaneto, F; Goes, P; Linhares, EV; Lisboa, MR; Marques, M; Martins, C; Ribeiro, I; Sousa, LH; Val, D, 2016)	2.27
"Atorvastatin has been shown to affect cognitive functions in rodents and humans. "	( Atorvastatin enhances kainate-induced gamma oscillations in rat hippocampal slices. Guo, FL; Li, C; Liu, Z; Lu, CB; Vreugdenhil, M; Wang, J; Wang, XF; Wang, Y; Zhao, J, 2016)	3.32
"Atorvastatin (ATV) has been reported to attenuate cognitive deficits after stroke, but precise mechanism for neuroprotection remains unknown."	( Atorvastatin Attenuates Ischemia/Reperfusion-Induced Hippocampal Neurons Injury Via Akt-nNOS-JNK Signaling Pathway. Chen, G; Ge, X; Guo, L; Li, K; Luo, L; Shao, S; Xu, M; Zhang, F; Zhou, J; Zhu, Z, 2017)	2.62
"Atorvastatin has favorable effects on biochemical markers of oxidative stress in SCI."	( Effects of Atorvastatin on Experimental Spinal Cord Ischemia-Reperfusion Injury in Rabbits. Aykol, S; Civi, S; Kardes, O; Omeroglu, S; Oyar, EO; Tufan, K, 2017)	1.57
"Atorvastatin has become a cornerstone in the prevention and treatment of atherosclerosis."	( Atorvastatin inhibits insulin synthesis by inhibiting the Ras/Raf/ERK/CREB pathway in INS-1 cells. Chang, B; Chen, L; Hou, N; Li, Y; Shan, C; Sun, B; Sun, H; Wang, J; Xu, J; Yang, J; Zeng, X; Zhang, Y; Zheng, M, 2016)	2.6
"Atorvastatin (Atv) has been shown to protect against atherosclerosis, cardiac fibrosis, ischemia/reperfusion injury, etc."	( Attenuation of Low Ambient Temperature-Induced Myocardial Hypertrophy by Atorvastatin via Promoting Bcl-2 Expression. Bi, C; Cao, X; Ding, F; Feng, D; Han, Z; Huang, Q; Liang, J; Liu, Y; Ma, W; Pan, Z; Yin, K; Zhang, L, 2017)	1.41
"Atorvastatin has a beneficial effect on bone metabolism in patients with acute ischemic heart disease (mainly males) by incrementing bone mineral density in which vitamin D levels are required to be higher than 30 nmol/l for the drug to be effective."	( Effect of atorvastatin on bone mineral density in patients with acute coronary syndrome. Abad, L; Dueñas, A; García-Porrero, M; Pérez-Castrillón, JL; Pinacho, F; Sanz-Cantalapiedra, A; Vega, G, )	1.98
"Atorvastatin has previously been shown to reduce the endogenous angiogenic response to chronic ischemia in a porcine model. "	( Atorvastatin increases myocardial indices of oxidative stress in a porcine model of hypercholesterolemia and chronic ischemia. Bianchi, C; Boodhwani, M; Clements, RT; Feng, J; Mieno, S; Ramlawi, B; Sellke, FW; Sodha, NR; Xu, SH, )	3.02
"Atorvastatin has been widely investigated among the older subjects and has the greatest magnitude of favorable effects on clinical outcomes of CHD."	( Atorvastatin and cardiovascular risk in the elderly--patient considerations. Acharjee, S; Welty, FK, 2008)	2.51
"Atorvastatin has cardioprotective effects in acute reperfusion injury. "	( Evaluation cardioprotective effects of atorvastatin in rats by real time myocardial contrast echocardiography. Buss, S; Filusch, A; Hansen, A; Hardt, S; Katus, HA; Kuecherer, HF, 2008)	2.06
"Atorvastatin 20 mg has a dramatic effect on the lipid but moderate effect on CRP. "	( Effect of atorvastatin on LDL & hs-CRP in a selected Thai population. Benjanuwatra, T; Boonbaichaiyapruck, S; Buakhamsri, A; Cheepudomwit, S; Moleelerkpoom, W; Panjavenin, P; Sukanandachai, B; Suthichaiyakul, T, 2008)	2.19
"Atorvastatin has previously been implicated in various cutaneous adverse events."	( [Atorvastatin-induced drug reaction with eosinophilia and systemic symptoms (DRESS)]. Dubertret, L; Gressier, L; Pruvost-Balland, C; Viguier, M, 2009)	1.98
"Atorvastatin has thus to be added to the list of medication potentially responsible for bile duct injury."	( Severe acute cholestatic hepatitis with prolonged cholestasis and bile-duct injury following atorvastatin therapy: a case report. Geubel, AP; Leclercq, I; Rahier, J; Rahier, JF, )	1.07
"Atorvastatin therapy has substantially beneficial effects on oxidative protein and DNA damage in hypercholesterolemic rabbits."	( Effects of atorvastatin therapy on protein oxidation and oxidative DNA damage in hypercholesterolemic rabbits. Altug, T; Aydin, S; Sozer, V; Uzun, H, 2009)	1.46
"Atorvastatin has been shown to reduce resistin expression in macrophages after pro-inflammatory stimulation. "	( Mechanism of inhibitory effect of atorvastatin on resistin expression induced by tumor necrosis factor-alpha in macrophages. Chua, SK; Kuan, P; Shyu, KG; Wang, BW, 2009)	2.07
"Atorvastatin has been shown to have an inhibitory effect on cardiac fibroblasts in vitro."	( Mechanism of the inhibitory effect of atorvastatin on endoglin expression induced by transforming growth factor-beta1 in cultured cardiac fibroblasts. Chen, WJ; Hung, CR; Kuan, P; Shyu, KG; Wang, BW, 2010)	1.35
"Atorvastatin has a beneficial effect on oxidative stress in rats fed with high-cholesterol diet. "	( Effect of atorvastatin and ezetimibe treatment on serum lipid profile and oxidative state in rats fed with a high-cholesterol diet. Ciralik, H; Gümüşalan, Y; Kilinc, M; Ozbag, D; Toru, H; Yasim, A, 2010)	2.21
"Atorvastatin has been employed as standard agent."	( Role of glucagon-like peptide- 1 in vascular endothelial dysfunction. Bijjem, KV; Goyal, S; Kumar, S; Singh, M, 2010)	1.08
"Atorvastatin has been associated with liver injury. "	( Atorvastatin-induced acute elevation of hepatic enzymes and the absence of cross-toxicity of pravastatin. Cheng, KA; Cheng, Z; Ding, L; Fang, F; Fang, Q; Liu, Y; Shi, GP, 2010)	3.25
"Atorvastatin has dramatic antiatherosclerotic effects, part of which seems to be due to the antioxidant features of the parent drug and/or its metabolites, favoring inhibition of LDL oxidation."	( Effect of atorvastatin therapy on oxidant-antioxidant status and atherosclerotic plaque formation. Nart, D; Onat, T; Sezer, ED; Sozmen, EY, 2011)	2.21
"Atorvastatin has anti-inflammatory and angioprotective effects in SS patients."	( [Pleiotropic effects of statins in systemic sclerosis]. Alekperov, RT; Aleksandrova, EN; Anan'eva, LP; Korzeneva, EG; Novikov, AA, 2011)	1.81
"Atorvastatin has a significant effect on lowering of PRA in sensitized hemodialysis patients waiting for kidney transplantation. "	( Alteration of panel-reactive antibodies following treatment with either atorvastatin or low-dose mycophenolate mofetil in sensitized hemodialysis patients. Aref, A; Ehsanpour, A; Ghorbani, A; Shahbazian, H, 2011)	2.04
"Atorvastatin has a further sympatholytic effect in CKD patients, who are on chronic aliskiren, which is independent of blood pressure and heart rate."	( Atorvastatin reduces sympathetic activity in patients with chronic kidney disease. Blankestijn, PJ; Joles, JA; Oey, PL; Siddiqi, L, 2011)	3.25
"Atorvastatin pretreatment has been reported to reduce myocardial damage in patients undergoing percutaneous coronary intervention (PCI). "	( Effects of atorvastatin pretreatment on infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Ahn, KJ; Choi, JH; Choi, SH; Choi, YJ; Gwon, HC; Hahn, JY; Jo, SH; Kim, HJ; Lee, KH; Lee, S; Lee, SH; Song, YB, 2011)	2.2
"Atorvastatin (AVA) has shown in vitro anti-malarial activity and has improved the activity of mefloquine (MQ) and quinine."	( Atorvastatin treatment is effective when used in combination with mefloquine in an experimental cerebral malaria murine model. Amalvict, R; Baret, E; Briolant, S; Dormoi, J; Mosnier, J; Pradines, B; Rogier, C; Savini, H; Soulard, R; Souraud, JB, 2012)	2.54
"Atorvastatin 10 mg daily has no beneficial effect on the natural history of PAH or CTEPH over 6 months."	( Atorvastatin in pulmonary arterial hypertension (APATH) study. Cheng, XS; Gu, Q; He, JG; Liu, ZH; Ni, XH; Shan, GL; Wilkins, MR; Xiong, CM; Xue, F; Zeng, WJ; Zhao, L; Zhao, ZH, 2012)	2.54
"Atorvastatin has neuroprotective effects, and there is some evidence that nitric oxide is involved in atorvastatin effects. "	( Chronic administration of atorvastatin induced anti-convulsant effects in mice: the role of nitric oxide. Dehpour, AR; Fakhrzad, A; Hassanipour, M; Hassanpour, S; Moezi, L; Shafaroodi, H, 2012)	2.12
"Atorvastatin has shown to possess neuroprotective, antiexcitotoxic, and antiepileptic effects besides its cholesterol-lowering properties. "	( Anticonvulsive effect of atorvastatin on pentylenetetrazole-induced seizures in mice: the role of nitric oxide pathway. Emamzadeh-Fard, S; Moazzami, K; Shabani, M, 2013)	2.14
"Atorvastatin has been shown to reduce efficiently the levels of atherogenic lipoproteins also in patients with renal failure, but pharmacokinetic data in haemodialysis patients are lacking."	( Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients. Dratwa, M; Lameire, NH; Lins, RL; Matthys, KE; Peeters, PC; Stolear, JC; Verpooten, GA, 2003)	1.36
"Atorvastatin has been shown to have pleiotropic immunomodulatory effects involving both antigen presenting cells and T cell compartment."	( [Effects of atorvastatin in multiple sclerosis]. Koh, CS, 2003)	1.42
"Atorvastatin has protective effects against membrane lipid peroxidation at pharmacologic concentrations."	( Hypothesis: atorvastatin has pleiotropic effects that translate into early clinical benefits on cardiovascular disease. Hennekens, CH; Novela, C, 2004)	1.42
"Atorvastatin has promoted more beneficial effects on TC and LDL-c, whereas estradiol was responsible for an increase in HDL-c. "	( Progesterone abolishes estrogen and/or atorvastatin endothelium dependent vasodilatory effects. Abdalla, DS; Aldrighi, JM; Bertolami, MC; Faludi, AA; Nakamura, Y; Pereira, IR; Ramires, JA; Saleh, MH; Silva, RA; Sousa, JE, 2004)	2.04
"Atorvastatin has also been shown to significantly reduce CHD events."	( Torcetrapib/atorvastatin combination therapy. Bays, H; Davidson, M; McKenney, J, 2005)	1.43
"Atorvastatin has an anti-inflammatory action benefiting the alleviation of secondary inflammatory damaged in acute cerebral infarction that is independent of lipid lowering."	( [Effects of atorvastatin on plasma hypersensitive C-reactive protein and interleukin-6 in patients with acute cerebral infarction]. Hu, ZP; Jiang, B; Nie, S; Tan, LM; Wu, J; Xiao, ZJ; Zhao, SP; Zhou, HN, 2005)	2.15
"Atorvastatin has been shown to reduce coronary events and revascularization procedures in patients with multiple risk factors for coronary heart disease. "	( Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Gibson, E; Luo, D; Newman, C; Szarek, M; Tsai, J, 2006)	2.09
"Atorvastatin has been employed in the present study as standard agent to improve vascular endothelial dysfunction."	( Involvement of Rho-kinase in experimental vascular endothelial dysfunction. Shah, DI; Singh, M, 2006)	1.06
"Atorvastatin has lipid-lowering and pleiotropic properties, including a protective effect on endothelial function."	( Early effects on endothelial function of atorvastatin 40 mg twice daily and its withdrawal. Borucki, K; Luley, C; Makarova, R; Schmidt-Lucke, C; Taneva, E; Westphal, S; Wiens, L, 2006)	1.32
"Atorvastatin has a parallel effect on systemic and local inflammatory process in patients with coronary artery disease."	( Relation between local temperature and C-reactive protein levels in patients with coronary artery disease: effects of atorvastatin treatment. Boudoulas, H; Stefanadi, E; Stefanadis, C; Toutouzas, K; Tsiamis, E; Tsioufis, C; Vavuranakis, M, 2007)	1.27
"Atorvastatin has been extensively studied in the primary and secondary prevention of cardiovascular events, and may have some clinical advantages over various other statins in these respects. "	( Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events. Arca, M; Gaspardone, A, 2007)	3.23
"Atorvastatin has also been shown to reduce levels of the inflammatory marker C-reactive protein; in comparative studies, this effect proved to be superior to that of simvastatin or pravastatin and equivalent to that of rosuvastatin."	( Effects of atorvastatin on the different phases of atherogenesis. Rubba, P, 2007)	1.45
"Atorvastatin has been found to be effective for reducing nonfatal myocardial infarctions and fatal CHD in hypertensive patients with three or more additional risk factors."	( Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin. Bybee, KA; Lee, JH; O'Keefe, JH, 2008)	1.35
"Atorvastatin has differential effects on SREBF1a and SCAP mRNA expression in PBMC that are associated with baseline transcription levels, triglycerides response to atorvastatin and SCAP A2386G polymorphism."	( Atorvastatin effects on SREBF1a and SCAP gene expression in mononuclear cells and its relation with lowering-lipids response. Arazi, SS; Bernik, M; Dorea, EL; Genvigir, FD; Hirata, MH; Hirata, RD; Willrich, MA, 2008)	3.23
"Atorvastatin has little or no ability to increase high density lipoprotein (HDL)-cholesterol, and this may be a disadvantage in patients with metabolic syndrome or diabetes, where low HDL-cholesterol is a key feature."	( Is atorvastatin superior to other statins? Analysis of the clinical trials with atorvastatin having cardiovascular endpoints. Doggrell, SA, 2006)	1.68
"Atorvastatin has become a popular addition to hospital formularies, even though formal pharmacoeconomic analyses are lacking."	( Atorvastatin: a hydroxymethylglutaryl-coenzyme A reductase inhibitor. Malinowski, JM, 1998)	2.46
"Atorvastatin has greater cholesterol-lowering efficacy than simvastatin in HFH."	( Treatment of heterozygous familial hypercholesterolemia: atorvastatin vs simvastatin. Bo, M; Fabris, F; Fiandra, U; Mercadante, G; Nicolello, MT; Piliego, T, 2001)	2
"Atorvastatin monotherapy has a better effect on LDL-C and apoprotein B than statin-fibrate combinations, but a lesser effect on HDL-C, TG and in the case of ciprofibrate combinations, fibrinogen."	( Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia. Athyros, VG; Athyrou, VV; Demitriadis, DS; Kontopoulos, AG; Papageorgiou, AA; Pehlivanidis, AN, 2002)	2.48

Actions

Atorvastatin can activate AMPK and the phosphorylation of AMPK results in eNOS activated, which provides a novel explanation for the multi-effect of statins on cardiovascular system. Atorvstatin may inhibit the proliferation of HL-60 cells and induce apoptosis by inhibiting PI3K/ATK/mTOR signaling pathway.

Excerpt	Reference	Relevance
"Atorvastatin can inhibit PAH in rats by suppressing the Notch pathway."	( Effect of atorvastatin on pulmonary hypertension rats through regulating notch signaling pathway. Cao, GQ; Liu, H; Liu, JY; Tang, MM; Zhang, XQ; Zhu, YT, 2020)	2.4
"Atorvastatin could inhibit the proliferation of HL-60 cells. "	( [Effects of Atorvastatin on Proliferation and Apoptosis of Leukemia Cell Line HL-60 and Its Mechanism of Signal Pathway]. Chen, ZZ; Dai, J; Liu, T; Pang, YX; Wang, K; Wang, Q, 2017)	2.28
"Atorvastatin may inhibit the proliferation of HL-60 cells and induce apoptosis by inhibiting the PI3K/ATK/mTOR signaling pathway."	( [Effects of Atorvastatin on Proliferation and Apoptosis of Leukemia Cell Line HL-60 and Its Mechanism of Signal Pathway]. Chen, ZZ; Dai, J; Liu, T; Pang, YX; Wang, K; Wang, Q, 2017)	2.28
"Atorvastatin was found to inhibit ALT and AST activities and to reduce FBG levels in rats with STZ-induced diabetes."	( Protective effect of atorvastatin on oxidative stress in streptozotocin-induced diabetic rats independently their lipid-lowering effects. Aktay, G; Gürsoy, ŞÖ; İlhan, N; Ünüvar, S; Uyumlu, U, 2019)	1.55
"Atorvastatin inhibit MMP-9 expression of aging myocytes by PPARalpha signal channel."	( [The effect of PPARalpha signal channel on atorvastatin inhibiting MMP-9 expression in aging myocytes]. Han, L; Li, MG; Ye, P, 2013)	2.1
"Atorvastatin can suppress cardiomyocyte apoptosis after I/R injury in rats, which may be related to the down-regulated expression of Mfn2."	( [Atorvastatin inhibits cardiomyocyte apoptosis via down-cegulation the expression mitofusin 2 after myocardial ischemia/reperfusion injury in rats]. Chen, L; Chen, M; Zhou, W, 2014)	2.76
"Atorvastatin did not lower plasma total cholesterol levels or affect plaque progression at this dosage; however, vulnerable plaque numbers were significantly reduced in the atorvastatin-treated group compared to control."	( Atorvastatin improves plaque stability in ApoE-knockout mice by regulating chemokines and chemokine receptors. Cai, Z; He, B; Hu, L; Jin, S; Li, D; Nie, P; Shao, Q; Shen, J; Shen, L; Xiao, H; Yi, J; Yu, Y, 2014)	2.57
"Atorvastatin can inhibit neointimal hyperplasia and promote SMCs apoptosis in neointimal layers, which may be mainly associated with down-regulation of survivin and Fas expression after CAI of rat."	( Inhibition of neointimal hyperplasia in rats treated with atorvastatin after carotid artery injury may be mainly associated with down-regulation of survivin and Fas expression. Fang, Z; Huang, D; Li, X; Liu, Q; Xu, Y; Zheng, C; Zhou, S, 2014)	2.09
"Atorvastatin could inhibit neuronal apoptosis and alleviate the cerebral I/R injury."	( Protection effect of atorvastatin in cerebral ischemia-reperfusion injury rats by blocking the mitochondrial permeability transition pore. Deng, JG; Liu, J; Song, T; Tao, X, 2014)	1.44
"Atorvastatin may primarily inhibit the nuclear translocation of pNFκB to prevent CCI-induced peripheral neuropathic pain."	( Atorvastatin prevents neuroinflammation in chronic constriction injury rats through nuclear NFκB downregulation in the dorsal root ganglion and spinal cord. Chen, JY; Chu, LW; Wu, BN; Wu, PC, 2015)	2.58
"Atorvastatin can inhibit VEGI and vascular endothelial growth factor expression to protect rats from diabetic retinopathy."	( Effect of atorvastatin on diabetic rat endothelial cells and retinal lesions. Bi, MC; Shi, H; Song, E; Song, XJ; Xu, CL; Xue, WX, 2015)	1.54
"Atorvastatin can enhance the existing effects of MSCs transplantation, and this combinational therapy is a superior cell/pharmacological therapeutic approach that merits future preclinical and clinical studies."	( Atorvastatin treatment improves effects of implanted mesenchymal stem cells: meta-analysis of animal models with acute myocardial infarction. Chen, H; Dai, G; Deng, Y; Gao, J; Li, Y; Luo, R; Wang, Y; Wu, X; Xu, Q; Yuan, W, 2015)	3.3
"Atorvastatin may inhibit Hcy-induced ROS accumulation and endothelium cell apoptosis through an NADPH oxidase and/or p38MAPK-dependent mechanisms, all of which may contribute to atorvastatin-induced beneficial effect on endothelial function."	( Atorvastatin attenuates homocysteine-induced apoptosis in human umbilical vein endothelial cells via inhibiting NADPH oxidase-related oxidative stress-triggered p38MAPK signaling. Bao, XM; Lu, GP; Wu, CF, 2009)	3.24
"Atorvastatin could inhibit tau hyperphosphorylation and decrease Abeta generation."	( Inhibition of tau hyperphosphorylation and beta amyloid production in rat brain by oral administration of atorvastatin. Li, X; Lu, F; Suo, AQ; Zhang, JW, 2010)	1.3
"Atorvastatin can activate AMPK and the phosphorylation of AMPK results in eNOS activated, which provides a novel explanation for the multi-effect of statins on cardiovascular system."	( Atorvastatin prevents mesenchymal stem cells from hypoxia and serum-free injury through activating AMP-activated protein kinase. Dong, Q; Qian, H; Song, L; Xu, Z; Yang, Y, 2011)	3.25
"Atorvastatin use may also increase Cp levels although this effect appears to be independent of its anti-oxidant effects."	( Effects of statin use on total oxidant and antoxidant capacity and ceruloplasmin activity. Aksoy, N; Bas, M; Buyukhatıpoglu, H; Celik, H; Demirbag, R; Guntekin, U; Polat, M; Sezen, Y; Taskin, A; Yildiz, A, 2010)	1.08
"Atorvastatin was able to activate all of the elements."	( Atorvastatin activates heme oxygenase-1 at the stress response elements. Handal, J; Kwok, SC; Samuel, SP, 2012)	2.54
"Atorvastatin treatment promotes functional restoration after PDT, but does not promote glioma growth in vitro and in vivo."	( Atorvastatin reduces functional deficits caused by photodynamic therapy in rats. Chopp, M; Ding, C; Jiang, F; Jiang, J; Lu, Y; Yang, H; Zhang, L; Zhao, D; Zheng, X, 2011)	2.53
"Atorvastatin can inhibit the signal transduction of TLR4 and reduce proinflammatory cytokines release induced by CRP on CD14 monocyte, and this might be one of the anti-inflammatory mechanisms of atorvastatin."	( [The effects of atorvastatin on C-reactive protein induced Toll-like receptor 4 expression on CD14+ monocyte]. Liu, JL; Luo, YT; Peng, L, 2011)	1.44
"Atorvastatin inhibited the increase in the production of IL-1β, PGE(2) and MMP-3 in submandibular glands treated with anti-M(3) peptide IgG."	( Atorvastatin inhibits the inflammatory response caused by anti-M(3) peptide IgG in patients with primary Sjögren's syndrome. Borda, E; Passafaro, D; Reina, S; Sterin-Borda, L, 2012)	2.54
"Atorvastatin did not cause a deterioration in insulin sensitivity."	( Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose. Buldak, L; Dulawa-Buldak, A; Labuzek, K; Okopien, B, 2012)	1.1
"Atorvastatin pretreatment inhibit cellular apoptosis induced by H₂O₂ (39.45%, 20.53% and 7.83%)."	( [Atorvastatin inhibits the H₂O₂-induced apoptosis of human vascular endothelial cells through a down-regulation of cleaved caspase-9/caspase-3]. Li, SJ; Wu, WZ; Xu, ZR; Yang, YM; Yao, HP, 2012)	2.01
"Atorvastatin could inhibit the TLR4 expression and TLR4-dependent downstream signaling in THP-1 cells. "	( Atorvastatin decreases Toll-like receptor 4 expression and downstream signaling in human monocytic leukemia cells. Fang, W; Li, R; Qu, X; Quan, Z; Yang, SS, 2012)	3.26
"Atorvastatin can increase eNOS synthesis in the vital organs of aging rats, which partially explains the organ-protective effect of atorvastatin against myocardial ischemia- reperfusion."	( [Effect of atorvastatin on eNOS synthesis in organs of aging rats with myocardial ischemia-reperfusion]. Wang, H; Ye, P; Zhang, J, 2012)	2.21
"Atorvastatin can inhibit IL-6 secretion in adipocytes possibly through upregulating PPARgamma, which may help to explain the anti-inflammatory effects of statins use."	( Atorvastatin reduces interleukin-6 plasma concentration and adipocyte secretion of hypercholesterolemic rabbits. Zhang, DQ; Zhao, SP, 2003)	3.2
"The atorvastatin-mediated increase in S-nitrosylation was associated with an enhanced enzymatic activity of thioredoxin (atorvastatin, 157+/-9% increase)."	( Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins. Dimmeler, S; Haendeler, J; Hoffmann, J; Zeiher, AM, 2004)	0.8
"Atorvastatin can inhibit leptin release and mRNA expression, and reduces serum leptin level in hypercholesterolemic rabbits."	( Atorvastatin reduces serum leptin concentration in hypercholesterolemic rabbits. Wu, ZH; Zhao, SP, 2005)	3.21
"As atorvastatin can enhance protective Th2 responses and has a different mechanism of action than glatiramer acetate (GA), a parenterally administered immunomodulatory agent approved for MS treatment, we tested whether the combination of these agents could be beneficial in EAE."	( Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. Hemmer, B; Nessler, S; Prod'homme, T; Sobel, RA; Steinman, L; Stüve, O; von Büdingen, HC; Weber, MS; Youssef, S; Zamvil, SS, 2006)	1.11
"Atorvastatin did not cause a redistribution of triglycerides but consistently lowered triglycerides in all lipoprotein fractions."	( Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. Bakker-Arkema, RG; Black, DM; Brown, WV; Davidson, MH; Davignon, J; Goldstein, RJ; Isaacsohn, JL; Keilson, LM; Miller, VT; Shurzinske, LJ; Weiss, SR, 1996)	1.26
"Atorvastatin may allow patients with combined hyperlipidemia to be treated with monotherapy and offers an efficacious and well-tolerated alternative to niacin for the treatment of patients with isolated hypertriglyceridemia."	( A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group. Black, DM; Kafonek, S; Koren, M; McCormick, LS; McKenney, JM; Weiss, S, 1998)	2.02

Treatment

Atorvastatin treatment did not affect the duration of status epilepticus or the development of epilepsy. Treatment significantly improved lipid profile across with increased apelin (from 0.307 ± 0.130 pg/ml to 1.537±0.427pg/ml; P < 0.001) and suppressed visfatin (from 21.54 ± 10.14 ng/ML to 15.13 ± 7.61 ng/ ML; P = 0.002) serum levels in diabetic patients.

Excerpt	Reference	Relevance
"Atorvastatin treatment had the highest inverse-correlation with the UC gene signature among non-oncolytic FDA-approved therapies. "	( Computational drug repositioning of atorvastatin for ulcerative colitis. Bai, L; Habtezion, A; Kalesinskas, L; Khatri, P; Scott, MKD; Shah, NH; Steinberg, E, 2021)	2.34
"Atorvastatin pretreatment exerted protective effect on CPB-associated kidney injury and inflammation in rats. "	( Atorvastatin Exerts Protective Effect on Cardiopulmonary Bypass Induced Renal Injury in Rats via PPAR-γ. Ge, J; Wei, C; Zhang, T, 2022)	3.61
"Atorvastatin pretreatment prevented kidney damage following exposure to toxic doses of cadmium."	( Atorvastatin prevents cadmium-induced renal toxicity in a rat model. Bandegi, AR; Dehdashti, A; Ghanbari, A; Goodarzi, Z; Karami, E; Yosefi, S, 2023)	3.07
"Atorvastatin treatment of HHcy in mice led to no changes in total cholesterol but decreases in total homocysteine in plasma. "	( Atorvastatin rescues hyperhomocysteinemia-induced cognitive deficits and neuroinflammatory gene changes. Bottiglieri, T; Fardo, DW; Johnson, SN; Qiao, Q; Rogers, CB; Sudduth, TL; Weekman, EM; Wilcock, DM; Xie, K, 2023)	3.8
"In atorvastatin (ator)-treated high-fat diet-fed mice, we found reduced pancreatic β-cell size and β-cell mass, fewer mature insulin granules, and reduced insulin secretion and glucose tolerance."	( Atorvastatin Targets the Islet Mevalonate Pathway to Dysregulate mTOR Signaling and Reduce β-Cell Functional Mass. Cheng, T; Cui, C; Feng, B; Fu, C; Fu, L; Gu, Y; Li, T; Li, X; Ni, Q; Nie, A; Qiu, Y; Shen, L; Wang, Q; Wang, W; Wang, Y, 2020)	2.51
"Atorvastatin treatment does not significantly affect circulating adiponectin. "	( Effect of atorvastatin treatment on circulating adiponectin: a meta-analysis of randomized controlled trials. Jia, G; Liu, X; Sun, R; Zhang, W; Zhao, M, 2019)	2.36
"Atorvastatin treatment improved cognitive function in the mouse model, attenuated neuroinflammation, and increased PPARγ expression in the hippocampus."	( Atorvastatin protects against postoperative neurocognitive disorder via a peroxisome proliferator-activated receptor-gamma signaling pathway in mice. Lin, D; Liu, J; Ma, D; Wei, C; Wu, A; Xiong, C; Yang, Y, 2020)	2.72
"Atorvastatin treatment provides significant benefits for dilated cardiomyopathy."	( The Impact of Atorvastatin on Cardiac Performance for Dilated Cardiomyopathy: A Meta-analysis of Randomized Controlled Studies. Fu, L; Shang, X; Zhang, X, 2020)	2.36
"Atorvastatin treatment increased EPC VEGFA protein levels, proliferation, migration, and angiogenesis."	( Atorvastatin improves the proliferation and migration of endothelial progenitor cells via the miR-221/VEGFA axis. Sun, L; Wang, J; Xing, S; Zhang, J; Zhang, Y, 2020)	2.72
"Atorvastatin treatment increased anti-oxidant enzyme levels (P<0.01)."	( Atorvastatin Prevents the Neuron Loss in the Hippocampal Dentate Gyrus Region through its Anti-Oxidant and Anti-Apoptotic Activities. Arani, HZ; Jangholi, E; Karimi, A; Movassaghi, S; Parsa, Y; Sharifi, ZN; Yadollah-Damavandi, S, 2021)	2.79
"Atorvastatin treatment in I/R rats decreases oxidative stress, production of ROS, apoptosis rate in neuronal cells, and improves the mitochondrial function. "	( Atorvastatin Prevents the Neuron Loss in the Hippocampal Dentate Gyrus Region through its Anti-Oxidant and Anti-Apoptotic Activities. Arani, HZ; Jangholi, E; Karimi, A; Movassaghi, S; Parsa, Y; Sharifi, ZN; Yadollah-Damavandi, S, 2021)	3.51
"Oral atorvastatin treatment in Göttingen Minipigs is associated with a reduced mitochondrial respiratory capacity in the liver that may be linked to increased content of atorvastatin in this organ."	( Atorvastatin impairs liver mitochondrial function in obese Göttingen Minipigs but heart and skeletal muscle are not affected. Christiansen, LB; Ciborowski, M; Desler, C; Dohlmann, TL; Kretowski, A; Larsen, S; Ludvigsen, TP; Martinussen, T; Olsen, LH; Orlando, P; Parfieniuk, E; Szczerbinski, L; Tiano, L, 2021)	2.52
"Atorvastatin treatment reduced the presence of immature vessels by 34% vs."	( Atorvastatin pleiotropically decreases intraplaque angiogenesis and intraplaque haemorrhage by inhibiting ANGPT2 release and VE-Cadherin internalization. Baganha, F; de Jong, RCM; de Vries, MR; Delibegovic, M; Jukema, JW; Peters, EA; Quax, PHA; Voorham, W, 2021)	2.79
"Atorvastatin treatment along with BaP in the embryonic period were able to bring the antioxidant status and sex hormones levels relatively close to normal."	( Effect of prenatal exposure to Benzo[a]pyrene on ovarian toxicity and reproductive dysfunction: Protective effect of atorvastatin in the embryonic period. Karimpour Malekshah, A; Rahmani, Z; Talebpour Amiri, F; Zargari, M, 2021)	1.55
"Atorvastatin treatment has been suggested as a therapeutic method for women with polycystic ovary syndrome (PCOS) in many clinical studies. "	( Effects of atorvastatin on the insulin resistance in women of polycystic ovary syndrome: A systematic review and meta-analysis. Chen, LL; Zheng, JH, 2021)	2.45
"Atorvastatin treatment resulted in enhanced graft take and wound closure of the full thickness wounds, faster resolution of neutrophils compared to all treatments and reduced alpha-smooth muscle actin positive cells compared to control treatment."	( Differential effects of Losartan and Atorvastatin in partial and full thickness burn wounds. Akershoek, JJ; Beelen, RHJ; Boekema, BKHL; Brouwer, KM; Middelkoop, E; Ulrich, MMW; Vlig, M, 2017)	1.45
"Atorvastatin treatment may alleviate cerebral vasospasm and mediate structural and functional remodeling of vascular endothelial cells, in addition to promoting anti‑apoptotic signaling."	( Protective effects of atorvastatin on cerebral vessel autoregulation in an experimental rabbit model of subarachnoid hemorrhage. Chen, JH; Chen, L; Hu, X; Li, PP; Wang, YH; Wu, T; Yang, LK; Zhu, J, 2018)	1.52
"Atorvastatin treatment and arsenic exposure alone are capable of generating apoptosis in pancreatic β-cells of Wistar rats with T2D. "	( Apoptosis in pancreatic β-cells is induced by arsenic and atorvastatin in Wistar rats with diabetes mellitus type 2. Cervantes-Flores, M; Delgado-León, TG; López-Guzmán, OD; Lozano-Guzmán, E; Martínez-Romero, A; Sálas-Pacheco, JM; Úrtiz-Estrada, N; Vazquez-Alaniz, F; Vértiz-Hernández, ÁA, 2018)	2.17
"Atorvastatin treatment during epileptogenesis had slight beneficial effects on seizure susceptibility. "	( Subtle improvement of seizure susceptibility by atorvastatin treatment during epileptogenesis. Fighera, MR; Furian, AF; Oliveira, CV; Oliveira, MS; Royes, LFF; Zorzi, VN, 2018)	2.18
"Atorvastatin treatment produces a relatively mild effect on sexual functioning and mood in women, affecting only selected elements of female sexual behaviour."	( The effect of atorvastatin on sexual function and depressive symptoms in young women with elevated cholesterol levels - a pilot study. Drosdzol-Cop, A; Krysiak, R; Okopień, B; Skrzypulec-Plinta, V, 2018)	2.28
"Atorvastatin treatment works for patients with carotid plaque by reducing LDL-cholesterol and improving plaque regression. "	( Evaluating the Efficacy of Atorvastatin on Patients with Carotid Plaque by an Innovative Ultrasonography. Bai, QK; Deng, SH; Jiang, Q; Jiang, XZ; Zhang, Y; Zhang, ZP; Zhu, YC, 2019)	2.25
"In atorvastatin-treated mice, total MK4 and percentage of deuterium-labeled MK4 in kidney were both approximately 45% lower compared to values in mice not given atorvastatin (all P < 0.05)."	( Atorvastatin Decreases Renal Menaquinone-4 Formation in C57BL/6 Male Mice. Booth, SL; Fu, X; Greenberg, A; Grusak, MA; Harshman, SG; Kuliopulos, A; Lamon-Fava, S; Shea, MK; Smith, D, 2019)	2.47
"The atorvastatin treatments to mice with PF resulted in significant increases at the TGF-β activation, cell proliferation and kidney damage and decreases in the levels of p-SMAD2, p-ELK1, p-ATF2 and p-c-Jun, but not change the p-SMAD3, ELK1 and ATF2 in kidneys."	( The effects of atorvastatin on the kidney injury in mice with pulmonary fibrosis. Bolkent, S; Karatug Kacar, A; Oztay, F; Yildirim, M, 2019)	1.35
"Atorvastatin treatment produced a significant decrease in MPV levels (9.3 ± 1.3 vs 9.1 ± 1.2 fL, P = .008) and platelet count (259 ± 61 vs 248 ± 51 10(9)/L, P = .005)."	( Effect of atorvastatin on hematologic parameters in patients with hypercholesterolemia. Akin, F; Akin, MN; Ayça, B; Canbek, TD; Güngör, O; Köse, N; Sahin, I, 2013)	1.51
"Atorvastatin pretreatment promoted increased cell viability after OGD and reoxygenation of hippocampal slices."	( Atorvastatin prevents cell damage via modulation of oxidative stress, glutamate uptake and glutamine synthetase activity in hippocampal slices subjected to oxygen/glucose deprivation. Bertoldo, DB; de Bem, AF; Herculano, BA; Mancini, G; Martins, WC; Tasca, CI; Vandresen-Filho, S, 2013)	2.55
"Atorvastatin pretreatment restored part of the up or down regulations."	( Altered microRNA expression in the ischemic-reperfusion spinal cord with atorvastatin therapy. Hu, JR; Lv, GH; Yin, BL, 2013)	1.34
"Atorvastatin treatment of HUVECs produced a time-dependent increase in GTP loading of all Rho GTPases, and induced the translocation of small Rho GTPases from the cellular membrane to the cytosol, which was reversed by 100 µM MVA and 10 µM GGPP, but not by 10 µM FPP."	( Inhibition of Rho and Rac geranylgeranylation by atorvastatin is critical for preservation of endothelial junction integrity. Ping, D; Qin, X; Xiao, H; Zuo, K, 2013)	1.37
"Atorvastatin treatment significantly reduced the active form of RhoC in vitro and diminished cell motility, invasion, proliferation and colony formation. "	( Atorvastatin inhibits RhoC function and limits head and neck cancer metastasis. Islam, M; Kumar, B; Sharma, S; Teknos, TN, 2013)	3.28
"Atorvastatin treatment was also associated with increased haemoglobin A1C levels from 7.45% to 7.77% (p = 0.008)."	( Impaired endothelium-dependent skin microvascular function during high-dose atorvastatin treatment in patients with type 1 diabetes. Adamson, U; Jörneskog, G; Lins, PE; Mobarrez, F; Tehrani, S; Wallén, HN, 2013)	1.34
"Atorvastatin treatment appeared to facilitate to reduce all-cause mortality (lnRR = 0.61, p = 0.05) and rehospitalisation for heart failure (lnRR = 0.44, p = 0.04) compared with non-atorvastatin therapy."	( Long-term clinical outcomes of statin use for chronic heart failure: a meta-analysis of 15 prospective studies. Dai, XP; Li, XR; Wang, JQ; Wang, Z; Wu, GR, 2014)	1.12
"Atorvastatin treatment increased cholesterol absorption by 52.3% in those with the lowest baseline campesterol levels, which attenuated the effect of LDL-C reduction."	( Association between cholesterol synthesis/absorption markers and effects of cholesterol lowering by atorvastatin among patients with high risk of coronary heart disease. Li, Y; Liu, J; Liu, X; Lv, Q; Ma, C; Qi, Y; Sun, J; Wang, M; Wang, W; Zhao, D, 2013)	1.33
"Atorvastatin and HT treatments reduced the mRNA levels of APOA1 and SCARB1, respectively, whereas ABCA1 expression was reduced after all treatments. "	( Atorvastatin and hormone therapy influence expression of ABCA1, APOA1 and SCARB1 in mononuclear cells from hypercholesterolemic postmenopausal women. Bertolami, MC; Cavalli, SA; Cerda, A; Faludi, AA; Genvigir, FD; Hirata, MH; Hirata, RD; Issa, MH; Rohde, CB, 2013)	3.28
"Atorvastatin treatment inhibited dose-dependently cell attachment to endothelium and differentiation."	( Atorvastatin inhibited Rho-associated kinase 1 (ROCK1) and focal adhesion kinase (FAK) mediated adhesion and differentiation of CD133+CD44+ prostate cancer stem cells. Chintala, M; Chintala, R; Guda, M; Komarraju, AL; Mangamoori, LN; Rentala, S, 2013)	2.55
"Atorvastatin treatment significantly reduced serum total cholesterol levels while probucol treatment led to significant reduction of high-density lipoprotein cholesterol levels without changing total cholesterol levels compared with those in the control group. "	( Probucol inhibits the initiation of atherosclerosis in cholesterol-fed rabbits. Fan, J; Keyamura, Y; Kohashi, M; Koyama, T; Niimi, M; Nozako, M; Yasufuku, R; Yoshikawa, T, 2013)	1.83
"Each atorvastatin-treated group demonstrated significant reductions in infarct and edema volumes compared with the vehicle-treated group 24h after reperfusion. "	( Continuous oral administration of atorvastatin ameliorates brain damage after transient focal ischemia in rats. Inaba, T; Kamiya, F; Katayama, Y; Katsura, K; Muraga, K; Nito, C; Saito, T; Ueda, M, 2014)	1.2
"Atorvastatin treatment of fructose-fed rats increased vascular BH4 content, which was associated with an increase in endothelial NO synthase activity as well as a reduction in endothelial O2(-) production."	( Effects of atorvastatin, amlodipine, and their combination on vascular dysfunction in insulin-resistant rats. Geddawy, A; Imamura, T; Iwasaki, H; Masada, M; Okamura, T; Shimosato, T; Shinozaki, K; Shintaku, H; Tawa, M; Yoshida, Y, 2014)	1.51
"Atorvastatin treatment failed to induce IL-4-producing Th2 cells in vivo; however, when T cells from atorvastatin-treated 4-GET mice were reactivated in vitro, T cells preferentially differentiated into Th2 cells, while antigen-specific T-cell proliferation and secretion of proinflammatory cytokines (interferon gamma, IL-17, tumor necrosis factor and IL-12) were reduced."	( Neither T-helper type 2 nor Foxp3+ regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity. Dunn, SE; Prod'homme, T; Steinman, L; Weber, MS; Youssef, S; Zamvil, SS, 2014)	1.34
"Atorvastatin treatment resulted in behavioral deficits as measured in paradigms for basic exploration (open field activity) and cognitive function (Barnes maze, startle response) without impairment in global motor function (Rotor Rod)."	( Long-term atorvastatin treatment leads to alterations in behavior, cognition, and hippocampal biochemistry. Cui, W; Drummond, JC; Godoy, JC; Head, BP; Niesman, IR; Patel, HH; Patel, PM; Risbrough, VB; Roth, DM; Schilling, JM; Zemljic-Harpf, AE, 2014)	1.53
"Atorvastatin treatment significantly increased VEGF-induced angiogenic responsiveness and the NO-releasing properties of cECs from all of the subgroups, compared with their respective non-treated subgroups except for the late-phase diabetic rat hearts that underwent ischemia-reperfusion, and the high dose of atorvastatin treatment groups."	( Effect of atorvastatin on the angiogenic responsiveness of coronary endothelial cells in normal and streptozotocin (STZ) induced diabetic rats. Chaudagar, KK; Mehta, AA, 2014)	1.53
"Atorvastatin treatment did not change the plasma CTSS mRNA levels, although it lowered the plasma CTSS concentrations and activity. "	( Interrelated cathepsin S-lowering and LDL subclass profile improvements induced by atorvastatin in the plasma of stable angina patients. Cerne, D; Djeric, M; Jelic-Ivanovic, Z; Kos, J; Marc, J; Milivojac, T; Mirjanic-Azaric, B; Pecar Fonovic, U; Vekic, J; Zeljkovic, A, 2014)	2.07
"Atorvastatin treatment may eliminate SDH and improve the neural function of the rats through its anti-inflammatory effects. "	( Effects of atorvastatin on the inflammation regulation and elimination of subdural hematoma in rats. Chen, J; Cui, W; Jiang, R; Li, T; Quan, W; Tian, Y; Wang, D; Wang, Y; Yu, H; Zhang, J; Zhou, L, 2014)	2.23
"Atorvastatin treatment exhibited significant analgesic activity in hot plate model (P = 0.022). "	( Atorvastatin exerts anti-nociceptive activity and decreases serum levels of high-sensitivity C-reactive protein and tumor necrosis factor-α in a rat endometriosis model. Gul, M; Ozerol, E; Ozerol, IH; Parlakpinar, H; Simsek, Y; Yilmaz, E, 2014)	3.29
"Atorvastatin treatment may have a therapeutic potential in the treatment of endometriosis through its anti-inflammatory and anti-nociceptive properties."	( Atorvastatin exerts anti-nociceptive activity and decreases serum levels of high-sensitivity C-reactive protein and tumor necrosis factor-α in a rat endometriosis model. Gul, M; Ozerol, E; Ozerol, IH; Parlakpinar, H; Simsek, Y; Yilmaz, E, 2014)	3.29
"All atorvastatin-treated groups showed higher expression of IRS-1, PI3K, Akt, GSK-3, IL-10, eNOS, VEGF, and ERK on Day 7."	( Effect of atorvastatin on wound healing in rats. Araujo, EP; Azevedo, FF; Caricilli, AM; do Amaral, ME; Lima, MH; Saad, MJ; Suzuki-Banhesse, VF, 2015)	1.3
"Atorvastatin treatment significantly decreased circulating low-density lipoprotein cholesterol (LDL-C) and total cholesterol concentrations by 42% and 24% (p<0.0001) respectively, and reached the efficacy objective of the protocol. "	( Evaluation of atorvastatin efficacy and toxicity on spermatozoa, accessory glands and gonadal hormones of healthy men: a pilot prospective clinical trial. Brugnon, F; Drevet, J; Gouby, G; Gremeau, AS; Grizard, G; Janny, L; Maqdasy, S; Marceau, G; Pereira, B; Pons-Rejraji, H; Sion, B; Tauveron, I, 2014)	2.21
"Atorvastatin treatment significantly increased AMD (18%) at 3 wk in group B, compared with week 0."	( Evaluation of statin therapy on endothelial function in hypercholesterolemic rabbits by automatic measurement of arterial wall movement using ultrasound images. Mokhtari-Dizaji, M; Rahmani-Cherati, T; Rostami, A; Vajhi, A, 2014)	1.12
"Atorvastatin treatment also decreased Fn14 expression in the atherosclerotic plaques of ApoE KO mice."	( [Atorvastatin inhibits the atherosclerotic lesion induced by tumor necrosis factor-like weak inducer of apoptosis in apolipoprotein E deficient mice]. Blanco-Colio, LM; Egido, J; Fernández-Laso, V; Martín-Ventura, JL; Sastre, C, )	1.76
"Atorvastatin treatment for 48 h after the infarction did not change GLUT4 expression, and after 7 days it had an additional negative effect on GLUT4 content (~ 39%, P = 0.030)."	( Atorvastatin administered before myocardial infarction in rats improves contractility irrespective of metabolic changes. Belló-Klein, A; Lehnen, AM; Lehnen, TE; Machado, UF; Markoski, MM; Schaan, B; Tavares, AM, 2014)	2.57
"Atorvastatin treatment efficiently reduced serum cholesterol levels. "	( Chemically induced mouse liver tumors are resistant to treatment with atorvastatin. Braeuning, A; Bucher, P; Buchmann, A; Hofmann, U; Schwarz, M, 2014)	2.08
"Atorvastatin treatment reduced spike frequencies and amplitudes significantly throughout the experiment."	( HMG-CoA reductase inhibitor rosuvastatin improves abnormal brain electrical activity via mechanisms involving eNOS. Caglayan, AB; Caglayan, B; Demirci, S; Dogan, A; Ekimci, N; Ethemoglu, MS; Kilic, E; Kilic, U; Oztezcan, S; Sahin, F; Seker, FB; Yilmaz, B, 2015)	1.14
"Atorvastatin treatment reduced infarct size in B6 mice by 19% (p<0.05). "	( Atorvastatin at reperfusion reduces myocardial infarct size in mice by activating eNOS in bone marrow-derived cells. French, BA; Linden, J; Tian, Y; Yang, Z, 2014)	3.29
"Atorvastatin treatment increased the expression levels of p85αPI3K, phosphorylated Akt, phosphorylated glycogen synthase kinase-3β, phosphorylated ERK, and Bcl-2, which are proteins related to survival."	( Atorvastatin Protects NSC-34 Motor Neurons Against Oxidative Stress by Activating PI3K, ERK and Free Radical Scavenging. Choi, H; Choi, NY; Huh, YM; Koh, SH; Lee, KY; Lee, SH; Lee, YJ; Park, J; Yu, HJ, 2016)	2.6
"Atorvastatin treatment significantly reduced overall cardiovascular (p=0.046) and coronary events (p=0.004), and coronary revascularisation (p=0.007) in these patients."	( High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease. Boekholdt, SM; Fayyad, R; Hovingh, GK; Laskey, R; Pedersen, TR; Stoekenbroek, RM; Tikkanen, MJ, 2015)	1.54
"Atorvastatin treatment of PC3 cells for 24 h increased the expression of green fluorescent protein‑LC3‑II by >25%, and expression continued for >72 h, while apoptosis was not significantly induced within this time period."	( Atorvastatin induces autophagic cell death in prostate cancer cells in vitro. He, Z; Qi, P; Wang, Z; Yuan, J; Zhang, L, 2015)	2.58
"Atorvastatin treatment (groups III and IV) significantly reduced the level of motor dysfunction."	( Neuroprotective effect of atorvastatin in spinal cord ischemia-reperfusion injury. Alpay, MF; Cakir, O; Colak, N; Nazli, Y; Uysal, S; Uzunlar, AK, 2015)	1.44
"Atorvastatin treatment partially restored endothelial function by increasing NO level by 98%, reducing ONOO(-) by 40% and favorably elevating [NO]/[ONOO(-)] to 1.1 ± 0.2 for diabetic SHR rats and 1.6 ± 0.3 for SHR rats."	( Atorvastatin enhanced nitric oxide release and reduced blood pressure, nitroxidative stress and rantes levels in hypertensive rats with diabetes. Corbalan, JJ; Dawoud, H; Jacob, RF; Malinski, T; Mason, RP, 2015)	2.58
"Atorvastatin treatment produced a significant 34% reduction in sputum neutrophil count, and a 57% reduction in CD45+ cells in lung biopsies (expressed as integrated optical density -IOD; median IOD 62.51% before, 27.01% after atorvastatin treatment, P=0.008)."	( Anti-inflammatory effects of atorvastatin treatment in chronic obstructive pulmonary disease. A controlled pilot study. Bierla, J; Boros, P; Chyczewska, E; Duszewska, AM; Lisowska, A; Lisowski, P; MacNee, W; Milewski, R; Minarowski, L; Mroz, RM; Musial, WJ; Sobkowicz, B; Trzeciak, PZ; Tycinska, A, 2015)	1.43
"Atorvastatin treatment increased the percentage and inhibitory ability of nTregs, decreased serum IFN-γ and hsCRP levels, and decreased IL-10 and TGF-β1 levels, as compared with the non-atorvastatin group.Our findings suggest that nTregs play an atheroprotective role in atherosclerosis."	( Changes of naturally occurring CD4(+)CD25(+) FOXP3(+) regulatory T cells in patients with acute coronary syndrome and the beneficial effects of atorvastatin treatment. Ding, Y; Feng, GK; Jiang, XJ; Li, XY; Wang, CQ; Wang, ZX, 2015)	1.34
"Atorvastatin pretreatment conferred 70-90% hepatic protection in all animals."	( Acute atorvastatin is hepatoprotective against ischaemia-reperfusion injury in mice by modulating eNOS and microparticle formation. Ajamieh, H; Chu, E; Farrell, GC; Lam, W; McCuskey, RS; Teoh, NC; Wong, HJ; Yu, J, 2015)	1.62
"Atorvastatin treatment prevented dyslipidemia, reversed hepatic steatosis, optimized composition of bone, and improved bone mechanical properties."	( The effects of atorvastatin on the prevention of osteoporosis and dyslipidemia in the high-fat-fed ovariectomized rats. Cui, L; Fu, Z; Huang, J; Lee, WY; Li, G; Liang, Y; Lin, S; Qin, L; Sun, Y; Wu, H; Wu, T; Xu, L, 2015)	1.49
"Atorvastatin calcium co-treatment inhibited the phenotype modulation and cytoskeleton rearrangements and improved the expression of contractile phenotype marker proteins such as α-SM actin, SM22α and calponin in comparison with PDGF-BB alone stimulated VSMCs."	( Atorvastatin calcium inhibits phenotypic modulation of PDGF-BB-induced VSMCs via down-regulation the Akt signaling pathway. Chen, S; Kong, D; Li, C; Li, S; Liu, B; Sun, Y; Wang, H, 2015)	2.58
"Atorvastatin pretreatment also prevented AβO-induced decreases in Akt and Erk1/2 kinase activity and the increases in GSK3β and Cdk5 kinase activity."	( Atorvastatin prevents Aβ oligomer-induced neurotoxicity in cultured rat hippocampal neurons by inhibiting Tau cleavage. Jin, Y; Liu, Z; Sui, HJ; Zhang, LL, 2015)	2.58
"Atorvastatin treatment increased total bilirubin concentration (median 6.95 μmol/L vs. "	( Atorvastatin treatment increases plasma bilirubin but not HMOX1 expression in stable angina patients. Cerne, D; Hallstroem, S; Jürgens, G; Marc, J; Mirjanic-Azaric, B; Rizzo, M; Srdic, S, 2015)	3.3
"Atorvastatin treatment could significantly suppress the increase of both IL-37 and Smad3."	( Increased IL-37 in Atherosclerotic Disease could be Suppressed by Atorvastatin Therapy. Hongcheng, F; Ming, D; Shaoyuan, C; Yulang, H, 2015)	1.38
"Atorvastatin treatment did not affect lesion inflammation (aortic arch mRNA levels of CXCL 1, ICAM-1, MCP-1, TNF-α, VCAM, IL-6, and IL-1β) or cellular composition (smooth muscle cell, macrophage, and T-cell content)."	( Imaging of Intracellular and Extracellular ROS Levels in Atherosclerotic Mouse Aortas Ex Vivo: Effects of Lipid Lowering by Diet or Atorvastatin. Adiels, M; Borén, J; Ekstrand, M; Fogelstrand, P; Gustafsson Trajkovska, M; Johansson, M; Levin, M; Mattsson-Hultén, L; Perman-Sundelin, J, 2015)	1.34
"Atorvastatin treatment improved cardiac function of rats with isoproterenol-induced chronic heart failure and decreased the Rac1, p47phox and p67phox mRNA expressions."	( Atorvastatin improves cardiac function of rats with chronic cardiac failure via inhibiting Rac1/P47phox/P67phox-mediated ROS release. An, LP; An, SK; Fu, SY; Wei, XH; Wu, HA, 2015)	2.58
"Atorvastatin pretreatment provides protection against oxidative stress in a rat kidney model of ischemia-reperfusion injury, reinforcing the evidence of a beneficial effect of statins beyond their cholesterol-lowering properties."	( N-Acetylcysteine and High-Dose Atorvastatin Reduce Oxidative Stress in an Ischemia-Reperfusion Model in the Rat Kidney. Caristo, ME; Ciavarella, LP; Citterio, F; Copponi, G; Crea, F; Cusumano, G; Giubilato, S; Liuzzo, G; Manchi, M; Romagnoli, J; Severino, A; Stigliano, E; Zannoni, GF, 2015)	2.15
"Atorvastatin treatment (Group D) abolished PPHTg which became comparable to controls, pioglitazone treatment partially blunted PPHTg resulting in intermediate PPHTg."	( Postprandial Hypertriglyceridemia Predicts Development of Insulin Resistance Glucose Intolerance and Type 2 Diabetes. Aggarwal, S; Aslam, M; Galav, V; Madhu, SV; Sharma, KK, 2016)	1.16
"Atorvastatin treatment also reduced the intensity of Oil Red O staining in pigs on high-fat diet."	( A Translational Model for Diet-related Atherosclerosis: Effect of Statins on Hypercholesterolemia and Atherosclerosis in a Minipig. Amuzie, C; Denham, S; Mais, DE; Rogers, CS; Swart, JR; Vihtelic, T, 2016)	1.16
"Atorvastatin pre-treatment dose-dependently decreased hs-CRP and resistin levels but increased adiponectin levels in mice."	( Inflammation Activation Contributes to Adipokine Imbalance in Patients with Acute Coronary Syndrome. Chen, LZ; Huang, XS; Li, R; Zhao, SP, 2016)	1.16
"Atorvastatin-treated group (n=50) received interferon β-1a similar to control group in addition to atorvastatin (40 mg/day) for 18-months."	( Interferon β-1a and Atorvastatin in the Treatment of Multiple Sclerosis. Faraji, F; Fazeli, M; Ghasami, K; Ghazavi, A; Mosayebi, G, 2016)	1.48
"Atorvastatin or fluoxetine treatment was effective in protecting mice hippocampal slices from glutamate toxicity by preventing the oxidative stress and mitochondrial dysfunction."	( Atorvastatin and Fluoxetine Prevent Oxidative Stress and Mitochondrial Dysfunction Evoked by Glutamate Toxicity in Hippocampal Slices. Binder, LB; Constantino, LC; Dal-Cim, T; Ludka, FK; Massari, C; Tasca, CI, 2017)	2.62
"Atorvastatin (10 mg/kg) treatment for 7 days prevented the QA-induced decrease in glutamate uptake, but had no effect on increased glutamate release induced by QA."	( Atorvastatin Prevents Glutamate Uptake Reduction Induced by Quinolinic Acid Via MAPKs Signaling. Bertoldo, DB; Leal, RB; Maestri, M; Martins, WC; Rieger, DK; Tasca, CI; Vandresen-Filho, S, 2016)	2.6
"An atorvastatin treatment (2.5 mg/kg/day) was tested against controls on 34 male 3 to 12 month-old WHHL rabbits. "	( A non-hypocholesterolemic atorvastatin treatment improves vessel elasticity by acting on elastin composition in WHHL rabbits. Aubry, T; Bourgeois, N; Desfontis, JC; Didier, R; Dubreuil, M; Gilard, M; Goanvec, C; Le Grand, Y; Mallem, Y; Mansourati, J; Pichavant-Rafini, K; Plee-Gautier, E; Roquefort, P; Theron, M; Tissier, F, 2016)	1.36
"Atorvastatin treatment resulted in a rise in both CK (2X) and myoglobin (6X) level with graded degrees of muscle necrosis."	( Elucidation of the mechanism of atorvastatin-induced myopathy in a rat model. Abdallah, D; El-Ganainy, SO; El-Khatib, AS; El-Mallah, A; Khattab, MM; Mohy El-Din, MM, 2016)	1.44
"Atorvastatin treatment did not affect glycemia levels. "	( Treatment with high dose of atorvastatin reduces vascular injury in diabetic rats. Botelho, T; de Batista, PR; Padilha, AS; Ribeiro-Júnior, RF; Simões, FV; Vassallo, DV, 2016)	2.17
"Atorvastatin treatment increased serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in casein injection mice."	( Inflammatory Stress Sensitizes the Liver to Atorvastatin-Induced Injury in ApoE-/- Mice. Chen, Y; Li, B; Moorhead, JF; Ruan, XZ; Varghese, Z; Wu, W; Yang, P; Zhao, L; Zhou, W, 2016)	1.42
"Atorvastatin treatment strongly inhibited proliferation in estrogen receptor (ER) negative cell lines and a commensurate response was also evident on the genome-wide transcriptional scale, with ER negative cells displaying a robust deregulation of genes involved in the regulation of cell cycle progression and apoptosis."	( High expression of cholesterol biosynthesis genes is associated with resistance to statin treatment and inferior survival in breast cancer. Borgquist, S; Bosch, A; Feldt, M; Kimbung, S; Lettiero, B, 2016)	1.16
"Atorvastatin treatment in vitro quantitatively and functionally improved BM EPCs derived from subjects with PGF through downregulation of the p38 MAPK pathway."	( Atorvastatin enhances endothelial cell function in posttransplant poor graft function. Huang, XJ; Kong, Y; Liu, KY; Shi, MM; Song, Y; Sun, YQ; Wang, Y; Xu, LP; Zhang, XH, 2016)	2.6
"Atorvastatin treatment increased flap survival rate and capillary density. "	( The Effect of Atorvastatin on the Viability of Ischemic Skin Flaps in Diabetic Rats. Chai, YM; Chen, HH; Jia, YC; Kang, QL; Xu, J, 2017)	2.26
"Atorvastatin treatment increases vitamin D (33%, p = 0.007) and decreases the individuals with vitamin D insufficiency. "	( Effect of atorvastatin on bone mineral density in patients with acute coronary syndrome. Abad, L; Dueñas, A; García-Porrero, M; Pérez-Castrillón, JL; Pinacho, F; Sanz-Cantalapiedra, A; Vega, G, )	1.98
"Atorvastatin treatment was associated with elevated levels of myocardial protein oxidation and lipid peroxidation. "	( Atorvastatin increases myocardial indices of oxidative stress in a porcine model of hypercholesterolemia and chronic ischemia. Bianchi, C; Boodhwani, M; Clements, RT; Feng, J; Mieno, S; Ramlawi, B; Sellke, FW; Sodha, NR; Xu, SH, )	3.02
"Atorvastatin treatment modified the expression of 86 genes."	( Monocyte gene-expression profile in men with familial combined hyperlipidemia and its modification by atorvastatin treatment. Alegret, M; Cofán, M; Laguna, JC; Llaverias, G; Pou, J; Ros, E; Sánchez, A; Sánchez, RM; Vázquez-Carrera, M; Zambón, D, 2008)	1.28
"Atorvastatin treatment of human PBMC before MLR reduced their response to stimulated WT (P<0.05) and GTKO (P<0.05) pAEC."	( Atorvastatin down-regulates the primate cellular response to porcine aortic endothelial cells in vitro. Ayares, D; Cooper, DK; Ezzelarab, M; Hara, H; Long, C; Torres, C; Welchons, D; Yeh, P, 2008)	2.51
"Atorvastatin treatment increased the superoxide dismutase level and inhibited the degree of renal tubular cell N-acetyl glucosaminidase compared with stone forming control group 3."	( Atorvastatin inhibits renal crystal retention in a rat stone forming model. Momohara, C; Nonomura, N; Okuyama, A; Tsujihata, M; Tsujimura, A; Yoshioka, I, 2008)	2.51
"Atorvastatin treatment was equally effective in patients with ischemic and nonischemic HF."	( Atorvastatin therapy is associated with reduced levels of N-terminal prohormone brain natriuretic peptide and improved cardiac function in patients with heart failure. Assmann, G; Breithardt, G; Nofer, JR; Schubert, A; Schulte, H; Stypmann, J; Welp, H, 2008)	2.51
"Atorvastatin treatment is associated with improved cardiac function in HF, and may represent an additional option for patients with this disease."	( Atorvastatin therapy is associated with reduced levels of N-terminal prohormone brain natriuretic peptide and improved cardiac function in patients with heart failure. Assmann, G; Breithardt, G; Nofer, JR; Schubert, A; Schulte, H; Stypmann, J; Welp, H, 2008)	3.23
"Atorvastatin treatment, alone and in combination with pioglitazone, revealed a significant regression in IMT (0.923+/-0.013 to 0.874+/-0.012 mm and 0.921+/-0.015 to 0.882+/-0.015 mm; mean +/- SEM; p<0.05 respectively) and Aix@75 (27.3+/-1.2 to 25.9+/-1.4; and 25.6+/-1.4 to 24.8+/-1.7%; p<0.05)."	( Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk. Forst, T; Fuchs, W; Hanefeld, M; Konrad, T; Lehmann, U; Müller, J; Pfützner, A; Schaper, F; Weber, M; Wilhelm, B, 2008)	1.31
"Atorvastatin treatment was similarly effective regardless of baseline lipoprotein levels."	( Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Amarenco, P; Callahan, A; Goldstein, LB; Hennerici, MG; O'Neill, BJ; Rudolph, AE; Sillesen, H; Simunovic, L; Welch, KM; Zivin, JA, 2009)	1.07
"Only atorvastatin treatment did not show any histological atheroprotective effect."	( Anti-atherosclerotic effect of atorvastatin and clopidogrel alone and in combination in rats. Annapurna, A; Reddy, YN; Srinivas, M, 2008)	1.09
"Atorvastatin treatment prevented fructose-induced ChREBP translocation and the increase in ChREBP DNA-binding activity while reducing SREBP-1c DNA-binding activity."	( Atorvastatin prevents carbohydrate response element binding protein activation in the fructose-fed rat by activating protein kinase A. Barroso, E; Coll, T; Laguna, JC; Merlos, M; Palomer, X; Rodríguez-Calvo, R; Sánchez, RM; Serrano, L; Vázquez-Carrera, M, 2009)	2.52
"Atorvastatin treatment of NaCl-infused rats had only marginal effects."	( Treatment with atorvastatin partially protects the rat heart from harmful catecholamine effects. Ehmke, H; El-Armouche, A; Eschenhagen, T; Grimm, M; Höppner, G; Schmechel, A; Schwoerer, AP, 2009)	1.43
"Atorvastatin treatment had no effect on plasma adiponectin levels."	( Role of plasma adiponectin on the HDL-cholesterol raising effect of atorvastatin in patients with type 2 diabetes. Dallinga-Thie, GM; Jansen, H; Kastelein, JJ; Sijbrands, EJ; van Hoek, M; van Tol, A; van Vark-van der Zee, LC, 2009)	1.31
"Atorvastatin treatment at different doses, particularly 80 mg, significantly reduced hsCRP serum concentrations. "	( Effect of atorvastatin on circulating hsCRP concentrations: a sub-study of the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study. Blanco-Colio, LM; de Teresa, E; Dilaghi, B; Egido, J; Farsang, C; Gaw, A; Gensini, GF; Gori, AM; Langer, A; Leiter, LA; Martineau, P; Nozza, A; Rostagno, C, 2010)	2.21
"Atorvastatin treatment was generally well tolerated."	( Effect of very low LDL-cholesterol on cortisol synthesis. Akbay, E; Corapcioglu, D; Emral, R; Gen, R; Sezer, K, 2008)	1.07
"Atorvastatin treatment prevented ischemia-reperfusion-induced up-regulation of both TNF-alpha and IL-10 mRNA, and improved left ventricular function (P<0.01)."	( Effect of atorvastatin on expression of IL-10 and TNF-alpha mRNA in myocardial ischemia-reperfusion injury in rats. Li, J; Li, X; Li, ZQ; Liu, YY; Pan, W; Sun, YM; Tian, Y; Wang, LF, 2009)	1.48
"In atorvastatin-treated SHRs, relaxation to acetylcholine was normalized, fully sensitive to N(G)-nitro-L-arginine methyl ester, and not affected by SC-560, DuP-697, SQ 29548, or antioxidants."	( Atorvastatin prevents endothelial dysfunction in mesenteric arteries from spontaneously hypertensive rats: role of cyclooxygenase 2-derived contracting prostanoids. Antonioli, L; Blandizzi, C; Colucci, R; Daghini, E; Del Tacca, M; Duranti, E; Fornai, M; Ghisu, N; Giannarelli, C; Taddei, S; Versari, D; Virdis, A, 2009)	2.31
"Atorvastatin treatment acutely reduces JNK expression and dendritic cells, resulting in reduced inflammatory cell content and expression of MMPs in the AAA wall."	( Short-term 20-mg atorvastatin therapy reduces key inflammatory factors including c-Jun N-terminal kinase and dendritic cells and matrix metalloproteinase expression in human abdominal aortic aneurysmal wall. Amano, A; Daida, H; Kajimoto, K; Kasai, T; Kojima, Y; Miyauchi, K; Niinami, H; Shimada, A; Shimada, K, 2009)	2.14
"Atorvastatin-treated groups had significantly lower bleeding rates (p = 0.0011) and infarct volume (p = 0.0007) compared with controls."	( Early atorvastatin reduces hemorrhage after acute cerebral ischemia in diabetic rats. El-Remessy, AB; Elewa, HF; Ergul, A; Fagan, SC; Frye, RF; Johnson, MH; Kozak, A, 2009)	1.56
"Atorvastatin treatment with 1 mg/kg/day did not significantly prevent QA-induced seizures (13.34%)."	( Atorvastatin prevents hippocampal cell death due to quinolinic acid-induced seizures in mice by increasing Akt phosphorylation and glutamate uptake. Boeck, CR; Carqueja, CL; Dal'agnolo, D; de Araújo Herculano, B; Martins, WC; Piermartiri, TC; Stroeh, E; Tasca, CI; Vandresen-Filho, S, 2009)	2.52
"Atorvastatin treatment was associated with a modest improvement in annual change in eGFR (net, 0.18 mL/min/1.73 m(2)/y; 95% confidence interval [CI], 0.04 to 0.32; P = 0.01) that was most apparent in those with albuminuria (net improvement, 0.38 mL/min/1.73 m(2)/y; P = 0.03)."	( Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Betteridge, DJ; Charlton-Menys, V; Colhoun, HM; DeMicco, DA; Durrington, PN; Fuller, JH; Hitman, GA; Livingstone, SJ; Neil, HA, 2009)	1.46
"Atorvastatin treatment is associated with less augmentation of the carotid BP waveform and less wave reflection from the body."	( Atorvastatin treatment is associated with less augmentation of the carotid pressure waveform in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT). Hughes, AD; Manisty, C; Mayet, J; McG Thom, SA; Poulter, N; Sever, PS; Tapp, RJ, 2009)	2.52
"Atorvastatin treatment lowered cholesterol, triglyceride, insulin, TNF-alpha, and IL-6 plasma levels, and restored whole-body insulin sensitivity."	( Anti-inflammatory effect of atorvastatin ameliorates insulin resistance in monosodium glutamate-treated obese mice. Favaro, RR; Furuya, DT; Machado, UF; Martins, JO; Poletto, AC; Zorn, TM, 2010)	1.38
"Atorvastatin treatment decreased cholesterol concentrations in all LDL subfractions (P<0.001 for each dose)."	( Atorvastatin treatment lowers fasting remnant-like particle cholesterol and LDL subfraction cholesterol without affecting LDL size in type 2 diabetes mellitus: Relevance for non-HDL cholesterol and apolipoprotein B guideline targets. Dallinga-Thie, GM; Dullaart, RP; Kappelle, PJ, 2010)	2.52
"Atorvastatin treatment resulted in significant decrease in sponge vascularization (Hb content) and in VEGF levels at both doses."	( Atorvastatin inhibits inflammatory angiogenesis in mice through down regulation of VEGF, TNF-alpha and TGF-beta1. Andrade, SP; Araújo, FA; Mendes, JB; Rocha, MA, 2010)	2.52
"Atorvastatin treatment significantly reduced the levels of total cholesterol (24.5%), low density lipoprotein (LDL) cholesterol (25.4%), triglycerides (24.4%), CD (4.4%), MDA (15.2%), TP (13.0%) and OSI (24.0%), and significantly increased the levels of TAS (27.3%), and PON1 activity (14.0%)."	( Effect of atorvastatin on paraoxonase1 (PON1) and oxidative status. Chinwattana, K; Deakin, S; Nagila, A; Permpongpaiboon, T; Porapakkham, P; Porntadavity, S; Tantrarongroj, S, )	1.26
"Atorvastatin treated groups showed smaller size of lipid deposits and a lower level of inflammation than non-treated groups."	( Effect of atorvastatin and diet on non-alcoholic fatty liver disease activity score in hyperlipidemic chickens. Adánez, G; Ayala, I; Castells, MT; Martín-Castillo, A; Pérez, BG; Polo, MT, 2010)	1.48
"Atorvastatin treatment significantly decreases the concentration of IL-6, and NT-proBNP in patients with DCM after 2 months of therapy. "	( The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy. Banach, M; Bielecka-Dabrowa, A; Goch, JH; Maciejewski, M; Mikhailidis, DP; Rysz, J, 2009)	2.14
"Atorvastatin-treated yeast cells display marked morphological deformities, have reduced cell viability and are highly vulnerable to perturbed mitochondrial function."	( Atorvastatin-induced cell toxicity in yeast is linked to disruption of protein isoprenylation. Andrews, S; Callegari, S; de Barros Lopes, MA; McKinnon, RA, 2010)	2.52
"Atorvastatin treatment decreased expression of IL-6, TNF-alpha, nuclear factor kappaB (NF-kappaB) and I-kappa-B (IkappaB) kinase-beta, but increased the expression of IkappaB, in adipose tissue."	( Atorvastatin improves insulin sensitivity in mice with obesity induced by monosodium glutamate. Huan, Y; Huang, H; Shen, ZF; Song, GM; Sun, SJ; Zhang, N, 2010)	2.52
"Atorvastatin treatment of PC3 cells for 40 hrs increased expression of LC3-II by more than 10 fold in a dose-dependent manner. "	( Statin-induced autophagy by inhibition of geranylgeranyl biosynthesis in prostate cancer PC3 cells. Childress, C; Deitrick, K; Lin, Q; Parikh, A; Rukstalis, D; Yang, W, 2010)	1.8
"Atorvastatin treatment led to a significantly lower expression of CD40L, CD11b and CD54 on monocytes (p<0.05) and neutrophils (p<0.05). "	( Effect of atorvastatin on cellular adhesion molecules on leukocytes in patients with normocholesterolemic coronary artery disease. Borggrefe, M; Dempfle, CE; Hoffmeister, HM; Suselbeck, T; Swoboda, S; Walter, T, )	1.98
"Atorvastatin treatment lowered plasma triglyceride but not cholesterol levels. "	( Atorvastatin protects renal function in the rat with acute unilateral ureteral obstruction. Chou, SY; Gulmi, FA; Kamdar, C; Kim, H; Mooppan, UM, 2010)	3.25
"Atorvastatin treatment affords protection of renal function in acute UUO and reduces urinary microalbumin levels without lowering cholesterol levels. "	( Atorvastatin protects renal function in the rat with acute unilateral ureteral obstruction. Chou, SY; Gulmi, FA; Kamdar, C; Kim, H; Mooppan, UM, 2010)	3.25
"On atorvastatin treatment there was a significant decrease in the LDL-C levels (p=0.021)."	( Effect of genetic variant (rs11887534) in ABCG8 gene in coronary artery disease and response to atorvastatin therapy. Garg, N; Mittal, B; Srivastava, A; Srivastava, K, 2010)	1.09
"Atorvastatin treatment was neuroprotective against cell degeneration induced by Aβ(1-40), reducing inflammatory and oxidative responses and increasing the expression of glutamatergic transporters."	( Atorvastatin prevents hippocampal cell death, neuroinflammation and oxidative stress following amyloid-β(1-40) administration in mice: evidence for dissociation between cognitive deficits and neuronal damage. Bezerra, SC; de Bem, AF; Duarte, FS; Figueiredo, CP; Mancini, G; Piermartiri, TC; Prediger, RD; Rial, D; Tasca, CI, 2010)	2.52
"Atorvastatin treatment alone decreased I(Ca,L) similar to rapid atrial pacing alone, currents were also further reduced by additional atrial tachypacing. "	( Atorvastatin treatment affects atrial ion currents and their tachycardia-induced remodeling in rabbits. Bentz, K; Eick, C; Kettering, K; Laszlo, R; Menzel, KA; Schreieck, J; Schreiner, B, 2010)	3.25
"Atorvastatin treatment alone reduced low density lipoprotein (LDL) cholesterol by 1.4 mmol/l (44%, p<0.001), triglycerides by 0.3 mmol/l (20%, p<0.0001) and lanosterol by 0.36 μmol/l (72%, p<0.001)."	( Impact of atorvastatin and omega-3 ethyl esters 90 on plasma plant sterol concentrations and cholesterol synthesis in type 2 diabetes: a randomised placebo controlled factorial trial. Ceglarek, U; Farmer, A; Holman, RR; Neil, HA; Paul, S; Thiery, J, 2010)	1.48
"Atorvastatin (Lipitor®) treatment was started at a fixed dose of 20 mg daily."	( Biomarker assessment of the immunomodulator effect of atorvastatin in stable renal transplant recipients and hypercholesterolemic patients. Brunet, M; Cofán, F; Cofán, M; Guillén, D; Millán, O; Ros, E, 2010)	2.05
"Atorvastatin treatment is safe and improves biomarkers of tubular damage or injury in non-diabetic patients with CKD."	( Atorvastatin improves tubular status in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study. Aleksandrowicz, E; Larczyński, W; Lysiak-Szydłowska, W; Neuwelt, A; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L; Ziętkiewicz, M, 2010)	3.25
"Atorvastatin treatment completely abolished histological signs of necroinflammation, reducing the hepatic expression of metallothionein-1 and nuclear factor kappa B binding."	( Reduction of liver fructokinase expression and improved hepatic inflammation and metabolism in liquid fructose-fed rats after atorvastatin treatment. Alegret, M; Ađalsteisson, GS; Laguna, JC; Merlos, M; Rebollo, A; Roglans, N; Vilà, L, 2011)	1.3
"Atorvastatin treatment did not affect diet induced body weight gain and did not lower plasma total cholesterol levels."	( Atorvastatin inhibits plaque development and adventitial neovascularization in ApoE deficient mice independent of plasma cholesterol levels. Biessen, EA; Bot, I; Jukema, JW; Lankhuizen, IM; van Berkel, TJ, 2011)	2.53
"Atorvastatin treatment did not decrease LDLoxab;(mU/mL, median [CI 95%]: baseline: 413 [187-1,196] and 24 weeks: 349 [101-1559])."	( [Atorvastatin and oxidized low density lipoprotein antibody. Relationship to age]. Cámara, C; Costo, A; Crespo, L; Fernández Pereira, L; Pereira, G; Sánchez Muñoz-Torrero, JF, 2011)	2
"Atorvastatin treatment for 1 year significantly decreased circulating levels of total cholesterol, LDL-cholesterol, triglycerides, and AGEs, while it increased HDL-cholesterol levels."	( Atorvastatin reduces proteinuria in non-diabetic chronic kidney disease patients partly via lowering serum levels of advanced glycation end products (AGEs). Fujiwara, N; Kawagoe, Y; Maeda, S; Nakamura, T; Sato, E; Takeuchi, M; Yamagishi, S, )	2.3
"Atorvastatin pre-treatment of EC was found to reduce the expression of adhesion molecules and P. "	( Atorvastatin prevents Plasmodium falciparum cytoadherence and endothelial damage. Arrouss, I; Assi, S; Mazier, D; N'dilimabaka, N; Pino, P; Rebollo, A; Soubrier, F; Taoufiq, Z, 2011)	3.25
"Atorvastatin treatment increased the SOD and catalase level compared with the stone-forming control group."	( Why does atorvastatin inhibit renal crystal retention? Nonomura, N; Okuyama, A; Tsujihata, M; Tsujimura, A; Yoshioka, I, 2011)	1.51
"Atorvastatin pretreatment, however, prevented the decrease in α(1D)-adrenoceptor mRNA expression in septic animals."	( Atorvastatin prevents vascular hyporeactivity to norepinephrine in sepsis: role of nitric oxide and α₁-adrenoceptor mRNA expression. Ahanger, AA; Choudhury, S; Kandasamy, K; Mishra, SK; More, AS; Parida, S; Prawez, S; Singh, TU, 2011)	2.53
"Atorvastatin treatment did not significantly preserve beta cell function although there may have been a slower decline of beta-cell function which merits further study."	( Residual beta cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin: the Randomized DIATOR Trial. Heinemann, L; Heise, T; Herder, C; Koenig, W; Kolb, H; Martin, S; Schloot, NC, 2011)	2.04
"Atorvastatin treatment resulted in a significant decrease of total, VLDL and LDL cholesterol, atherosclerotic lesion size and endoglin serum levels in comparison with CHOL mice."	( Endoglin as a possible marker of atorvastatin treatment benefit in atherosclerosis. Andrys, C; Brcakova, E; Micuda, S; Mullerova, Z; Nachtigal, P; Rathouska, J; Slanarova, M; Strasky, Z; Vecerova, L, 2011)	1.37
"In atorvastatin-treated patients, NGAL decreased (mean, -7.4 ng/mL/year; SD 128.4), whereas it increased in the placebo group [mean, 4.6 ng/mL/year; SD 56.6), the difference being statistically significant (P = 0.049)."	( Effects of atorvastatin on NGAL and cystatin C in chronic kidney disease: a post hoc analysis of the LORD trial. Ball, MJ; Cardinal, JW; Coombes, JS; Fassett, RG; Geraghty, DP; Robertson, IK, 2012)	1.28
"Atorvastatin treatment did not affect the duration of status epilepticus or the development of epilepsy. "	( Atorvastatin treatment during epileptogenesis in a rat model for temporal lobe epilepsy. Aronica, E; Gorter, JA; Holtman, L; Schmitz, LJ; van Vliet, EA; Wadman, WJ, 2011)	3.25
"Atorvastatin treatment significantly improved lipid profile across with increased apelin (from 0.307 ± 0.130 pg/ml to 1.537 ± 0.427 pg/ml; P < 0.001) and suppressed visfatin (from 21.54 ± 10.14 ng/ml to 15.13 ± 7.61 ng/ml; P = 0.002) serum levels in our diabetic patients."	( Effects of atorvastatin on apelin, visfatin (nampt), ghrelin and early carotid atherosclerosis in patients with type 2 diabetes. Kadoglou, NP; Kapelouzou, A; Kostakis, A; Lampropoulos, S; Liapis, CD; Sailer, N; Vitta, I, 2012)	1.49
"Atorvastatin treatment did not alter BMD compared with the control group, even in the highest dose of atorvastatin group."	( Effects of atorvastatin on bone metabolism and bone mineral density in Wistar rats. Chang, B; Chen, L; Fang, P; Li, H; Lu, S; Yang, J, 2011)	1.48
"Atorvastatin treatment in a certain extent inhibits bone resorption and promotes bone formation, but has no significant effects on bone mineral density in healthy rats."	( Effects of atorvastatin on bone metabolism and bone mineral density in Wistar rats. Chang, B; Chen, L; Fang, P; Li, H; Lu, S; Yang, J, 2011)	2.2
"Atorvastatin treatment promotes functional restoration after PDT, but does not promote glioma growth in vitro and in vivo."	( Atorvastatin reduces functional deficits caused by photodynamic therapy in rats. Chopp, M; Ding, C; Jiang, F; Jiang, J; Lu, Y; Yang, H; Zhang, L; Zhao, D; Zheng, X, 2011)	2.53
"Atorvastatin pretreatment attenuated bronchoalveolar lavage MMP-2 increases."	( Sildenafil improves the beneficial hemodynamic effects exerted by atorvastatin during acute pulmonary thromboembolism. Czaikoski, PG; Dias-Junior, CA; Neto-Neves, EM; Pereira, RP; Spiller, F; Tanus-Santos, JE; Uzuelli, JA, 2011)	1.33
"Atorvastatin treatment do not modify APOE expression, however those individuals without LDL cholesterol goal achievement after atorvastatin treatment according to the IV Brazilian Guidelines for Dyslipidemia and Atherosclerosis Prevention had lower APOE expression than patients with desirable response after the treatment (p < 0.05)."	( Apolipoprotein E mRNA expression in mononuclear cells from normolipidemic and hypercholesterolemic individuals treated with atorvastatin. Arazi, SS; Bernik, MM; Bertolami, MC; Cerda, A; Dorea, EL; Faludi, AA; Genvigir, FD; Hirata, MH; Hirata, RD; Willrich, MA, 2011)	1.3
"Atorvastatin treatment for 4 weeks in subjects with SCR significantly improved endothelial function and suppressed systemic inflammatory status by decreasing circulating levels of IL-1b and sVCAM-1."	( Effects of atorvastatin on endothelial function and the expression of proinflammatory cytokines and adhesion molecules in young subjects with successfully repaired coarctation of aorta. Antoniades, C; Antonopoulos, AS; Bakogiannis, C; Brili, S; Hatzis, G; Papageorgiou, N; Stefanadis, C; Tousoulis, D, 2012)	2.21
"Atorvastatin pretreatment has been reported to reduce myocardial damage in patients undergoing percutaneous coronary intervention (PCI). "	( Effects of atorvastatin pretreatment on infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Ahn, KJ; Choi, JH; Choi, SH; Choi, YJ; Gwon, HC; Hahn, JY; Jo, SH; Kim, HJ; Lee, KH; Lee, S; Lee, SH; Song, YB, 2011)	2.2
"Atorvastatin treatment for 6 months caused a significant reduction in the following biomarkers compared with baseline: BNP, from median (interquartile range) 268 (190-441) pg/mL to 185 (144-344) pg/mL; high-sensitivity C-reactive protein (hs-CRP), from 5.26 (1.95 -9.29) mg/L to 3.70 (2.34-6.81) mg/L; and PIIINP, from 4.65 (1.86) to 4.09 (1.25) pg/mL (all P < 0.05 baseline vs 6 months)."	( Long-term statin therapy in patients with systolic heart failure and normal cholesterol: effects on elevated serum markers of collagen turnover, inflammation, and B-type natriuretic peptide. Abulhul, E; Baugh, J; Hennessy, M; Ledwidge, M; Martos, R; McDonald, K; O'Loughlin, C; Phelan, D; Spiers, JP; Watson, C, 2012)	1.1
"In atorvastatin-treated patients, the decrease in LpPLA2 was associated with reduced fatal risk [HR per standard deviation 0·74 (0·62-0·90); P = 0·002], an effect not seen in the placebo group."	( Lipoprotein-associated phospholipase A2 and outcome in patients with type 2 diabetes on haemodialysis. Drechsler, C; Hoffmann, MM; Krane, V; Wanner, C; Winkler, K, 2012)	0.89
"Atorvastatin treatment of lipemia was followed by a decrease in the total LP-C, total LDL-C (LDL(1-3)-C subfraction), and the LDL(1-3)-TG subfraction."	( Influence of atorvastatin and carboxymethylated glucan on the serum lipoprotein profile and MMP activity of mice with lipemia induced by poloxamer 407. Cherkanova, MS; Filjushina, EE; Johnston, TP; Kaledin, VI; Korolenko, TA; Loginova, VM; Tuzikov, FV; Tuzikova, NA, 2012)	1.47
"Atorvastatin pretreatment significantly reduced the occurrence of AF after bypass grafting; nonetheless, the difference between the beneficial effects of intensive and routine atorvastatin treatments on postoperative AF was not significant."	( The effect of a high dose of atorvastatin on the occurrence of atrial fibrillation after coronary artery bypass grafting. Bidhendi, LM; Bina, P; Fathollahi, MS; Karimi, A; Molai, M; Rezvanfard, M; Sadeghian, S; Yousefi, A; Zare, E, 2012)	2.11
"Atorvastatin treatment may be effective in slowing the decline of beta cell function in a patient subgroup defined by above median levels of CRP and other inflammation associated immune mediators."	( Improved preservation of residual beta cell function by atorvastatin in patients with recent onset type 1 diabetes and high CRP levels (DIATOR trial). Heinemann, L; Heise, T; Herder, C; Koenig, W; Kolb, H; Martin, S; Roden, M; Schloot, NC; Simon, MC; Strom, A, 2012)	2.07
"Atorvastatin treatment significantly decreased development of new brain MRI T2 lesion activity, although it did not achieve the composite clinical and imaging PEP."	( Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study. Bar-Or, A; Calabresi, PA; Cohen, JA; Cross, A; Ding, L; Goodman, A; Iklé, D; Kachuck, N; Kita, M; Kopetskie, H; Mass, M; Miller, A; Mokhtarani, M; Murphy, S; Pelletier, D; Preiningerova, J; Racke, M; Rosenberg, E; Schwid, S; Spencer, C; Stüve, O; Vollmer, T; Waubant, E; Weinstock-Guttman, B; Zamvil, SS, 2012)	2.11
"Atorvastatin donor pre-treatment of brain dead organ donors combined with 24h of cold preservation has no influence on graft rejection and infiltration with ED1 or MHCII positive cells in an allogeneic rat renal transplantation model. "	( Atorvastatin donor pre-treatment in a model of brain death and allogeneic kidney transplantation in rat. Benck, U; Gottmann, U; Hoeger, S; Krämer, BK; Petrov, K; Schnuelle, P; Waldherr, R; Yard, BA, )	3.02
"Atorvastatin treatment significantly decreased total plasma cholesterol levels at 4, 8 and 12 weeks (12 weeks: 6.7 ± 4.2 mmol/L versus control 38.7 ± 10.6 mmol/L, p<0.0002)."	( Statin therapy prevents expansive remodeling in venous bypass grafts. Butany, J; Fefer, P; Fujii, H; Leong-Poi, H; Nili, N; Osherov, AB; Qiang, B; Samuel, M; Sparkes, JD; Strauss, BH; Toma, J, 2012)	1.1
"The atorvastatin treatment also produced a repression of microRNA 21 and genes involved in cell proliferation and neointimal formation (vascular endothelial growth factor [VEGF] A, VEGF receptor 1, VEGFC)."	( Lysophosphatidic acid pretreatment prevents micromolar atorvastatin-induced endothelial cell death and ensures the beneficial effects of high-concentration statin therapy on endothelial gene expression. Alaminos, M; Esteban, M; Garrido, JM; Roda, O; Sánchez-Montesinos, I, 2012)	1.11
"Atorvastatin pretreatment was independently associated with a decreased risk of CIN (OR 0.084, 95% CI 0.015-0.462, p = 0.004)."	( Beneficial effects of high-dose atorvastatin pretreatment on renal function in patients with acute ST-segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention. Fan, W; Fu, X; Geng, W; Gu, X; Hao, G; Jiang, Y; Li, S; Li, W; Li, X; Wang, X; Wang, Y; Wu, W; Yang, Z, 2012)	1.38
"Atorvastatin pretreatment can accelerate both neointimal coverage and re-endothelialization after SES implantation, which may be mediated by the mobilization of EPC and enhancement of the endothelial function of the neointima."	( Atorvastatin accelerates both neointimal coverage and re-endothelialization after sirolimus-eluting stent implantation in a porcine model: new findings from optical coherence tomography and pathology. Jin, C; Mintz, GS; Tang, Y; Tian, Y; Wang, TJ; Xu, B; Yang, YJ; Zhang, Q, 2012)	3.26
"Atorvastatin treatment inhibits proliferation, apoptosis and cytokine production of MFB in bile duct-ligated (BDL) rats in vivo."	( Atorvastatin inhibits proliferation and apoptosis, but induces senescence in hepatic myofibroblasts and thereby attenuates hepatic fibrosis in rats. Fürst, DO; Granzow, M; Huss, S; Klein, S; Klösel, J; Körner, C; Lammert, F; Mazar, IG; Nattermann, J; Pieper-Fürst, U; Sauerbruch, T; Schierwagen, R; Trebicka, J; van den Ven, PF; Weber, S, 2012)	2.54
"Atorvastatin pretreatment inhibit cellular apoptosis induced by H₂O₂ (39.45%, 20.53% and 7.83%)."	( [Atorvastatin inhibits the H₂O₂-induced apoptosis of human vascular endothelial cells through a down-regulation of cleaved caspase-9/caspase-3]. Li, SJ; Wu, WZ; Xu, ZR; Yang, YM; Yao, HP, 2012)	2.01
"Atorvastatin treatment for 2 and 8 weeks restored BBB integrity, indicated by a substantial reduction of IgG and apo B, particularly within the hippocampus. "	( Restoration of dietary-fat induced blood-brain barrier dysfunction by anti-inflammatory lipid-modulating agents. Clark, K; Galloway, S; Lam, V; Mamo, J; Pallebage-Gamarallage, M; Takechi, R, 2012)	1.82
"Atorvastatin treatment of HepG2 cells resulted in increased HMGCR-1b mRNA levels, but unaltered proximal promoter activity compared to untreated cells."	( A novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) splice variant with an alternative exon 1 potentially encoding an extended N-terminus. Berg, JP; Grimholt, RM; Kringen, MK; Piehler, AP; Stormo, C, 2012)	1.1
"Atorvastatin treatment increased total myocardial protein oxidation and serum lipid peroxidation."	( Atorvastatin increases oxidative stress and modulates angiogenesis in Ossabaw swine with the metabolic syndrome. Chu, LM; Elmadhun, NY; Feng, J; Lassaletta, AD; Liu, Y; Sellke, FW, 2012)	2.54
"Atorvastatin treatment was associated with increased myocardial and serum oxidative stress, which might contribute to the lack of collateral-dependent perfusion in the setting of angiogenesis."	( Atorvastatin increases oxidative stress and modulates angiogenesis in Ossabaw swine with the metabolic syndrome. Chu, LM; Elmadhun, NY; Feng, J; Lassaletta, AD; Liu, Y; Sellke, FW, 2012)	2.54
"Atorvastatin treatment increases RANKL levels with no measurable effect on bone metabolism and mobilization of progenitor cells from BM to PB. "	( Atorvastatin-induced increase in progenitor cell levels is rather caused by enhanced receptor activator of NF-kappaB ligand (RANKL) cell proliferation than by bone marrow mobilization. Arnal, JF; Lucanus, E; Nickenig, G; Pelster, B; Steinmetz, M; Werner, N, 2013)	3.28
"Atorvastatin treatment decreased serum low-density lipoprotein (-39%, P=0.0001), total cholesterol (-32%, P=0.0001), and triglycerides (-22%, P=0.0001), and increased high-density lipoprotein (+13%, P=0.0001) at 12 weeks compared to baseline. "	( Effects of short-term atorvastatin treatment on global fibrinolytic capacity, and sL-selectin and sFas levels in hyperlipidemic patients with coronary artery disease. Açil, T; Aksöyek, S; Atalar, E; Haznedaroglu, I; Kes, S; Ovünç, K; Ozer, N; Ozmen, F, 2002)	2.07
"Atorvastatin treatment resulted in a significant decrease (i.e., 30-37%) in levels of total triglyceride, cholesterol, LDL-C, and apoB in all six patients."	( Effect of atorvastatin on plasma apoE metabolism in patients with combined hyperlipidemia. Barrett, PH; Batal, R; Bernier, L; Cohn, JS; Davignon, J; Dubreuil, D; Jacques, H; Mamer, O; Rodriguez, C; Roy, M; Tremblay, M; Veilleux, L, 2002)	1.44
"Atorvastatin treatment of either APC or T cells suppressed antigen-specific T-cell activation."	( The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Bravo, M; Hur, EM; Mitchell, DJ; Patarroyo, JC; Radosevich, JL; Ruiz, PJ; Sobel, RA; Steinman, L; Stüve, O; Youssef, S; Zamvil, SS, 2002)	1.32
"Atorvastatin treatment resulted in a 32% reduction in total serum cholesterol (CH), 41% reduction in low density lipoprotein (LDL) CH, 16% reduction in triglycerides and a 21% increase in high density lipoprotein CH. "	( [Effect of atorvastatin on endothelial function in patients with familial hypercholesterolemia]. At'kov, OIu; Balakhonova, TV; Kobylianskiĭ, AG; Kukharchuk, VV; Kuznetsova, TV; Masenko, VP; Pogorelova, OA; Susekov, AV; Titov, VN; Tvorogova, MG, 2002)	2.15
"Atorvastatin treatment in diabetic dyslipidemia results in a significant dose-dependent decrease in HL activity, regardless of sex or the LIPC promoter variant."	( Atorvastatin dose-dependently decreases hepatic lipase activity in type 2 diabetes: effect of sex and the LIPC promoter variant. Berk-Planken, II; Bootsma, AH; Hoogerbrugge, N; Jansen, H; Stolk, RP, 2003)	2.48
"Atorvastatin treatment was effective with a mean percentage reduction of total cholesterol of 41 +/- 10% (p < 0.01 vs."	( Atorvastatin treatment for hyperlipidemia in pediatric renal transplant recipients. Aitken, M; Argent, E; Kainer, G; Mackie, FE; Rosenberg, AR, 2003)	2.48
"Atorvastatin treatment significantly reduced plasma total cholesterol, LDL-cholesterol and triglyceride levels and increased plasma HDL-cholesterol."	( Effects of atorvastatin on electrophoretic characteristics of LDL particles among subjects with heterozygous familial hypercholesterolemia. Bergeron, J; Couture, P; Gagné, C; Hogue, JC; Lamarche, B; Larivière, M; Pirro, M, 2003)	1.43
"Atorvastatin treatment significantly reduced CETP mass dose-dependently by 18% (A10) and 29% (A80; both vs."	( Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes. Banga, JD; Dallinga-Thie, GM; Erkelens, DW; Sijmonsma, TP; Stolk, RP; van Tol, A; van Venrooij, FV, 2003)	1.27
"Atorvastatin treatment significantly decreased plasma triglycerides (P < 0.05), total and LDL cholesterol (P < 0.05), apoB100 in LDL, IDL, and VLDL (P < 0.05)."	( Effect of atorvastatin on apolipoprotein B100 containing lipoprotein metabolism in type-2 diabetes. Charbonnel, B; Krempf, M; Laouenan, H; Magot, T; Marchini, JS; Ouguerram, K; Zaïr, Y, 2003)	1.44
"With atorvastatin treatment initiated 1 day after stroke, animals exhibited significant increases in vascular endothelial growth factor, cyclic guanosine monophosphate, angiogenesis, endogenous cell proliferation and neurogenesis, and an increase in the synaptic protein, synaptophysin."	( Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Chen, J; Chopp, M; Feldkamp, CS; Jiang, H; Katakowski, M; Li, Y; Lu, M; Wang, L; Wang, Y; Zhang, C; Zhang, ZG, 2003)	0.77
"Atorvastatin treatment did not produce any change in oral glucose tolerance categories or induce any change in glucose and insulin response in OGTT."	( Effects of atorvastatin on glucose homeostasis, postprandial triglyceride response and C-reactive protein in subjects with impaired fasting glucose. Alvarez, L; Casals, E; Casamitjana, R; Conget, I; Costa, A; Gomis, R; Hernández, G; Masramón, X; Morales, J, 2003)	1.43
"Atorvastatin treatment reduced total and LDL-cholesterol by 31% and 40%, respectively."	( Increased levels of pregnancy-associated plasma protein-A in patients with hypercholesterolemia: the effect of atorvastatin treatment. Ceska, R; Fialová, L; Malbohan, I; Malík, J; Soukupová, J; Stulc, T, 2003)	1.25
"Atorvastatin treatment significantly reduces SUA levels in patients with CHD, thus offsetting an additional factor associated with CHD risk."	( Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Athyros, VG; Bouloukos, VI; Elisaf, M; Mikhailidis, DP; Milionis, HJ; Papageorgiou, AA; Pehlivanidis, AN; Symeonidis, AN, 2004)	1.24
"Atorvastatin treatment increased sFasL concentrations (111 pg/ml, p < 0.0001), reaching normal values."	( Decreased circulating Fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis: normalization by atorvastatin. Blanco-Colio, LM; Díaz, C; Egido, J; Hernández, G; Martín-Ventura, JL; Sol, JM, 2004)	1.25
"Atorvastatin treatment decreased the serum total cholesterol level with a mean of 38 and 28% in the elderly and the young, respectively (P < 0.001)."	( Effect of atorvastatin on impaired vascular function in healthy old men. Blauw, GJ; Meinders, AE; Weverling-Rijnsburger, AW, 2004)	1.45
"Atorvastatin 10- and 80-mg treatment significantly decreased plasma apoC-III (atorvastatin 10 mg, 21%, and 80 mg, 27%), HDL apoC-III (atorvastatin 10 mg, 22%, and 80 mg, 28%) and LpB:C-III (atorvastatin 10 mg, 23%, and 80 mg, 28%; all P < 0.001)."	( Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides. Berk-Planken, II; Bootsma, AH; Dallinga-Thie, GM; Jansen, H, 2004)	2.49
"Atorvastatin treatment resulted in a significant dose-dependent reduction in plasma apoC-III, HDL apoC-III, and LpB:C-III levels in patients with type 2 diabetes. "	( Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides. Berk-Planken, II; Bootsma, AH; Dallinga-Thie, GM; Jansen, H, 2004)	3.21
"The atorvastatin-treated ICH group showed better performance on Rotorod and limb placing tests when compared with the vehicle-treated group (P<0.01). "	( HMG-CoA reductase inhibitor, atorvastatin, promotes sensorimotor recovery, suppressing acute inflammatory reaction after experimental intracerebral hemorrhage. Chu, K; Han, SY; Jeong, SW; Jung, KH; Kim, JY; Kim, M; Lee, ST; Roh, JK, 2004)	1.17
"Atorvastatin treatment led to a significant down-regulation of HLA-DR and the CD38 activation marker on peripheral T cells, whereas simvastatin up-regulated both of these molecules."	( Statin-induced immunomodulatory effects on human T cells in vivo. Ammann, P; Fehr, T; Fierz, W; Joller-Jemelka, HI; Kahlert, C; Rickli, H; Riesen, WF; Wüthrich, RP, 2004)	1.04
"Atorvastatin treatment decreases inflammatory and proteolytic activity in patients with hypercholesterolemia."	( Atorvastatin treatment decreases inflammatory and proteolytic activity in patients with hypercholesterolemia. Akin, M; Aliyev, E; Altuglu, I; Ercan, E; Ercan, HE; Sekuri, C; Tengiz, I, 2004)	3.21
"Atorvastatin treatment resulted in a 55% reduction of low-density lipoprotein (LDL) cholesterol (from mean of 162 (SD 32) to 72 (20) mg/dl)."	( Short-term effect of atorvastatin on ischaemic threshold in hypercholesterolaemic patients with stable ischaemic heart disease. Carlier, M; Claeys, MJ; Cools, F; Cosyns, B; De Meester, A; Dewit, B; Gobin, E; Hoffer, E; Missault, L; Vermeersch, P, 2004)	1.36
"Atorvastatin treatment resulted in a 30% reduction of total and a 45% reduction of LDL cholesterol (6.06 +/- 1.39 mmol/L versus 4.14 +/- 1.27 mmol/L and 4.11 +/- 1.13 mmol/L versus 2.27 +/- 0.89 mmol/L, both P < 0.0001)."	( Atorvastatin improves diabetic dyslipidemia and increases lipoprotein lipase activity in vivo. Dugi, KA; Hamann, A; Nawroth, PP; Parhofer, KG; Schiekofer, S; Schneider, JG; Volkmer, JE; von Eynatten, M, 2004)	2.49
"Atorvastatin treatment had a favourable effect on lipid profile and increased the activity of HDL-associated PON."	( Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinaemia. Balogh, Z; Harangi, M; Illyés, L; Kovács, P; Paragh, G; Seres, I; Törocsik, D, 2004)	1.3
"Atorvastatin treatment did not affect the creatinine kinase level, and no classical adverse effects were observed during the study."	( Effects of atorvastatin on triglyceride-rich lipoproteins, low-density lipoprotein subclass, and C-reactive protein in hemodialysis patients. Adachi, M; Gushiken, N; Hirano, T; Hyodo, T; Ikejiri, A; Murayama, S; Taira, T; Yoshino, G, 2004)	1.43
"Atorvastatin treatment lowered triglycerides, LDL-cholesterol and coenzyme Q(10) levels (all p<0.001) and improved endothelium-dependent vasodilatation during acetylcholine infusion (p=0.015)."	( Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure. Florkowski, CM; Frampton, CM; George, PM; Molyneux, SL; Scott, RS; Strey, CH; Young, JM, 2005)	1.05
"Atorvastatin treatment had no effect on Th1 and Th2 cytokine transcription. "	( The effects of atorvastatin in experimental autoimmune uveitis. Albini, T; Evans, M; Giri, RK; Rao, NA; See, RF; Thomas, PB, 2005)	2.12
"Atorvastatin treatment profoundly lowered LDL-C, but had minimal effect on HDL-C."	( High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Ezekowitz, MD; Ganz, P; Oliver, MF; Olsson, AG; Sasiela, WJ; Schwartz, GG; Szarek, M; Waters, D; Zeiher, A, 2005)	1.05
"Atorvastatin treatment activated peroxisome proliferator activated receptor gamma and increased LXR-mediated gene expression suggesting that atorvastatin induces cholesterol efflux through a molecular cascade involving inhibition of RhoA signaling, leading to increased peroxisome proliferator activated receptor gamma activity, enhanced LXR activation, increased ABCA1 expression, and cholesterol efflux."	( Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition: a role for RhoA in ABCA1-mediated cholesterol efflux. Argmann, CA; Edwards, JY; Hegele, RA; Huff, MW; O'Neil, CH; Pickering, JG; Sawyez, CG, 2005)	1.05
"Atorvastatin treatment may be of some clinical benefit and could be established as an effective therapy for Alzheimer disease if the current findings are substantiated by a much larger multicenter trial."	( Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Browne, P; Connor, DJ; Johnson-Traver, S; Launer, LJ; Lochhead, J; Lopez, J; Sabbagh, MN; Sparks, DL; Wasser, D; Ziolwolski, C, 2005)	3.21
"Atorvastatin treatment compared to placebo resulted in a significant decrease in serum cholesterol (5.85 +/- 1.04 mmol/l vs. "	( The effect of atorvastatin on serum lipoproteins in acromegaly. Davies, R; Durrington, P; Gibson, M; Kaushal, K; Mackness, M; Mishra, M; Ray, DW; Siddals, KW, 2005)	2.13
"Atorvastatin treatment was safe, well tolerated and effective in improving the atherogenic lipoprotein profile in acromegaly."	( The effect of atorvastatin on serum lipoproteins in acromegaly. Davies, R; Durrington, P; Gibson, M; Kaushal, K; Mackness, M; Mishra, M; Ray, DW; Siddals, KW, 2005)	2.13
"Atorvastatin treatment was associated with an improvement in the stiffness of leg arteries in type 2 diabetes mellitus. "	( Effect of atorvastatin on regional arterial stiffness in patients with type 2 diabetes mellitus. Emoto, M; Fujiwara, S; Fukumoto, S; Hatsuda, S; Kimoto, E; Koyama, H; Maeno, T; Nishizawa, Y; Shinohara, K; Shoji, T; Yokoyama, H, 2005)	2.17
"In atorvastatin-treated NRCM, a second band of Ggamma3 with a lower apparent molecular weight appeared in cytosol and particulate fractions that was absent in vehicle-treated NRCM, but also seen after GGTI-298, a geranylgeranyl transferase inhibitor."	( Atorvastatin desensitizes beta-adrenergic signaling in cardiac myocytes via reduced isoprenylation of G-protein gamma-subunits. Eschenhagen, T; Mühlhäuser, U; Münzel, F; Rau, T; Wieland, T; Zolk, O, 2006)	2.29
"Atorvastatin treatment reduced myocardial infarction which has been reflected by improvement in serum parameters, ATPase activities and histopathological lesions."	( Effect of atorvastatin treatment on isoproterenol-induced myocardial infarction in rats. Balaraman, R; Bothara, SB; Majithiya, JB; Trivedi, CJ, 2006)	1.46
"Atorvastatin treatment decreased HDL-cholesterol levels (3.56 +/- 0.24 vs. "	( Effects of atorvastatin on high-density lipoprotein apolipoprotein A-I metabolism in dogs. Briand, F; Krempf, M; Magot, T; Nguyen, P; Ouguerram, K, 2006)	2.17
"Atorvastatin treatment also induced a significant decrease in neointimal vascular smooth muscle cells and cellular density (respectively: 2.0 +/- 0.2 vs."	( Short-term atorvastatin treatment does not modify neointimal morphology but reduces MMP-2 expression in normocholesterolemic rabbit stented arteries. Busseuil, D; Collin, B; Cottin, Y; Duvillard, L; Korandji, C; Pitois-Merli, I; Rioufol, G; Rochette, L; Zeller, M, 2006)	1.45
"Atorvastatin treatment resulted in decreased PLTP activity (10 mg atorvastatin: -8.3%, P < 0.05; 80 mg atorvastatin: -12.1%, P < 0.002)."	( Plasma phospholipid transfer protein activity is decreased in type 2 diabetes during treatment with atorvastatin: a role for apolipoprotein E? Dallinga-Thie, GM; Hattori, H; Rensen, PC; Sijbrands, EJ; van Tol, A, 2006)	1.27
"Atorvastatin treatment resulted in a 1.7- to 8.0-fold increase in CEPs from baseline levels (P < 0.0001), but the numbers returned to within baseline levels at posttreatment."	( Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis. Ikeda, Y; Kaburaki, J; Kawakami, Y; Kuwana, M; Okazaki, Y; Yasuoka, H, 2006)	1.31
"Atorvastatin treatment decreased plasma triglycerides, APOA5, APOC3 and APOE (all p<0.0001)."	( Plasma apolipoprotein A5 and triglycerides in type 2 diabetes. Dallinga-Thie, GM; Hattori, H; Jansen, H; Sijbrands, EJ; van Tol, A; van Vark-van der Zee, LC, 2006)	1.06
"Atorvastatin pretreatment prevented these increases, blunted expression of membrane subunit gp91(phox), and prevented translocation of cytoplasmic subunit p47(phox) to the membrane in the penumbra 2 h after reperfusion."	( Atorvastatin protects against cerebral infarction via inhibition of NADPH oxidase-derived superoxide in ischemic stroke. Chen, AF; Hong, H; Kaufman, DI; Kreulen, DL; Zeng, JS, 2006)	2.5
"Atorvastatin treatment was associated with increased phosphorylation of Akt (5.7-fold increase versus NORM; P=0.001), decreased vascular endothelial growth factor expression (-68+/-8%; P<0.001 versus NORM), and increased expression of the antiangiogenic protein endostatin (210+/-48%; P=0.004 versus NORM)."	( High-dose atorvastatin improves hypercholesterolemic coronary endothelial dysfunction without improving the angiogenic response. Bianchi, C; Boodhwani, M; Feng, J; Laham, R; Li, J; Mieno, S; Nakai, Y; Ramlawi, B; Sellke, FW; Voisine, P, 2006)	1.46
"Atorvastatin pre-treatment reduced hypernociception induced by bradykinin and cytokines (TNF-alpha, IL-1beta and KC), and the release of IL-1beta and PGE(2) in paw skin, induced by lipopolysaccharide."	( Atorvastatin inhibits inflammatory hypernociception. Cunha, FQ; Cunha, TM; Ferreira, SH; Parada, CA; Poole, S; Santodomingo-Garzón, T; Valério, DA; Verri, WA, 2006)	2.5
"In atorvastatin treatment group, the increments of these two factors were attenuated significantly at the two time points, respectively."	( Tubulointerstitial macrophage accumulation is regulated by sequentially expressed osteopontin and macrophage colony-stimulating factor: implication for the role of atorvastatin. Chu, G; Ding, G; Jia, R; Tian, S, 2006)	1.04
"In 3 atorvastatin treated groups mice were fed the same diet as described above except atorvastatin was added to the diet at the dosage of 10 mg/kg per day for the last 8 weeks before euthanasia."	( Atorvastatin has distinct effects on endothelial markers in different mouse models of atherosclerosis. Jamborova, G; Nachtigal, P; Pospechova, K; Pospisilova, N; Semecky, V; Solichova, D; Zdansky, P, 2006)	2.23
"Atorvastatin treatment of human umbilical vein endothelial cells (HUVEC) and human microvascular endothelial cells (HMEC-1) resulted in significant increase in ATP breakdown and adenosine formation both if analysed in intact cell studies and as enzyme activity in cell lysates."	( Stimulatory effects of atorvastatin on extracellular nucleotide degradation in human endothelial cells. Amrani, M; Isley, C; Osman, L; Smolenski, RT; Yacoub, MH, 2006)	1.37
"Atorvastatin treatment resulted in a 38% reduction in relative risk ([95% CI -58 to -8], P = 0.017) of first major cardiovascular events in older patients and a 37% reduction ([-57 to -7], P = 0.019) in younger patients. "	( Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). Betteridge, DJ; Colhoun, HM; DeMicco, DA; Durrington, PN; Fuller, JH; Hitman, GA; Livingstone, SJ; Luo, D; Neil, HA, 2006)	2
"Atorvastatin treatment, in addition to its beneficial effect on cholesterol levels, improved the inflammatory state of these patients without modifying fibrinolytic balance."	( Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. Abad, S; Cachofeiro, V; de Vinuesa, SG; Goicoechea, M; Gómez-Campderá, F; Lahera, V; Luño, J; Vega, A, 2006)	1.45
"Atorvastatin treatment prevented the elevation of autoantibody titers against all forms of oxidized LDL."	( Short- and long-term elevation of autoantibody titers against oxidized LDL in patients with acute coronary syndromes. Role of the lipoprotein-associated phospholipase A2 and the effect of atorvastatin treatment. Goudevenos, JA; Lourida, ES; Papathanasiou, AI; Tselepis, AD; Tsironis, LD, 2008)	1.26
"Atorvastatin treatment reverses hypercholesterolemia-induced endothelial dysfunction without appreciable improvements in collateral-dependent myocardial perfusion in response to vascular endothelial growth factor treatment. "	( High-dose atorvastatin is associated with impaired myocardial angiogenesis in response to vascular endothelial growth factor in hypercholesterolemic swine. Boodhwani, M; Feng, J; Li, J; Mieno, S; Sellke, FW; Sodha, N; Voisine, P, 2006)	2.18
"Atorvastatin treatment inhibited ACE induction during differentiation."	( Atorvastatin inhibits angiotensin-converting enzyme induction in differentiating human macrophages. Fyhrquist, F; Nyman, T; Saijonmaa, O, 2007)	2.5
"Atorvastatin treatment decreased total (P < 0.001) and LDL-cholesterol (P < 0.001) but had no effect on high-density lipoprotein."	( Impact of atorvastatin treatment on platelet-activating factor acetylhydrolase and 15-F(2trans)-isoprostane in hypercholesterolaemic patients. Benndorf, R; Böger, RH; Kom, GD; Maas, R; Schneider, L; Schwedhelm, E, 2007)	1.46
"Atorvastatin treatment decreased microalbuminuria and helped preserve filtration function in chronic unilateral ureteral obstruction without altering plasma cholesterol levels, suggesting that pleiotropic renal protection is offered by this statin."	( Atorvastatin preserves renal function in chronic complete unilateral ureteral obstruction. Chou, SY; Gulmi, FA; Kim, H; Michli, E; Mooppan, UM, 2007)	3.23
"Atorvastatin-treated patients experienced greater low-density lipoprotein cholesterol reductions than did pravastatin-treated patients, a trend toward fewer major acute cardiovascular events (hazard ratio, 0.71; 95% confidence interval, 0.46, 1.09; P=0.114), and a significantly greater reduction in all-cause death (hazard ratio, 0.33; 95% confidence interval, 0.13, 0.83; P=0.014)."	( Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Bairey Merz, CN; Cosin-Aguilar, J; Deedwania, P; Koylan, N; Luo, D; Ouyang, P; Piotrowicz, R; Schenck-Gustafsson, K; Sellier, P; Stein, JH; Stone, PH; Thompson, PL; Tzivoni, D, 2007)	1.06
"Atorvastatin treatment was associated with decreases of sICAM-1 (from 274.2+/-92.2 to 197.9+/-70.0 ng/ml; p<0.01) and hsCRP (from 0.57+/-0.45 to 0.18+/-0.15 mg/dl; p<0.01), whereas placebo treatment had no effect on these markers."	( Effect of atorvastatin on peripheral endothelial function and systemic inflammatory markers in patients with stable coronary artery disease. Alber, HF; Dichtl, W; Dörler, J; Frick, M; Pachinger, O; Stocker, EM; Süssenbacher, A; Weidinger, F, 2007)	1.46
"Atorvastatin treatment produced a statistically significant decrease in cholesterol and triglyceride levels and an increase in vitamin D levels (41+/-19 vs 47+/-19 nmol/L, p=0.003)."	( Effects of Atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Abad, L; Chaves, J; Dueñas, A; Hernandez, G; Pérez-Castrillón, JL; Sanz, A; Vega, G, 2007)	1.45
"Atorvastatin treatment was associated with significantly greater reductions in TC, LDL-C, and TG in the majority of dose comparisons with simvastatin."	( A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin. Clarke, PJ; Grobler, MP; Levison, DB; Liew, D; Magliano, DJ; Rogers, SL; Webb, K, 2007)	1.29
"Atorvastatin treatment increased PAAT and reduced right ventricular pressure, right ventricular hypertrophy, and vascular remodeling over the 4-wk course."	( Serotonin transporter protein in pulmonary hypertensive rats treated with atorvastatin. Christians, U; Kaisers, U; Laudi, S; McMurtry, IF; Mutlak, H; Schmitz, V; Steudel, W; Trump, S; Weimann, J; West, J, 2007)	1.29
"Atorvastatin treatment significantly decreased total cholesterol as well as low-density lipoprotein cholesterol plasma levels, but did not modify mean blood pressure (MBP), proteinuria, creatinine clearance, or inflammatory factors."	( Atorvastatin treatment in the short term: does it induce renoprotection or vasculoprotection in renal transplantation? Bayés, B; Blanco, S; Bonet, J; Lauzurica, R; Navarro-Muñoz, M; Romero, R, 2007)	2.5
"Atorvastatin treatment was associated with 50% reduction in non-haemorrhagic stroke (95% confidence interval 9%-72%P = 0.024), similar to the 48% reduction (11%-69%) for all strokes combined."	( Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS). Betteridge, DJ; Colhoun, H; Durrington, PN; Fuller, J; Hitman, GA; Livingstone, S; Neil, HA; Newman, C; Szarek, M, 2007)	1.32
"In 2 atorvastatin-treated groups, mice were fed the same diets (chow or atherogenic) as described above except atorvastatin was added at the dosage of 10 mg x kg(-1) x day(-1) for the last 8 weeks before euthanasia."	( Endothelial expression of endoglin in normocholesterolemic and hypercholesterolemic C57BL/6J mice before and after atorvastatin treatment. Andrys, C; Jamborova, G; Nachtigal, P; Pospechova, K; Pospisilova, N; Semecky, V; Solichova, D; Zdansky, P, 2007)	1
"Atorvastatin-treated rats showed fewer neurologic deficits than control animals as measured at day 3-5."	( Atorvastatin attenuates mitochondrial toxin-induced striatal degeneration, with decreasing iNOS/c-Jun levels and activating ERK/Akt pathways. Chu, K; Han, Z; Hong, NH; Im, WS; Jung, KH; Kang, L; Kim, M; Kim, MW; Lee, ST; Park, JE, 2008)	2.51
"Atorvastatin treatment prevented the further progression of atherosclerosis by maintaining LDL-C below 100 mg/dl in patients with CHD and hypercholesterolemia (100	( Randomized evaluation of atorvastatin in patients with coronary heart disease: a serial intravascular ultrasound study. Azuma, A; Matsubara, H; Sasaki, S; Sawada, T; Yamada, T, 2007)	2.09
"Atorvastatin treatment may have beneficial effects on LV hypertrophy in spontaneously hypertensive rats."	( Atorvastatin prevents connexin43 remodeling in hypertrophied left ventricular myocardium of spontaneously hypertensive rats. Chen, HJ; Chen, JZ; Chen, TG; Wang, LH; Yao, L; Yu, M, 2007)	2.5
"Atorvastatin treatment improved lipid profile and significantly reduced hsCRP (p=0.002), WBC count (p=0.041), OPN (p<0.001) and OPG levels (p<0.001)."	( Intensive lipid-lowering therapy ameliorates novel calcification markers and GSM score in patients with carotid stenosis. Bandios, S; Fotiadis, G; Gerasimidis, T; Kadoglou, NP; Kapelouzou, A; Karayannacos, PE; Katinios, A; Kougias, P; Liapis, CD; Moumtzouoglou, A; Sailer, N; Vitta, I; Voliotis, K, 2008)	1.07
"Atorvastatin treatment led to a substantial reduction in the number and volume of CEL in two-sided multivariate analysis (p = 0.003 and p = 0.008)."	( Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis. Aktas, O; Bellmann-Strobl, J; Dörr, J; Haertle, M; Paul, F; Volk, HD; Waiczies, H; Waiczies, S; Wernecke, KD; Wuerfel, J; Zipp, F, 2008)	1.42
"Atorvastatin treatment also dose-dependently reduced liver X receptor alpha (LXRalpha) expression and Rho activation."	( Atorvastatin inhibits ABCA1 expression and cholesterol efflux in THP-1 macrophages by an LXR-dependent pathway. Hill, JS; Qiu, G, 2008)	2.51
"Atorvastatin-treated rats showed a modest reduction in SBP that remained in the hypertensive range (174 +/- 8 mmHg)."	( Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-beta, and fibronectin with concomitant increase in nitric oxide bioavailability. Jaimes, EA; Raij, L; Schuman, IH; Zhou, MS, 2008)	1.07
"Atorvastatin treatment was significantly more effective on apolipoprotein B levels in patients with AB+BB phenotype than in the AA phenotype group."	( The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters. Derdak, Z; Harangi, M; Mirdamadi, HZ; Paragh, G; Seres, I; Sztanek, F, 2008)	1.07
"In atorvastatin treatment groups, total serum triglyceride levels decreased in a dose-dependent manner, reductions in the 20-mg and 80-mg groups were statistically significant (P < .05) compared with placebo. "	( Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. Bakker-Arkema, RG; Black, DM; Brown, WV; Davidson, MH; Davignon, J; Goldstein, RJ; Isaacsohn, JL; Keilson, LM; Miller, VT; Shurzinske, LJ; Weiss, SR, 1996)	1.16
"Atorvastatin treatment significantly reduced plasma total cholesterol, LDL cholesterol, total triglyceride, and VLDL triglyceride concentrations by 16%, 31%, 19%, and 28%, respectively (P < .01)."	( Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs. Barrett, PH; Burnett, JR; Huff, MW; Kleinstiver, SJ; Newton, RS; Telford, DE; Wilcox, LJ, 1997)	1.3
"In atorvastatin-treated rats, the half-life of the receptor was decreased by over 60%."	( Atorvastatin action involves diminished recovery of hepatic HMG-CoA reductase activity. Chambers, CM; Lopez, D; Ness, GC, 1998)	2.26
"Atorvastatin-treated patients required a lower median dose than other treatments."	( Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. Bakker-Arkema, RG; Black, DM; Brown, AS; Campbell, CF; Guthrie, R; Henley, RW; Koren, M; McLain, R; Woo, W; Yellen, L, 1998)	1.22
"Atorvastatin treatment also decreased the mRNA for the microsomal triglyceride transfer protein (MTP) by 22% (P < 0.02)."	( Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin. Barrett, PH; Huff, MW; Wilcox, LJ, 1999)	1.24
"Atorvastatin treatment significantly reduced this prolongation to 46%."	( Pharmacokinetics and pharmacodynamics of nifedipine in untreated and atorvastatin-treated hyperlipidemic rats. Eliot, LA; Jamali, F, 1999)	1.26
"With atorvastatin (10 mg/day) treatment for 4 weeks in 19 type IIa hyperlipidemic patients, total cholesterol level was lowered by 23%, LDL-cholesterol was lowered by 32% and triacylglycerol was lowered by 19% as compared with dietary therapy alone."	( Effects of atorvastatin treatment on the oxidatively modified low density lipoprotein in hyperlipidemic patients. Choy, PC; Dembinski, T; Hatch, G; Kroeger, EA; McMaster, J; Mymin, D; Zhu, Q, 2000)	1.15
"The atorvastatin treatment significantly improved ACh-stimulated FBF: at highest dose the FBF increased to 14.9+/-1.5 ml.100 ml tissue(-1)."	( Effects of atorvastatin and vitamin C on endothelial function of hypercholesterolemic patients. Candigliota, M; Ceravolo, R; Chello, M; Cloro, C; Maio, R; Mastroroberto, P; Mattioli, PL; Mongiardo, A; Perticone, F; Scozzafava, A, 2000)	1.18
"Atorvastatin treatment provided significant lowering of serum lipoprotein levels: low-density lipoprotein -53% (p = 0.0001), very low density lipoprotein -43% (p = 0.0001), and triglycerides -35% (p < 0.0001)."	( Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients. Altman, R; Black, DM; Dujovne, CA; Harris, WS; Overhiser, RW, 2000)	1.43
"Atorvastatin treatment only reduced plasma levels in dyslipidemic rabbits (P < 0.05), which were nevertheless higher than those of controls."	( The protective role of atorvastatin on function, structure and ultrastructure in the aorta of dyslipidemic rabbits. Aragoncillo, P; Cachofeiro, V; Díaz, C; Hernández, G; Lahera, V; Maeso, R; Navarro-Cid, J; Ruilope, LM; Vázquez-Pérez, S, 2000)	1.34
"Atorvastatin treatment reduced plasma lipid levels and lesion size in dyslipidemic animals."	( Effect of atorvastatin on endothelium-dependent constrictor factors in dyslipidemic rabbits. Aragoncillo, P; Cachofeiro, V; Diaz, C; Hernández, G; Lahera, V; Maeso, R; Navarro-Cid, J; Ruilope, LM, 2000)	1.43
"Atorvastatin treatment prevented vascular and most glomerular changes associated with hypercholesterolaemia even in the presence of very high cholesterol levels."	( Atorvastatin prevents glomerulosclerosis and renal endothelial dysfunction in hypercholesterolaemic rabbits. Aragoncillo, P; Cachofeiro, V; Cediel, E; de Las Heras, N; Díaz, C; Hernández, G; Lahera, V; Navarro-Cid, J; Ruilope, LM; Sanz-Rosa, D; Vázquez-Pérez, S, 2001)	2.47
"Atorvastatin treatment downregulated aortic AT(1) receptor mRNA expression to 44+/-12% of control and reduced mRNA expression of the essential NAD(P)H oxidase subunit p22phox to 63+/-7% of control."	( HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Ahlbory, K; Bäumer, AT; Böhm, M; Itter, G; Laufs, U; Linz, W; Müller, K; Nickenig, G; Rösen, R; Wassmann, S, 2001)	1.03
"Atorvastatin treatment increased the further functional activity of EPCs, as assessed by their migratory capacity."	( Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Adler, K; Aicher, A; Dimmeler, S; Fichtlscherer, S; Martin, H; Vasa, M; Zeiher, AM, 2001)	1.03
"Atorvastatin treatment also reduced cellular CE mass, exhibiting both time- and dose-dependency."	( Prolonged inhibition of cholesterol synthesis by atorvastatin inhibits apo B-100 and triglyceride secretion from HepG2 cells. Arai, Y; Funatsu, T; Goto, M; Ida, M; Kakuta, H; Miyata, K; Nishijima, S; Suzuki, K; Tanaka, H; Yasuda, S, 2001)	1.29
"Atorvastatin treatment generally resulted in small, non significant increases in CTx."	( Effects of statins on biomarkers of bone metabolism: a randomised trial. Farnier, M; Mercuri, M; Stein, EA; Waldstreicher, J, 2001)	1.03
"Atorvastatin-treated patients were more likely to maintain their target levels from week 6 to week 54."	( Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Andrews, TC; Ballantyne, CM; Hsia, JA; Kramer, JH, 2001)	1.03
"Atorvastatin treatment was also associated with a greater percent decrease from baseline to week 6 in triglycerides, with a trend toward statistical significance (p = 0.0982)."	( Comparison of the efficacy of atorvastatin versus cerivastatin in primary hypercholesterolemia. Davidson, M; Hunninghake, D; Insull, W; Jones, P; Kafonek, S; Knopp, R; Lohrbauer, L, 2001)	1.32
"Atorvastatin treatment did not produce consistent changes in the appearance of apoB degradation fragments in plasma."	( Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes. Adeli, K; Cheung, RC; Parris, W; Pontrelli, L, 2002)	2.48
"Atorvastatin treatment reduced total and low-density lipoprotein cholesterol and triglyceride levels by 36 +/- 2% (p < 0.001), 48 +/- 3% (p < 0.001) and 23 +/- 5% (p = 0.003), respectively, and increased high density lipoprotein cholesterol by 7 +/- 3% (p = 0.03). "	( Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. Baguet, JP; Cameron, JD; Dart, AM; Ferrier, KE; Jennings, GL; Kingwell, BA; Muhlmann, MH, 2002)	1.76
"Atorvastatin treatment reduced significantly the fasting plasma concentrations of VLDL cholesterol, LDL cholesterol and VLDL triglycerides (median% change) by 29, 44 and 27%, respectively, and increased high density lipoprotein (HDL) cholesterol by 19%, compared with baseline."	( Effects of atorvastatin on postprandial plasma lipoproteins in postinfarction patients with combined hyperlipidaemia. Boquist, S; Danell-Toverud, K; Hamsten, A; Karpe, F, 2002)	1.43
"Atorvastatin treatment had a significant main effect of decreasing plasma hs-CRP (-0.87 mg/L; 95% confidence interval, -0.10 to -1.60 mg/L; P <0.01) and IL-6 (-70 pg/L; 10 to -140 pg/L; P <0.01), but this was not seen with fish oil."	( Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity. Barrett, PH; Beilin, LJ; Chan, DC; Mori, TA; Watts, GF, 2002)	1.44
"Treatment with atorvastatin possibly increases the abundance of"	( Atorvastatin Inhibits High-Fat Diet-Induced Lipid Metabolism Disorders in Rats by Inhibiting He, X; Li, H; Ma, X; Wang, S; Yu, H; Yu, W, 2022)	2.5
"Mice treated with atorvastatin post-infection showed a remarkable decrease in their survival rate."	( Atorvastatin increases the production of proinflammatory cytokines and decreases the survival of Escherichia coli-infected mice. Abdelnoor, AM; Al-Khoury, DK; Hussein, HM; Rahal, EA, 2019)	2.28
"Co-treatment of atorvastatin + tamoxifen could strongly enhance the expression of pro/apoptotic factors of Bax and cytochrome c in melanoma cells compared to the tamoxifen and atorvastatin groups."	( Atorvastatin enhances apoptotic effects of tamoxifen on melanoma cancer cells. Esfahani, HN; Ghasemi, A; Ghasemi, M; Javanmard, SH; Malek, M; Vaseghi, G, 2019)	2.3
"Treatment with atorvastatin reduced the number of TUNEL-positive cells."	( Atorvastatin Prevents the Neuron Loss in the Hippocampal Dentate Gyrus Region through its Anti-Oxidant and Anti-Apoptotic Activities. Arani, HZ; Jangholi, E; Karimi, A; Movassaghi, S; Parsa, Y; Sharifi, ZN; Yadollah-Damavandi, S, 2021)	2.4
"Treatment with Atorvastatin resulted in a reduction in 25OHD concentrations; further, its efficacy in reducing LDL-C concentrations was related to the 25OHD concentrations."	( To study impact of treatment with Rosuvastatin versus Atorvastatin on 25 hydroxy Vitamin D concentrations among adult Indian men- a randomized control trial. Chiplonkar, SA; Khadilkar, AV; Khadilkar, VV; Mughal, ZM; Padidela, R; Patwardhan, VG, )	0.73
"Pre-treatment with atorvastatin did not protect cholestatic livers from hepatocellular damage after I/R. "	( Atorvastatin does not protect against ischemia-reperfusion damage in cholestatic rat livers. Dekker, AM; Heger, M; van Golen, RF; van Gulik, TM; Verheij, J; Wiggers, JK, 2017)	2.23
"Treatment with atorvastatin decreased cell viability and increased the mRNA expression levels of Fads1, Fads2 and ELOVL fatty acid elongase 5 (Elovl5) in a dose‑dependent manner."	( Atorvastatin increases Fads1, Fads2 and Elovl5 gene expression via the geranylgeranyl pyrophosphate-dependent Rho kinase pathway in 3T3-L1 cells. Ishihara, N; Nagayama, D; Saiki, A; Suzuki, S; Tanaka, S; Tanaka, T; Tatsuno, I; Watanabe, Y, 2017)	2.24
"Pretreatment with atorvastatin significantly delayed the onset of arrhythmia and asystole compared with vehicle-treated group (p < .01, p < .001, respectively). "	( Involvement of IL-1β and IL-6 in antiarrhythmic properties of atorvastatin in ouabain-induced arrhythmia in rats. Bakhtiarian, A; Hojati, V; Mousavi, Z; Najjari, M; Nikoui, V; Vaezi, G, 2018)	1.06
"Treatment with atorvastatin significantly reduced albuminuria, and improved both urine concentrating ability and glomerular filtration rate."	( Renal protection by atorvastatin in a murine model of sickle cell nephropathy. Archer, DR; Ataga, KI; Brown, LA; Chappa, P; Yin, H; Zahr, RS, 2018)	1.14
"Treatment with atorvastatin was performed via inhalation for 10 min once a day."	( Atorvastatin dose-dependently promotes mouse lung repair after emphysema induced by elastase. Barroso, MV; Cattani-Cavalieri, I; Gitirana, LB; Lanzetti, M; Melo, AC; Quesnot, N; Valença, SS, 2018)	2.26
"Cotreatment with atorvastatin reduced total cholesterol, rescued LDL receptor protein levels, and normalized serum LDL-C."	( FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver. Dong, B; Lewis, RD; Liu, J; Liu, X; Papazyan, R; Plummer, EM; Roth, JD; Young, MA, 2018)	0.81
"Treatment with atorvastatin inhibited the hypertrophy induced by the AV shunt."	( Effect of atorvastatin on cardiomyocyte hypertrophy through suppressing MURC induced by volume overload and cyclic stretch. Cheng, WP; Chua, SK; Lo, HM; Shyu, KG; Wang, BW, 2019)	1.26
"Treatment with atorvastatin (1 or 10 mg/kg/day) or fluoxetine prevented LPS-induced increase in lipid peroxidation and the reduction of glutathione levels in the hippocampus and prefrontal cortex."	( Atorvastatin prevents lipopolysaccharide-induced depressive-like behaviour in mice. Buss, ZS; Doneda, DL; Ferreira, YS; Fraga-Junior, EB; Lima, E; Lopes, L; Rios-Santos, F; Stupp, IJV; Taniguti, EH; Vandresen-Filho, S; Viola, GG, 2019)	2.3
"Mice treated with atorvastatin showed a significant reduction in cell influx in response to zymosan, and in the expression of proinflammatory cytokines and chemokines such as interleukin-1α, monocyte chemoattractant protein-1 and prostaglandin E2."	( Heme oxygenase-1-Dependent anti-inflammatory effects of atorvastatin in zymosan-injected subcutaneous air pouch in mice. Badran, B; El-Achkar, GA; Habib, A; Hamade, E; Jaffa, AA; Motterlini, R; Mouawad, CA; Mrad, MF, 2019)	1.08
"Treatment with atorvastatin (10 and 20 mg/kg) and fluvastatin (10 mg/kg) for 21 days significantly improved the behavioral alterations [increased number of wheel rotations and locomotor activity, and anxiety like behavior (decreased number of entries and time spent in open arm)], oxidative defence and mitochondrial complex enzyme activities in brain."	( Protective effect of HMG CoA reductase inhibitors against running wheel activity induced fatigue, anxiety like behavior, oxidative stress and mitochondrial dysfunction in mice. Kalonia, H; Kumar, A; Kumar, P; Mishra, J; Vashist, A, 2012)	0.72
"Treatment with atorvastatin alone did not demonstrate an effect significantly different from no treatment (p = 0.0573). "	( Impact of methylene blue and atorvastatin combination therapy on the apparition of cerebral malaria in a murine model. Briolant, S; Desgrouas, C; Dormoi, J; Pradines, B, 2013)	1.03
"Treatment with atorvastatin resulted in a mean reduction of total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), and triglyceride (TG) of 8.7 %, 9.2 %, and 4.1 %, respectively, and a mean increase of high density lipoprotein cholesterol (HDL-C) of 1 %. "	( Do MDR1 and SLCO1B1 polymorphisms influence the therapeutic response to atorvastatin? A study on a cohort of Egyptian patients with hypercholesterolemia. Bakhoum, SW; Issac, MS; Mishriki, AA; Shabana, MF, 2013)	0.98
"Treatment with atorvastatin was associated with significant decreases in total cholesterol, triglycerides, and LDL-C and an elevation of HDL-C. "	( Atorvastatin therapy is not associated with slowing the progression of aortic stenosis: findings of a randomized controlled trial. Dadjou, Y; Panahi, Y; Pishgoo, B; Rakhshankhah, AS; Sahebkar, A; Taghipour, HR, 2013)	2.19
"Treatment with atorvastatin enhanced the activity of SOD and prevented from GSH decrement during hypertension."	( Effects of atorvastatin on the hypertension-induced oxidative stress in the rat brain. Amini, R; Jahanbakhsh, Z; Mohammadi, MT; Shekarforoush, S, 2013)	1.12
"Treatment with atorvastatin (n = 10), but not with fluvastatin (n = 10), resulted in 3-fold higher expression of SLCO2B1 compared with placebo-treated patients (n = 9) (P < 0.05)."	( Atorvastatin treatment induces uptake and efflux transporters in human liver. Bergström, H; Björkhem-Bergman, L; Ekström, L; Eriksson, M; Johansson, M; Parini, P; Rane, A, 2013)	2.17
"Treatment with atorvastatin increased BRS after 12 months (from 6.46 ± 2.79 ms/mmHg to 8.05 ± 4.28 ms/mmHg, p = 0.03), while no effect was seen with low-fat diet."	( Effect of atorvastatin on baroreflex sensitivity in subjects with type 2 diabetes and dyslipidaemia. Eleftheriadou, I; Grigoropoulou, P; Katsilambros, N; Makrilakis, K; Margeli, A; Papassotiriou, I; Perrea, D; Tentolouris, N; Zoupas, C, 2014)	1.14
"Treatment with atorvastatin prevented all these changes induced by TWEAK in atherosclerotic lesions."	( [Atorvastatin inhibits the atherosclerotic lesion induced by tumor necrosis factor-like weak inducer of apoptosis in apolipoprotein E deficient mice]. Blanco-Colio, LM; Egido, J; Fernández-Laso, V; Martín-Ventura, JL; Sastre, C, )	1.38
"Treatment with atorvastatin 40 mg/d significantly increased circulating EPC (p = 0.002), FMD (p = 0.001) and reduced TNF-α (p = 0.01) compared to baseline. "	( Atorvastatin treatment improves endothelial function through endothelial progenitor cells mobilization in ischemic heart failure patients. Athanasiou, D; Chrysohoou, C; Hatzis, G; Mazaris, S; Mourouzis, K; Oikonomou, E; Papavassiliou, AG; Siasos, G; Stefanadis, C; Tourikis, P; Tousoulis, D; Zaromitidou, M; Zisimos, K, 2015)	2.21
"Pretreatment with atorvastatin (0.5, 1, 2.5 μmol/L) dose-dependently inhibited AβO-induced activation of calpain and caspase-3/7 proteases, and effectively diminished the generation of Tau fragments, attenuated synaptic damage and increased neuronal survival."	( Atorvastatin prevents Aβ oligomer-induced neurotoxicity in cultured rat hippocampal neurons by inhibiting Tau cleavage. Jin, Y; Liu, Z; Sui, HJ; Zhang, LL, 2015)	2.18
"Pretreatment with atorvastatin and the angiotensin-receptor antagonist valsartan significantly attenuated the increase of endoglin and β-MHC induced by infarction."	( MicroRNA-208a Increases Myocardial Endoglin Expression and Myocardial Fibrosis in Acute Myocardial Infarction. Cheng, WP; Lo, HM; Shyu, KG; Wang, BW, 2015)	0.74
"Treatment with atorvastatin and valsartan can decrease myocardial fibrosis induced by AMI through attenuating miR-208a and endoglin expression."	( MicroRNA-208a Increases Myocardial Endoglin Expression and Myocardial Fibrosis in Acute Myocardial Infarction. Cheng, WP; Lo, HM; Shyu, KG; Wang, BW, 2015)	0.76
"Treatment with atorvastatin decreased 4βHC and 5α,6α-epoxycholesterol concentrations by 40% and 23%, respectively. "	( The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. Hukkanen, J; Hyötyläinen, T; Morin-Papunen, L; Orešič, M; Piltonen, T; Puurunen, J; Ruokonen, A; Savolainen, MJ; Tapanainen, JS, 2015)	1.13
"Treatment with atorvastatin 20 mg/day, and especially with 40 mg/day, resulted in a decrease in free fatty acid levels."	( Dose-dependent effects of atorvastatin on myocardial infarction. Barbarash, O; Belik, E; Dyleva, Y; Gruzdeva, O; Karetnikova, V; Uchasova, E, 2015)	1.06
"Treatment with atorvastatin and/or sildenafil was associated with attenuation of 2K1C hypertension-induced increases in these pro-fibrotic factors."	( Atorvastatin and sildenafil decrease vascular TGF-β levels and MMP-2 activity and ameliorate arterial remodeling in a model of renovascular hypertension. Ceron, CS; Gerlach, RF; Guimarães, DA; Martins-Oliveira, A; Rizzi, E; Shiva, S; Tanus-Santos, JE, 2015)	2.2
"Treatment with atorvastatin along with imipenem reduced the lung bacterial load and pro-inflammatory cytokines (IL-1β and TNFα) level in BALF."	( Atorvastatin along with imipenem attenuates acute lung injury in sepsis through decrease in inflammatory mediators and bacterial load. Addison, MP; Choudhury, S; Darzi, SA; Dash, JR; Kandasamy, K; Kasa, JK; Maruti, BS; Mishra, SK; Parida, S; Singh, TU; Singh, V, 2015)	2.2
"Treatment with atorvastatin+L-carnitine restored BMD, BMC, and bone strength to near normal levels. "	( L-Carnitine, but not coenzyme Q10, enhances the anti-osteoporotic effect of atorvastatin in ovariectomized rats. Murad, HA, 2016)	1.02
"Pretreatment with atorvastatin could attenuate the induction of PTEN."	( Atorvastatin Inhibits Myocardial Apoptosis in a Swine Model of Coronary Microembolization by Regulating PTEN/PI3K/Akt Signaling Pathway. Chen, H; Li, L; Liu, T; Su, Q; Wang, J; Wang, XT; Zhou, Y, 2016)	2.2
"Treatment with atorvastatin 40 mg plus ezetimibe 10 mg achieved significantly greater reductions in LDLc (p < 0.001), total cholesterol (p < 0.001) and non-HDLc (p < 0.001)."	( [Utility of treatment with atorvastatin 40 mg plus ezetimibe 10 mg versus atorvastatin 80 mg in reducing the levels of LDL cholesterol in patients with ischaemic stroke or transient ischaemic attack]. Acha-Salazar, O; Larrosa-Campo, D; Novo-Robledo, F; Oterino, A; Palacio, E; Revilla, M; Viadero-Cervera, R, 2016)	1.07
"Treatment with atorvastatin decreased the number and size of necrotic cores, increased collagen content, and downregulated tumor necrosis factor (TNF)‑α and matrix metalloproteinase (MMP)‑9 mRNA expression, as compared with the methionine group."	( Atorvastatin attenuates atherosclerotic plaque destabilization by inhibiting endoplasmic reticulum stress in hyperhomocysteinemic mice. Chen, Z; Jia, F; Lu, G; Sun, J; Wu, C, 2016)	2.22
"Treatment with atorvastatin prevented atrial remodeling in a rabbit model of RAP-induced AF. "	( Effects of atorvastatin on atrial remodeling in a rabbit model of atrial fibrillation produced by rapid atrial pacing. Dang, Y; Hao, X; Li, Y; Qi, X; Song, X; Yang, Q, 2016)	1.18
"Pretreatment with atorvastatin combined with RIPC can exert a synergistic cardioprotective effects by reducing the possible biochemical changes related to ischemic reperfusion injury."	( Cardioprotective effect of atorvastatin alone or in combination with remote ischemic preconditioning on the biochemical changes induced by ischemic/reperfusion injury in a mutual prospective study with a clinical and experimental animal arm. El Desoky, ES; Fadil, SA; Hassan, AKM; Salem, SY; Taha, AF, 2016)	1.07
"Pretreatment with atorvastatin significantly improved the recovery of cells viability from OGD/R (p<0.05). "	( Atorvastatin Protects Myocardium Against Ischemia-Reperfusion Injury Through Inhibiting miR-199a-5p. Cui, W; Hu, H; Wang, Y; Zuo, Y, 2016)	2.21
"Treatment of atorvastatin inhibits the expression of TRB3 and cardiomyocyte apoptosis induced by AMI and hypoxia."	( Atorvastatin alleviates cardiomyocyte apoptosis by suppressing TRB3 induced by acute myocardial infarction and hypoxia. Cheng, WP; Chua, SK; Lo, HM; Lu, MJ; Shyu, KG; Wang, BW, 2017)	2.27
"Treatment with atorvastatin for 4 weeks was able to attenuate ventricular dysfunction, fibrosis, and left ventricular hypertrophy after MI in rats, perhaps in part through effects on collagen metabolism and inflammation. "	( Atorvastatin Improves Ventricular Remodeling after Myocardial Infarction by Interfering with Collagen Metabolism. Carvalho Sposito, A; da Mota Silveira-Filho, L; de Souza Vilarinho, KA; Diógenes de Carvalho, D; Galluce Torina, A; Martins de Oliveira, PP; Pereira do Carmo, HR; Petrucci, O; Reichert, K, 2016)	2.23
"The treatment with atorvastatin and simvastatin was administered via inhalation (15 min with 1 mg/mL once a day)."	( Atorvastatin and Simvastatin Promoted Mouse Lung Repair After Cigarette Smoke-Induced Emphysema. Barroso, MV; Carvalho, GMC; Cattani-Cavalieri, I; Gitirana, LB; Graca-Reis, A; Kennedy-Feitosa, E; Lanzetti, M; Melo, AC; Pinho-Ribeiro, V; Porto, LC; Valença, SS; Zin, WA, 2017)	2.22
"Treatment with atorvastatin was associated with increased levels of myocardial tissue protein and lipid oxidative stress biomarkers and a reduced functional endogenous angiogenic response, but improved coronary microvascular reactivity. "	( Atorvastatin increases myocardial indices of oxidative stress in a porcine model of hypercholesterolemia and chronic ischemia. Bianchi, C; Boodhwani, M; Clements, RT; Feng, J; Mieno, S; Ramlawi, B; Sellke, FW; Sodha, NR; Xu, SH, )	1.93
"Pretreatment with atorvastatin significantly reduced the occurrence of postoperative AF after off-pump CABG."	( The effects of atorvastatin on the occurrence of postoperative atrial fibrillation after off-pump coronary artery bypass grafting surgery. Kim, JH; Kim, JS; Kim, WS; Lee, SH; Lee, YT; On, YK; Shin, DH; Song, YB; Sung, J, 2008)	1.03
"Treatment with atorvastatin decreased cholesterol content and HMGCoA reductase expression and activity in all four tissues of SHR. "	( Tissue-specific effects of atorvastatin on 3-hydroxy-3-methylglutarylcoenzyme A reductase expression and activity in spontaneously hypertensive rats. Chen, GP; Hu, SJ; Li, L; Lu, X; Yao, L, 2008)	1
"When treated with atorvastatin, 90% of patients achieved a LDL C<1 g/L, compared to 51% when treated with fibrate (P=0.001)."	( Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile. Giraudeaux, V; Guillausseau, PJ; Kévorkian, JP; Laloi-Michelin, M; Meas, T; Peynet, J; Virally, M, 2009)	0.68
"Treatment with atorvastatin (80 mg) over a lifetime horizon resulted in increased costs (Can$16,542 vs. "	( Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada. Chu, P; Goetghebeur, M; Merikle, E; Pandya, A; Taylor, DC; Wagner, M, 2009)	0.94
"Treatment with atorvastatin not only reduced the overproduction of TNF-alpha and IFN-gamma, but also enhanced the expression of Cx43 and Cx45, therefore attenuating myocardial injury and improving the survival rate of viral myocarditis."	( Immunomodulation by atorvastatin upregulates expression of gap junction proteins in coxsackievirus B3 (CVB3)-induced myocarditis. Wu, S; Zhang, A; Zhang, H, 2010)	1.02
"Pretreatment with atorvastatin 20 mg/qn for 2 to 3 days could significantly reduce procedural inflammatory reaction, attenuate urinary protein and the effect of degrading GFR in coronary angiography patients."	( [Atorvastatin attenuated contrast induced renal function damage]. Chen, GL; Su, JZ, 2009)	1.59
"Treatment with atorvastatin has been shown to increase EPC count in patients with coronary artery disease."	( Atorvastatin increases the number of endothelial progenitor cells after cardiac surgery: a randomized control study. Alfano, G; Casacalenda, A; Chello, M; Covino, E; Genovese, J; Pollari, F; Spadaccio, C, 2010)	2.14
"Treatment with atorvastatin did not alter the mRNA level of NOX1, a catalytic subunit of NADPH oxidase, but decreased the levels of other NOX isoforms, NOX2 and NOX4, in the ApoE-deficient mice fed a high-fat diet."	( NADPH oxidase isoforms and anti-hypertensive effects of atorvastatin demonstrated in two animal models. Cui, W; Ibi, M; Ikami, K; Iwata, K; Kakehi, T; Katsuyama, M; Matsuno, K; Sasaki, M; Yabe-Nishimura, C; Zhu, K, 2009)	0.94
"Oral treatment with Atorvastatin dramatically reduced albuminuria and histological changes in the kidneys as compared to vehicle-treated control animals."	( Atorvastatin attenuates murine anti-glomerular basement membrane glomerulonephritis. Eller, K; Eller, P; Mayer, G; Patsch, JR; Reinstadler, SJ; Rosenkranz, AR; Tagwerker, A; Wolf, AM, 2010)	2.12
"Oral treatment with atorvastatin decreases SNA through antioxidant effects in the RVLM of stroke-prone spontaneously hypertensive rats (SHRSP)."	( Sympathoinhibition induced by centrally administered atorvastatin is associated with alteration of NAD(P)H and Mn superoxide dismutase activity in rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats. Hirooka, Y; Kishi, T; Konno, S; Sunagawa, K, 2010)	0.92
"Treatment with atorvastatin induces a significant reduction in fractional sodium excretion compared with placebo, and sodium clearance tends to be reduced."	( Acute effects of atorvastatin on glomerular filtration rate, tubular function, blood pressure, and vasoactive hormones in patients with type 2 diabetes. Bech, JN; Matthesen, SK; Paulsen, L; Pedersen, EB; Starklint, J, 2010)	1.04
"Treatment with atorvastatin caused an increase in the numbers of intraislet endothelial cells at postnatal day 14 and the percentage of endothelial cells undergoing DNA synthesis, suggesting that angiogenesis had preceded the increase in beta-cell mass."	( Effects of atorvastatin on the regeneration of pancreatic {beta}-cells after streptozotocin treatment in the neonatal rodent. Arany, EJ; Hill, DJ; Marchand, KC, 2010)	1.09
"Treatment with atorvastatin enhanced the circulating pool of EPCs with fortified migratory and adherent capacity."	( Intensive statin therapy: a favorable adjunct to the improvement of small-diameter vascular grafts. Huang, MQ; Li, XX; Liu, DY; Lu, WM; Wang, SM; Yu, JX; Zhu, YF, 2010)	0.7
"Treatment with Atorvastatin reduced the histological damage and protected the morphological integrity of the sciatic nerve in streptozotocin induced diabetes."	( Statin treatment reduces oxidative stress-associated apoptosis of sciatic nerve in diabetes mellitus. Barut, T; Ekerbiçer, N; Gürpınar, T; Harzadın, NU; Tarakçı, F; Tuglu, MI, 2011)	0.71
"Treatment with atorvastatin prior to induction of AMI was associated with a significant reduction of serum CRP, TNF-alpha, plasma PAI-1 and an increase of serum IL-10."	( Atorvastatin restores the balance between pro-inflammatory and anti-inflammatory mediators in rats with acute myocardial infarction. Abdel-Aziz, NA; Abo-Elmatty, DM; Ghattas, MH; Tawfik, MK, 2010)	2.14
"Treatment with atorvastatin combined with vitamins E and C significantly reduced the odds of NAFLD at the end of follow-up, 70 vs."	( Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Ahmadi, N; Budoff, MJ; Foster, T; Gordon, C; Guerci, AD; Saab, S, 2011)	2.15
"Treatment with atorvastatin may be beneficial for brain aging by reducing BACE1 protein and omega6:omega3 ratio, however, the potential adverse cognitive outcomes reported here should be more carefully explored given their relevance to human clinical outcomes."	( Changes in cognition and amyloid-β processing with long term cholesterol reduction using atorvastatin in aged dogs. Astarita, G; Barrett, E; Beckett, TL; Dowling, AL; Head, E; Kryscio, RJ; Levine, H; Lin, Y; Morales, J; Murphy, MP; Piomelli, D; Studzinski, CM; Wang, X; Weidner, A, 2010)	0.92
"When treated with atorvastatin plus ezetimibe, MHR and HR patients had greater attainment of LDL-C, most lipids and lipoproteins and/or hs-CRP targets compared with doubling their atorvastatin dose. "	( Attainment of Canadian and European guidelines' lipid targets with atorvastatin plus ezetimibe vs. doubling the dose of atorvastatin. Bays, H; Conard, S; Hanson, ME; Leiter, LA; Lin, J; Shah, A; Tershakovec, AM, 2010)	0.93
"Treatment with atorvastatin in type 2 diabetes did not change median total plasma plant sterol concentrations, but LDL cholesterol was reduced most efficaciously in high cholesterol synthesisers with low intestinal cholesterol absorption."	( Impact of atorvastatin and omega-3 ethyl esters 90 on plasma plant sterol concentrations and cholesterol synthesis in type 2 diabetes: a randomised placebo controlled factorial trial. Ceglarek, U; Farmer, A; Holman, RR; Neil, HA; Paul, S; Thiery, J, 2010)	1.12
"Treatment with atorvastatin before PCI can reduce myocardial damage during the peri-PCI period."	( Effect of different loading doses of atorvastatin on percutaneous coronary intervention for acute coronary syndromes. Gao, Y; Pang, X; Qi, G; Sun, Y; Zhang, H; Zhang, Z; Zhao, W, 2010)	0.97
"Pretreatment with atorvastatin diminished the increase in TNF-α and IL-1β."	( Effect atorvastatin on serum tumor necrosis factor alpha and interleukin-1β following acute pulmonary embolism. Li, L; Sun, TW; Wang, LX; Zhang, JY, 2011)	1.15
"Treatment with atorvastatin was associated with a 76% reduction in lathosterol and significant increases in sitosterol (70%)."	( Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men. Benjannet, S; Couture, P; Davis, HR; Hoos, L; Lamarche, B; Lemelin, V; Seidah, NG; Tremblay, AJ, 2011)	2.15
"Treatment with atorvastatin or simvastatin inhibited AngII-induced Smad activation and related-fibrosis."	( Statins inhibit angiotensin II/Smad pathway and related vascular fibrosis, by a TGF-β-independent process. Civantos, E; Egido, J; Lavoz, C; Mezzano, S; Ortiz, A; Rayego-Mateos, S; Rodrigues Díez, R; Rodrigues-Díez, R; Rodríguez-Vita, J; Ruiz-Ortega, M, 2010)	0.7
"Treatment with atorvastatin (ATO) or dietary control has been demonstrated to benefit patients with non-alcoholic fatty liver disease (NAFLD) and hyperlipidemia. "	( Comparison of dietary control and atorvastatin on high fat diet induced hepatic steatosis and hyperlipidemia in rats. Ji, G; Jiang, Z; Leng, L; Liu, P; Zhao, X, 2011)	1
"Pretreatment with atorvastatin of septic animals completely restored NE-induced contractions to levels similar to those of sham-operated controls and significantly increased survival time and mean arterial pressure."	( Atorvastatin prevents vascular hyporeactivity to norepinephrine in sepsis: role of nitric oxide and α₁-adrenoceptor mRNA expression. Ahanger, AA; Choudhury, S; Kandasamy, K; Mishra, SK; More, AS; Parida, S; Prawez, S; Singh, TU, 2011)	2.14
"The treatment of atorvastatin improved the pathologic changes in the aging rats significantly, especially in the first group."	( [The effects of atorvastatin on aging kidney]. Cheng, QL; Ye, P; Zhao, JH, 2011)	1.04
"Treatment with atorvastatin (20mg/kg qd) significantly downregulated the expression of RAGE and MCP-1."	( Atorvastatin exerts its anti-atherosclerotic effects by targeting the receptor for advanced glycation end products. Feng, B; Hu, JF; Liu, F; Wang, H; Xu, L; Xue, J; Yan, X, 2011)	2.15
"Treatment with atorvastatin limited LDL oxidation significantly (LDL thiobarbituric acid reactive substances 2.19 nmol/mg protein, LDL-conjugated diene 222 μmol/mg protein)."	( Effect of atorvastatin therapy on oxidant-antioxidant status and atherosclerotic plaque formation. Nart, D; Onat, T; Sezer, ED; Sozmen, EY, 2011)	1.11
"Treatment with atorvastatin or pitavastatin ameliorated the activation of MMP-9."	( Progressive neurovascular disturbances in the cerebral cortex of Alzheimer's disease-model mice: protection by atorvastatin and pitavastatin. Abe, K; Ikeda, Y; Kozuki, M; Kurata, T; Miyazaki, K; Morimoto, N; Ohta, Y, 2011)	0.92
"Treatment with atorvastatin and irbesartan, initiated on day 3 after acute ischemic stroke, did not appear to substantially modify infarct growth."	( A randomized placebo controlled trial of early treatment of acute ischemic stroke with atorvastatin and irbesartan. Beer, C; Blacker, D; Bynevelt, M; Hankey, GJ; Puddey, IB, 2012)	0.95
"Treatment with atorvastatin was followed by a 35.6% decline in LDL cholesterol. "	( Effect of low-dose atorvastatin on plasma concentrations of adipokines in patients with metabolic syndrome. Adamczak, M; Chudek, J; Czerwienska, B; Szotowska, M; Wiecek, A, 2012)	1.06
"Treatment with atorvastatin and carboplatin reduced the growth of xenograft A549 tumors in nude mice and enhanced the survival rate compared with carboplatin alone."	( Atorvastatin sensitizes human non-small cell lung carcinomas to carboplatin via suppression of AKT activation and upregulation of TIMP-1. An, Y; Chen, J; Hou, J; Lan, T; Li, X; Liu, J; Pan, Y; Tie, L; Zhang, J, 2012)	2.16
"Treatment with atorvastatin significantly restored 40.9% of the widened intima and even down-regulated the ratio of intima/media by 55.5%."	( Effects of atorvastatin on expression of ICAM-1 in atherosclerotic rabbits. Cao, H; Cui, W; Du, B; Lin, S; Liu, Y; Qin, L; Xu, G, 2013)	1.12
"Treatment with atorvastatin reversed both PUMA expression and apoptosis induced by mechanical stress in cardiomyocytes."	( Regulation of PUMA induced by mechanical stress in rat cardiomyocytes. Cheng, WP; Shyu, KG; Wang, BW; Wu, GJ, 2012)	0.72
"Treatment with atorvastatin was well tolerated and no serious side effects were reported."	( Long term efficacy and safety of atorvastatin in the treatment of severe type III and combined dyslipidaemia. de Beer, F; Havekes, LM; Kastelein, JJ; Lansberg, PJ; Prins, MH; Smelt, AH; Trip, MD; van Dam, M; Zwart, M, 2002)	0.94
"Treatment with atorvastatin is well tolerated and cost-effective."	( Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Athyros, VG; Athyrou, VV; Basayannis, EO; Demitriadis, DS; Kontopoulos, AG; Mercouris, BR; Papageorgiou, AA; Symeonidis, AN, 2002)	1.01
"Treatment with atorvastatin reduced serum total cholesterol concentration from 310+/-29 mg/dl in a basal situation to 203+/-34 mg/dl ( P<0.001) at the end of the treatment and low-density lipoprotein (LDL) cholesterol concentration from 225+/-30 mg/dl to 126+/-30 mg/dl ( P<0.001), respectively."	( The effect of atorvastatin on erythrocyte membranes and serum lipids in patients with type-2 hypercholesterolemia. Broncel, M; Chojnowska-Jezierska, J; Franiak, I; Klikczynska, K; Koter, M, 2002)	1.01
"Treatment with atorvastatin conferred stroke protection by 40% after filamentous occlusion of the middle cerebral artery followed by reperfusion. "	( Withdrawal of statin treatment abrogates stroke protection in mice. Böhm, M; Dirnagl, U; Endres, M; Gertz, K; Laufs, U; Lindauer, U; Nickenig, G, 2003)	0.67
"Treatment with atorvastatin for 12 months was effective and safe for pediatric subjects with known familial hypercholesterolemia or severe hypercholesterolemia."	( Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. Marais, AD; McCrindle, BW; Ose, L, 2003)	0.98
"When treated with atorvastatin, patients with peripheral arterial disease may experience improvement in symptoms to complement the anticipated reduction in cardiovascular events reported in other studies of statins."	( Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Creager, MA; Hiatt, WR; Mohler, ER, 2003)	0.94
"Cotreatment with atorvastatin (0.1-10 microM) dose dependently inhibited VEGF-induced ACE upregulation."	( Atorvastatin completely inhibits VEGF-induced ACE upregulation in human endothelial cells. Fyhrquist, F; Nyman, T; Saijonmaa, O; Stewen, P, 2004)	2.09
"Treatment with atorvastatin and fenofibrate reduced serum cholesterol by 30 % and 21 % (p = 0.046) (p-values for differences between treatment groups), triglycerides by 32 % and 45 %, LDL cholesterol by 28 % and 16 %, and increased HDL cholesterol by 3 % and 6 %, respectively. "	( Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL. Baumstark, MW; Friedrich, I; Hauck, P; Hoffmann, MM; März, W; Nickell, HH; Schmitz, H; Weltzien, P; Wieland, H; Winkler, K, 2004)	0.92
"Pretreatment with atorvastatin 40 mg/d for 7 days significantly reduces procedural myocardial injury in elective coronary intervention. "	( Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Di Sciascio, G; Nusca, A; Pasceri, V; Patti, G; Pristipino, C; Richichi, G, 2004)	0.98
"Treatment with atorvastatin may be a potential strategy to reduce oxLDL and inhibit monocyte migration to inflamed tissue, thus attenuating the inflammatory response."	( Circulating monocytes and plasma inflammatory biomarkers in active Crohn's disease: elevated oxidized low-density lipoprotein and the anti-inflammatory effect of atorvastatin. Grip, O; Janciauskiene, S; Lindgren, S, 2004)	0.86
"Treatment with atorvastatin resulted in significant decreases of serum t-chol, TG, and LDL-chol levels but not serum HDL-chol and VLDL-chol."	( Effects of atorvastatin on serum lipids, lipoproteins, and hemostasis. Abe, Y; Kushiya, F; Nakasaki, T; Nobori, T; Noda, M; Ooi, K; Sakaguchi, A; Sakurai, Y; Shiku, H; Tsukada, T; Wada, H, 2005)	1.06
"Treatment with atorvastatin reduced total cholesterol, triglycerides (TG), low-density lipoprotein (LDL) cholesterol, apolipoprotein B (apoB) and levels of oxidised LDL (oxLDL) with 30-43%. "	( Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial. Bilo, HJ; Diepeveen, SH; Dikkeschei, LD; Kolsters, G; Offerman, JJ; Stalenhoef, AF; Van Der Palen, J; Van Tits, LJ; Verhoeven, GW, 2005)	1.07
"Treatment with atorvastatin is effective in lowering plasma total cholesterol, TG, LDL, apoB and oxLDL in a population of stable dialysis patients and might therefore be an effective tool in improving the poor cardiovascular outcome in these patients. "	( Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial. Bilo, HJ; Diepeveen, SH; Dikkeschei, LD; Kolsters, G; Offerman, JJ; Stalenhoef, AF; Van Der Palen, J; Van Tits, LJ; Verhoeven, GW, 2005)	1.07
"Treatment with atorvastatin for one and three days significantly reduced infarct size versus controls (38.9 +/- 3.1% vs. "	( Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten? Mensah, K; Mocanu, MM; Yellon, DM, 2005)	0.91
"Treatment with atorvastatin was not associated with significant changes in lipoprotein profile as determined by nuclear magnetic resonance (NMR) spectroscopy."	( Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis. Chin, H; Denu-Ciocca, CJ; Dornbrook-Lavender, KA; Hogan, SL; Joy, MS; Pieper, JA, 2005)	1.06
"Treatment with atorvastatin did not affect LDL particle size but was associated with a sizable, yet nonsignificant, reduction in CRP concentrations. "	( Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis. Chin, H; Denu-Ciocca, CJ; Dornbrook-Lavender, KA; Hogan, SL; Joy, MS; Pieper, JA, 2005)	1.07
"Oral treatment with atorvastatin (1-10 mg/kg) from days 10 to 15 after arthritis induction caused inhibition of the increase in paw volume."	( Anti-inflammatory and analgesic effects of atorvastatin in a rat model of adjuvant-induced arthritis. Barsante, MM; Castro, MS; Pinho, V; Roffê, E; Souza, DG; Tafuri, WL; Teixeira, MM; Yokoro, CM, 2005)	0.91
"Treatment with atorvastatin resulted in a dose-dependent improvement in whole body insulin sensitivity in both lean and fatty rats, with an approximately two-fold increase in glucose infusion rate and glucose disposal (Rd) in ATORVA_50 versus CONT (p<0.01)."	( Atorvastatin induces insulin sensitization in Zucker lean and fatty rats. Fantus, IG; Lewis, GF; Stavar, L; Szeto, L; Uffelman, K; Wang, CH; Wong, V, 2006)	2.12
"Treatment with atorvastatin achieved a statistically significant decrease in lipid profile. "	( Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients. Bayés, B; Bonet, J; Granada, ML; Lauzurica, R; Llopis, MA; Navarro, M; Pastor, MC; Romero, R, 2005)	0.99
"Treatment with atorvastatin resulted in an 80% reduction of lesion area as compared with the untreated group (P < 0.001)."	( Anti-atherosclerotic effect of amlodipine, alone and in combination with atorvastatin, in APOE*3-Leiden/hCRP transgenic mice. de Maat, M; Emeis, J; Havekes, L; Jukema, W; Maas, A; Offerman, E; Princen, H; Szalai, A; Trion, A; van der Laarse, A, 2006)	0.91
"Treatment with atorvastatin decreased mean low-density lipoprotein cholesterol by 43% and resulted in an improvement with sildenafil in domain score of 7.8 (P = 0.036); an effect was apparent by 6 weeks."	( Can atorvastatin improve the response to sildenafil in men with erectile dysfunction not initially responsive to sildenafil? Hypothesis and pilot trial results. Bradbury, D; Herrmann, HC; Kimmel, SE; Levine, LA; Macaluso, J; Mohler, ER; Schwartz, S; Walsh, M, 2006)	1.23
"Treatment with atorvastatin improved sexual function and the response to oral sildenafil in men who did not initially respond to treatment with sildenafil. "	( Can atorvastatin improve the response to sildenafil in men with erectile dysfunction not initially responsive to sildenafil? Hypothesis and pilot trial results. Bradbury, D; Herrmann, HC; Kimmel, SE; Levine, LA; Macaluso, J; Mohler, ER; Schwartz, S; Walsh, M, 2006)	1.24
"Pretreatment with atorvastatin significantly reduces cytokine release and neutrophil adhesion to the venous endothelium in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass."	( Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery. Agrò, F; Candura, D; Carassiti, M; Chello, M; Covino, E; Di Sciascio, G; Mastrobuoni, S; Patti, G, 2006)	1.06
"Treatment with atorvastatin inhibited the changes above in a dose-dependent manner, but no change was found in treated with DMSO."	( [Atorvastatin upregulates the expression of PPAR alpha/gamma and inhibits the hypertrophy of cardiac myocytes in vitro]. Liu, YX; Sheng, L; Ye, P, 2005)	1.58
"Treatment with atorvastatin inhibited adipocyte maturation, SLC2A4 and C/EBPalpha expressions and insulin action in 3T3-L1 cells. "	( Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Ishibashi, S; Kusaka, I; Matsuoka, H; Nagasaka, S; Nakata, M; Yada, T, 2006)	0.69
"Treatment with atorvastatin 80 mg significantly reduced the rate of hospitalization for HF (2.3% vs. "	( Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. Braunwald, E; Cannon, CP; Jarolim, P; McCabe, CH; Morrow, DA; Ray, KK; Sabatine, MS; Scirica, BM; Shui, A, 2006)	0.69
"Treatment with atorvastatin decreased plasma APOA5, APOC3, APOE and triglycerides."	( Plasma apolipoprotein A5 and triglycerides in type 2 diabetes. Dallinga-Thie, GM; Hattori, H; Jansen, H; Sijbrands, EJ; van Tol, A; van Vark-van der Zee, LC, 2006)	0.67
"Treatment with atorvastatin for 4 weeks markedly decreased the slow (s)-migrating TRL subfraction and both fast- and slow-migrating low-density lipoprotein (LDL) subfractions, but did not affect the fast (f)-migrating TRL subfraction in this patient. "	( Effects of atorvastatin and apoA-I/phosphatidylcholine discs on triglyceride-rich lipoprotein subfractions as characterized by capillary isotachophoresis. Arishima, H; Katafuchi, R; Matsunaga, A; Rye, KA; Saku, K; Zhang, B, 2006)	1.08
"Treatment with atorvastatin for 3 days dose-dependently reduced hypernociception induced by lipopolysaccharide (LPS) or that following antigen challenge in sensitized animals. "	( Atorvastatin inhibits inflammatory hypernociception. Cunha, FQ; Cunha, TM; Ferreira, SH; Parada, CA; Poole, S; Santodomingo-Garzón, T; Valério, DA; Verri, WA, 2006)	2.13
"Treatment with atorvastatin 40 mg/d, initiated 7 days before surgery, significantly reduces the incidence of postoperative AF after elective cardiac surgery with cardiopulmonary bypass and shortens hospital stay. "	( Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Candura, D; Chello, M; Covino, E; D'Ambrosio, A; Di Sciascio, G; Pasceri, V; Patti, G, 2006)	1.01
"Treatment with atorvastatin significantly reduced neointimal formation at day 14 (14 days after injury) and NADPH oxidase-dependent superoxide production at day 2 in ovariectomy, but not in intact and castrated males."	( Gender difference of atorvastatin's vasoprotective effect in balloon-injured rat carotid arteries. Hayashi, T; Kimura, S; Kitaura, Y; Kurumazuka, D; Matsumoto, N; Matsumura, Y; Mori, T; Nakano, D; Shirakawa, H, 2006)	0.99
"Pretreatment with atorvastatin was associated with 49% higher nitrite/nitrate levels compared with controls (p < .05)."	( Protective effects of atorvastatin in rat models of acute pulmonary embolism: involvement of matrix metalloproteinase-9. Alves-Filho, JC; Cunha, FQ; Figueiredo-Lopes, L; Gerlach, RF; Semprini, MC; Souza-Costa, DC; Tanus-Santos, JE, 2007)	0.98
"Pretreatment with atorvastatin caused remarkable decrease in both oxidative stress and neutrophil accumulation."	( Attenuation of contractile dysfunction by atorvastatin after intestinal ischemia reperfusion injury in rats. Cetin, A; Igdem, AA; Ozacmak, ID; Ozacmak, VH; Sayan, H, 2007)	0.93
"Treatment with atorvastatin leads to an improvement in endothelial function and a reduction in inflammatory markers in patients with stable CAD. "	( Effect of atorvastatin on peripheral endothelial function and systemic inflammatory markers in patients with stable coronary artery disease. Alber, HF; Dichtl, W; Dörler, J; Frick, M; Pachinger, O; Stocker, EM; Süssenbacher, A; Weidinger, F, 2007)	1.1
"Treatment with atorvastatin in the dyslipidaemic patients to lower LDL-C, was also accompanied by a reduction of proteinuria in this group (P < 0.001)."	( Dyslipidaemia as predictor of progressive renal failure and the impact of treatment with atorvastatin. Arisz, L; Kastelein, JJ; Koopman, MG; Ozsoy, RC; van der Steeg, WA, 2007)	0.9
"Treatment with atorvastatin led to a significant reduction in levels of PAI-1 and hs-CRP; however, the elevation of vWF level was observed."	( Effect of atorvastatin on endothelial function and inflammation in long-duration type 1 diabetic patients without coronary heart disease and arterial hypertension. Cieslik, G; Fedak, D; Galicka-Latala, D; Konduracka, E; Naskalski, J; Piwowarska, W; Rostoff, P; Sieradzki, J, 2008)	1.09
"Treatment with atorvastatin abrogated the risk associated with elevated markers of inflammation in this study, a finding that provides a novel rationale for the use of statins in acute coronary syndromes."	( Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study. Ganz, P; Kinlay, S; Libby, P; Olsson, AG; Rifai, N; Schwartz, GG; Szarek, M; Waters, DD, 2008)	0.69
"Treatment with atorvastatin to the NCEP LDL-C goal compared with 'usual care' significantly reduced CHD morbidity and mortality in both men and women. "	( Effects of statin treatment in men and women with stable coronary heart disease: a subgroup analysis of the GREACE Study. Anagnostis, P; Athyros, VG; Kakafika, AI; Karagiannis, A; Koumaras, C; Mikhailidis, DP; Pagourelias, E; Papageorgiou, AA; Paraskevas, KI; Tziomalos, K, 2008)	0.7
"Treatment with atorvastatin significantly improved post-MI LV function (fractional shortening, +120%; dP/dt(max), +147%; and LV end-diastolic pressure, -27%)."	( Atorvastatin enhances interleukin-10 levels and improves cardiac function in rats after acute myocardial infarction. Arnold, M; Daniel, WG; Garlichs, CD; Petzi, S; Raaz, D; Seybold, K; Stumpf, C; Wasmeier, G; Yilmaz, A, 2009)	2.14
"Pretreatment with atorvastatin (ATV) reduces infarct size (IS) and increases myocardial expression of phosphorylated endothelial nitric oxide synthase (p-eNOS), inducible NOS (iNOS), and cyclooxygenase-2 (COX2) in the rat. "	( The role of eNOS, iNOS, and NF-kappaB in upregulation and activation of cyclooxygenase-2 and infarct size reduction by atorvastatin. Birnbaum, Y; Lin, Y; Martinez, JD; Perez-Polo, RJ; Uretsky, BF; Ye, Y, 2008)	0.89
"Treatment with atorvastatin significantly reduced low density lipoprotein cholesterol levels, and was associated with a 36% reduction in ischemic events and a significant delay in time to first ischemic event."	( Medical therapy versus revascularization: the atorvastatin versus revascularization treatment AVERT trial. Waters, DD, 2000)	0.9
"Treatment with atorvastatin achieved the target in 83% of patients, while simvastatin (or simvastatin plus cholestyramine) achieved the target in 66% of the patients (P<0.005)."	( Achievement of target plasma cholesterol levels in hypercholesterolaemic patients being treated in general practice. Barter, PJ; O'Brien, RC, 2000)	0.65
"The treatment with atorvastatin induced significant reduction of microalbuminuria and fibrinogen levels (p<0.01)."	( Atorvastatin for the management of Type 2 diabetic patients with dyslipidaemia. A mid-term (9 months) treatment experience. Cernigoi, AM; Merni, M; Tortul, C; Velussi, M, 1999)	2.07
"Treatment with atorvastatin at an early stage may have an impact on the progression of atherosclerosis in these high risk patients."	( Atorvastatin but not L-arginine improves endothelial function in type I diabetes mellitus: a double-blind study. Deanfield, JE; Donald, AE; Mullen, MJ; Thomson, H; Thorne, S; Wright, D, 2000)	2.09
"Pretreatment with atorvastatin inhibited angiotensin II-induced ROS production."	( Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Bäumer, AT; Böhm, M; Konkol, C; Laufs, U; Müller, K; Nickenig, G; Sauer, H; Wassmann, S, 2001)	0.63
"Treatment with atorvastatin reduced red cell aggregation (P<0.01), whole blood viscosity (P<0.01), plasma viscosity (P<0.01) and platelet aggregation (P<0.05), but caused a slight increase in plasma fibrinogen (by 5%; P<0.01)."	( Atorvastatin improves blood rheology in patients with familial hypercholesterolemia (FH) on long-term LDL apheresis treatment. Alt, E; Banyai, M; Banyai, S; Derfler, K; Falger, J; Jansen, M; Koppensteiner, R, 2001)	2.09
"Treatment with atorvastatin reduced vascular mRNA expression of p22phox and nox1 and increased aortic catalase expression."	( Cellular antioxidant effects of atorvastatin in vitro and in vivo. Ahlbory, K; Bäumer, AT; Böhm, M; Konkol, C; Laufs, U; Linz, W; Müller, K; Nickenig, G; Wassmann, S, 2002)	0.94
"Treatment with atorvastatin resulted in a statistically significant reduction in total cholesterol (41%), LDL cholesterol (55%), triglycerides (TG) (32%), and apoB (40%)."	( Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes. Adeli, K; Cheung, RC; Parris, W; Pontrelli, L, 2002)	2.1

Toxicity

In the short-term trials, the incidence of all-causality adverse events (AEs) and serious AEs (SAEs) was similar to or lower than that observed with other statins or placebo. discontinuations due to treatment-related AEs/SAEs were infrequent. Atorvastatin use in very young children with KD is safe but should be closely monitored.

Excerpt	Reference	Relevance
"To assess the lipid-lowering effect of atorvastatin (a new 3-hydroxy-3-methylglutaryl coenzyme A [HMG-CoA] reductase inhibitor) on levels of serum triglycerides and other lipoprotein fractions in patients with primary hypertriglyceridemia, determine if atorvastatin causes a redistribution of triglycerides in various lipoprotein fractions, and assess its safety by reporting adverse events and clinical laboratory measurements."	( Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. Bakker-Arkema, RG; Black, DM; Brown, WV; Davidson, MH; Davignon, J; Goldstein, RJ; Isaacsohn, JL; Keilson, LM; Miller, VT; Shurzinske, LJ; Weiss, SR, 1996)	0.81
" The most common adverse events reported after atorvastatin-headache and nausea-occurred as frequently after placebo."	( Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Cilla, DD; Gibson, DM; Posvar, EL; Sedman, AJ; Whitfield, LR, 1996)	0.79
" Safety was assessed by recording adverse events and measuring clinical laboratory parameters."	( Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Bertolini, S; Bon, GB; Campbell, LM; Egros, F; Farnier, M; Fayyad, R; Langan, J; Mahla, G; Nawrocki, JW; Pauciullo, P; Sirtori, C, 1997)	0.61
" Safety profiles as determined by change from baseline in laboratory evaluations, ophthalmologic parameters, and reporting of adverse events were similar for the 2 reductase inhibitors."	( Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. Bakker-Arkema, R; Black, D; Davidson, M; Fayyad, R; McKenney, J; Schrott, H; Stein, E, 1997)	0.56
" No serious adverse events were considered associated with treatment."	( A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Best, J; Black, D; Bracs, P; d'Emden, M; Dart, A; Hamilton-Craig, I; Jerums, G; Nicholson, G; Sullivan, D; Tallis, G; West, M, 1997)	0.53
"Transaminase and creatine phosphokinase levels and adverse events were recorded."	( An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor. Bakker-Arkema, RG; Black, DM; Nawrocki, JW, 1998)	0.56
"Atorvastatin was well tolerated; fewer than 2% of the atorvastatin-treated patients withdrew due to drug-attributable adverse events."	( An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor. Bakker-Arkema, RG; Black, DM; Nawrocki, JW, 1998)	2
" Atorvastatin was well-tolerated, and no serious or medically important adverse events were observed."	( Efficacy and safety of a new cholesterol synthesis inhibitor, atorvastatin, in comparison with simvastatin and pravastatin, in subjects with hypercholesterolemia. Black, DM; Mahla, G; Muller, D; Pentrup, A; Wolffenbuttel, BH, 1998)	1.45
"We conclude that atorvastatin is a safe and very efficacious cholesterol-lowering agent, which also possesses significant triglyceride-lowering properties."	( Efficacy and safety of a new cholesterol synthesis inhibitor, atorvastatin, in comparison with simvastatin and pravastatin, in subjects with hypercholesterolemia. Black, DM; Mahla, G; Muller, D; Pentrup, A; Wolffenbuttel, BH, 1998)	0.88
" Adverse event rates were statistically equivalent (p<0."	( Safety of low-density lipoprotein cholestrol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE trial). Klein, G; März, W; Neiss, A; Wehling, M; Wollschläger, H, 1999)	0.55
" The frequency of treatment-associated adverse events (AEs) in the atorvastatin LDL-C < or =80 mg/dl (2."	( Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels. Bakker-Arkema, RG; Black, DM; Nawrocki, JW, 2000)	0.88
" Only one patient withdrew due to a possible drug-related adverse event."	( Efficacy and safety of atorvastatin in hyperlipidemic, type 2 diabetic patients. A 34-week, multicenter, open-label study. Aguilar-Salinas, CA; Alvarado Vega, A; Angélica Gómez-Díaz, R; Eduardo Romero-Nava, L; Gómez-Pérez, FJ; Guillén, LE; Gulías-Herrero, A; Meaney, E; Mendoza Pérez, E; Moguel, R; Novoa, G; Posadas-Romero, C; Salinas-Orozco, S; Vázquez-Chávez, C, 2000)	0.62
" Fewer than 6% of patients in either treatment group experienced drug-attributable adverse events, which were mostly mild to moderate in nature."	( Comparison of efficacy and safety of atorvastatin (10mg) with simvastatin (10mg) at six weeks. ASSET Investigators. Goldner, D; Insull, W; Kafonek, S; Zieve, F, 2001)	0.58
" Withdrawal rates related to adverse events are low (< or =3%)."	( Safety of HMG-CoA reductase inhibitors: focus on atorvastatin. Bernini, F; Paoletti, R; Poli, A, 2001)	0.57
"Data from 185 patients were retrospectively evaluated for adverse events, duration of exposure (person-days), and the mean atorvastatin dose exposure."	( Safety and efficacy of atorvastatin in heart transplant recipients. Aaronson, KD; Baliga, RR; Cody, RJ; Dyke, DB; Koelling, TM; Lake, KD; Pagani, FD; Patel, DN, 2002)	0.83
"Data from 185 patients were retrospectively evaluated for adverse events, duration of exposure (person-days), and the mean atorvastatin dose exposure."	( Safety and efficacy of atorvastatin in heart transplant recipients. Aaronson, KD; Baliga, RR; Cody, RJ; Dyke, DB; Koelling, TM; Lake, KD; Pagani, FD; Patel, DN, 2002)	0.83
"Atorvastatin, when used at moderate doses and with close biochemical and clinical monitoring, appears to be safe and is effective in aggressively lowering LDL in heart transplant recipients when treatment with other statins has failed to achieve LDL goals."	( Safety and efficacy of atorvastatin in heart transplant recipients. Aaronson, KD; Baliga, RR; Cody, RJ; Dyke, DB; Koelling, TM; Lake, KD; Pagani, FD; Patel, DN, 2002)	2.07
" There were no significant adverse events."	( A randomized, double-blind, placebo-controlled, 8-week study to evaluate the efficacy and safety of once daily atorvastatin (10 mg) in patients with elevated LDL-cholesterol. Ting, CT; Wang, KY, 2001)	0.52
" Ezetimibe was safe and well tolerated."	( Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Bruckert, E; Gagné, C; Gaudet, D, 2002)	0.56
"In hypercholesterolemia patients, atorvastatin 10 mg every other day is safe and effective in lowering TC, TG, with LDL-c and a slight increase in HDL-c."	( Efficacy and safety of atorvastatin 10 mg every other day in hypercholesterolemia. Chatlaong, B; Laothavorn, P; Nasawadi, C; Piamsomboon, C; Pongsiri, K; Saguanwong, S; Tanprasert, P, 2002)	0.9
" Data obtained by monitoring lipid profiles, adverse events, and laboratory tests during the 16 weeks of study were used to assess the efficacy and safety of both treatments."	( Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol--a multinational, multicenter, double-blind study. Hin, AT; Lee, YT; Suyono, S; Sy, R; Tanphaichitr, V; Wu, CC, 2002)	0.59
" No deaths occurred in the study population and the incidence of treatment-emergent adverse events was the same in the two groups (28%)."	( Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol--a multinational, multicenter, double-blind study. Hin, AT; Lee, YT; Suyono, S; Sy, R; Tanphaichitr, V; Wu, CC, 2002)	0.59
" 3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors are efficacious and safe and can lower the incidence of graft coronary artery disease after heart transplantation in adults."	( Efficacy and safety of atorvastatin after pediatric heart transplantation. Bernstein, D; Chin, C; Gamberg, P; Luikart, H; Miller, J, 2002)	0.63
" Data included medication use, clinic visits, adverse events, LDL-C and other laboratory measures."	( An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS). McBurney, CR; Smith, DG, 2003)	0.61
"Treatment with atorvastatin for 12 months was effective and safe for pediatric subjects with known familial hypercholesterolemia or severe hypercholesterolemia."	( Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. Marais, AD; McCrindle, BW; Ose, L, 2003)	0.98
" A retrospective analysis was conducted and included treatment-associated adverse events, serious adverse events, and musculoskeletal and hepatic adverse events."	( Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Newman, CB; Palmer, G; Silbershatz, H; Szarek, M, 2003)	0.72
"The estimated likelihood of the side effect occurring."	( Comparison of two methods of presenting risk information to patients about the side effects of medicines. Berry, DC; Knapp, P; Raynor, DK, 2004)	0.32
"The mean likelihood estimate given for the constipation side effect was 34."	( Comparison of two methods of presenting risk information to patients about the side effects of medicines. Berry, DC; Knapp, P; Raynor, DK, 2004)	0.32
" The use of verbal descriptors to improve the level of information about side effect risk leads to overestimation of the level of harm and may lead patients to make inappropriate decisions about whether or not they take the medicine."	( Comparison of two methods of presenting risk information to patients about the side effects of medicines. Berry, DC; Knapp, P; Raynor, DK, 2004)	0.32
" Safety evaluations included adverse event (AE) reports and laboratory test results."	( Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. Alizadeh, J; Ballantyne, CM; Lipka, LJ; Sager, PT; Strony, J; Suresh, R; Veltri, EP, 2004)	0.57
" Therefore, both placebo- and statin-treated patients with familial hypercholesterolemia are best treated with high-dose atorvastatin, a therapeutic regimen that induces atherosclerosis regression and is safe and well tolerated over a 4-year period."	( Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia. Kastelein, JJ; Smilde, TJ; Stalenhoef, AF; Trip, MD; van Wissen, S, 2005)	0.8
"Atorvastatin initiated at doses of 10, 20, 40, and 80 mg is effective and safe for the treatment of patients with dyslipidemia."	( Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia. Downey, J; Jones, PH; Karalis, DG; McKenney, JM, 2005)	2.04
"The authors reviewed adverse events (AEs) reported to the United States Food and Drug Administration to determine the percentage of statin-associated AE reports with concurrent amiodarone use for simvastatin, atorvastatin, and pravastatin."	( Adverse events with concomitant amiodarone and statin therapy. Alsheikh-Ali, AA; Karas, RH, 2005)	0.52
" On safety assessment, there was no adverse effect with the use of Chunghyul-dan in hepatic or renal toxicity."	( Efficacy and safety of chunghyul-dan (qingwie-dan) in patients with hypercholesterolemia. Cho, KH; Jung, WS; Kang, HS; Moon, SK; Park, SU, 2005)	0.33
" The clinical benefits of preventing vascular events, myocardial infarction, stroke, and need for revascularization outweigh the low rates of adverse events associated with high-dose statin therapy in high- and intermediate-risk patients."	( Safety of high-dose atorvastatin therapy. Waters, DD, 2005)	0.65
"Compared with patients treated with an accepted LDL goal (80 to 100 mg/dl), there was no adverse effect on safety with lower achieved LDL levels, and apparent improved clinical efficacy."	( Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. Braunwald, E; Cannon, CP; Morrow, DA; Pfeffer, MA; Ray, KK; Wiviott, SD, 2005)	0.33
"Although the medication caused no severe adverse events, we recommend caution when using atorvastatin for severe CKD patients until further evidence of its safety and efficacy is verified."	( Safety and efficacy of atorvastatin in patients with severe renal dysfunction. Brännström, M; Bucht, B; Crougneau, V; Dimeny, E; Ekspong, A; Granroth, B; Gröntoft, KC; Hadimeri, H; Holmberg, B; Ingman, B; Isaksson, B; Johansson, G; Lindberger, K; Lundberg, L; Mikaelsson, L; Olausson, E; Persson, B; Stegmayr, BG; Welin, D; Wikdahl, AM, 2005)	0.86
" The study compared the safety of atorvastatin 10 mg (n = 7,258), atorvastatin 80 mg (n = 4,798), and placebo (n = 2,180) and included analyses on treatment-associated adverse events; nonserious and serious adverse events related to the musculoskeletal, hepatic, and renal systems; the incidence of elevations of creatine kinase >10 times the upper limit of normal (ULN); and hepatic transaminases >3 times ULN."	( Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Gibson, E; Luo, D; Newman, C; Szarek, M; Tsai, J, 2006)	0.93
" Adverse effects have been related to the use of certain statins, high statin dosages, comorbidities, and coadministration with cyclosporine."	( Safety of statins when response is carefully monitored: a study of 336 heart recipients. Aldama-López, G; Campo-Pérez, R; Castro-Beiras, A; Crespo-Leiro, MG; Llinares-García, D; Marzoa-Rivas, R; Muñiz-Garcia, J; Paniagua-Marin, MJ; Piñón-Esteban, P, 2005)	0.33
"Between April 1991 and December 2003, we retrospectively evaluated 336 heart transplant patients (including 55 women) with regard to the occurrence of possible adverse effects of statins (rhabdomyolysis, myalgia, hepatotoxicity, high CK without muscle symptoms, and others)."	( Safety of statins when response is carefully monitored: a study of 336 heart recipients. Aldama-López, G; Campo-Pérez, R; Castro-Beiras, A; Crespo-Leiro, MG; Llinares-García, D; Marzoa-Rivas, R; Muñiz-Garcia, J; Paniagua-Marin, MJ; Piñón-Esteban, P, 2005)	0.33
"Possible adverse events of statins were suffered by 60 patients, all of them men."	( Safety of statins when response is carefully monitored: a study of 336 heart recipients. Aldama-López, G; Campo-Pérez, R; Castro-Beiras, A; Crespo-Leiro, MG; Llinares-García, D; Marzoa-Rivas, R; Muñiz-Garcia, J; Paniagua-Marin, MJ; Piñón-Esteban, P, 2005)	0.33
"Some 10% to 20% of HT patients appear to suffer adverse side effects of initial statin therapy."	( Safety of statins when response is carefully monitored: a study of 336 heart recipients. Aldama-López, G; Campo-Pérez, R; Castro-Beiras, A; Crespo-Leiro, MG; Llinares-García, D; Marzoa-Rivas, R; Muñiz-Garcia, J; Paniagua-Marin, MJ; Piñón-Esteban, P, 2005)	0.33
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."	( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004)	0.32
" Following coadministered treatment, the adverse events reported were similar to either agent alone."	( Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. Bakris, GL; Ferrera, D; Flack, JM; Houston, MC; Lee, E; Messerli, FH; Neutel, JM; Petrella, RJ; Sun, W, 2006)	0.58
" However, clinical data consistently support the view that adverse events are uncommon even when intensive therapy is used to reach aggressive low-density lipoprotein cholesterol goals."	( How safe is aggressive statin therapy? Guthrie, RM, 2006)	0.33
" Pravastatin was not toxic up to 1 mmol/l."	( Toxicity of statins on rat skeletal muscle mitochondria. Brecht, K; Kaufmann, P; Krähenbühl, S; Török, M; Waldhauser, KM; Zahno, A, 2006)	0.33
" The incidence of all-causality and treatment-related adverse events was similar across placebo and torcetrapib treatment groups with no evidence of a dose-related response."	( Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. Davidson, MH; McKenney, JM; Revkin, JH; Shear, CL, 2006)	0.52
" The serums lipid profiles and adverse effects were assessed in all the patients before treatment, and 4 and 8 weeks after treatment."	( [Efficacy and safety of extended-release niacin alone or with atorvastatin for lipid profile modification]. Duan, J; Li, XP; Tan, MY; Xu, ZM; Zhang, DQ; Zhao, SP, 2006)	0.57
" (3) Adverse effect, such as flushing (15."	( [Efficacy and safety of extended-release niacin alone or with atorvastatin for lipid profile modification]. Duan, J; Li, XP; Tan, MY; Xu, ZM; Zhang, DQ; Zhao, SP, 2006)	0.57
" Combined statin with niacin may produce a more global and effective improvement in lipid blood levels than monotherapy and is generally safe and well tolerable."	( [Efficacy and safety of extended-release niacin alone or with atorvastatin for lipid profile modification]. Duan, J; Li, XP; Tan, MY; Xu, ZM; Zhang, DQ; Zhao, SP, 2006)	0.57
" Current drug labeling warns of an increased risk of adverse events with statin and niacin combinations."	( Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system). Alsheikh-Ali, AA; Karas, RH, 2007)	0.57
" Nineteen patients reported at least one adverse event during the study; the majority were mild in severity and considered unrelated to atorvastatin."	( Efficacy and safety of atorvastatin in South Asian patients with dyslipidemia: an open label noncomparative pilot study. Gupta, S; Hughes, EA; Lie, F; Patel, JV, 2005)	0.84
" Clinical chemistry profiles and the incidence of adverse events were similar in both groups."	( Efficacy and safety of ezetimibe co-administered with atorvastatin in untreated patients with primary hypercholesterolaemia and coronary heart disease. Blagden, MD; Chipperfield, R, 2007)	0.59
" There were no clinically important differences in adverse event rates across quintiles."	( Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). Greten, H; Grundy, SM; Kastelein, JJ; Kostis, JB; LaRosa, JC, 2007)	0.65
" Comparison of adverse events profile in both the groups shows that more number of patients from atorvastatin alone group (n = 14, 28%) had adverse reactions than the number of patients from the combination group (n = 4, 8%; p < 005)."	( Randomised study to compare the efficacy and safety of isapgol plus atorvastatin versus atorvastatin alone in subjects with hypercholesterolaemia. Jayaram, S; Langade, DG; Mane, PR; Prasad, HB; Sovani, VB, 2007)	0.79
" Atorvastatin is generally well tolerated across the range of therapeutic dosages, with the exception of a slightly higher rate of liver enzyme elevations with atorvastatin 80 mg/day which does not appear to confer an increased risk of clinically important adverse events."	( Atorvastatin: a safety and tolerability profile. Arca, M, 2007)	2.69
" Overall, coadministered atorvastatin and amlodipine was well tolerated and without adverse pharmacodynamic interaction; combination treatment did not affect the low-density lipoprotein cholesterol-lowering efficacy and safety of atorvastatin, or the systolic blood pressure-lowering efficacy and safety of amlodipine."	( A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial. Dykstra, G; Gillen, D; Harvey, P; Herfert, O; Jukema, JW; Preston, RA; Sun, F, 2007)	0.85
" AC, the world's best selling drug is associated with poor oral bioavailability and serious adverse effects like rhabdomyolysis on chronic administration."	( Oral nanoparticulate atorvastatin calcium is more efficient and safe in comparison to Lipicure in treating hyperlipidemia. Ankola, DD; Chandraiah, G; Kumar, MN; Meena, AK; Rao, PR; Ratnam, DV, 2008)	0.66
" Both drugs were well-tolerated and the incidence and type of adverse events were similar in each group."	( A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study). Lee, YT; Ro, YM; Sim, KH; Sriratanasathavorn, C; Tomlinson, B; Zhu, JR, 2007)	0.57
" The percentages of patients experiencing treatment-associated adverse events (AEs), serious AEs and discontinuations due to AEs in the atorvastatin (n=1,428) and placebo (n=1,410) groups were 23."	( The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS). Auster, S; Betteridge, DJ; Colhoun, HM; Demicco, DA; Durrington, PN; Fuller, JH; Hitman, GA; Neil, HA; Newman, CB; Szarek, M, 2008)	0.83
" Among the adverse effects observed for this lipid-lowering agent, clinical cases of cutaneous adverse reactions have been reported and associated with photosensitivity disorders."	( A mechanistic study on the phototoxicity of atorvastatin: singlet oxygen generation by a phenanthrene-like photoproduct. Iesce, MI; Lhiaubet-Vallet, V; Miranda, MA; Montanaro, S; Previtera, L, 2009)	0.61
" CPK surveillance is recommended because of a slight continued risk of adverse effects."	( The efficacy and safety of ezetimibe for treatment of dyslipidemia after heart transplantation. Castro-Beiras, A; Crespo-Leiro, MG; Flores, X; Franco, R; Grille, Z; Marzoa, R; Mosquera, V; Naya, C; Paniagua, MJ; Rodriguez, JA, 2008)	0.35
" The incidences of clinical and laboratory adverse experiences were generally similar between groups."	( Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease. Bays, HE; Bird, SR; Conard, SE; Leiter, LA; Lowe, RS; Rubino, J; Tershakovec, AM; Tomassini, JE, 2008)	0.61
" Safety and tolerability profiles and incidence of liver and muscle adverse experiences were generally similar between groups."	( Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. Bays, H; Bird, S; Conard, S; Hanson, ME; Leiter, LA; Rubino, J; Tershakovec, AM; Tomassini, JE, 2008)	0.61
" Using data from the Rating Atherosclerotic Disease Change by Imaging with a New CETP Inhibitor [corrected] (RADIANCE) trials, which assessed the impact of torcetrapib on carotid intima-media thickness (cIMT), we sought to explore potential mechanisms underlying this adverse outcome."	( Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Basart, DC; Bots, ML; Evans, GW; Grobbee, DE; Kastelein, JJ; Sijbrands, EJ; Stalenhoef, AF; Stroes, ES; van Leuven, SI; Vergeer, M; Visseren, FL, 2008)	0.35
"These analyses support mineralocorticoid-mediated off-target toxicity in patients receiving torcetrapib as a contributing factor to an adverse outcome."	( Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Basart, DC; Bots, ML; Evans, GW; Grobbee, DE; Kastelein, JJ; Sijbrands, EJ; Stalenhoef, AF; Stroes, ES; van Leuven, SI; Vergeer, M; Visseren, FL, 2008)	0.35
" Anacetrapib was well tolerated, and the incidence of adverse events was similar for placebo and all active treatment groups."	( Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Bloomfield, D; Carlson, GL; Littlejohn, TW; McKenney, JM; Mitchel, Y; Pasternak, RC; Sapre, A; Sisk, CM; Tribble, D, 2009)	0.56
" Rates of any reported serious adverse event were higher in older patients, but did not differ between the 2 statin groups."	( Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study). Cater, NB; Faergeman, O; Holme, I; Kastelein, JJ; Larsen, ML; Lindahl, C; Olsson, AG; Pedersen, TR; Szarek, M; Tikkanen, MJ, 2009)	0.63
" No major adverse events or clinical myopathy occurred in either groups."	( Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol. Ajit Kumar, VK; Harikrishnan, S; Krishnamoorthy, KM; Nair, K; Rajeev, E; Sivasankaran, S; Tharakan, JA; Titus, T, )	0.37
" The most common adverse events were peripheral oedema (11."	( International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme. Bauer, B; da Silva, PM; Feldman, RD; Genest, J; Gensini, G; Harvey, P; Jenssen, TG; John Mancini, GB; Manolis, AJ; Richard Hobbs, FD, 2009)	0.57
" The incidence of liver, muscle, and gastrointestinal-, hepatitis- and allergic reaction/rash-related adverse events were low and generally similar to those in previous studies of ezetimibe/simvastatin and/or atorvastatin."	( Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). Adewale, AJ; Ballantyne, CM; Grundy, SM; Hsueh, WA; Parving, HH; Polis, AB; Robinson, JG; Rosen, JB; Tershakovec, AM; Tomassini, JE, 2009)	0.78
" The results of the present study indicate that intensive statin therapy with high-dose (80 mg/day) atorvastatin is more efficacious than and as safe as 20 mg/day atorvastatin when administered to elderly patients during early hospitalization for UA."	( Efficacy and safety of atorvastatin during early hospitalization in elderly patients with unstable angina. Ge, ZM; Geng, J; Kang, WQ; Wang, W; Zhang, Y; Zhao, Z, 2009)	0.88
" This study aimed to investigate the effects of combined application of extended-release niacin and atorvastatin on lipid profile modification and the risks of adverse events in patients with coronary artery disease."	( Combined use of extended-release niacin and atorvastatin: safety and effects on lipid modification. Chen, SY; Li, YG; Li, YH; Sang, ZC; Wang, F; Wang, HP; Zhou, Q, 2009)	0.83
" Plasma lipid profile, glucose, and adverse events were assessed at the hospitalization, and 6 and 12 months after treatment."	( Combined use of extended-release niacin and atorvastatin: safety and effects on lipid modification. Chen, SY; Li, YG; Li, YH; Sang, ZC; Wang, F; Wang, HP; Zhou, Q, 2009)	0.61
" Combination therapy with niacin ER and atorvastatin was well tolerated and safe in patients with coronary artery disease."	( Combined use of extended-release niacin and atorvastatin: safety and effects on lipid modification. Chen, SY; Li, YG; Li, YH; Sang, ZC; Wang, F; Wang, HP; Zhou, Q, 2009)	0.88
"Lipid-lowering drugs have been associated with severe adverse effects on skeletal muscle, including rhabdomyolysis."	( Statins and fibrate target ClC-1 - from side effects to CLC pharmacology. Zdebik, AA, 2009)	0.35
" We defined a composite adverse event (CAE) as discontinuation for any side effect, myalgia, or CK >3x upper limit of normal during follow-up."	( The SLCO1B1*5 genetic variant is associated with statin-induced side effects. Ali, S; Ginsburg, GS; Reed, CR; Salisbury, BA; Shah, SH; Spasojevic, I; Voora, D, 2009)	0.35
" There were no drug-related serious adverse events."	( A multicenter study in Malaysia to determine the efficacy and safety of a generic atorvastatin. Leekha, S; Lena, YL; Ong, LM; Punithavathi, N, 2009)	0.58
"Mean percentage changes in lipid parameters, percentages of patients achieving optimal serum lipid/apolipoprotein levels, and incidence of adverse events."	( Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. Cusi, K; Davidson, MH; Jones, PH; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC; Thakker, K, 2010)	0.36
" Incidence of adverse events was generally similar among treatments."	( Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. Cusi, K; Davidson, MH; Jones, PH; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC; Thakker, K, 2010)	0.36
" Pitavastatin 1 mg once daily may be an alternative regimen with cost-saving benefits but without a significant decrease in therapeutic benefit or increase in adverse events in patients with hypercholesterolemia."	( Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia. Dhumma-Upakorn, R; Putwai, P; Sansanayudh, N; Wongwiwatthananukit, S, 2010)	0.6
" Most importantly, Zhibitai is safe to use."	( Evaluation of the lipid lowering ability, anti-inflammatory effects and clinical safety of intensive therapy with Zhibitai, a Chinese traditional medicine. Chen, C; Huang, QY; Liu, L; Shu, J; Wasti, B; Xu, DY; Zhao, SP, 2010)	0.36
" We retrieved data from randomized controlled trials, meta-analyses, post-marketing studies, reports to regulatory bodies and case reports of rare adverse events."	( Atorvastatin: safety and tolerability. Athyros, VG; Karagiannis, A; Mikhailidis, DP; Tziomalos, K, 2010)	1.8
"The reader will gain insight into the incidence, severity, prevention and management of the major adverse effects of atorvastatin (i."	( Atorvastatin: safety and tolerability. Athyros, VG; Karagiannis, A; Mikhailidis, DP; Tziomalos, K, 2010)	2.01
" Simvastatin was more toxic than atorvastatin and the lactone form more toxic than the acid form."	( Cytotoxicity of atorvastatin and simvastatin on primary rainbow trout (Oncorhynchus mykiss) hepatocytes. Asberg, A; Ellesat, KS; Hylland, K; Thomas, KV; Tollefsen, KE, 2010)	0.99
" Most importantly, it is safe to use Zhibitai clinically."	( [A comparative study of the efficacy and safety Zhibitai and atorvastatin]. Huang, QY; Liu, L; Shu, J; Xu, DY; Zhao, SP, 2010)	0.6
" Overall, adverse events were similar in the 2 treatment groups."	( Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia. Goldberg, AC; Jones, PH; Kelly, MT; Knapp, HR; Setze, CM; Sleep, DJ; Stolzenbach, JC, 2010)	0.6
" It is concluded that MEGX test widens opportunities for personalization and safe pharmacotherapy."	( [Individual pharmacotherapy safety in the assessment of cytochrome P-450 3A4 (CYP3A4) isoenzyme activity]. Kukes, IV; Paukov, SV; Ruvinov, IuV; Sivkov, AS, 2010)	0.36
" We studied the toxic effects of high glucose (50 mmol/L and 83 mmol/L) and its reversal by atorvastatin (0."	( Atorvastatin reduces high glucose toxicity in rat peritoneal mesothelial cells. Carrión, B; Ceña, V; Gómez-Roldán, C; Monteagudo, S; Pérez-Carrión, MD; Pérez-Martínez, FC; Pérez-Martínez, J, )	1.79
" These toxic effects could be reversed by atorvastatin."	( Atorvastatin reduces high glucose toxicity in rat peritoneal mesothelial cells. Carrión, B; Ceña, V; Gómez-Roldán, C; Monteagudo, S; Pérez-Carrión, MD; Pérez-Martínez, FC; Pérez-Martínez, J, )	1.84
" Safety was assessed in terms of adverse event rates, including abnormal clinical laboratory variables related to liver and kidney function and skeletal muscle."	( Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial. Noda, K; Saku, K; Zhang, B, 2011)	0.62
" LDL-C target was maintained in 81% and 69% of patients at week 8 and 52 respectively without drug related serious adverse events."	( Long-term efficacy and safety of a generic atorvastatin in usual clinical care setting. Leekha, S; Lena, YL; Mahanim, O; Ong, LM; Punithavathi, N, 2011)	0.63
" Adverse experiences (AEs) typically associated with niacin (flushing, pruritus, increased glucose, increased uric acid) were more common with ERN/LRPT+SIMVA, and hepatic-related laboratory AEs were more common with ATORVA."	( Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia. Blomqvist, P; Chen, E; Chen, F; Davidson, M; Maccubbin, D; McKenney, JM; Sirah, W; Sisk, CM; Yan, L, 2013)	0.6
" The purpose of this case report is to illustrate the clinical and radiological findings of focal myositis as a side effect of statins and fibrates in 2 patients with forearm involvement."	( [Focal myositis as a side effect of antilipidemics - 2 patients with involvement of the forearm]. Hohendorff, B; Mühldorfer-Fodor, M; Prommersberger, KJ; Schmitt, R; Wagner, M, 2012)	0.38
" One patient on SAR236553 experienced a serious adverse event of leukocytoclastic vasculitis."	( Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. Ferrand, AC; Hanotin, C; Kereiakes, DJ; Koren, MJ; McKenney, JM; Stein, EA, 2012)	0.57
" Polymorphisms within these genes are increasingly being implicated in disease and may also trigger adverse drug reactions."	( Polymorphisms in the mitochondrial ribosome recycling factor EF-G2mt/MEF2 compromise cell respiratory function and increase atorvastatin toxicity. Andrews, S; Bellon, J; Callegari, S; de Barros Lopes, MA; Gregory, PA; McKinnon, RA; Sykes, MJ, 2012)	0.59
" These adverse events (AEs) can have serious impact, and form a significant barrier to therapy adherence."	( A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class. Dimbil, M; Golomb, BA; Hoffman, KB; Kraus, C, 2012)	0.38
" These results indicate that muscle cells may be particularly susceptible to a statin-induced suppression of essential antioxidant selenoproteins, which provides an explanation for the disposition of these drugs to evoke adverse muscular side-effects."	( Prooxidative toxicity and selenoprotein suppression by cerivastatin in muscle cells. Fuhrmeister, J; Kromer, A; Moosmann, B; Tews, M, 2012)	0.38
" However, its clinical uses are limited due to its dose-dependent adverse effects particularly cardiac and testicular toxicities."	( Protective role of atorvastatin against doxorubicin-induced cardiotoxicity and testicular toxicity in mice. Jena, GB; Kushwaha, S; Ramanjaneyulu, SV; Trivedi, PP; Vikram, A, 2013)	0.72
" Hepatotoxicity is one of the serious adverse effects of statins, and the exact mechanism of hepatotoxicity is not yet clear."	( Mechanisms of the statins cytotoxicity in freshly isolated rat hepatocytes. Abdoli, N; Azarmi, Y; Eghbal, MA; Heidari, R, 2013)	0.39
" Atorvastatin use in very young children with KD is safe but should be closely monitored."	( Atorvastatin safety in Kawasaki disease patients with coronary artery aneurysms. Chahal, N; Manlhiot, C; McCrindle, BW; Niedra, E; Yeung, RS, 2014)	2.76
" ANA was well tolerated, and dose-dependent relationships for adverse events were not observed across treatment groups."	( Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with dyslipidemia. Kikuchi, M; McCrary Sisk, C; Nakagomi, M; Numaguchi, H; Shirakawa, M; Surks, HK; Tamura, S; Teramoto, T, 2013)	0.39
"Statins reduce cardiovascular morbidity and mortality but their administration is associated with a broad array of potential adverse effects."	( Safety and tolerability of the use of atorvastatin 40 mg in common daily practice in short-term observation in 3,227 patients. Dabrowski, M; Wiliński, J, 2013)	0.66
"6% of all study participants) interrupted atorvastatin therapy due to drug-related adverse effects, which comprised mainly increased liver transaminases (0."	( Safety and tolerability of the use of atorvastatin 40 mg in common daily practice in short-term observation in 3,227 patients. Dabrowski, M; Wiliński, J, 2013)	0.93
"Atorvastatin in daily dose of 40 mg is a safe and well tolerable medication for the treatment for dyslipidemic disorders in patients of different clinic profile and cardiovascular risk groups in common medical practice."	( Safety and tolerability of the use of atorvastatin 40 mg in common daily practice in short-term observation in 3,227 patients. Dabrowski, M; Wiliński, J, 2013)	2.1
" Reports of adverse experiences were generally similar among groups."	( Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia. Averna, M; Bays, HE; Brudi, P; De Pellegrin, A; Farnier, M; Giezek, H; Lee, R; Lowe, RS; Majul, C; Muller-Wieland, D; Triscari, J, 2013)	0.65
" Saroglitazar was found to be safe and well tolerated by patients."	( A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRES Bhansali, A; Jani, RH; Jariwala, G; Jha, P; Joshi, S; Mukhopadhyay, S; Pai, V, 2014)	0.59
"Saroglitazar appeared to be an effective and safe therapeutic option for improving hypertriglyceridemia in patients with T2DM."	( A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRES Bhansali, A; Jani, RH; Jariwala, G; Jha, P; Joshi, S; Mukhopadhyay, S; Pai, V, 2014)	0.59
"The NR1I3 rs2307424 genotype distribution was different between subjects with and without adverse drug reactions."	( Influence of PPARA, RXRA, NR1I2 and NR1I3 gene polymorphisms on the lipid-lowering efficacy and safety of statin therapy. Almeida, S; Bruxel, EM; Ferreira, ME; Fiegenbaum, M; Hutz, MH; Lima, LO; Pires, RC; Van der Sand, CR; Van der Sand, LC, 2013)	0.39
" Mean percentage change from baseline in triglycerides (TGLs), non-high-density lipoprotein cholesterol (non-HDL-C), HDL-C, low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), and TC-HDL ratio, incidence of adverse effects, and cost-effectiveness were compared in both the groups."	( Efficacy and safety of alternate day therapy with atorvastatin and fenofibrate combination in mixed dyslipidemia: a randomized controlled trial. David, DC; Haribalaji, N; Harivenkatesh, N; Sudhakar, MK, 2014)	0.66
" Incidence of adverse events was reasonably less in alternate day therapy group."	( Efficacy and safety of alternate day therapy with atorvastatin and fenofibrate combination in mixed dyslipidemia: a randomized controlled trial. David, DC; Haribalaji, N; Harivenkatesh, N; Sudhakar, MK, 2014)	0.66
"Alternate day therapy with atorvastatin-fenofibrate combination is an effective and safe alternative to daily therapy in mixed dyslipidemia."	( Efficacy and safety of alternate day therapy with atorvastatin and fenofibrate combination in mixed dyslipidemia: a randomized controlled trial. David, DC; Haribalaji, N; Harivenkatesh, N; Sudhakar, MK, 2014)	0.95
" The serum levels of total cholesterol (TC), TG, low-density lipoprotein cholesterol (LDL-C) and HDL-C were assessed before and after 6 and 12 weeks treatment, side effects and adverse events were recorded."	( [The lipid-regulating effect and safety of combined statin and bezafibrate therapy in acute coronary syndrome patients complicating with dyslipidemia]. Gong, HR; Huang, WY; Li, XP; Zhao, SP, 2013)	0.39
"The combined statin and bezafibrate treatment is safe and could increase the ratios of reaching target lipid levels in ACS patients complicating with increased TG and (or) decreased HDL-C."	( [The lipid-regulating effect and safety of combined statin and bezafibrate therapy in acute coronary syndrome patients complicating with dyslipidemia]. Gong, HR; Huang, WY; Li, XP; Zhao, SP, 2013)	0.39
"Statins are potent cholesterol-lowering drugs that can have serious adverse effects on the muscles and liver."	( Efficiency of hepatocyte pretreatment with coenzyme Q10 against statin toxicity. Abdoli, N; Azarmi, Y; Eghbal, MA, 2014)	0.4
" The proportion of patients experiencing any adverse event was similar among the three treatment groups."	( Efficacy and safety of intensive statin therapy in Chinese patients with atherosclerotic intracranial arterial stenosis: a single-center, randomized, single-blind, parallel-group study with one-year follow-up. Cao, Z; Feng, Y; Gao, P; Lu, Z; Wang, P; Wang, S; Zhang, G; Zhou, P, 2014)	0.4
"In conclusion, long-term use of IAT appears to be a safe and effective treatment at least for Chinese patients with AICAS."	( Efficacy and safety of intensive statin therapy in Chinese patients with atherosclerotic intracranial arterial stenosis: a single-center, randomized, single-blind, parallel-group study with one-year follow-up. Cao, Z; Feng, Y; Gao, P; Lu, Z; Wang, P; Wang, S; Zhang, G; Zhou, P, 2014)	0.4
" Evacetrapib monotherapy or in combination with atorvastatin was not likely to be associated with any significant change in blood pressure and did not have any adverse effects on mineralocorticoid or glucocorticoid measures."	( Efficacy, safety, tolerability, and pharmacokinetic profile of evacetrapib administered as monotherapy or in combination with atorvastatin in Japanese patients with dyslipidemia. Krueger, KA; Morisaki, Y; Ruotolo, G; Takeuchi, M; Teramoto, T, 2014)	0.86
" We evaluated the risk of renal-associated serious adverse events (SAEs) using statins versus placebo trials and the high-dose versus low-dose statin trials that were available to us."	( Statin and the risk of renal-related serious adverse events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and other placebo-controlled trials. Bangalore, S; DeMicco, DA; Fayyad, R; Hovingh, GK; Laskey, R; Vogt, L; Waters, DD, 2014)	0.4
" However, the primary adverse effect limiting their use is myopathy."	( Red yeast rice and coenzyme Q10 as safe alternatives to surmount atorvastatin-induced myopathy in hyperlipidemic rats. Abdelbaset, M; Agha, AM; Mahmoud, SS; Negm, SA; Safar, MM, 2014)	0.64
" Intolerance was defined as inability to take at least 2 different statins because of muscle-related adverse events (AEs), 1 at the lowest approved starting dose."	( Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. Baccara-Dinet, MT; Bruckert, E; Gipe, D; Guyton, JR; Jacobson, TA; Moriarty, PM; Thompson, PD, )	0.13
"The aim of this study was to evaluate the effect of atorvastatin on lipid lowering, cardiovascular (CV) events, and adverse events in women compared with men in 6 clinical trials."	( Impact of female sex on lipid lowering, clinical outcomes, and adverse effects in atorvastatin trials. Betteridge, J; Bittner, VA; Fayyad, R; Hsue, PY; Laskey, R; Waters, DD; Wenger, NK, 2015)	0.89
" Study medications were generally safe and well tolerated."	( Efficacy and safety of fixed dose combination of atorvastatin and hydroxychloroquine: a randomized, double-blind comparison with atorvastatin alone among Indian patients with dyslipidemia. Agarwal, M; Agrawal, N; Chandurkar, N; Dhruv, U; Khyalappa, R; Legha, R; Mathur, SL; Pai, V; Pareek, A; Parmar, M; Pednekar, S; Salkar, HR; Saxena, S; Sriram, U; Thulaseedharan, NK, 2015)	0.67
" Statin therapy significantly lowers plasma TC and LDL levels in HIV-positive patients and is associated with low rates of adverse events."	( Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis. Ballocca, F; Barbero, U; Biondi-Zoccai, G; Bonora, S; Calcagno, A; Cannillo, M; Cerrato, E; D'Ascenzo, F; DiNicolantonio, JJ; Gaita, F; Gasparini, M; Gili, S; Grosso Marra, W; Lavie, CJ; Lonni, E; Mancone, M; Montefusco, A; Moretti, C; Omedè, P; Pianelli, M, 2016)	0.43
" To our knowledge, no meta-analysis focusing on assessing the safety profile of atorvastatin 80 mg/day has been performed; therefore, our aim was to evaluate the tolerability and adverse event (AE) patterns of this drug/dose."	( Safety Profile of Atorvastatin 80 mg: A Meta-Analysis of 17 Randomized Controlled Trials in 21,910 Participants. Cheng, G; Li, H; Li, R; Sun, S; Wang, C; Zhang, S; Zou, M, 2016)	1
" Nephrotoxicity, a serious side-effect of gentamicin, is related to an increase in reactive oxygen species in the kidney."	( Atorvastatin improves renal organic anion transporter 3 and renal function in gentamicin-induced nephrotoxicity in rats. Arjinajarn, P; Chatsudthipong, V; Chattipakorn, N; Jaikumkao, K; Lungkaphin, A; Pongchaidecha, A; Promsan, S, 2016)	1.88
" We aimed to quantify co-administration of MQAB with interacting drugs and associated adverse drug reactions."	( Drug safety of macrolide and quinolone antibiotics in a tertiary care hospital: administration of interacting co-medication and QT prolongation. Corti, N; Hoppe, L; Kovari, H; Maechler, S; Niedrig, D; Russmann, S, 2016)	0.43
" Electrocardiographic (ECG) monitoring and associated adverse events were validated in medical records."	( Drug safety of macrolide and quinolone antibiotics in a tertiary care hospital: administration of interacting co-medication and QT prolongation. Corti, N; Hoppe, L; Kovari, H; Maechler, S; Niedrig, D; Russmann, S, 2016)	0.43
" Forty-four MQAB users had contraindicated co-administrations of simvastatin, atorvastatin, or tizanidine and three of those related adverse drug reactions."	( Drug safety of macrolide and quinolone antibiotics in a tertiary care hospital: administration of interacting co-medication and QT prolongation. Corti, N; Hoppe, L; Kovari, H; Maechler, S; Niedrig, D; Russmann, S, 2016)	0.66
" However, adverse drug reactions were rarely found, and costs vs."	( Drug safety of macrolide and quinolone antibiotics in a tertiary care hospital: administration of interacting co-medication and QT prolongation. Corti, N; Hoppe, L; Kovari, H; Maechler, S; Niedrig, D; Russmann, S, 2016)	0.43
" However, there is no comprehensive study on the role of NOXs in high glucose (HG)-induced toxic effect in neural tissues."	( Studying neuroprotective effect of Atorvastatin as a small molecule drug on high glucose-induced neurotoxicity in undifferentiated PC12 cells: role of NADPH oxidase. Dehpour, AR; Rayegan, S; Sharifi, AM, 2017)	0.73
" Curcumin is one of the safe spices that have chemoprotection and cytoprotection effects against endogenous and exogenous noxious stimuli."	( Curcumin improves atorvastatin-induced myotoxicity in rats: Histopathological and biochemical evidence. El-Kenawy, AE; Elshama, SS; Osman, HH, 2016)	0.77
" In the short-term trials, the incidence of all-causality adverse events (AEs) and serious AEs (SAEs) in Asian patients treated with atorvastatin was similar to or lower than that observed with other statins or placebo, and discontinuations due to treatment-related AEs/SAEs were infrequent (2."	( Safety of atorvastatin in Asian patients within clinical trials. Bao, W; Chan, JC; Fayyad, R; Kong, AP; Laskey, R, 2016)	1.04
"Statins (including atorvastatin) are a widely used class of drugs, and like all medications, they have a potential for adverse effects."	( Toxicity of Atorvastatin on Pancreas Mitochondria: A Justification for Increased Risk of Diabetes Mellitus. Amirsheardost, Z; Hajhashemi, V; Minaiyan, M; Naserzadeh, P; Pourahmad, J; Sadighara, M; Salimi, A; Seydi, E, 2017)	1.16
"Liver injury is a common adverse effect of atorvastatin."	( The enhanced atorvastatin hepatotoxicity in diabetic rats was partly attributed to the upregulated hepatic Cyp3a and SLCO1B1. Hu, M; Li, F; Ling, Z; Liu, L; Liu, P; Liu, X; Shu, N; Sun, B; Wang, F; Xie, Q; Xu, P; Zhang, M; Zhong, Z, 2016)	1.07
" Safety outcomes were evaluated by the risk of adverse events (AE)."	( Efficacy and safety of long-term treatment with statins for coronary heart disease: A Bayesian network meta-analysis. Bai, Y; Chan, C; Chang, X; Cheng, N; Cheng, Z; Lu, Y; Zhao, Y, 2016)	0.43
"Myopathy is the most commonly reported adverse effect of statins."	( Rosuvastatin safety: An experimental study of myotoxic effects and mitochondrial alterations in rats. Abdallah, D; El-Ganainy, SO; El-Khatib, AS; El-Mallah, A; Khattab, MM; Mohy El-Din, MM, 2017)	0.46
"Statins are generally well tolerated and adverse effects are relatively rare."	( Hepatotoxicity of statins and other lipid-lowering agents. Björnsson, ES, 2017)	0.46
" ATOR showed similar cytotoxic effect as TMZ to glioma cells, and it may be a safer drug, regarding side effect induction, than chemotherapic agents."	( Atorvastatin Promotes Cytotoxicity and Reduces Migration and Proliferation of Human A172 Glioma Cells. Dal-Cim, T; Lopes, FG; Ludka, FK; Nedel, CB; Oliveira, KA; Tasca, CI, 2018)	1.92
"In blinded randomised controlled trials, statin therapy has been associated with few adverse events (AEs)."	( Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension p Collier, T; Collins, R; Dahlof, B; Gupta, A; Poulter, N; Sever, P; Thompson, D; Whitehouse, A, 2017)	0.46
" These results will help assure both physicians and patients that most AEs associated with statins are not causally related to use of the drug and should help counter the adverse effect on public health of exaggerated claims about statin-related side-effects."	( Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension p Collier, T; Collins, R; Dahlof, B; Gupta, A; Poulter, N; Sever, P; Thompson, D; Whitehouse, A, 2017)	0.46
"9 million clinical reports submitted to FDA Adverse Event Reporting System (FAERS) from 2004 to 2015."	( Effect of statins on blood pressure: Analysis on adverse events released by FDA. Ding, F; Hou, XD; Liu, XG; Wang, XK; Xie, HH; Xie, XD; Yi, K; You, T; Zhang, P, 2017)	0.46
"To our knowledge, this is the first pooled analysis on large-scale data of adverse events to identify the BP-lowering effect of statins."	( Effect of statins on blood pressure: Analysis on adverse events released by FDA. Ding, F; Hou, XD; Liu, XG; Wang, XK; Xie, HH; Xie, XD; Yi, K; You, T; Zhang, P, 2017)	0.46
" No serious adverse events (AEs) related to bococizumab treatment occurred and all treatment-emergent AEs were mild or moderate in severity."	( Efficacy and Safety of Bococizumab (RN316/PF-04950615), a Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, in Hypercholesterolemic Japanese Subjects Receiving a Stable Dose of Atorvastatin or Treatment-Naive　- Results From a Rand Chaudhuri, S; Imai, K; Kanada, S; Matsuoka, N; Matsuoka, O; Sekino, H; Tabira, J; Teramoto, T; Yokote, K, 2017)	0.64
"Statins are generally well-tolerated and serious side effects are infrequent, but some patients experience adverse events and reduce their statin dose or discontinue treatment altogether."	( Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale. Baccara-Dinet, MT; Harada-Shiba, M; Ishigaki, Y; Kawabata, Y; Kiyosue, A; Kondo, A; Ozaki, A; Sata, M; Teramoto, T; Tobita, K, 2017)	0.46
" No deaths or serious adverse events were reported."	( Efficacy and Safety of the Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib in Combination With Atorvastatin in Japanese Patients With Primary Hypercholesterolemia. Iimura, T; Kiyosue, A; Murakami, M; Riesmeyer, JS; Takita, Y; Teramoto, T, 2017)	0.67
" The rate of ≥1 adverse event was similar with rosuvastatin 5 mg (12."	( Efficacy and safety of rosuvastatin versus atorvastatin in high-risk Chinese patients with hypercholesterolemia: a randomized, double-blind, active-controlled study. Peng, D; Zhao, S, 2018)	0.74
"Despite being a potent hypolipidemic drug, atorvastatin (AS) possesses certain adverse effects."	( Evaluating Efficacy and Safety of Combination Medication of Atorvastatin and a Herbal Formula Containing Salvia miltiorrhiza and Pueraria lobata on Hyperlipidemia. Chan, JY; Cheung, DW; Fung, KP; Hung, AS; Ko, CH; Koon, CM; Lau, KM; Wang, YP; Wat, E; Waye, MM; Wong, PH; Yau, KC, 2017)	0.96
" Safety outcomes included adverse events and events of interest identified in the FOURIER trial."	( Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial. Ferreira, J; Giugliano, RP; Huber, K; Keech, A; Lewis, BS; Murphy, SA; Pedersen, TR; Pineda, AL; Sabatine, MS; Sever, PS; Somaratne, R; Tokgozoglu, SL, 2017)	0.46
" Uncertainty persists about whether they cause symptomatic muscle adverse effects, such as pain and weakness, in the absence of statin myopathy."	( Study protocol for statin web-based investigation of side effects (StatinWISE): a series of randomised controlled N-of-1 trials comparing atorvastatin and placebo in UK primary care. Armitage, J; Beaumont, D; Brack, K; Goldacre, B; Herrett, E; MacDonald, T; Prowse, D; Roberts, I; Shakur-Still, H; Smeeth, L; Staa, TV; Williamson, E; Youssouf, N, 2017)	0.66
" Moreover, the AC-NPs treatments were associated with significant adverse effects observed biochemically and histologically."	( Efficacy and Safety Profiles of Oral Atorvastatin-Loaded Nanoparticles: Effect of Size Modulation on Biodistribution. Abd-Rabo, MM; Ahmed, IS; El Hosary, R; Haider, M; Hassan, MA, 2018)	0.75
"Lawyer-submitted reports may have unintended consequences on safety signal detection in spontaneous adverse event reporting systems."	( Effect of Lawyer-Submitted Reports on Signals of Disproportional Reporting in the Food and Drug Administration's Adverse Event Reporting System. Bohn, JM; Connolly, JG; Desai, RJ; Fischer, MA; Gagne, JJ; Kesselheim, AS; Khan, NF; Rogers, JR; Sarpatwari, A, 2019)	0.51
"Our objective was to assess the impact of lawyer-submitted reports primarily for one adverse event (AE) on the ability to detect a signal of disproportional reporting for another AE for the same drug in the US FDA Adverse Event Reporting System (FAERS)."	( Effect of Lawyer-Submitted Reports on Signals of Disproportional Reporting in the Food and Drug Administration's Adverse Event Reporting System. Bohn, JM; Connolly, JG; Desai, RJ; Fischer, MA; Gagne, JJ; Kesselheim, AS; Khan, NF; Rogers, JR; Sarpatwari, A, 2019)	0.51
" No significant adverse events were reported."	( Safety and Efficacy of Atorvastatin for Chronic Subdural Hematoma in Chinese Patients: A Randomized ClinicalTrial. Dong, JF; Fei, Z; Feng, H; Gao, G; Hao, J; Hu, J; Hu, R; Jiang, R; Jiao, B; Kang, D; Lei, P; Li, J; Li, X; Liu, N; Liu, X; Lu, Y; Mao, Y; Poon, WS; Su, N; Sun, T; Tian, Y; Wang, D; Wang, R; Wei, H; Wei, J; Yin, G; Yu, R; Yu, X; Yuan, X; Zhang, J; Zhao, S; Zhao, Y; Zhu, X, 2018)	0.79
"Atorvastatin may be a safe and efficacious nonsurgical alternative for treating patients with CSDH."	( Safety and Efficacy of Atorvastatin for Chronic Subdural Hematoma in Chinese Patients: A Randomized ClinicalTrial. Dong, JF; Fei, Z; Feng, H; Gao, G; Hao, J; Hu, J; Hu, R; Jiang, R; Jiao, B; Kang, D; Lei, P; Li, J; Li, X; Liu, N; Liu, X; Lu, Y; Mao, Y; Poon, WS; Su, N; Sun, T; Tian, Y; Wang, D; Wang, R; Wei, H; Wei, J; Yin, G; Yu, R; Yu, X; Yuan, X; Zhang, J; Zhao, S; Zhao, Y; Zhu, X, 2018)	2.23
" Therefore, all reported cases of IMNM in VigiBase, the WHO global database of individual case safety reports (ICSRs) including the underlying reporting patterns, were analysed to characterize more detailed this adverse drug reaction."	( Statin-associated immune-mediated necrotizing myopathy: a retrospective analysis of individual case safety reports from VigiBase. Essers, D; Kullak-Ublick, GA; Schäublin, M; Weiler, S, 2019)	0.51
"To evaluate the onset timing of musculoskeletal adverse events (MAEs) that develop during statin monotherapy and to determine whether concomitant drugs used concurrently with statin therapy shifts the onset timing of MAEs."	( Onset timing of statin-induced musculoskeletal adverse events and concomitant drug-associated shift in onset timing of MAEs. Akimoto, H; Inoue, N; Kobayashi, D; Negishi, A; Numajiri, S; Ohshima, S; Okita, M; Oshima, S, 2018)	0.48
" Both rosuvastatin and atorvastatin were well tolerated, with similar incidences of adverse events."	( Efficacy and safety of rosuvastatin vs. atorvastatin in lowering LDL cholesterol : A meta-analysis of trials with East Asian populations. Ge, J; Jiang, H; Yu, Y; Zhang, L; Zhang, S, 2020)	1.14
" However, some patients have to reduce drug doses or discontinue atorvastatin therapy mainly due to adverse drug reactions (ADRs)."	( Association of SLCO1B1 Polymorphisms and Atorvastatin Safety and Efficacy: A Meta-analysis. Chen, Z; Du, Y; Li, X; Sun, S; Wang, S; Zhao, Z, 2018)	0.98
" The primary endpoints included the incidence of adverse cardiovascular events and changed in blood lipids and high-sensitivity C-reactive protein (hs-CRP)."	( Efficacy and Safety of Ezetimibe in Combination with Atorvastatin for Acute Coronary Syndrome Patients Accompanied with Type 2 Diabetes: A Single-Center, Non-randomized Cohort Study. Huang, Z; Li, Q; Li, X; Ye, W; Zhang, Q, 2019)	0.76
" Moreover, using C+P did not lead to any serious adverse effects when compared to the treatment group."	( Low dose concomitant treatment with chlorpromazine and promethazine is safe in acute ischemic stroke. Chandra, A; Cheng, Z; Ding, Y; Du, H; Geng, X; Tong, Y; Zhu, H, 2019)	0.51
"While the addition of low dose chlorpromazine and promethazine to standard of care for acute ischemic stroke did not have any significant improvement in functional outcomes, there were no serious adverse effects."	( Low dose concomitant treatment with chlorpromazine and promethazine is safe in acute ischemic stroke. Chandra, A; Cheng, Z; Ding, Y; Du, H; Geng, X; Tong, Y; Zhu, H, 2019)	0.51
"BACKGROUND Patients with diabetes mellitus (DM) commonly receive statins to suppress vulnerability to adverse cardiovascular events."	( Atorvastatin Induces Hepatotoxicity in Diabetic Rats via Oxidative Stress, Inflammation, and Anti-Apoptotic Pathway. Liu, Z; Zeng, H, 2019)	1.96
" In conclusion, atorvastatin nanocrystals are safe and efficacious drug delivery system confirming potent competence in treatment of hyperlipidemic conditions with ease of scalability for commercialization."	( Surface stabilized atorvastatin nanocrystals with improved bioavailability, safety and antihyperlipidemic potential. Mehta, I; Sharma, M, 2019)	1.19
" Our objective was to evaluate the possible benefits on endothelial function and vascular stiffness, as well as adverse effects of atorvastatin in SAMs."	( Safety of Atorvastatin in Patients With Stable Systemic Autoimmune Myopathies: A Pilot Longitudinal Study. Bortolotto, LA; de Oliveira, DS; Dos Santos, AM; Hong, VAC; Misse, RG; Pires Borges, IB; Shinjo, SK, 2021)	1.23
" Myotoxicity of statins in certain individuals is often a severe side effect leading to withdrawal."	( Resveratrol for protection against statin toxicity in C2C12 and H9c2 cells. Attalah Nee Rezkallah, C; Chen, QM; Thongkum, A; Zhu, C, 2020)	0.56
"Paclitaxel-induced peripheral neuropathy (PIPN) is a common and dose-limiting adverse event."	( P-Glycoprotein Inhibition Exacerbates Paclitaxel Neurotoxicity in Neurons and Patients With Cancer. Hammer, HS; Khalaf, S; Kroetz, DL; Mortensen, C; Nielsen, F; Poetz, O; Rodriguez-Antona, C; Stage, TB; Steffensen, V; Svenningsen, ÅF; Xiong, C, 2020)	0.56
" Demographics, burn total body surface area, atorvastatin doses, creatinine phosphokinase, aspartate aminotransferase levels and adverse events were analyzed."	( Safety profile of atorvastatin in the role of burn wound injury conversion. Boyko, T; Flynn, W; Furnari, G; Lukan, JK; Marin, C, 2020)	1.15
" No adverse events associated with atorvastatin were identified."	( Safety profile of atorvastatin in the role of burn wound injury conversion. Boyko, T; Flynn, W; Furnari, G; Lukan, JK; Marin, C, 2020)	1.17
"Atorvastatin administered to patients with burn injuries was not associated with any adverse events or attributable lab abnormalities."	( Safety profile of atorvastatin in the role of burn wound injury conversion. Boyko, T; Flynn, W; Furnari, G; Lukan, JK; Marin, C, 2020)	2.33
"This study aimed to evaluate whether the high frequency of reported statin adverse effects (AEs) may be associated with the nocebo effect."	( Examining the Nocebo Effect of Statins Through Statin Adverse Events Reported in the Food and Drug Administration Adverse Event Reporting System. Cohen Sedgh, R; Jackevicius, CA; Moon, J, 2021)	0.62
"A retrospective cohort study was conducted using the Food and Drug Administration Adverse Event Reporting System between January 2010 and December 2019 for statins, including, atorvastatin, lovastatin, pravastatin, rosuvastatin, and simvastatin."	( Examining the Nocebo Effect of Statins Through Statin Adverse Events Reported in the Food and Drug Administration Adverse Event Reporting System. Cohen Sedgh, R; Jackevicius, CA; Moon, J, 2021)	0.81
" The obtained results suggested a promising, easy-to-manufacture and effective ATC proniosomal gel for safe treatment of hyperlipidemia."	( Optimization of transdermal atorvastatin calcium - Loaded proniosomes: Restoring lipid profile and alleviating hepatotoxicity in poloxamer 407-induced hyperlipidemia. Abdel-Rahman, RF; El-Kayal, M; Eltellawy, YA; Salah, S; Shaker, DS, 2021)	0.92
" For validation of this cell model, alirocumab, a human antibody against proprotein convertase subtilisin kexin type 9 (PCSK9), was selected as an emerging safe lipid-lowering drug; atorvastatin, a common statin (the most effective type of lipid-lowering drug), was used as a drug with reported side effects at high concentrations, while doxorubicin was chosen as a positive cardiotoxic drug."	( Establishment of an in vitro safety assessment model for lipid-lowering drugs using same-origin human pluripotent stem cell-derived cardiomyocytes and endothelial cells. Ding, FY; Ding, N; Han, XL; Hu, SJ; Lei, W; Ni, X; Wu, HC; Xu, GY; Yang, ZZ; Ye, LQ; Yu, M; Zhao, DD; Zhao, ZA, 2022)	0.91
" The primary efficacy end points were the percentage change from baseline in non-high density lipoprotein cholesterol (non-HDL-C) level at the end of treatment and the adverse events recorded during treatment."	( Comparison of the Efficacy and Safety of Atorvastatin 40 mg/ω-3 Fatty Acids 4 g Fixed-dose Combination and Atorvastatin 40 mg Monotherapy in Hypertriglyceridemic Patients who Poorly Respond to Atorvastatin 40 mg Monotherapy: An 8-week, Multicenter, Random Cha, DH; Cho, EJ; Chung, WJ; Hong, SJ; Hong, TJ; Jeon, DS; Jeon, DW; Jeong, JC; Jeong, JO; Jeong, MH; Kim, CJ; Kim, KS; Kim, MH; Kim, SK; Kwan, J; Lee, HY; Lee, JH; Lee, JW; Park, CG; Shin, J; Woo, JS; Youn, HJ, 2021)	0.89
"In patients with residual hypertriglyceridemia despite receiving statin treatment, a combination of high-dose atorvastatin/Ω-3 fatty acid was associated with a greater reduction of triglyceride and non-HDL-C compared with atorvastatin + placebo, without significant adverse events."	( Comparison of the Efficacy and Safety of Atorvastatin 40 mg/ω-3 Fatty Acids 4 g Fixed-dose Combination and Atorvastatin 40 mg Monotherapy in Hypertriglyceridemic Patients who Poorly Respond to Atorvastatin 40 mg Monotherapy: An 8-week, Multicenter, Random Cha, DH; Cho, EJ; Chung, WJ; Hong, SJ; Hong, TJ; Jeon, DS; Jeon, DW; Jeong, JC; Jeong, JO; Jeong, MH; Kim, CJ; Kim, KS; Kim, MH; Kim, SK; Kwan, J; Lee, HY; Lee, JH; Lee, JW; Park, CG; Shin, J; Woo, JS; Youn, HJ, 2021)	1.1
" The aim of this study is to compare the risk of statin-associated adverse events among potent statins."	( Real-World Analyses of the Safety Outcome among a General Population Treated with Statins: An Asian Population-Based Study. Chen, PS; Li, YH; Lin, HW; Lin, JL; Lin, SH; Tsai, LM, 2022)	0.72
" There were no significant effects on non-vascular mortality, site-specific cancer, or other serious adverse events."	( Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease. Angermann, C; Armitage, J; Baigent, C; Barter, P; Baxter, A; Blaustein, R; Bowman, L; Braunwald, E; Brenner, S; Cannon, C; Chen, F; Chen, Y; Chen, Z; Collins, R; Dayanandan, R; DeLucca, P; Ertl, G; Fabbri, G; Fajardo-Moser, M; Goodenough, R; Goto, S; Gray, A; Hao, D; Haynes, R; Herrington, W; Hill, M; Hopewell, JC; Knott, C; Landray, M; Lay, M; Liu, J; Lucci, D; Macdonnell, S; Maggioni, A; Mihaylova, B; Mitchel, Y; Mosegaard, S; Murphy, K; Sammons, E; Stevens, W; Tobert, J; Valdes-Marquez, E; Wallendszus, K; Wanner, C; Wincott, E; Wiviott, S; Wuhan, B; Zhang, H, 2022)	0.72
"The beneficial effects of anacetrapib on major coronary events increased with longer follow-up, and no adverse effects emerged on non-vascular mortality or morbidity."	( Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease. Angermann, C; Armitage, J; Baigent, C; Barter, P; Baxter, A; Blaustein, R; Bowman, L; Braunwald, E; Brenner, S; Cannon, C; Chen, F; Chen, Y; Chen, Z; Collins, R; Dayanandan, R; DeLucca, P; Ertl, G; Fabbri, G; Fajardo-Moser, M; Goodenough, R; Goto, S; Gray, A; Hao, D; Haynes, R; Herrington, W; Hill, M; Hopewell, JC; Knott, C; Landray, M; Lay, M; Liu, J; Lucci, D; Macdonnell, S; Maggioni, A; Mihaylova, B; Mitchel, Y; Mosegaard, S; Murphy, K; Sammons, E; Stevens, W; Tobert, J; Valdes-Marquez, E; Wallendszus, K; Wanner, C; Wincott, E; Wiviott, S; Wuhan, B; Zhang, H, 2022)	0.72
" They were tolerated well by all participants and found safe during the course of treatment."	( Evaluating the safety and efficacy of a polyherbal Unani formulation in dyslipidaemia-a prospective randomized controlled trial. Ahmad, T; Ain, Q; Kazmi, MH; Naikodi, MAR; Nawab, M, 2022)	0.72
" Among the data extracted in this meta-analysis, bone mineral density (BMD) was the primary outcome measurement, while total effective rate, VAS, osteoprotegerin (OPG), bone Gla protein (BGP), bone alkaline phosphatase (BAP), blood P and Ca, and adverse effects were secondary outcome measurements."	( Meta-Analysis of the Efficacy and Safety of Alendronate Combined with Atorvastatin in the Treatment of Osteoporosis in Diabetes Mellitus. Shu, L; Tang, X; Xiong, Z; Yi, P; Zhang, C, 2022)	0.96
"The results of this meta-analysis indicate that alendronate combined with atorvastatin is a better treatment for osteoporosis in diabetes mellitus, showing more effective and higher BMD and fewer adverse events than alendronate alone."	( Meta-Analysis of the Efficacy and Safety of Alendronate Combined with Atorvastatin in the Treatment of Osteoporosis in Diabetes Mellitus. Shu, L; Tang, X; Xiong, Z; Yi, P; Zhang, C, 2022)	1.19
"There is a growing concern about the association between the combined use of daptomycin (DAP) and statins and the occurrence of musculoskeletal adverse events (MAEs), but this remains controversial."	( Association Between Statin Use and Daptomycin-related Musculoskeletal Adverse Events: A Mixed Approach Combining a Meta-analysis and a Disproportionality Analysis. Asada, M; Bando, T; Chuma, M; Goda, M; Hamano, H; Ishizawa, K; Izawa-Ishizawa, Y; Kondo, Y; Miyata, K; Nakamoto, A; Niimura, T; Okada, N; Takechi, K; Tasaki, Y; Yagi, K; Yanagawa, H; Yoshioka, T; Zamami, Y, 2022)	0.72
" Second, we conducted a disproportionality analysis using the US Food and Drug Administration Adverse Events Reporting System (FAERS) to further confirm the results of the meta-analysis and to examine the effect of each type of statin on DAP-related MAEs in a large population."	( Association Between Statin Use and Daptomycin-related Musculoskeletal Adverse Events: A Mixed Approach Combining a Meta-analysis and a Disproportionality Analysis. Asada, M; Bando, T; Chuma, M; Goda, M; Hamano, H; Ishizawa, K; Izawa-Ishizawa, Y; Kondo, Y; Miyata, K; Nakamoto, A; Niimura, T; Okada, N; Takechi, K; Tasaki, Y; Yagi, K; Yanagawa, H; Yoshioka, T; Zamami, Y, 2022)	0.72
" Subjects diagnosed with any type of dyslipidemia (population 4804) and received pitavastatin (interventions) versus comparator (comparison) with the primary efficacy endpoint of minimization of LDL-C and non- HDL-C, had an increase in HDL-C and/or reduction in major adverse cardiac events (MACE, cardiovascular death, myocardial infarction (fatal/nonfatal), and stroke (fatal/nonfatal) and/or their composite (outcomes)."	( A Systematic Review of Randomized Clinical Trials on the Efficacy and Safety of Pitavastatin. Alkaabi, M; Amoodi, AA; Baraka, MA; Don, J; Elnour, AA; Farah, FH; Mazrouei, NA; Ramadan, A; Sadeq, A; Sam, KG, 2023)	0.91
" Proportion of patients achieving target lipid levels (LDL-C ≤ 100 mg/dL and non-HDL-C ≤ 120 mg/dL) and adverse events were assessed at 24 weeks."	( Short-term safety and efficacy of escalating doses of atorvastatin for dyslipidemia in children with predialysis chronic kidney disease stage 2-5. Bagga, A; Hari, P; Khandelwal, P; Lakshmy, R; Ramesh, PL; Sinha, A, 2023)	1.16
" No differences were noted in adverse events due to atorvastatin 10 or 20 mg/day."	( Short-term safety and efficacy of escalating doses of atorvastatin for dyslipidemia in children with predialysis chronic kidney disease stage 2-5. Bagga, A; Hari, P; Khandelwal, P; Lakshmy, R; Ramesh, PL; Sinha, A, 2023)	1.41
"Atorvastatin (10-20 mg/day) administered for 24 weeks was safe and effectively reduced LDL-C and non-HDL-C in children with CKD stages 2-5."	( Short-term safety and efficacy of escalating doses of atorvastatin for dyslipidemia in children with predialysis chronic kidney disease stage 2-5. Bagga, A; Hari, P; Khandelwal, P; Lakshmy, R; Ramesh, PL; Sinha, A, 2023)	2.6
" Atorvastatin pretreatment prevented kidney damage following exposure to toxic doses of cadmium."	( Atorvastatin prevents cadmium-induced renal toxicity in a rat model. Bandegi, AR; Dehdashti, A; Ghanbari, A; Goodarzi, Z; Karami, E; Yosefi, S, 2023)	3.26
" However, the clinical application of DOX is limited mainly by dose-related adverse drug reactions."	( Therapeutic effects of atorvastatin on doxorubicin-induced hepatotoxicity in rats via antioxidative damage, anti-inflammatory, and anti-lipotoxicity. Chen, NN; Li, JX; Ma, XD; Su, SW; Wang, CC; Wang, KX; Wu, YZ; Xiong, C, 2023)	1.22
" No toxicities or adverse effects were observed in any cohort receiving inclisiran, either alone or in combination."	( The N-Acetylgalactosamine-conjugated small interfering RNA inclisiran can be coadministered safely with atorvastatin in cynomolgus monkeys resulting in additive low-density lipoprotein cholesterol reductions. Brown, AP; Kallend, D; Lehoux, D; Wijngaard, PLJ; Zerler, B, 2023)	1.12
" There was no difference in adverse events."	( Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines. Abdel-Qadir, H; Amir, E; Billia, F; Brezden-Masley, C; Chan, J; Connelly, KA; Hanneman, K; Houbois, C; Huang, F; Kei, T; Marwick, TH; Maze, D; Pezo, RC; Power, C; Prica, A; Runeckles, K; Saha, S; Shalmon, T; Thavendiranathan, P; Thorpe, KE; Wintersperger, BJ, 2023)	0.91
" However, CyA greatly increases the plasma concentration of AT; therefore, concomitant use might increase the frequency of statin-induced adverse effects."	( Safety Profile of the Concomitant Use of Atorvastatin and Cyclosporine in Renal Transplant Recipients. Harabayashi, R; Nagayama, K; Nakamura, Y; Sugimoto, T; Takahashi, K; Takahashi, M; Uchida, J, 2023)	1.18
" There was no significant difference in the adverse events rates between RSV 10 mg/AML 5 mg, RSV 20 mg/AML 5 mg, and ATV 20 mg/AML 5 mg."	( Randomized, multicenter, parallel, open, phase 4 study to compare the efficacy and safety of rosuvastatin/amlodipine polypill versus atorvastatin/amlodipine polypill in hypertension patient with dyslipidemia. Bae, HJ; Cho, EJ; Choi, JY; Han, KR; Hong, BK; Hong, SP; Hyon, MS; Jin, HY; Jung, HW; Kim, CY; Kim, KS; Kim, SY; Kim, U; Lee, JB; Lee, KH; Lee, KJ; Lee, SR; Lee, SY; Nam, CW; Park, CG; Park, SJ; Park, TH; Rhee, MY; Ryu, JK; Seol, SH; Shin, JH; Yang, DH; Yu, GW, 2023)	1.11
"To evaluate the impact of high-dose atorvastatin on secondary prevention of MACE and adverse events."	( [Efficacy and safety of atorvastatin in major cardiovascular events: Meta-analysis]. García-Rivero, AA; González-Tovar, NB; Rivas-Ruíz, R; Rivera-Lara, P; Villegas-Quintero, VE, 2023)	1.49
" The drug has adverse events that should be taken into account in secondary prevention."	( [Efficacy and safety of atorvastatin in major cardiovascular events: Meta-analysis]. García-Rivero, AA; González-Tovar, NB; Rivas-Ruíz, R; Rivera-Lara, P; Villegas-Quintero, VE, 2023)	1.22

Pharmacokinetics

This study shows that the SLCO1B1*15 allele may be associated with the individual difference in the AUC0-infinity of atorvastatin. The ABCB1 TT-TT diplotype may affect the elimination half-life of the drug in the Korean population.

Excerpt	Reference	Relevance
" In addition, mean area under the concentration-time curve (AUC0-infinity) and half-life (t1/2) were 27."	( Effect of age and gender on pharmacokinetics of atorvastatin in humans. Bron, NJ; Gibson, DM; Hounslow, NJ; Richens, A; Sedman, AJ; Whitfield, LR, 1996)	0.55
"The pharmacodynamic effects and pharmacokinetics of atorvastatin, a potent investigational inhibitor of HMG-CoA reductase, were studied in 16 normolipidemic subjects after administration of 40 mg daily for 15 days in the morning or evening."	( Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening. Cilla, DD; Gibson, DM; Sedman, AJ; Whitfield, LR, 1996)	0.8
" Plasma elimination half-life (t1/2) ranged from 14."	( Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects. Cilla, DD; Posvar, EL; Radulovic, LL; Sedman, AJ; Whitfield, LR, 1996)	0.55
" Atorvastatin peak concentration and area under the plasma concentration-time curve (AUC) values increased more than proportionally with atorvastatin dose after both single and multiple drug doses."	( Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Cilla, DD; Gibson, DM; Posvar, EL; Sedman, AJ; Whitfield, LR, 1996)	1.44
" Pharmacokinetic parameters and lipid responses were analyzed by regression on calculated creatinine clearance."	( Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin. Abel, RB; Horton, M; Moore, S; Olson, SC; Stern, RH; Yang, BB, 1997)	0.52
" Steady-state pharmacokinetic parameters (based on an enzyme inhibition assay) and lipid responses were compared."	( Cimetidine does not alter atorvastatin pharmacokinetics or LDL-cholesterol reduction. Gibson, DM; Stern, RH; Whitfield, LR, 1998)	0.6
" For terfenadine, atorvastatin coadministration produced an 8% decrease in maximum concentration (Cmax), a 35% increase in area under the concentration-time curve extrapolated to infinity (AUC0-infinity), and a 2% decrease in elimination half-life (t1/2)."	( Atorvastatin does not produce a clinically significant effect on the pharmacokinetics of terfenadine. Olson, SC; Smithers, JA; Stern, RH, 1998)	2.08
" In general, the pharmacokinetic consequences of hyperlipidemia include increased total drug concentrations and decreased unbound fraction in plasma."	( Pharmacokinetics and pharmacodynamics of nifedipine in untreated and atorvastatin-treated hyperlipidemic rats. Eliot, LA; Jamali, F, 1999)	0.54
" Indeed, pharmacokinetic interactions (e."	( New insights into the pharmacodynamic and pharmacokinetic properties of statins. Baetta, R; Bellosta, S; Bernini, F; Corsini, A; Fumagalli, R; Paoletti, R, 1999)	0.3
" Steady-state atorvastatin pharmacokinetic parameters were estimated on the last day of each dosing period."	( Pharmacodynamics and pharmacokinetic-pharmacodynamic relationships of atorvastatin, an HMG-CoA reductase inhibitor. Abel, RB; Hounslow, NJ; MacMahon, M; Olson, SC; Stern, RH; Yang, BB, 2000)	0.9
" Pharmacokinetic parameters [AUC(0-infinity), AUC(0-tn), peak concentration (Cmax), time to reach Cmax (tmax), and half-life (t1/2)] were determined for parent statins and major metabolites."	( Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Agarwal, V; Lasseter, KC; Lettieri, J; Mazzu, AL; Shamblen, EC; Sundaresen, P, 2000)	0.57
" However, itraconazole dramatically increased atorvastatin AUC (150%), Cmax (38%), and t1/2 (30%) (P < ."	( Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Agarwal, V; Lasseter, KC; Lettieri, J; Mazzu, AL; Shamblen, EC; Sundaresen, P, 2000)	0.83
"2% lower mean Cmax and 29."	( Effect of food on the pharmacodynamics and pharmacokinetics of atorvastatin, an inhibitor of HMG-CoA reductase. Abel, R; Gibson, DM; Sedman, AJ; Stern, RH; Whitfield, LR, )	0.37
" Pharmacokinetic assessment was performed on days 14 and 28."	( Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Hsyu, PH; Kerr, BM; Lewis, RH; Lillibridge, JH; Schultz-Smith, MD, 2001)	0.52
"The authors assessed the mutual influence of the immunosuppressant everolimus (Certican) and the HMG-CoA reductase inhibitors atorvastatin and pravastatin when coadministered based on pharmacokinetic and pharmacodynamic measures."	( Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus. Berthier, S; Hartmann, S; Hubert, M; Kovarik, JM; Rordorf, C; Rosenkranz, B; Schneider, W, 2002)	0.52
"Fifty-six subjects completed both pharmacokinetic study days."	( Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. Aberg, JA; Alston, B; Aweeka, F; Blaschke, T; Fang, F; Fichtenbaum, CJ; Gerber, JG; Kosel, B; Rosenkranz, SL; Segal, Y, 2002)	0.31
"The goal of this study was to develop a preliminary pharmacodynamic model for dosing of the hydroxymethylglutaryl coenzyme A (HMG-CoA)-reductase inhibitors simvastatin and atorvastatin using neural network analysis."	( A preliminary evaluation of neural network analysis for pharmacodynamic modeling of the dosing of the hydroxymethylglutaryl coenzyme A-reductase inhibitors simvastatin and atorvastatin. Moon, A; Smith, T, 2002)	0.7
" However, the potential bilateral pharmacokinetic interaction between atorvastatin and CsA in renal transplant recipients has not previously been examined."	( Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. Asberg, A; Bergan, S; Fjeldså, E; Hartmann, A; Holdaas, H, 2001)	0.78
" Atorvastatin has been shown to reduce efficiently the levels of atherogenic lipoproteins also in patients with renal failure, but pharmacokinetic data in haemodialysis patients are lacking."	( Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients. Dratwa, M; Lameire, NH; Lins, RL; Matthys, KE; Peeters, PC; Stolear, JC; Verpooten, GA, 2003)	1.55
" Plasma levels of atorvastatin and its active and inactive metabolites were measured by LC/MS/MS, and pharmacokinetic parameters (C(max), t(max), AUC, t(1/2)) compared between single and multiple dosing, and between the different doses."	( Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients. Dratwa, M; Lameire, NH; Lins, RL; Matthys, KE; Peeters, PC; Stolear, JC; Verpooten, GA, 2003)	0.98
"The pharmacokinetic parameters of the parent drug atorvastatin acid were not significantly different after single and 2-week multiple dosing; they showed dose-proportionality between the 40 and 80 mg dose, and were comparable to findings in healthy volunteers."	( Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients. Dratwa, M; Lameire, NH; Lins, RL; Matthys, KE; Peeters, PC; Stolear, JC; Verpooten, GA, 2003)	0.9
" The total plasma clearance of atorvastatin acid is 625 mL/min and the half-life is about 7 hours."	( Clinical pharmacokinetics of atorvastatin. Lennernäs, H, 2003)	0.9
" A 10-point pharmacokinetic profile was performed prior to and on day 14 after commencement of atorvastatin therapy."	( Effect of atorvastatin on cyclosporine pharmacokinetics in liver transplant recipients. Allen, J; Butler, M; Kubler, PA; Lynch, SV; Pillans, PI; Taylor, PJ, 2004)	0.94
" No significant change was evident for other cyclosporine pharmacokinetic parameters."	( Effect of atorvastatin on cyclosporine pharmacokinetics in liver transplant recipients. Allen, J; Butler, M; Kubler, PA; Lynch, SV; Pillans, PI; Taylor, PJ, 2004)	0.73
" No significant changes were detected in any pravastatin pharmacokinetic parameter examined when pravastatin was taken with GFJ."	( Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese. Fukazawa, I; Uchida, E; Uchida, N; Yasuhara, H, 2004)	0.58
" In the 15 subjects completing the study, no pharmacokinetic interaction was detected between atorvastatin and ximelagatran for all parameters investigated, including melagatran (the active form of ximelagatran) area under the plasma concentration versus time curve (AUC) and maximum plasma concentration, atorvastatin acid AUC, and AUC of active 3-hydroxy-3-methyl-glutaryl-coenzyme-A (HMG-CoA) reductase inhibitors."	( No pharmacokinetic or pharmacodynamic interaction between atorvastatin and the oral direct thrombin inhibitor ximelagatran. Dorani, H; Eriksson, UG; Kalies, I; Ohlsson, L; Sarich, TC; Schützer, KM; Wall, U, 2004)	0.79
" Studies compared the multiple-dose pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with 4 inhibitors of cytochrome P450-3A4 isoenzymes in healthy subjects."	( Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Jacobson, TA, 2004)	0.76
"Statins (HMG-CoA reductase inhibitors) are one of the most widely prescribed classes of drugs throughout the world, because of their excellent cholesterol-lowering effect and overall safety profile except for rare but fatal rhabdomyolysis arising either directly or indirectly by pharmacokinetic interactions with certain other drugs."	( A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan. Hasegawa, R; Hirata-Koizumi, M; Miyake, S; Saito, M; Urano, T, 2005)	0.33
"A MEDLINE search from 1996 to June 2004 was carried out to identify studies on clinical pharmacokinetic drug interactions for the five statins."	( A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan. Hasegawa, R; Hirata-Koizumi, M; Miyake, S; Saito, M; Urano, T, 2005)	0.33
"All pharmacokinetic drug interactions including relevant quantitative data for potential effectors and details on mechanisms of interaction need to be given in package inserts as soon as the information becomes available, to ensure safe and proper use of the drugs concerned."	( A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan. Hasegawa, R; Hirata-Koizumi, M; Miyake, S; Saito, M; Urano, T, 2005)	0.33
" No statistically significant changes in any of the calculated pharmacokinetic variables [AUC(0-12), maximum whole blood concentration (C(max)), whole blood concentration 12 h post dose (C(12)), time to C(max) (t(max)), terminal half-life (t(1/2))] for cyclosporine or the two metabolites, AM1 and AM9, upon atorvastatin treatment were observed."	( Atorvastatin does not affect the pharmacokinetics of cyclosporine in renal transplant recipients. Asberg, A; Christensen, H; Hartmann, A; Hermann, M; Holdaas, H; Reubsaet, JL, 2005)	1.95
" The present validated method was successfully used for pharmacokinetic studies of atorvastatin in human subjects."	( A simple and rapid HPLC method for the determination of atorvastatin in human plasma with UV detection and its application to pharmacokinetic studies. Foroutan, SM; Khoddam, A; Shafaati, A; Zarghi, A, 2005)	0.8
" Blood samples for pharmacokinetic analysis were obtained immediately before and up to 72 hours after administration during each of the 4 treatment periods."	( An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers. Braun, SL; Guha-Ray, DK; Penn, R; Rains, KT; Sawyers, WG; Williams, RX, 2006)	0.54
" ATV was administered orally (10 mg/kg) and intravenously (2 mg/kg) to rats in the absence and presence of a single intravenous dose of RIF (20 mg/kg), and pharmacokinetic parameters were compared between control and RIF-treatment groups."	( Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Benet, LZ; Huang, Y; Lau, YY; Okochi, H, 2006)	0.66
" The method was used for pharmacokinetic study of ATV and HATV."	( Validated HPLC-MS-MS method for simultaneous determination of atorvastatin and 2-hydroxyatorvastatin in human plasma-pharmacokinetic study. Barrett, B; Borek-Dohalský, V; Huclová, J; Jelínek, I; Nemec, B; Ulc, I, 2006)	0.57
" Pharmacokinetic parameters of diltiazem and desacetyldiltiazem were determined in rats after oral administration of diltiazem (15 mg x kg(-1)) to rats pretreated with atorvastatin (0."	( Effect of atorvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats. Chang, KS; Choi, DH; Choi, JS; Hong, SP, 2007)	0.94
" The pharmacokinetic parameters of verapamil were measured after an oral (9 mg/kg) or intravenous (3 mg/kg) administration of verapamil to rats in the presence and absence of atorvastatin."	( Effect of atorvastatin on the intravenous and oral pharmacokinetics of verapamil in rats. Chang, KS; Choi, DH; Choi, JS; Han, HK; Hong, SP, 2008)	0.94
" Potential pharmacodynamic interaction between drugs should be investigated as part of developing single-pill combinations."	( A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial. Dykstra, G; Gillen, D; Harvey, P; Herfert, O; Jukema, JW; Preston, RA; Sun, F, 2007)	0.54
"The pharmacokinetic parameters of verapamil and one of its metabolites, norverapamil, were compared after oral administration of verapamil (60 mg) in the presence or absence of oral atorvastatin (40 mg) in 12 healthy volunteers."	( Drug interaction between oral atorvastatin and verapamil in healthy subjects: effects of atorvastatin on the pharmacokinetics of verapamil and norverapamil. Choi, DH; Choi, JS; Shin, WG, 2008)	0.83
" Furthermore, the terminal half-life predictions for all three compounds were within 2-fold of the observed values."	( Prediction of the pharmacokinetics of atorvastatin, cerivastatin, and indomethacin using kinetic models applied to isolated rat hepatocytes. Gardiner, P; Paine, SW; Parker, AJ; Riley, RJ; Webborn, PJ, 2008)	0.62
"This study investigated the potential pharmacokinetic interaction between the direct renin inhibitor aliskiren and modulators of P-glycoprotein and cytochrome P450 3A4 (CYP3A4)."	( Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. Bizot, MN; Camenisch, G; Dieterich, HA; Dole, WP; Howard, D; Reynolds, C; Schuetz, H; Vaidyanathan, S; Yeh, CM, 2008)	0.57
"The pharmacokinetic parameters of atorvastatin were measured after intravenous (2 mg/kg) and intragastric (10 mg/kg) administration of atorvastatin in rats, which were pretreated with cyclosporin A (5, 10, and 20 mg/kg) or itraconazole (5, 10, and 20 mg/kg)."	( Effects of cyclosporin A and itraconazole on the pharmacokinetics of atorvastatin in rats. Chen, XJ; Dong, J; Sun, YB; Wang, GJ; Wang, L; Yu, X, 2008)	0.86
" The lack of a clinically meaningful effect of high-dose atorvastatin on the pharmacodynamic response to prasugrel after the loading or maintenance dose indicates that no dosage adjustment should be necessary in patients receiving these drugs concomitantly."	( Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects. Brandt, JT; Ernest, CS; Farid, NA; Jakubowski, JA; Konkoy, CS; Li, YG; Payne, CD; Salazar, DE; Small, DS; Winters, KJ, 2008)	0.99
"ABCB1 haplotypes were determined in 534 healthy Finnish volunteers, of whom 24 participated in a pharmacokinetic study on simvastatin and atorvastatin."	( ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Keskitalo, JE; Kurkinen, KJ; Neuvoneni, PJ; Niemi, M, 2008)	0.76
"421C>A single-nucleotide polymorphism (SNP) was determined in 660 healthy Finnish volunteers, of whom 32 participated in a pharmacokinetic crossover study involving the administration of 20 mg atorvastatin and rosuvastatin."	( ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Fromm, MF; Keskitalo, JE; Kurkinen, KJ; Neuvonen, PJ; Niemi, M; Zolk, O, 2009)	0.78
"To identify pharmacokinetic (PK) drug-drug interactions between tipranavir-ritonavir (TPV/r) and rosuvastatin and atorvastatin, we conducted two prospective, open-label, single-arm, two-period studies."	( Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers. Barditch-Crovo, P; Cameron, DW; Elgadi, MM; Flexner, C; Fuchs, E; la Porte, CJ; Lee, LS; Pham, PA; Piliero, PJ; Sabo, JP; van Heeswijk, R, 2009)	0.81
"290 Koreans were genotyped for SLCO1B1, ABCB1 and CYP3A5, and 28 subjects were selected for the pharmacokinetic study."	( Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects. Chung, JY; Jang, SB; Lee, MG; Lee, YJ; Lim, LA, 2010)	0.6
" In lactone forms, no significant pharmacokinetic difference was found among the genotypes."	( Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects. Chung, JY; Jang, SB; Lee, MG; Lee, YJ; Lim, LA, 2010)	0.6
"This study shows that the SLCO1B1*15 allele may be associated with the individual difference in the AUC0-infinity of atorvastatin whereas the ABCB1 TT-TT diplotype may affect the elimination half-life of the drug in the Korean population."	( Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects. Chung, JY; Jang, SB; Lee, MG; Lee, YJ; Lim, LA, 2010)	0.81
" The absence of a significant pharmacokinetic interaction between fenofibrate and atorvastatin is consistent with recent results showing no difference in safety profile between atorvastatin as monotherapy or in combination with fenofibric acid."	( Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin. Abel, R; Alvey, C; Bullen, W; Hartman, D; Porcari, AR; Whitfield, LR, 2011)	0.83
" The developed assay method was successfully applied to a pharmacokinetic study in human male volunteers."	( Simultaneous determination of atorvastatin, amlodipine, ramipril and benazepril in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. Inamadugu, JK; Karra, VK; Mullangi, R; Pilli, NR; Rao, JV; Vaidya, JR, 2011)	0.66
" Pharmacokinetic parameters, including C(max), T(max), t((1/2)), AUC(0-t), and AUC(0-infinity)), were calculated."	( Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males. Jia, JY; Li, GX; Liu, GY; Liu, YM; Lu, C; Pu, HH; Wang, W; Weng, LP; Xu, RJ; Yu, C; Zhang, MQ, 2010)	0.6
"7] kg/m(2)) were included in the pharmacokinetic and bioequivalence analyses; 1 subject was excluded from these analyses because he mistakenly received the same formulation in both periods."	( Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males. Jia, JY; Li, GX; Liu, GY; Liu, YM; Lu, C; Pu, HH; Wang, W; Weng, LP; Xu, RJ; Yu, C; Zhang, MQ, 2010)	0.6
" Our objectives were to develop a population pharmacokinetic model for atorvastatin acid and its lactone metabolite and to identify patient characteristics that are predictive of variability in the pharmacokinetic parameters of the parent drug and its lactone metabolite."	( Development of a population pharmacokinetic model for atorvastatin acid and its lactone metabolite. Akhlaghi, F; Asberg, A; Hermann, M; Narwal, R; Rosenbaum, SE, 2010)	0.84
" The main pharmacokinetic parameters of atorvastatin acid (mean [relative standard error {RSE}]) for a subject with mean covariate values were the first-order absorption rate constant (3."	( Development of a population pharmacokinetic model for atorvastatin acid and its lactone metabolite. Akhlaghi, F; Asberg, A; Hermann, M; Narwal, R; Rosenbaum, SE, 2010)	0.88
"To investigate the pharmacokinetic effects of co-administration of atorvastatin or rosuvastatin with aleglitazar."	( Aleglitazar, a balanced PPARα/γ agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatin. Foley-Comer, AJ; Jordan, P; Russell-Yarde, F; Young, AM, 2011)	0.82
" Plasma concentrations of each drug were measured and pharmacokinetic parameters determined on day 7 in each period."	( Aleglitazar, a balanced PPARα/γ agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatin. Foley-Comer, AJ; Jordan, P; Russell-Yarde, F; Young, AM, 2011)	0.58
"Co-administration of aleglitazar with a statin does not alter the pharmacokinetic profile of either drug."	( Aleglitazar, a balanced PPARα/γ agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatin. Foley-Comer, AJ; Jordan, P; Russell-Yarde, F; Young, AM, 2011)	0.58
" In co-treated group, the pharmacokinetic parameters like clearance (27."	( Influence of atorvastatin on the pharmacokinetics and pharmacodynamics of glyburide in normal and diabetic rats. Gade, J; Neerati, P, 2011)	0.74
" Serial pharmacokinetic sampling of atorvastatin was conducted on day 7 of atorvastatin dosing and day 70 of lamotrigine + atorvastatin dosing or day 28 of phenytoin + atorvastatin dosing."	( Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers. Alexander, S; Bullman, J; Fleck, R; Messenheimer, J; Miller, J; Nicholls, A; Van Landingham, K; Vuong, A, 2011)	0.88
" Blood samples were collected pre-dose and up to 72 hours post-dose in each period for determination of plasma atorvastatin/metformin concentrations and calculation of the respective pharmacokinetic parameters."	( Pharmacokinetics of a fixed-dose combination of atorvastatin and metformin extended release versus concurrent administration of individual formulations: a randomized, open-label, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivale Arora, R; Dey, S; Kandhwal, K; Monif, T; Nazarudheen, S; Rao, S; Reyar, S; Singh, MK; Thudi, NR, 2011)	0.84
" Prospective, two-phase, randomized-sequence, open-label pharmacokinetic study."	( Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin. Frye, RF; Johnson, JA; Langaee, T; Pacanowski, MA; Pauly, DF; Shin, J, 2011)	0.63
" This phase I trial evaluated the pharmacokinetic (PK) and drug-drug interactions of bexarotene with chemotherapy and a lipid-lowering agent (atorvastatin or fenofibrate)."	( The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer. Chu, Q; Dunlop, D; Hao, D; Jacobs, CD; Leighl, N; Lopez-Anaya, A; Middleton, G; Ramlau, R; Rodon, J; Rowinsky, EK; Takimoto, CH; Wakelee, HA; Zatloukal, P, 2012)	0.87
" The developed assay method was successfully applied to a pharmacokinetic study in humans."	( Simultaneous determination of atorvastatin and niacin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. Gajula, R; Inamadugu, JK; Mullangi, R; Pilli, NR; Ponneri, V; Ravi, VB, 2012)	0.67
" Nonlinear mixed-effects modelling was employed to determine the population pharmacokinetic estimates for atorvastatin acid and atorvastatin lactone."	( Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes. Akhlaghi, F; Dostalek, M; Gohh, RY; Macwan, JS; Paryani, KR; Sam, WJ, 2012)	0.86
" The optimal population pharmacokinetic model for atorvastatin acid and atorvastatin lactone consisted of a two- and one-compartment model, respectively, with interconversion between atorvastatin acid and atorvastatin lactone."	( Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes. Akhlaghi, F; Dostalek, M; Gohh, RY; Macwan, JS; Paryani, KR; Sam, WJ, 2012)	0.89
"The main pharmacokinetic parameters of test and reference formulations were as follows: the values of C(max) for AT were (10."	( [Pharmacokinetics and bioequivalence of atorvastatin calcium tablets in healthy male Chinese volunteers]. Chen, XY; Guo, LX; Shen, Y; Zhang, YF; Zhong, DF, 2012)	0.65
" The pharmacokinetic parameters of CLZ (6 mg/kg, twice daily) were determined in male Wistar rats after 7 days co-administration with ATV (5 mg/kg, once daily) in order to assess the interaction potential between CLZ and ATV on chronic treatment."	( Drug-drug interaction study to assess the effects of atorvastatin co-administration on pharmacokinetics and anti-thrombotic properties of cilostazol in male Wistar rats. Arla, R; Rajak, S; Varanasi, KV; Vats, R; Veeraraghvan, S, 2012)	0.63
"The pharmacokinetic parameters of ATV were determined in Wistar rats after per-oral pre-treatment with CLZ for 7 days in order to assess the interaction potential between ATV and CLZ."	( Effect of multidose cilostazol on pharmacokinetic and lipid profile of atorvastatin in male Wistar rats. Arla, R; Murthy, AN; Rajak, S; Varanasi, KV; Vats, R; Veeraraghavan, S, 2012)	0.61
" In conclusion, this study suggests that OATP1B1 phenotype is more important than CYP3A4 and MDR1 phenotypes for the individual pharmacokinetic variability of atorvastatin."	( Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects. Andersson, TB; Asberg, A; Bremer, S; Christensen, H; Hjelmesæth, J; Jakobsen, GS; Molden, E; Sandbu, R; Skottheim, IB; Ulvestad, M, 2013)	0.8
"The objectives of this study were to determine if ABCB1 polymorphisms are associated with interindividual variability in sitagliptin pharmacokinetics and if atorvastatin alters the pharmacokinetic disposition of sitagliptin in healthy volunteers."	( Effect of ABCB1 polymorphisms and atorvastatin on sitagliptin pharmacokinetics in healthy volunteers. Aquilante, CL; Kosmiski, LA; Predhomme, JA; Sidhom, MS; Wempe, MF, 2013)	0.87
" A 24-h pharmacokinetic study followed each sitagliptin dose, and the study phases were separated by a 14-day washout period."	( Effect of ABCB1 polymorphisms and atorvastatin on sitagliptin pharmacokinetics in healthy volunteers. Aquilante, CL; Kosmiski, LA; Predhomme, JA; Sidhom, MS; Wempe, MF, 2013)	0.67
"Sitagliptin pharmacokinetic parameters did not differ significantly between ABCB1 CGC/CGC, CGC/TTT, and TTT/TTT diplotype groups during the monotherapy phase."	( Effect of ABCB1 polymorphisms and atorvastatin on sitagliptin pharmacokinetics in healthy volunteers. Aquilante, CL; Kosmiski, LA; Predhomme, JA; Sidhom, MS; Wempe, MF, 2013)	0.67
"The goal of this study was to investigate the impact of high-dose atorvastatin on the pharmacodynamic (PD) effects of double-dose clopidogrel in statin-naive patients with stable coronary artery disease (CAD) and high-on-treatment platelet reactivity (HTPR) while on standard-dose clopidogrel before percutaneous coronary intervention (PCI)."	( High-dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) study. Abbate, R; Angiolillo, DJ; Bellandi, F; Giusti, B; Leoncini, M; Maioli, M; Marcucci, R; Toso, A, 2013)	1.03
" In patients with high on-treatment platelet reactivity (HTPR) while on standard-dose clopidogrel, high-dose atorvastatin enhances the pharmacodynamic (PD) effects of double-dose clopidogrel."	( Pharmacodynamic effects of adjunctive high dose atorvastatin on double dose clopidogrel in patients with high on-treatment platelet reactivity depending on diabetes mellitus status. Abbate, R; Angiolillo, DJ; Bellandi, F; Giusti, B; Leoncini, M; Maioli, M; Marcucci, R; Toso, A, 2014)	0.87
"The object of this study is to investigate the pharmacokinetic interaction of pioglitazone hydrochloride and atorvastatin calcium in healthy adult Beagle dogs following single and multiple oral dose administration."	( [Pharmacokinetic interaction of pioglitazone hydrochloride and atorvastatin calcium in Beagle dogs]. Chen, HL; Dang, HW; Wang, XY; Yang, FY; Yang, WC; Zhang, WP, 2013)	0.84
"Although organic anion transporting polypeptide (OATP)-mediated hepatic uptake is generally conserved between rodents and humans at a gross pharmacokinetic level, the presence of three major hepatic OATPs with broad overlap in substrate and inhibitor affinity, and absence of rodent-human orthologs preclude clinical translation of single-gene knockout/knockin findings."	( Utility of Oatp1a/1b-knockout and OATP1B1/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin, simvastatin, and carboxydichlorofluorescein. Bao, JQ; Fallon, JK; Higgins, JW; Ke, AB; Manro, JR; Smith, PC; Zamek-Gliszczynski, MJ, 2014)	0.6
"Coamorphous ATC-NIC has improved physicochemical and pharmacokinetic properties as compared to ATC."	( Coamorphous atorvastatin calcium to improve its physicochemical and pharmacokinetic properties. Ghavimi, H; Hamishekar, H; Jouyban, A; Shayanfar, A, 2013)	0.77
" The peak plasma concentration, Tmax and apparent clearance of 2-hydroxyatorvastatin (CL/Fm) were significantly different between subjects with the CYP3A4*1G/*1G genotype and the wild-type."	( The effect of CYP3A4*1G allele on the pharmacokinetics of atorvastatin in Chinese Han patients with coronary heart disease. He, BX; Qiu, J; Shi, L; Zeng, XH; Zhao, SJ, 2014)	0.88
" Pharmacokinetic parameters were calculated using non-compartmental model."	( Effects of silymarin on the pharmacokinetics of atorvastatin in diabetic rats. Alizadeh-Fanalou, S; Amniattalab, A; Hassani-Dizaj, S; Malekinejad, H; Rezabakhsh, A; Rokhsartalab-Azar, S, 2014)	0.66
" We verified if the pharmacodynamic effects of CYP3A4-metabolized statins (atorvastatin) and non-CYP3A4-metabolized statins (pitavastatin) differ in patients with coronary artery disease (CAD) treated with DAPT."	( Pharmacodynamic comparison of pitavastatin versus atorvastatin on platelet reactivity in patients with coronary artery disease treated with dual antiplatelet therapy. Franzoni, F; Gaudio, C; Greco, C; Marazzi, G; Pelliccia, F; Polacco, M; Rosano, G; Speziale, G; Spoletini, I; Vitale, C, 2014)	0.89
" Aim of this study was to verify if atorvastatin and rosuvastatin have different pharmacodynamic effects also when platelet reactivity while on dual antiplatelet therapy (DAPT) is normal at baseline."	( Pharmacodynamic effects of atorvastatin versus rosuvastatin in coronary artery disease patients with normal platelet reactivity while on dual antiplatelet therapy--the PEARL randomized cross-over study. Franzoni, F; Gaudio, C; Greco, C; Marazzi, G; Pelliccia, F; Polacco, M; Rosano, G; Speziale, G; Spoletini, I; Vitale, C, 2014)	0.97
" No difference of EVL Cmax or Tmax was found after atorvastatin coadministration."	( Effects of atorvastatin on the pharmacokinetics of everolimus among kidney transplant recipients. Avihingsanon, Y; Chancharoenthana, W; Praditpornsilpa, K; Somparn, P; Townamchai, N; Vadcharavivad, S; Wanitchanont, A, 2014)	1.04
" Notably, plasma evacetrapib concentrations were mostly undetectable, and all pharmacodynamic biomarkers (HDL-C and LDL-C levels and CETP mass and activity) returned to baseline after a 4- to 6-week washout."	( Efficacy, safety, tolerability, and pharmacokinetic profile of evacetrapib administered as monotherapy or in combination with atorvastatin in Japanese patients with dyslipidemia. Krueger, KA; Morisaki, Y; Ruotolo, G; Takeuchi, M; Teramoto, T, 2014)	0.61
" The method was applicable for the quality control of the mentioned drugs in raw material, bulk drug and pharmaceutical formulations as well as in pharmacokinetic studies."	( Liquid Chromatographic Method for Simultaneous Quantitation of Clopidogrel, Aspirin and Atorvastatin in Rat Plasma and Its Application to the Pharmacokinetic Study. Akhalaque Ahmad, RA; Chatpalliwar, VA; Chhajed, SS; Porwal, PK, 2015)	0.64
"Volume of distribution is one of the most important pharmacokinetic properties of a drug candidate."	( Volume of Distribution in Drug Design. Beaumont, K; Di, L; Maurer, TS; Smith, DA, 2015)	0.42
" Intensive steady-state 12- and 24-hour pharmacokinetic blood sampling was performed."	( Pharmacokinetic Drug-Drug Interaction Study Between Raltegravir and Atorvastatin 20 mg in Healthy Volunteers. Blonk, M; Burger, D; Colbers, A; Schouwenberg, B; van Beek, M, 2015)	0.65
" The purpose of the present study is to develop a physiologically based pharmacokinetic (PBPK) model for atorvastatin and its two primary metabolites, 2-hydroxy-atorvastatin acid and atorvastatin lactone, using in vitro and in vivo data."	( Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for atorvastatin and its metabolites. Zhang, T, 2015)	0.85
" Blood samples for pharmacokinetic analysis were taken until 168 hours postdose."	( Evaluation of the effects of the weak CYP3A inhibitors atorvastatin and ethinyl estradiol/norgestimate on lomitapide pharmacokinetics in healthy subjects. Dutta, S; Foulds, P; King, A; Korb, S; Patel, G; Sumeray, M; Wade, JR, 2016)	0.68
" With the endogenous molecules, which showed a good correlation with pharmacokinetic parameters, a refined partial least-squares model was calculated based on predose data from a training set of 36 individuals and exhibited good predictive capability for the other 12 individuals in the prediction set."	( A Pharmacometabonomic Approach To Predicting Metabolic Phenotypes and Pharmacokinetic Parameters of Atorvastatin in Healthy Volunteers. Aa, J; Cao, B; Huang, Q; Jia, H; Liu, L; Shi, J; Song, Q; Tao, C; Wang, G; Xin, X; Yong, Y; Zhou, G; Zou, B, 2015)	0.63
" The plasma concentrations of atorvastatin were measured for 48 h using Tandem Liquid Chromatography-Mass Spectrometry, LC-MS-MS, and the peak plasma concentration (C(max)), time to peak plasma concentration (T(max)), elimination half-life (t1/2), constant rate of elimination (k(el)), mean residence time (MRT, expo), volume of distribution (Vd/kg), clearance (CL/kg), area under curve AUC(0."	( Effects of single nucleotide polymorphisms and haplotypes of the SLCO1B1 gene on the pharmacokinetic profile of atorvastatin in healthy Macedonian volunteers. Daka, A; Dimovski, A; Eftimov, A; Geshkovska, MN; Jakjovski, K; Kapedanovska, A; Labachevski, N; Mladenovska, K; Nebija, D; Vavlukis, M, 2015)	0.92
" A new model was developed for the prediction of AUC of statins that utilized the slopes of the above 2 models, with pharmacokinetic (Cmax) and a pharmacodynamic (IC50 value) components for the statins."	( Dual Incorporation of the in vitro Data (IC50) and in vivo (Cmax) Data for the Prediction of Area Under the Curve (AUC) for Statins using Regression Models Developed for Either Pravastatin or Simvastatin. Srinivas, NR, 2016)	0.43
" Other pharmacokinetic parameters of both products were also determined."	( Single dose pharmacokinetics of atorvastatin oral formulations using a simple HPLC-UV method. Ahmad, M; Minhas, MU; Sohail, M, 2016)	0.72
" Physiologically based pharmacokinetic (PBPK) models have, however, demonstrated ability to predict complex DDIs."	( Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs). Duan, P; Zhang, L; Zhao, P, 2017)	0.69
"No clinically significant pharmacokinetic or pharmacodynamic interactions were identified and no new safety issues observed with combined treatment with semaglutide."	( Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects. Anderson, TW; Derving Karsbøl, J; Golor, G; Hausner, H; Holst, AG; Jacobsen, JB; Wagner, FD, 2017)	0.69
" As a validation, we perform mechanistic pharmacokinetic modeling for SLCO1B1 (encoding OATP1B1) and ABCG2 (encoding BCRP) genotyped pharmacokinetic data from 18 clinical studies with healthy Caucasian and/or Asian subjects."	( Explaining Ethnic Variability of Transporter Substrate Pharmacokinetics in Healthy Asian and Caucasian Subjects with Allele Frequencies of OATP1B1 and BCRP: A Mechanistic Modeling Analysis. Barton, HA; Li, R, 2018)	0.48
"Simulations based on the current hypothesis reasonably describe SLCO1B1 and ABCG2 genotyped pharmacokinetic time course data for five transporter substrates (atorvastatin, pitavastatin, pravastatin, repaglinide, and rosuvastatin) in Caucasian and Asian populations."	( Explaining Ethnic Variability of Transporter Substrate Pharmacokinetics in Healthy Asian and Caucasian Subjects with Allele Frequencies of OATP1B1 and BCRP: A Mechanistic Modeling Analysis. Barton, HA; Li, R, 2018)	0.68
" We aimed to develop a semiphysiologically based pharmacokinetic (semi-PBPK) model involving both enzyme and transporters for predicting the contributions of altered function and expression of CYP3a and transporters to atorvastatin transport in diabetic rats by combining high-fat diet feeding and low-dose streptozotocin injection."	( Prediction of Atorvastatin Pharmacokinetics in High-Fat Diet and Low-Dose Streptozotocin-Induced Diabetic Rats Using a Semiphysiologically Based Pharmacokinetic Model Involving Both Enzymes and Transporters. Chen, N; Chen, Y; Geng, D; Li, P; Liang, L; Liu, L; Liu, X; Wang, Z; Xu, J; Yang, H; Zhang, X; Zhao, K, 2019)	1.06
" The method was applied in a pharmacokinetic study following administration of a single oral 20, 40 or 80 mg ATV dose in healthy volunteers (n = 15)."	( Simultaneous analysis of the total plasma concentration of atorvastatin and its five metabolites and the unbound plasma concentration of atorvastatin: Application in a clinical pharmacokinetic study of single oral dose. Cestari, RN; de Oliveira, RDR; Lanchote, VL; Marques, MP; Rocha, A, 2019)	0.76
" Though the statin-induced rhabdomyolysis is not common during statin therapy, its incidence will significantly increase due to pharmacokinetic drug-drug interactions (DDIs) with inhibitor drugs which inhibit atorvastatin's and its lactone's metabolism and hepatic uptake."	( Prediction of pharmacokinetic drug-drug interactions causing atorvastatin-induced rhabdomyolysis using physiologically based pharmacokinetic modelling. Cai, W; Dai, Y; Han, B; Jiao, Z; Jin, Z; Li, S; Lin, H; Ma, G; Xiang, X; Yu, Y, 2019)	0.94
" In this work, we aim to employ the physiologically based pharmacokinetic (PBPK) model with the drug-target residence time model to predict and characterize both the pharmacokinetics (PK) and pharmacodynamics (PD) of topiroxostat in humans."	( Prediction of the pharmacokinetics and pharmacodynamics of topiroxostat in humans by integrating the physiologically based pharmacokinetic model with the drug-target residence time model. Han, X; Huang, H; Ji, Y; Liu, Y; Luo, Z; Sun, W; Wang, G; Yang, T; Yu, G, 2020)	0.56
"There were significant differences in the pharmacokinetic parameters of the H4 active metabolite of CLP in the atorvastatin and rosuvastatin group divided according to their CYP2C19 genotype."	( Impact of genetic variants of selected cytochrome P450 isoenzymes on pharmacokinetics and pharmacodynamics of clopidogrel in patients co-treated with atorvastatin or rosuvastatin. Burchardt, P; Danielak, D; Główka, F; Karaźniewicz-Łada, M; Krzyżańska, D; Rzeźniczak, J; Słomczyński, M, 2020)	0.97
"This study aimed to describe the pharmacokinetic profile of atorvastatin and its major metabolite, and to evaluate drug-drug interactions (DDIs) with antiretrovirals (ARVs)."	( Influence of Drug-Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV. Alves Saldanha, S; Buclin, T; Cavassini, M; Courlet, P; Csajka, C; Decosterd, LA; Guidi, M; Marzolini, C; Stader, F; Stoeckle, M, 2020)	1.04
"The atorvastatin pharmacokinetic profile was best described by a two-compartment model with first-order absorption and elimination."	( Influence of Drug-Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV. Alves Saldanha, S; Buclin, T; Cavassini, M; Courlet, P; Csajka, C; Decosterd, LA; Guidi, M; Marzolini, C; Stader, F; Stoeckle, M, 2020)	1.36
"Full pharmacokinetic profiles (98 atorvastatin + 62 o-OH-atorvastatin concentrations) and sparse concentrations (78 and 53 for atorvastatin and o-OH-atorvastatin, respectively) were collected in 59 PLWH."	( Influence of Drug-Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV. Alves Saldanha, S; Buclin, T; Cavassini, M; Courlet, P; Csajka, C; Decosterd, LA; Guidi, M; Marzolini, C; Stader, F; Stoeckle, M, 2020)	1.08
" We aimed to establish a whole-body physiologically-based pharmacokinetic (PBPK) model which predicts disposition of CsA and nine victim drugs including atorvastatin, cerivastatin, pravastatin, rosuvastatin, fluvastatin, simvastatin, lovastatin, repaglinide and bosentan, as well as drug-drug interactions (DDIs) of CsA with nine victim drugs to investigate the integrated effect of enzymes and transporters in liver, intestinal and kidney on drug disposition."	( Prediction of Cyclosporin-Mediated Drug Interaction Using Physiologically Based Pharmacokinetic Model Characterizing Interplay of Drug Transporters and Enzymes. Li, P; Liu, L; Liu, X; Wang, Z; Yang, Y; Zhang, Z, 2020)	0.76
" The pharmacokinetic (PK) interactions studies on co-administration of ATR (8."	( Pharmacokinetics and Pharmacodynamic Herb-Drug Interaction of Piperine with Atorvastatin in Rats. Choudhary, DC; Nagrik, SS; Raje, A; Thomas, AB, 2021)	0.85
" This study aimed to evaluate the pharmacokinetic interaction of atorvastatin and fixed-dose combination of sofosbuvir/ledipasvir "FDCSL" with rationalization to the underlying mechanism."	( Pharmacokinetic interaction between atorvastatin and fixed-dose combination of sofosbuvir/ledipasvir in healthy male Egyptian volunteers. Abdelaziz, AE; Abdelkawy, KS; Ali, AA; Belal, F; Elbarbry, F; Elmekawy, HA, 2021)	1.13
"This phase 1, 2-part, 2-period, open-label, drug-drug interaction study evaluated the potential for pharmacokinetic interactions between upadacitinib and rosuvastatin, an organic anion transporting polypeptide (OATP) 1B1 and breast cancer resistance protein substrate, or atorvastatin, a cytochrome P450 3A, OATP1B1, and OATP1B3 substrate, in 36 healthy volunteers."	( Effect of Upadacitinib on the Pharmacokinetics of Rosuvastatin or Atorvastatin in Healthy Subjects. Camp, HS; Coppola, S; Feng, T; Kim, E; Mohamed, MF; Othman, AA, 2021)	1.04
" Because pharmacodynamic interaction between statins and bempedoic acid is complex, a dose-response model was developed to predict LDL-C pharmacodynamics following administration of statins combined with bempedoic acid."	( Pharmacodynamic effect of bempedoic acid and statin combinations: predictions from a dose-response model. Amore, BM; Barrett, PHR; Catapano, AL; Chapel, S; Crass, RL; Emery, MG; Jadhav, SB; Kerschnitzki, M; Sasiela, WJ; Watts, GF, 2022)	0.72
"This method was successfully applied to a pharmacokinetic interaction study in Wistar rats."	( High-throughput LC-MS/MS Method for Simultaneous Determination of Pantoprazole and Atorvastatin in Rat Plasma: Application to a Pharmacokinetic Interaction Study. Chen, X; Hong, Z; Le, J; Li, S; Liao, Y, 2021)	0.85
" Serial pharmacokinetic blood samples were collected, and safety was assessed."	( Assessment of the Effect of Filgotinib on the Pharmacokinetics of Atorvastatin, Pravastatin, and Rosuvastatin in Healthy Adult Participants. Alani, M; Anderson, K; Gong, Q; Nelson, CH; Othman, AA; Tarnowski, T, 2022)	0.96
" Our aim was to develop a flexible approach based on therapeutic drug monitoring (TDM), nonparametric population pharmacokinetic modeling, and Monte Carlo simulation to differentiate adherent patients from partially and nonadherent individuals in a nonrandomized, unicentric, observational study."	( A pharmacokinetics-based approach to the monitoring of patient adherence to atorvastatin therapy. Imreh, É; Karádi, I; Karvaly, GB; Neely, MN; Prohászka, Z; Trojnár, E; Vásárhelyi, B; Vincze, I; Zsáry, A, 2021)	0.85
"The pharmacokinetic parameters of AC combined with GQD were significantly affected (P < 0."	( Influence of Gegenqinlian Decoction on Pharmacokinetics and Pharmacodynamics of Atorvastatin Calcium in Hyperlipidemic Rats. Chen, T; Cui, M; Sui, Y; Yan, X; Yin, Y; Zhu, F, 2022)	0.95
" To assess the pharmacokinetic profile of daclatasvir in vivo, rats were divided into three groups receiving either saline, standard P-gp inhibitor verapamil (25 mg/kg), or atorvastatin (10 mg/kg), 2 hrs prior to a single dose of daclatasvir (7 mg/kg)."	( Effect of Atorvastatin on Single Oral Pharmacokinetics and Safety of Daclatasvir in Rats: Emphasis on P-glycoprotein and Cytochrome P450. El-Demerdash, E; Elbadawy, HA; Wahdan, SA, 2022)	1.32
" In vivo, Cmax (peak plasma concentration) and area under the curve (AUC (0-t)) of daclatasvir after atorvastatin treatment increased compared to the vehicle group but not in a significant manner."	( Effect of Atorvastatin on Single Oral Pharmacokinetics and Safety of Daclatasvir in Rats: Emphasis on P-glycoprotein and Cytochrome P450. El-Demerdash, E; Elbadawy, HA; Wahdan, SA, 2022)	1.34
"Co-intake of ATR with Acai berry resulted in slight decrease in Cmax from 41."	( Investigation of the effect of Acai berry on the pharmacokinetics of Atorvastatin, Alogliptin and Empagliflozin: a herb-drug interaction study. Nanjappan, SK; Ravichandiran, V; Somabattini, RA, 2022)	0.96
"There was a significant change in the AUC0-t and Cmax of ATR, ALO and EMPA after co-administration with Acai berry."	( Investigation of the effect of Acai berry on the pharmacokinetics of Atorvastatin, Alogliptin and Empagliflozin: a herb-drug interaction study. Nanjappan, SK; Ravichandiran, V; Somabattini, RA, 2022)	0.96
" Further studies using physiologically based pharmacokinetic modelling are required to investigate the drug-drug interactions between these drugs."	( Simvastatin, but Not Atorvastatin, Is Associated with Higher Peak Rivaroxaban Serum Levels and Bleeding: an Asian Cohort Study from Singapore. Chan, ECY; Soh, XQ; Tan, DS, 2023)	1.23
" The objective of the current analysis was to evaluate the effects on the gastric emptying rate caused by semaglutide on pharmacokinetic model parameters of paracetamol and atorvastatin in healthy subjects."	( Population pharmacokinetic of paracetamol and atorvastatin with co-administration of semaglutide. Kristensen, K; Langeskov, EK, 2022)	1.17
" This study aimed to investigate the pharmacokinetic interactions among atorvastatin, its active metabolite 2-hydroxy atorvastatin, and tangeretin after oral administration of atorvastatin with tangeretin in rats."	( Ultra-high performance supercritical fluid chromatography-tandem mass spectrometry method for simultaneous determination of atorvastatin, 2-hydroxy atorvastatin, and tangeretin in rat plasma and its application to the pharmacokinetic study. Gong, L; Jiang, Q; Li, W; Li, Y; Ni, D; Wang, S; Wang, W; Wu, W; Xu, X; Zhang, J; Zhang, T; Zhang, Y, 2022)	1.16
" To investigate whether there are pharmacokinetic interactions among ATV, its metabolite 2-hydroxy atorvastatin (2-ATV), and NG, in the current study, we developed and validated a simple, rapid, and specific UPLC-MS/MS method to simultaneously determine the concentrations of these analytes in the rat plasma."	( Development of a UPLC-MS/MS method for the simultaneous determination of atorvastatin, 2-hydroxy atorvastatin, and naringenin in rat plasma and its application to pharmacokinetic interaction studies. Li, W; Li, Y; Wang, S; Xu, X; Zhang, T; Zhang, Y, 2023)	1.36
" Several physiologically based pharmacokinetic (PBPK) models have been developed to assess its non-straightforward pharmacokinetics (PK) as well as that of its metabolites and have been only applied to assess drug-drug interactions (DDI)."	( A physiologically based pharmacokinetic model for open acid and lactone forms of atorvastatin and metabolites to assess the drug-gene interaction with SLCO1B1 polymorphisms. García-Arieta, A; Mangas-Sanjuán, V; Merino-Sanjuan, M; Reig-López, J, 2022)	0.95
" Physiologically-based pharmacokinetic (PBPK) modeling, in lieu of a clinical trial, is a promising tool for evaluating these complex DDDIs in patients."	( Understanding Statin-Roxadustat Drug-Drug-Disease Interaction Using Physiologically-Based Pharmacokinetic Modeling. Ahlström, C; Dong, J; Elebring, M; Huang, Y; Lundahl, A; Någård, M; Prieto Garcia, L; Sjögren, E; Tang, W; Vildhede, A, 2023)	0.91
" The objective of this study was to develop physiologically-based pharmacokinetic (PBPK) models that could describe drug-drug interactions (DDIs) of simeprevir with concomitant drugs via CYP3A4 and OATP1B inhibition, and also to capture the effects on coproporphyrin-I (CP-I), an endogenous biomarker of OATP1B."	( Physiologically-based pharmacokinetic modeling for investigating the effect of simeprevir on concomitant drugs and an endogenous biomarker of OATP1B. Nakayama, S; Snoeys, J; Sugiyama, Y; Toshimoto, K; Yamazaki, S, 2023)	0.91

Compound-Compound Interactions

The aim of this study was to test the efficacy and possible drug-drug interactions of the new HMG-CoA reductase inhibitors (statins) atorvastatin and cerivastatin in cyclosporin A (CsA)-treated renal transplant patients.

Excerpt	Reference	Relevance
" The aim of this study was to test the efficacy and possible drug-drug interactions of the new HMG-CoA reductase inhibitors (statins) atorvastatin and cerivastatin in cyclosporin A (CsA)-treated renal transplant patients."	( Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients. Burkhardt, K; Hauser, IA; Koch, C; Mayer-Kadner, I; Renders, L; Schärffe, S; Schmieder, RE; Veelken, R, 2001)	0.74
"This study evaluated the effects of rosiglitazone therapy on lipids and the efficacy and safety of rosiglitazone in combination with atorvastatin in patients with type 2 diabetes mellitus."	( Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Biswas, N; Brunzell, JD; Cohen, BR; Freed, MI; Kreider, MM; Marcovina, SM; Ratner, R, 2002)	0.77
" Pravastatin does not appear to interact with warfarin but has caused an increased INR when combined with the anticoagulant fluindione."	( Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature. Andrus, MR, 2004)	0.32
" Since DDIs are associated with adverse reactions, we performed a cross-sectional study to assess the prevalence of potentially critical drug-drug and drug-statin interactions in an outpatient adult population with dyslipidaemia."	( Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy. Hess, L; Krähenbühl, S; Krähenbühl-Melcher, A; Rätz Bravo, AE; Schlienger, RG; Tchambaz, L, 2005)	0.33
"To report the case of a patient who underwent orthotopic heart transplant (OHT) and demonstrated a supratherapeutic response to ezetimibe when administered with cyclosporine."	( Supratherapeutic response to ezetimibe administered with cyclosporine. Burton, I; Koshman, SL; Lalonde, LD; Pearson, GJ; Tymchak, WJ, 2005)	0.33
"The objective of the study was to demonstrate the effect of pioglitazone and pioglitazone in combination with statin on East Indian patients with hyperinsulinemia and hyperlipidemia."	( Effect of pioglitazone and its combination with statins in coronary artery disease patients with hyperinsulinemia. Baxi, H; Chag, M; Chandarana, A; Goyal, R; Mehta, A; Naik, A; Parikh, K; Shah, K; Shah, U, 2007)	0.34
"This study was undertaken to investigate the effect of ezetimibe (10 mg/day) alone or in combination with atorvastatin (10 mg twice a week) on hypercholesterolemia in 56 high-risk patients intolerant to daily statin use."	( Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients. Athyros, VG; Kakafika, AI; Karagiannis, A; Koumaras, H; Mikhailidis, DP; Tziomalos, K, 2008)	0.79
" We studied the effects of a statin (atorvastatin) and its combination with an acyl-CoA:cholesterol O-acyltransferase (ACAT) inhibitor (avasimibe) on atherosclerotic regression and plaque stability as measured by matrix metalloproteinase 1 and 3 (MMP-1 and MMP-3) levels."	( Statin therapy alone and in combination with an acyl-CoA:cholesterol O-acyltransferase inhibitor on experimental atherosclerosis. Badimon, JJ; Chew, DP; Corti, R; Fallon, JT; Fayad, ZA; Fuster, V; Helft, G; Worthley, MI; Worthley, SG; Zaman, AG, 2007)	0.61
"Ezetimibe did not alter serum visfatin concentrations, either when administered as monotherapy or combined with a statin."	( Effects of ezetimibe, either alone or in combination with atorvastatin, on serum visfatin levels: a pilot study. Derdemezis, C; Elisaf, M; Filippatos, T; Mikhailidis, D; Tselepis, A, 2008)	0.59
" A comprehensive, controlled clinical trial programme was thus designed to evaluate three separate statins in combination with ABT-335, a new formulation of fenofibric acid."	( Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme. Bays, HE; Buttler, SM; Davidson, MH; Jones, PH; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC, 2008)	0.35
" The current review focuses distinctly on three aspects: (a) an in-depth coverage on the bioanalytical methods for the quantification of clopidogrel and its inactive carboxylic acid metabolite as well as the active metabolite in pre-clinical and clinical samples; (b) an overview of the pharmacokinetic/pharmacodynamic aspects of clopidogrel; and (c) enumerating the key findings from drug-drug interaction studies of clopidogrel with various co-substrates such as lanzoprazole, fluvastatin, atorvastatin, pravastatin, digoxin, ketoconazole, donezepil and theophylline."	( Clopidogrel: review of bioanalytical methods, pharmacokinetics/pharmacodynamics, and update on recent trends in drug-drug interaction studies. Mullangi, R; Srinivas, NR, 2009)	0.51
" As statins are the standard of clinical care, any new therapies must have adjunctive activity, when given in combination with statins."	( Thyroid hormone beta receptor activation has additive cholesterol lowering activity in combination with atorvastatin in rabbits, dogs and monkeys. Cable, EE; Chi, B; Erion, MD; Fujitaki, JM; Ito, BR; Linemeyer, DL; MacKenna, DA; Song, X; van Poelje, PD; Wilker, CE; Zhang, BH, 2009)	0.57
"We evaluated the activity of a liver-targeted prodrug, MB07811, of a novel TH receptor beta agonist, MB07344, as monotherapy and in combination with atorvastatin in rabbits, dogs and monkeys."	( Thyroid hormone beta receptor activation has additive cholesterol lowering activity in combination with atorvastatin in rabbits, dogs and monkeys. Cable, EE; Chi, B; Erion, MD; Fujitaki, JM; Ito, BR; Linemeyer, DL; MacKenna, DA; Song, X; van Poelje, PD; Wilker, CE; Zhang, BH, 2009)	0.77
" This multicenter, double-blind, active-controlled study evaluated ABT-335 (fenofibric acid) in combination with 2 doses of atorvastatin in patients with mixed dyslipidemia."	( Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Ballantyne, CM; Bays, HE; Buttler, SM; Goldberg, AC; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC, 2009)	0.79
"We hypothesized that atorvastatin combined with amlodipine has additive beneficial vascular and metabolic effects that are superior to monotherapy in patients with hypertension."	( Additive beneficial effects of atorvastatin combined with amlodipine in patients with mild-to-moderate hypertension. Han, SH; Kim, SJ; Koh, KK; Koh, Y; Lee, Y; Park, JB; Quon, MJ; Shin, EK, 2011)	0.97
"Atorvastatin combined with amlodipine therapy improves endothelial function and increases adiponectin levels and insulin sensitivity to a greater extent than monotherapy with either drug in hypertensive patients."	( Additive beneficial effects of atorvastatin combined with amlodipine in patients with mild-to-moderate hypertension. Han, SH; Kim, SJ; Koh, KK; Koh, Y; Lee, Y; Park, JB; Quon, MJ; Shin, EK, 2011)	2.1
"To evaluate the long-term therapeutic effects of atorvastatin via cytochrome P450 (CYP)3A4 pathway or a non-CYP 3A4 pathway statin, pravastatin, combined with clopidogrel for the patients undergoing coronary stenting."	( [Comparison on long-term effects of atorvastatin or pravastatin combined with clopidogrel for patients undergoing coronary stenting: a randomized controlled trial]. Han, YL; Jing, QM; Li, Y; Wang, DM; Wang, SL; Wang, ZL; Zhang, ZL, 2009)	0.88
"The 12 month clinical outcomes were similar between patients receiving atorvastatin 20 mg/d or pravastatin 20 mg/d combined with clopidogrel after coronary stenting."	( [Comparison on long-term effects of atorvastatin or pravastatin combined with clopidogrel for patients undergoing coronary stenting: a randomized controlled trial]. Han, YL; Jing, QM; Li, Y; Wang, DM; Wang, SL; Wang, ZL; Zhang, ZL, 2009)	0.86
" We compared the effects of two statins (rosuvastatin and atorvastatin) combined with exercise on coenzyme Q10 and HDL-C levels in CAD patients."	( Rosuvastatin combined with regular exercise preserves coenzyme Q10 levels associated with a significant increase in high-density lipoprotein cholesterol in patients with coronary artery disease. Iwasaki, Y; Jinnouchi, H; Matsui, K; Ogawa, H; Oka, H; Sugiyama, S; Sumida, H; Tanaka, T; Tayama, S; Toyama, K, 2011)	0.61
"Compared to atorvastatin, rosuvastatin combined with exercise significantly preserved ubiquinol levels associated with an increase in HDL-C."	( Rosuvastatin combined with regular exercise preserves coenzyme Q10 levels associated with a significant increase in high-density lipoprotein cholesterol in patients with coronary artery disease. Iwasaki, Y; Jinnouchi, H; Matsui, K; Ogawa, H; Oka, H; Sugiyama, S; Sumida, H; Tanaka, T; Tayama, S; Toyama, K, 2011)	0.75
"To establish in vitro and in silico models that predict clinical drug-drug interactions (DDIs) with the OATP1B1 (SLCO1B1) transporter."	( In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions. Ahlin, G; Artursson, P; Bergström, CA; Karlgren, M; Palm, J; Svensson, R, 2012)	0.38
" Few studies have documented the efficacy and safety of CETP inhibitors in combination with commonly used statins."	( Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. Brewer, HB; Hu, B; Kastelein, JJ; Krueger, KA; McErlean, E; Nicholls, SJ; Nissen, SE; Shao, M; Wang, MD, 2011)	0.37
"To examine the biochemical effects, safety, and tolerability of evacetrapib, as monotherapy and in combination with statins, in patients with dyslipidemia."	( Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. Brewer, HB; Hu, B; Kastelein, JJ; Krueger, KA; McErlean, E; Nicholls, SJ; Nissen, SE; Shao, M; Wang, MD, 2011)	0.37
" In combination with statin therapy, evacetrapib, 100 mg/d, produced increases in HDL-C of 42."	( Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. Brewer, HB; Hu, B; Kastelein, JJ; Krueger, KA; McErlean, E; Nicholls, SJ; Nissen, SE; Shao, M; Wang, MD, 2011)	0.37
"Compared with placebo or statin monotherapy, evacetrapib as monotherapy or in combination with statins increased HDL-C levels and decreased LDL-C levels."	( Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. Brewer, HB; Hu, B; Kastelein, JJ; Krueger, KA; McErlean, E; Nicholls, SJ; Nissen, SE; Shao, M; Wang, MD, 2011)	0.37
" There were differences in the incidence, time to cerebral malaria and the level of parasitaemia when the drug combination was administered to mice."	( Atorvastatin treatment is effective when used in combination with mefloquine in an experimental cerebral malaria murine model. Amalvict, R; Baret, E; Briolant, S; Dormoi, J; Mosnier, J; Pradines, B; Rogier, C; Savini, H; Soulard, R; Souraud, JB, 2012)	1.82
" Mean plasma concentration-time profiles for atazanavir, tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), darunavir (DRV, administered with ritonavir [RTV]), and drospirenone/ethinylestradiol were similar following co-administration of GSK2248761."	( Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor. de Serres, M; Gould, E; Johnson, M; Kim, J; Lou, Y; Mayers, D; Pietropaolo, K; Piscitelli, S; White, S; Zhou, XJ, 2012)	0.38
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."	( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012)	0.38
" In the present study, the drug-drug interaction potential of multi-dose ATV co-administration with CLZ on both pharmacokinetics and the anti-thrombotic property of CLZ is demonstrated."	( Drug-drug interaction study to assess the effects of atorvastatin co-administration on pharmacokinetics and anti-thrombotic properties of cilostazol in male Wistar rats. Arla, R; Rajak, S; Varanasi, KV; Vats, R; Veeraraghvan, S, 2012)	0.63
"SilverHawk Plaque Excision combined with aggressive pharmacotherapy in this presented high-risk population is associated with promising long-term outcomes that compare favorably with accepted standards of care."	( Long-term results of plaque excision combined with aggressive pharmacotherapy in high-risk patients with advanced peripheral artery disease (SAVE a LEG registry). Buszman, PE; Buszman, PP; Kiesz, RS; Konkolewska, MD; Martin, JL; Radvany, MG; Szymanski, R; Wiernek, BK; Wiernek, SL, 2013)	0.39
" The objective of this study was to evaluate the prevalence and clinical consequences of potential drug-drug interactions of clopidogrel with drugs affecting CYP3A4 activity."	( Epidemiology of CYP3A4-mediated clopidogrel drug-drug interactions and their clinical consequences. Heikkilä, P; Huupponen, R; Laine, K; Tirkkonen, T; Vahlberg, T, 2013)	0.39
" The aim of this study was to determine the effects of statins combined with exercise on the renal function of CAD patients."	( Statins combined with exercise are associated with the increased renal function mediated by high-molecular-weight adiponectin in coronary artery disease patients. Iwasaki, Y; Jinnouchi, H; Ogawa, H; Oka, H; Sugiyama, S; Sumida, H; Tanaka, T; Tayama, S; Toyama, K, 2014)	0.4
"We performed a sub-analysis of a clinical trial that determined the 20-week-effects of two statins (rosuvastatin, n=14; atorvastatin, n=14) combined with regular exercise on renal function, as assessed by the estimated glomerular filtration rates (eGFRs) of CAD patients."	( Statins combined with exercise are associated with the increased renal function mediated by high-molecular-weight adiponectin in coronary artery disease patients. Iwasaki, Y; Jinnouchi, H; Ogawa, H; Oka, H; Sugiyama, S; Sumida, H; Tanaka, T; Tayama, S; Toyama, K, 2014)	0.61
" Both atorvastatin and rosuvastatin combined with regular exercise produced increases in eGFR."	( Statins combined with exercise are associated with the increased renal function mediated by high-molecular-weight adiponectin in coronary artery disease patients. Iwasaki, Y; Jinnouchi, H; Ogawa, H; Oka, H; Sugiyama, S; Sumida, H; Tanaka, T; Tayama, S; Toyama, K, 2014)	0.88
"Statins combined with exercise significantly increased eGFR in CAD patients, and these improvements in renal function were correlated with increases in HMW-adiponectin levels."	( Statins combined with exercise are associated with the increased renal function mediated by high-molecular-weight adiponectin in coronary artery disease patients. Iwasaki, Y; Jinnouchi, H; Ogawa, H; Oka, H; Sugiyama, S; Sumida, H; Tanaka, T; Tayama, S; Toyama, K, 2014)	0.4
"The aim of this study was to observe the effects of atorvastatin combined with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia."	( Effects of atorvastatin in combination with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia. Du, S; Han, YG; Li, L; Luo, P; Wang, GG; Wang, LX; Wu, SL; Zhu, HH, 2014)	1.04
" Colchicine is a potent anti-inflammatory agent and whether colchicine combined with atorvastatin has synergistic effects on inflammation amelioration and endothelial function improvement is unknown."	( Synergistic effects of colchicine combined with atorvastatin in rats with hyperlipidemia. Cen, C; Ding, X; Huang, C; Wang, C; Zhan, H, 2014)	0.88
"5 mg/kg body weight/day), or atorvastatin combined with colchicines (same dosages) were prescribed for 2 weeks."	( Synergistic effects of colchicine combined with atorvastatin in rats with hyperlipidemia. Cen, C; Ding, X; Huang, C; Wang, C; Zhan, H, 2014)	0.95
"Colchicine combined with atorvastatin may have stronger protective effects on improving endothelial function and ameliorating inflammation in rats with hyperlipidemia."	( Synergistic effects of colchicine combined with atorvastatin in rats with hyperlipidemia. Cen, C; Ding, X; Huang, C; Wang, C; Zhan, H, 2014)	0.96
" In the present study, we aimed to investigate the effect of berberine combined with atorvastatin on LOX‑1 and explore the underlying molecular mechanism involved."	( Berberine combined with atorvastatin downregulates LOX‑1 expression through the ET‑1 receptor in monocyte/macrophages. Chi, L; Hu, X; Pan, N; Peng, L; Zhang, Y, 2014)	0.93
"The cholesteryl ester transfer protein (CETP) inhibitor evacetrapib has been previously shown to increase high-density lipoprotein cholesterol (HDL-C) and decrease low-density lipoprotein cholesterol (LDL-C) levels, as monotherapy or in combination with statins."	( Efficacy, safety, tolerability, and pharmacokinetic profile of evacetrapib administered as monotherapy or in combination with atorvastatin in Japanese patients with dyslipidemia. Krueger, KA; Morisaki, Y; Ruotolo, G; Takeuchi, M; Teramoto, T, 2014)	0.61
" The interindividual differences in transporter expression and CLupt resulted in marked differences in drug-drug interactions due to isoform-specific inhibition."	( Hepatic uptake of atorvastatin: influence of variability in transporter expression on uptake clearance and drug-drug interactions. Artursson, P; Karlgren, M; Lai, Y; Norén, A; Svedberg, EK; Vildhede, A; Wisniewski, JR, 2014)	0.74
"In a comparative aspect, the dynamics of indices of lipidogram, functional state of liver and level of C-reactive of protein have been analyzed in 79 patients with myocardial infarction in combination with non-alcoholic steatohepatitis, who received a 9-months treatment by rosuvastatin of 20 mg, atorvastatin of 80 mg, as well as rosuvastatin of 10 mg, atorvastatin of 40 mg in combination with ursodeoxycholic acid (UDCA)."	( [Optimization of long-term hypolipidemia treatment of patients with myocardial infarction in combination with non-alcoholic steatohepatitis]. , 2014)	0.58
"Compound danshen dripping pills combined with atorvastatin produces better effects than the drugs used alone in inhibiting vascular smooth muscle cell proliferation in rabbits after abdominal aorta angioplasty possibly due to a decreased expression of MCP-1 as a result of NF-κB inhibition."	( [Effect of compound Danshen dripping pills combined with atorvastatin on restenosis after angioplasty in rabbits]. Chen, C; Li, P; Song, J; Zeng, J; Zhang, L; Zhang, Y, 2014)	0.91
" However, the effects on platelet activation of high levels of LDL-C combined with low levels of HDL-C (HLC) have not yet been reported."	( High levels of LDL-C combined with low levels of HDL-C further increase platelet activation in hypercholesterolemic patients. Chan, LW; Gu, XY; Li, J; Liu, L; Luo, XP; Ni, HC; Qiao, J; Shi, HM; Wen, ZC, 2015)	0.42
"To determine the effects of atorvastatin alone and in combination with inhaled corticosteroid on a range of sputum cytokines, chemokines and growth factors implicated in the pathogenesis of asthma, and their association with asthma control questionnaire (ACQ) and/or asthma quality of life questionnaire (AQLQ) scores."	( Atorvastatin in combination with inhaled beclometasone modulates inflammatory sputum mediators in smokers with asthma. Charron, CE; Chaudhuri, R; Ito, K; McSharry, C; Spears, M; Thomson, NC, 2015)	2.15
" Atorvastatin significantly reduced sputum concentrations of CCL7, IL-12p70, sCD40L, FGF-2, CCL4, TGF-α and MMP-8 compared with placebo and, when combined with inhaled beclometasone, reduced sputum concentrations of MMP-8, IL-1β, IL-10, MMP-9, sCD40L, FGF-2, IL-7, G-CSF and CCL7 compared to ICS alone."	( Atorvastatin in combination with inhaled beclometasone modulates inflammatory sputum mediators in smokers with asthma. Charron, CE; Chaudhuri, R; Ito, K; McSharry, C; Spears, M; Thomson, NC, 2015)	2.77
"Short-term treatment with atorvastatin alone or in combination with inhaled beclometasone reduces several sputum cytokines, chemokines and growth factors concentrations unresponsive to inhaled corticosteroids alone, in smokers with asthma."	( Atorvastatin in combination with inhaled beclometasone modulates inflammatory sputum mediators in smokers with asthma. Charron, CE; Chaudhuri, R; Ito, K; McSharry, C; Spears, M; Thomson, NC, 2015)	2.16
"Ion mobility was performed on stored plasma samples collected from patients before and after treatment with anacetrapib alone (150 and 300 mg/d) or in combination with atorvastatin (20 mg/d) in a previously conducted 8-week phase IIb study."	( Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin. Dansky, HM; Johnson-Levonas, AO; Krauss, RM; Liu, Y; Pinto, CA, )	0.53
"The results of investigations had showed the high efficiency of the combination of atorvastatin with telmisartan in patients with arterial hypertension combined with obesity and NAFLD."	( Combined effect of appointment telmisartan and atorvastatin on hemodynamic indicators and the indicators of lipid profile in patients with arterial hypertension combined with obesity and steatohepatitis. Bochar, OM, 2014)	0.88
"To study the protective effects of valsartan (Val) and benazepril, (Ben) combined with atorvastatin (Ato), on cardiorenal syndrome (CRS) in rats."	( Protective effects of valsartan and benazepril combined with atorvastatin on cardiorenal syndrome in rats. Chen, J; Hu, YJ; Peng, DF; Tang, SY, 2015)	0.88
"Valsartan and benazepril, combined with atorvastatin, can have significant protective effects on cardiorenal functions of rats with CRS, with no significant difference between these two drugs."	( Protective effects of valsartan and benazepril combined with atorvastatin on cardiorenal syndrome in rats. Chen, J; Hu, YJ; Peng, DF; Tang, SY, 2015)	0.93
"To observe the clinical effect of acupuncture therapy combined with Lipitor in the treatment of primary hyperlipidemia (spleen deficiency and food stagnation type)."	( [Clinical trials for treatment of primary hyperlipidemia by using acupuncture in combination with Lipitor]. Song, J; Sun, YZ, 2015)	0.42
"Acupuncture combined with administration of Lipitor is effective in improving primary hyperlipidemia in patients, which is superior to administration of simple Lipitor."	( [Clinical trials for treatment of primary hyperlipidemia by using acupuncture in combination with Lipitor]. Song, J; Sun, YZ, 2015)	0.42
"The aims to investigate the different protective effects of valsartan and benazepril when combined with atorvastatin in the cardio-renal functions of cardio-renal syndrome (CRS) patients."	( Comparison of valsartan and benazepril when combined with atorvastatin in protecting patients with early cardio-renal syndrome (CRS). Chen, J; Hu, YJ; Huang, Q; Peng, DF; Peng, X; Tang, SY, 2015)	0.88
"When combined with atorvastatin, both valsartan and benazepril effectively improved the cardio-renal functions of early CRS patients."	( Comparison of valsartan and benazepril when combined with atorvastatin in protecting patients with early cardio-renal syndrome (CRS). Chen, J; Hu, YJ; Huang, Q; Peng, DF; Peng, X; Tang, SY, 2015)	0.99
" The model was used to predict the pharmacokinetic profiles and drug-drug interaction (DDI) effect for atorvastatin and its metabolites in different DDI scenarios."	( Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for atorvastatin and its metabolites. Zhang, T, 2015)	0.85
"To investigate the effects of atorvastatin combined with trimetazidine on periprocedural myocardial injury and serum inflammatory mediators in unstable angina pectoris (UAP) patients following percutaneous coronary intervention (PCI) treatment."	( Effects of atorvastatin combined with trimetazidine on myocardial injury and inflammatory mediator in unstable angina patients during perioperative of percutaneous coronary intervention. Cui, W; Du, H; Hao, J; Li, WW; Liu, F; Lu, JC; Yang, XC; Zhao, ZF, 2015)	1.1
" The control group had 42 patients were treated with atorvastatin alone, while the experimental group had 48 cases treated with atorvastatin combined with trimetazidine."	( Effects of atorvastatin combined with trimetazidine on myocardial injury and inflammatory mediator in unstable angina patients during perioperative of percutaneous coronary intervention. Cui, W; Du, H; Hao, J; Li, WW; Liu, F; Lu, JC; Yang, XC; Zhao, ZF, 2015)	1.06
"No unexpected symptom was found in patients with large dose atorvastatin combined with large dose trimetazidine."	( Effects of atorvastatin combined with trimetazidine on myocardial injury and inflammatory mediator in unstable angina patients during perioperative of percutaneous coronary intervention. Cui, W; Du, H; Hao, J; Li, WW; Liu, F; Lu, JC; Yang, XC; Zhao, ZF, 2015)	1.05
" EPA inhibition was enhanced when combined with atorvastatin metabolite at low equimolar concentrations."	( Eicosapentaenoic Acid Inhibits Oxidation of ApoB-containing Lipoprotein Particles of Different Size In Vitro When Administered Alone or in Combination With Atorvastatin Active Metabolite Compared With Other Triglyceride-lowering Agents. Jacob, RF; Mason, RP; Sherratt, SC, 2016)	0.89
" As several HF patients are likely to use statins as co-medications, the potential for a pharmacokinetic drug-drug interaction between atorvastatin and LCZ696 was evaluated."	( Assessment of Drug-Drug Interaction Potential Between Atorvastatin and LCZ696, A Novel Angiotensin Receptor Neprilysin Inhibitor, in Healthy Chinese Male Subjects. Ayalasomayajula, S; Han, Y; Langenickel, T; Pal, P; Pan, W; Rajman, I; Sunkara, G; Yang, F; Yuan, Y; Zhou, W, 2017)	0.91
" The aim of the study was to investigate possible effect of this drug alone and in combination with RIPC on the biochemical changes induced by ischemic/reperfusion injury (I/R) in a combined study with a clinical and experimental animal arm."	( Cardioprotective effect of atorvastatin alone or in combination with remote ischemic preconditioning on the biochemical changes induced by ischemic/reperfusion injury in a mutual prospective study with a clinical and experimental animal arm. El Desoky, ES; Fadil, SA; Hassan, AKM; Salem, SY; Taha, AF, 2016)	0.73
"Clinical and experimental parts showed that groups with RIPC combined with atorvastatin pre-treatment showed a synergistic protective effect against I/R injury as evidenced by significant reduction (P<0."	( Cardioprotective effect of atorvastatin alone or in combination with remote ischemic preconditioning on the biochemical changes induced by ischemic/reperfusion injury in a mutual prospective study with a clinical and experimental animal arm. El Desoky, ES; Fadil, SA; Hassan, AKM; Salem, SY; Taha, AF, 2016)	0.96
"Pretreatment with atorvastatin combined with RIPC can exert a synergistic cardioprotective effects by reducing the possible biochemical changes related to ischemic reperfusion injury."	( Cardioprotective effect of atorvastatin alone or in combination with remote ischemic preconditioning on the biochemical changes induced by ischemic/reperfusion injury in a mutual prospective study with a clinical and experimental animal arm. El Desoky, ES; Fadil, SA; Hassan, AKM; Salem, SY; Taha, AF, 2016)	1.07
"The disposition of statins varies and involves both metabolizing enzymes and transporters, making predictions of statin drug-drug interactions (DDIs) challenging."	( Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs). Duan, P; Zhang, L; Zhao, P, 2017)	0.69
" In vitro and clinical data suggest that doravirine is unlikely to cause significant drug-drug interactions via major drug-metabolizing enzymes or transporters."	( Results of a Doravirine-Atorvastatin Drug-Drug Interaction Study. Fan, L; Iwamoto, M; Jordan, H; Khalilieh, S; Maklad, N; Martell, M; Sanchez, RI; Triantafyllou, I; Yee, KL, 2017)	0.76
"This study aims to investigate the drug-drug interactions (DDIs) between orally administered atorvastatin (ATV) and rifampicin (RIF) in rats."	( Quantitative Analysis of the Transporter-Mediated Drug-Drug Interaction Between Atorvastatin and Rifampicin Using a Stable Isotope-IV Method. Hasegawa, T; Higashino, H; Kataoka, M; Minami, K; Mutaguchi, K; Tachihara, M; Togashi, K; Yamashita, S, 2017)	0.9
"The aim of this study was to evaluate the efficacy of ezetimibe combined with atorvastatin in treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease (CHD)."	( Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease. Ai, XB; Li, L; Wang, F; Wang, J; Yi, XL; Zou, YW, 2017)	0.96
"Evacetrapib daily in combination with atorvastatin was superior to placebo in lowering LDL-C after 12 weeks, and resulted in a statistically significant increase of HDL-C compared with placebo."	( Efficacy and Safety of the Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib in Combination With Atorvastatin in Japanese Patients With Primary Hypercholesterolemia. Iimura, T; Kiyosue, A; Murakami, M; Riesmeyer, JS; Takita, Y; Teramoto, T, 2017)	0.94
" They were often used in combination with antibiotics, blood-activating and stasis-dissolving prescription, and adrenal cortical hormone drugs."	( [Real world analysis to explore clinical features of Shenxiong glucose injection combined with other medications]. Jia, PP; Liu, H; Wang, GQ; Xie, YM; Zhang, Y; Zhuang, Y, 2017)	0.46
" Three months later, he was noted to have elevated creatine kinase (CK), thought to be related to a potential drug-drug interaction between ticagrelor and atorvastatin."	( Elevated Creatine Kinase due to Potential Drug Interaction With Ticagrelor and Atorvastatin. Beavers, JC, 2019)	0.94
"A probable drug-drug interaction occurred with concomitant ticagrelor and atorvastatin."	( Elevated Creatine Kinase due to Potential Drug Interaction With Ticagrelor and Atorvastatin. Beavers, JC, 2019)	0.97
"56%) was the most common triple Western medicine therapy, often combined with antibiotics and blood stasis drugs in use."	( [Drug combination characteristics of Shenxiong glucose injection in treating ischemic cerebrovascular disease in real world]. Jia, PP; Liu, H; Wang, GQ; Xie, YM; Zhang, Y; Zhuang, Y, 2017)	0.46
" We studied the effect of high-dose atorvastatin combined with ticagrelor loading on endothelial dysfunction in a model of forearm vascular ischemia-reperfusion (IR) injury."	( Atorvastatin combined with ticagrelor prevent ischemia-reperfusion induced vascular endothelial dysfunction in healthy young males - A randomized, placebo-controlled, double-blinded study. Kerbel, T; Litschauer, B; Weisshaar, S; Wolzt, M, 2018)	2.2
"Chronic atorvastatin treatment combined with ticagrelor loading prevents against endothelial dysfunction after acute forearm ischemia."	( Atorvastatin combined with ticagrelor prevent ischemia-reperfusion induced vascular endothelial dysfunction in healthy young males - A randomized, placebo-controlled, double-blinded study. Kerbel, T; Litschauer, B; Weisshaar, S; Wolzt, M, 2018)	2.36
" Due to drug-drug interactions caused by the inhibition or induction of cytochrome P450 enzymes, changes in drug metabolism are the major causes of drug toxicity, CYP3A4 is one of the key isozymes, and involved in the metabolism of over 60% of clinical drugs."	( The enhancement of cardiotoxicity that results from inhibiton of CYP 3A4 activity and hERG channel by berberine in combination with statins. Fang, L; Fang, Q; Feng, P; Guo, F; Li, B; Liang, Z; Xu, X; Zhan, G; Zhang, B; Zhao, L, 2018)	0.48
" To explore the efficacy and safety of ezetimibe in combination with atorvastatin for the treatment of patients with T2DM and acute coronary syndrome (ACS)."	( Efficacy and Safety of Ezetimibe in Combination with Atorvastatin for Acute Coronary Syndrome Patients Accompanied with Type 2 Diabetes: A Single-Center, Non-randomized Cohort Study. Huang, Z; Li, Q; Li, X; Ye, W; Zhang, Q, 2019)	1
" This study was designed to find out whether there is an augmentation of the therapeutic effectiveness of the antiinflammatory drugs like diclofenac sodium (NSAID), prednisolone (steroid) and atorvastatin (statin) when used in combination with ascorbic acid (antioxidant)."	( Evaluation of the Anti-Inflammatory Activities of Diclofenac Sodium, Prednisolone and Atorvastatin in Combination with Ascorbic Acid. Ahmed, T; Ahsan, CR; Al Shoyaib, A; Archie, SR; Chowdhury, FA; Faruk, A, 2020)	0.97
" The inhibitions of such responses were measured after administering a drug alone and in combination with ascorbic acid."	( Evaluation of the Anti-Inflammatory Activities of Diclofenac Sodium, Prednisolone and Atorvastatin in Combination with Ascorbic Acid. Ahmed, T; Ahsan, CR; Al Shoyaib, A; Archie, SR; Chowdhury, FA; Faruk, A, 2020)	0.78
" As the management of drug-drug interactions (DDIs) constitutes a key aspect of the care of PLWH, the magnitude of pharmacokinetic DDIs between cardiovascular and anti-HIV drugs needs to be more thoroughly characterized."	( UHPLC-MS/MS assay for simultaneous determination of amlodipine, metoprolol, pravastatin, rosuvastatin, atorvastatin with its active metabolites in human plasma, for population-scale drug-drug interactions studies in people living with HIV. Alves Saldanha, S; Buclin, T; Cavassini, M; Courlet, P; Csajka, C; Decosterd, LA; Desfontaine, V; Marzolini, C; Spaggiari, D, 2019)	0.73
" Though the statin-induced rhabdomyolysis is not common during statin therapy, its incidence will significantly increase due to pharmacokinetic drug-drug interactions (DDIs) with inhibitor drugs which inhibit atorvastatin's and its lactone's metabolism and hepatic uptake."	( Prediction of pharmacokinetic drug-drug interactions causing atorvastatin-induced rhabdomyolysis using physiologically based pharmacokinetic modelling. Cai, W; Dai, Y; Han, B; Jiao, Z; Jin, Z; Li, S; Lin, H; Ma, G; Xiang, X; Yu, Y, 2019)	0.94
": The risk of drug-drug interactions (DDIs) is elevated in aging people living with HIV (PLWH) because of highly prevalent age-related comorbidities leading to more comedications."	( Aging does not impact drug--drug interaction magnitudes with antiretrovirals. Battegay, M; Cavassini, M; Courlet, P; Decosterd, L; Marzolini, C; Saldanha, SA; Stader, F; Stoeckle, M, 2020)	0.56
"In this study, we aimed to determine the drug-drug interaction potential between atorvastatin (ATOR), and talinolol (TAL)."	( Effects of atorvastatin on talinolol absorption: A potential drug-drug interaction. Baktir, G; Kara, ZP; Okyar, A; Orman, MN; Ozturk, D; Ozturk, N, 2020)	1.17
"This study aimed to describe the pharmacokinetic profile of atorvastatin and its major metabolite, and to evaluate drug-drug interactions (DDIs) with antiretrovirals (ARVs)."	( Influence of Drug-Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV. Alves Saldanha, S; Buclin, T; Cavassini, M; Courlet, P; Csajka, C; Decosterd, LA; Guidi, M; Marzolini, C; Stader, F; Stoeckle, M, 2020)	1.04
" Here, we aim to explore the effects of atorvastatin combined with bivalirudin on coagulation function, cardiac function, and inflammatory factors in elderly patients with AMI who underwent PCI."	( Effects of atorvastatin combined with bivalirudin on coagulation function, cardiac function, and inflammatory factors of percutaneous coronary intervention in elderly patients with acute myocardial infarction. Chen, X; Ding, S; Wu, S; Xu, S, 2020)	1.22
"Atorvastatin combined with bivalirudin can improve the efficiency of clinical treatment in elderly AMI patients who undergo PCI, while simultaneously improving blood coagulation function and reducing the occurrence of bleeding, compared with bivalrudin alone."	( Effects of atorvastatin combined with bivalirudin on coagulation function, cardiac function, and inflammatory factors of percutaneous coronary intervention in elderly patients with acute myocardial infarction. Chen, X; Ding, S; Wu, S; Xu, S, 2020)	2.39
" This study evaluated the efficacy of atorvastatin in combination with standard therapy in patients with glioblastoma."	( Atorvastatin in combination with radiotherapy and temozolomide for glioblastoma: a prospective phase II study. Aldanan, S; Alghareeb, WA; Alhussain, H; AlNajjar, FH; Alsaeed, E; Alsharm, AA; Altwairgi, AK; Balbaid, AAO; Orz, Y, 2021)	2.34
"This study evaluated the cardioprotective effects of NXT alone and in combination with ticagrelor (TIC) and atorvastatin (ATO)."	( Protective effects of Naoxintong capsule alone and in combination with ticagrelor and atorvastatin in rats with Qi deficiency and blood stasis syndrome. He, Y; Li, PB; Lin, QW; Liu, H; Su, WW; Wang, YG; Wu, H; Yan, ZH; Yao, HL; Zhang, WJ, 2020)	0.99
" Drug-drug interaction (DDI) of CsA with victim drugs occurs via disordering interplay of transporters and enzymes."	( Prediction of Cyclosporin-Mediated Drug Interaction Using Physiologically Based Pharmacokinetic Model Characterizing Interplay of Drug Transporters and Enzymes. Li, P; Liu, L; Liu, X; Wang, Z; Yang, Y; Zhang, Z, 2020)	0.56
"Self-controlled designs, specifically the case-crossover (CCO) and the self-controlled case series (SCCS), are increasingly utilized to generate real-world evidence (RWE) on drug-drug interactions (DDIs)."	( Drug-Drug Interaction Surveillance Study: Comparing Self-Controlled Designs in Five Empirical Examples in Real-World Data. Bykov, K; Gagne, JJ; Kim, S; Li, H; Lo Re, V; Vine, SM, 2021)	0.62
" Compared to vehicle controls, the most effective drug combination consisted of low doses of levetiracetam, atorvastatin and ceftriaxone, which markedly reduced the incidence of electrographic seizures (by 60%; p<0."	( Systematic evaluation of rationally chosen multitargeted drug combinations: a combination of low doses of levetiracetam, atorvastatin and ceftriaxone exerts antiepileptogenic effects in a mouse model of acquired epilepsy. Bergin, DH; Johne, M; Klein, P; Löscher, W; Schidlitzki, A; Twele, F; Welzel, L, 2021)	1.04
" Combined atorvastatin with celecoxib and tipifarnib synergistically decreased the sphere forming ability of Panc-1 cells and the drug combination also strongly inhibited cell proliferation and promoted apoptosis in the sphere-forming cells."	( Effects of atorvastatin in combination with celecoxib and tipifarnib on proliferation and apoptosis in pancreatic cancer sphere-forming cells. Chen, J; Goodin, S; Li, DL; Ma, YR; Ma, YY; Ren, X; Wang, X; Xu, XT; Zhang, K; Zhao, DG; Zheng, X; Zhou, RP, 2021)	1.41
" In this study, we evaluated the drug-drug interaction potential of the hepatitis C virus inhibitors elbasvir (EBR) and grazoprevir (GZR) with statins."	( Evaluation of Pharmacokinetic Drug Interactions of the Direct-Acting Antiviral Agents Elbasvir and Grazoprevir with Pitavastatin, Rosuvastatin, Pravastatin, and Atorvastatin in Healthy Adults. Butterton, JR; Caro, L; Fandozzi, CM; Feng, HP; Fraser, IP; Guo, Z; Iwamoto, M; Levine, V; Panebianco, D; Prueksaritanont, T; Swearingen, D; Wolford, D; Yeh, WW, 2021)	0.82
" This study assessed the potential protective effects of coenzyme Q10 (CoQ10) alone or combined with N-acetyl cysteine (NAC) or atorvastatin against CIN in diabetic rats."	( Evaluation of coenzyme Q10 combined with or without N-acetyl cysteine or atorvastatin for preventing contrast-induced kidney injury in diabetic rats. Alshogran, OY; Alzoubi, KH; El-Elimat, T; Nusair, SD; Obeidat, A; Sweidan, M, 2021)	1.06
"This open-label, repeat-dose, fixed-sequence study in healthy subjects examined pharmacokinetic drug-drug interactions between the components of a novel fixed-dose combination product containing ramipril, amlodipine, and atorvastatin."	( Mechanistic Considerations About an Unexpected Ramipril Drug-Drug Interaction in the Development of a Triple Fixed-Dose Combination Product Containing Ramipril, Amlodipine, and Atorvastatin. Gundlach, K; Hermann, R; Seiler, D, 2021)	1
" Our study aimed to determine whether pioglitazone combined with atorvastatin can restrain the progression of atherosclerosis and promote plaque stabilization in a rabbit model."	( Pioglitazone combined with atorvastatin promotes plaque stabilization in a rabbit model. Chen, X; Liang, Z; Nie, M; Yan, Y; Zhang, X; Zhao, Q, 2022)	1.26
" Pioglitazone combined with atorvastatin can further restrain the progression of atherosclerosis and promote plaque stabilization in a rabbit model."	( Pioglitazone combined with atorvastatin promotes plaque stabilization in a rabbit model. Chen, X; Liang, Z; Nie, M; Yan, Y; Zhang, X; Zhao, Q, 2022)	1.31
"This study aimed to investigate the effect of the therapy of amiodarone combined with atorvastatin on cardiac function of patients with acute myocardial infarction after percutaneous coronary intervention (PCI)."	( Effect of the therapy of amiodarone combined with atorvastatin on cardiac function of patients with acute myocardial infarction after percutaneous coronary intervention (PCI). Li, Z; Tu, Y; Zhang, J; Zhang, M; Zhou, Q; Zong, W, 2021)	1.1
" We wish to extend this evidence in a study that aims to determine the efficacy and safety of atorvastatin combined with low-dose dexamethasone in patients with CSDH."	( Atorvastatin combined with dexamethasone in chronic subdural haematoma (ATOCH II): study protocol for a randomized controlled trial. Anderson, CS; De Zhu, X; Gao, C; Huang, Y; Ji, HM; Jiang, RC; Jiang, XC; Kang, Z; Lei, P; Li, X; Liu, JF; Qu, Y; Quan, W; Song, LL; Sun, XC; Tian, Y; Wang, D; Wang, JJ; Wang, RZ; Wei, HJ; Wei, JJ; Yue, SY; Zhang, JN; Zhang, S; Zhao, SG; Zhao, ZM; Zhu, XG, 2021)	2.28
"The second ATorvastatin On Chronic subdural Hematoma (ATOCH-II) study is a multi-centre, randomized, placebo-controlled, double-blind trial which aims to enrol 240 adult patients with a conservative therapeutic indication for CSDH, randomly allocated to standard treatment with atorvastatin 20 mg combined with low-dose dexamethasone (or matching placebos) daily for 28 days, and with 152 days of follow-up."	( Atorvastatin combined with dexamethasone in chronic subdural haematoma (ATOCH II): study protocol for a randomized controlled trial. Anderson, CS; De Zhu, X; Gao, C; Huang, Y; Ji, HM; Jiang, RC; Jiang, XC; Kang, Z; Lei, P; Li, X; Liu, JF; Qu, Y; Quan, W; Song, LL; Sun, XC; Tian, Y; Wang, D; Wang, JJ; Wang, RZ; Wei, HJ; Wei, JJ; Yue, SY; Zhang, JN; Zhang, S; Zhao, SG; Zhao, ZM; Zhu, XG, 2021)	2.45
" The aim of this study was to perform a meta-analysis of the effects of alendronate combined with atorvastatin compared with alendronate alone in the treatment of osteoporosis in diabetes mellitus."	( Meta-Analysis of the Efficacy and Safety of Alendronate Combined with Atorvastatin in the Treatment of Osteoporosis in Diabetes Mellitus. Shu, L; Tang, X; Xiong, Z; Yi, P; Zhang, C, 2022)	1.17
" Our results showed that alendronate combined with atorvastatin is more effective than alendronate alone, with higher BMD, OPG, BGP, and BAP, more significant pain relief, and fewer adverse events."	( Meta-Analysis of the Efficacy and Safety of Alendronate Combined with Atorvastatin in the Treatment of Osteoporosis in Diabetes Mellitus. Shu, L; Tang, X; Xiong, Z; Yi, P; Zhang, C, 2022)	1.21
"The results of this meta-analysis indicate that alendronate combined with atorvastatin is a better treatment for osteoporosis in diabetes mellitus, showing more effective and higher BMD and fewer adverse events than alendronate alone."	( Meta-Analysis of the Efficacy and Safety of Alendronate Combined with Atorvastatin in the Treatment of Osteoporosis in Diabetes Mellitus. Shu, L; Tang, X; Xiong, Z; Yi, P; Zhang, C, 2022)	1.19
"This research aimed to study the optimization effects of the low-rank matrix denoising (LRMD) algorithm based on the Gaussian mixture model (GMM) on MRI images of stroke patients, aiming to evaluate the effects of atorvastatin combined with folic acid on poststroke cognitive impairment (PSCI) in patients with ischemic stroke."	( Evaluation of the Effects of Folic Acid Combined with Atorvastatin on the Poststroke Cognitive Impairment by Low-Rank Matrix Denoising Algorithm-Based MRI Imaging. Fang, F; Fang, Z; Li, J; Li, X; Li, Y; Wang, J; Wang, X, 2022)	1.16
" First three groups were treated with Acai berry (PO; 250 mg/kg); fourth, fifth and sixth groups received sodium CMC (vehicle) for 10 days and on eleventh day, first and fourth groups were administered with ATR (PO; 10 mg/kg); second and fifth groups with ALO (PO; 25 mg/kg) and third and sixth groups received EMPA (PO; 25 mg/kg)."	( Investigation of the effect of Acai berry on the pharmacokinetics of Atorvastatin, Alogliptin and Empagliflozin: a herb-drug interaction study. Nanjappan, SK; Ravichandiran, V; Somabattini, RA, 2022)	0.96
"To analyze the significance of ezetimibe in combination with low- to moderate-intensity atorvastatin adjuvant aspirin therapy for cerebrovascular disease."	( Implications of Ezetimibe in Combination with Low- to Moderate-Intensity Atorvastatin Adjuvant Aspirin Therapy for Cerebrovascular Disease. Tang, X; Wang, L, 2022)	1.18
"Ezetimibe combined with medium- and low-intensity atorvastatin with aspirin in the treatment of cerebrovascular diseases can effectively improve the coagulation function of patients, reduce the level of inflammatory factors in patients, and improve the level of blood lipids in patients, with high safety and worthy of clinical application."	( Implications of Ezetimibe in Combination with Low- to Moderate-Intensity Atorvastatin Adjuvant Aspirin Therapy for Cerebrovascular Disease. Tang, X; Wang, L, 2022)	1.21
"Our previous studies have confirmed that aspirin combined with Lipitor inhibited the development of prostate cancer (PCa), but the mechanisms need to be comprehensively expounded."	( Identification of target and pathway of aspirin combined with Lipitor treatment in prostate cancer through integrated bioinformatics analysis. Chen, M; Li, D; Liu, J; Liu, W; Ma, Y; Sheng, Z; Wang, X; Wu, Y; Xu, X; Zhao, D; Zheng, X, 2022)	0.72
" The effects of silent DNA replication and sister chromatid cohesion 1 (siDSCC1) combined with Lipitor and aspirin on DSCC1 expression, viability, invasion and migration of PCa cells were detected by qRT-PCR, Wound healing and transwell assays."	( Identification of target and pathway of aspirin combined with Lipitor treatment in prostate cancer through integrated bioinformatics analysis. Chen, M; Li, D; Liu, J; Liu, W; Ma, Y; Sheng, Z; Wang, X; Wu, Y; Xu, X; Zhao, D; Zheng, X, 2022)	0.72
"The enrichment pathways and targets of Lipitor combined with aspirin in PCa are discovered, and DSCC1 silencing can potentiate the effect of Lipitor combined with aspirin in the treatment of PCa."	( Identification of target and pathway of aspirin combined with Lipitor treatment in prostate cancer through integrated bioinformatics analysis. Chen, M; Li, D; Liu, J; Liu, W; Ma, Y; Sheng, Z; Wang, X; Wu, Y; Xu, X; Zhao, D; Zheng, X, 2022)	0.72
"To explore the related factors of cerebral hemorrhage transformation after cerebral infarction and the value of atorvastatin calcium tablets combined with early intensive care measures."	( Related Factors of Cerebral Hemorrhage after Cerebral Infarction and the Effect of Atorvastatin Combined with Intensive Nursing Care. Li, X; Yang, Q; Yang, Y, 2022)	1.16
" For patients with bleeding transformation, atorvastatin calcium tablets combined with early intensive nursing intervention has a certain value for improving the prognosis of patients."	( Related Factors of Cerebral Hemorrhage after Cerebral Infarction and the Effect of Atorvastatin Combined with Intensive Nursing Care. Li, X; Yang, Q; Yang, Y, 2022)	1.21
" The symptoms were presumably caused by a drug-drug interaction between an antiretroviral drug combination and atorvastatin."	( [Rhabdomyolysis due to drug-drug interaction of atorvastatin and cobicistat]. Hennersdorf, F; Intert, E; Knop, K; Krause, M; Rosenkranz, T, 2022)	1.19
"Epidemiological and clinical evidence suggests that high-dose intake of omega 3 fatty acids (n-3 FA) have a favorable role in altering serum triglycerides (TG) and non-high density lipoprotein cholesterol (non-HDL-C) when combined with statins in hyperlipidemic patients."	( N-3 fatty acid supplementation mediates lipid profile, including small dense LDL, when combined with statins: a randomized double blind placebo controlled trial. Dogay Us, G; Mushtaq, S, 2022)	0.72
" In addition, this case used amiodarone (AMD), and it has been reported that the RDV concentration increases when used in combination with AMD."	( [Significant Prolongation of the International Normalized Ratio Associated with COVID-19 Treatment: Possible Drug Interaction with Remdesivir]. Bando, Y; Ishii, H; Otori, K; Yokota, N, 2022)	0.72
" In this light, we investigated whether inhibition of IL-1β combined with cholesterol-lowering therapies can reduce OA development in dyslipidemic APOE∗3Leiden mice under pro-inflammatory dietary conditions."	( IL-1β inhibition combined with cholesterol-lowering therapies decreases synovial lining thickness and spontaneous cartilage degeneration in a humanized dyslipidemia mouse model. Blom, AB; Kruisbergen, NNL; Pieterman, EJ; Princen, HMG; van den Bosch, MHJ; van der Kraan, PM; van Gemert, Y; van Lent, PLEM, 2023)	0.91
" Treatments included atorvastatin alone or with an anti-IL1β antibody, and atorvastatin combined with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor alirocumab without or with the anti-IL1β antibody."	( IL-1β inhibition combined with cholesterol-lowering therapies decreases synovial lining thickness and spontaneous cartilage degeneration in a humanized dyslipidemia mouse model. Blom, AB; Kruisbergen, NNL; Pieterman, EJ; Princen, HMG; van den Bosch, MHJ; van der Kraan, PM; van Gemert, Y; van Lent, PLEM, 2023)	1.23
" Synovial thickening and cartilage degeneration were significantly decreased in mice that received cholesterol-lowering treatment combined with inhibition of IL-1β (P < 0."	( IL-1β inhibition combined with cholesterol-lowering therapies decreases synovial lining thickness and spontaneous cartilage degeneration in a humanized dyslipidemia mouse model. Blom, AB; Kruisbergen, NNL; Pieterman, EJ; Princen, HMG; van den Bosch, MHJ; van der Kraan, PM; van Gemert, Y; van Lent, PLEM, 2023)	0.91
"These results indicate that inhibition of IL-1β combined with cholesterol-lowering therapy diminishes synovial thickening and cartilage degeneration in mice and may imply that this combination therapy could be beneficial in patients with metabolic inflammation."	( IL-1β inhibition combined with cholesterol-lowering therapies decreases synovial lining thickness and spontaneous cartilage degeneration in a humanized dyslipidemia mouse model. Blom, AB; Kruisbergen, NNL; Pieterman, EJ; Princen, HMG; van den Bosch, MHJ; van der Kraan, PM; van Gemert, Y; van Lent, PLEM, 2023)	0.91
" However, there are few studies on the regulation and efficacy of atorvastatin combined with amlodipine on Th17/Treg balance in hypertension combined with carotid atherosclerosis."	( Effects of amlodipine combined with atorvastatin on Th17/Treg imbalance and vascular microcirculation in hypertensive patients with atherosclerosis: A double-blind, single-center randomized controlled trial. Qiu, Y; Yang, G, 2023)	1.42
"These data indicate that amlodipine combined with atorvastatin can improve Th17/Treg imbalance, vascular endothelial function and efficacy in patients with hypertension and atherosclerosis."	( Effects of amlodipine combined with atorvastatin on Th17/Treg imbalance and vascular microcirculation in hypertensive patients with atherosclerosis: A double-blind, single-center randomized controlled trial. Qiu, Y; Yang, G, 2023)	1.44
" Our objective was to evaluate potential drug-drug interactions of cilofexor as a victim and as a perpetrator."	( Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions for Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor (FXR) Agonist. Kirby, BJ; Nelson, C; Othman, AA; Shen, G; Watkins, TR; Weber, E; Xiao, D; Younis, I, 2023)	0.91
"In this Phase 1 study, healthy adult participants (n = 18-24 per each of the 6 cohorts) were administered cilofexor in combination with either perpetrators or substrates of cytochrome P-450 (CYP) enzymes and drug transporters."	( Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions for Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor (FXR) Agonist. Kirby, BJ; Nelson, C; Othman, AA; Shen, G; Watkins, TR; Weber, E; Xiao, D; Younis, I, 2023)	0.91
" Linear discriminant analysis effect size (LEfSe) analysis combined with receiver operating characteristic (ROC) curves revealed the marker bacteria associated with taking medication were g_Parabacteroides（AUC = 0."	( Effects of long-term regular oral aspirin combined with atorvastatin to prevent ischemic stroke on human gut microbiota. Chen, C; Chen, G; Cui, J; Liao, Y; Ming, J; Song, W; Wang, X; Wang, Z; Xu, K, 2023)	1.16
"A different drug-drug interaction (DDI) scenario may exist in patients with chronic kidney disease (CKD) compared with healthy volunteers (HVs), depending on the interplay between drug-drug and disease (drug-drug-disease interaction (DDDI))."	( Understanding Statin-Roxadustat Drug-Drug-Disease Interaction Using Physiologically-Based Pharmacokinetic Modeling. Ahlström, C; Dong, J; Elebring, M; Huang, Y; Lundahl, A; Någård, M; Prieto Garcia, L; Sjögren, E; Tang, W; Vildhede, A, 2023)	0.91
" This study aimed to investigate the effects of evolocumab, alone or in combination with atorvastatin, on the progression of atherosclerosis."	( The effect of evolocumab alone and in combination with atorvastatin on atherosclerosis progression and TLRs expression. Ali, N; Gali, F; Hadi, NR; Qassam, H; Saud, A, 2023)	1.38
"To investigate the application of atorvastatin (AT) combined with ezetimibe (EZ) in elderly patients with hypertension (HY) combined with type 2 diabetes mellitus (T2DM) and the significance analysis of changes in serum bilirubin levels during treatment."	( Application of Atorvastatin Combined with Ezetimibe in Elderly Patients with Hypertension Combined with T2DM and Analysis of Significance of Changes in Serum Bilirubin Levels During Treatment. Du, M; Wang, Q; Wang, T; Zhu, S, 2023)	1.54
"One hundred and twelve elderly patients with HY combined with T2DM admitted to our hospital from September 2019 to March 2022 were selected and divided into a control group (AT) and a combined group (AT + EZ) according to the random number table method, with 56 cases in each group."	( Application of Atorvastatin Combined with Ezetimibe in Elderly Patients with Hypertension Combined with T2DM and Analysis of Significance of Changes in Serum Bilirubin Levels During Treatment. Du, M; Wang, Q; Wang, T; Zhu, S, 2023)	1.26
"AT combined with EZ can effectively improve glucose, lipids, inflammation and upregulate serum bilirubin in patients with HY combined with T2DM."	( Application of Atorvastatin Combined with Ezetimibe in Elderly Patients with Hypertension Combined with T2DM and Analysis of Significance of Changes in Serum Bilirubin Levels During Treatment. Du, M; Wang, Q; Wang, T; Zhu, S, 2023)	1.26

Bioavailability

Atorvastatin directly improves vascular NO bioavailability and reduces vascular O(2)(·-) through tetrahydrobiopterin-mediated endothelial NO synthase coupling. Quercetin does not alter the oral bioavailability of AtorVastatin Calcium in rats.

Excerpt	Reference	Relevance
" The bioavailability of atorvastatin capsules was similar to that of solution."	( Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects. Cilla, DD; Posvar, EL; Radulovic, LL; Sedman, AJ; Whitfield, LR, 1996)	0.86
"Grapefruit juice greatly increases the bioavailability of lovastatin and simvastatin."	( Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Kivistö, KT; Lilja, JJ; Neuvonen, PJ, 1999)	0.56
" Lovastatin, Atorvastatin, Pravastatin and Simvastatin demonstrate variable potency to enhance the NO/O2- concentration ratio after stimulation of NOS, resulting in an increase of NO bioavailability in endothelial cells."	( Statin-stimulated nitric oxide release from endothelium. Dobrucki, IT; Dobrucki, LW; Kalinowski, L; Malinski, T, )	0.5
" Nevertheless, an increase in pravastatin bioavailability has been reported in the presence of cyclosporine A, possibly because of an interaction at the level of biliary excretion."	( Pharmacological interactions of statins. Bellosta, S; Corsini, A; Paoletti, R, 2002)	0.31
" However, atorvastatin acid is subject to extensive first-pass metabolism in the gut wall as well as in the liver, as oral bioavailability is 14%."	( Clinical pharmacokinetics of atorvastatin. Lennernäs, H, 2003)	1.01
" Hypertensive Dahl salt-sensitive (DS) rats have endothelial dysfunction and cardiorenal injury associated with decreased NO bioavailability and increased superoxide (O2-) production linked to a functional upregulation of angiotensin II."	( Atorvastatin prevents end-organ injury in salt-sensitive hypertension: role of eNOS and oxidant stress. Jaimes, EA; Raij, L; Zhou, MS, 2004)	1.77
"Endothelial nitric oxide (eNO) bioavailability is severely reduced after myocardial infarction (MI) and in heart failure."	( Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Bahlmann, FH; Drexler, H; Engberding, N; Fuchs, M; Haller, H; Heineke, A; Hilfiker-Kleiner, D; Hornig, B; Kotlarz, D; Landmesser, U; Mueller, M; Schaefer, A; Spiekermann, S; Templin, C; Wiencke, A, 2004)	0.32
" eNO bioavailability after MI likely represents an important therapeutic target in heart failure after MI and mediates beneficial effects of statin treatment after MI."	( Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Bahlmann, FH; Drexler, H; Engberding, N; Fuchs, M; Haller, H; Heineke, A; Hilfiker-Kleiner, D; Hornig, B; Kotlarz, D; Landmesser, U; Mueller, M; Schaefer, A; Spiekermann, S; Templin, C; Wiencke, A, 2004)	0.32
"The study was designed to evaluate the relative bioavailability of two formulations of atorvastatin (CAS 134523-03-8)."	( Bioequivalence study of atorvastatin tablets. Alpan, RS; Erenmemisoglu, A; Koytchev, R; Ozalp, Y; van der Meer, MJ, 2004)	0.85
" Damage to the endothelium leads to reduced NO bioavailability and facilitates vessel wall permeability to low-density lipoprotein."	( A rationale for combination therapy in risk factor management: a mechanistic perspective. Mason, RP, 2005)	0.33
" Dose optimization and use of novel controlled drug delivery systems may help in increasing the bioavailability and distribution of statins to the bone microenvironment."	( Statins and osteoporosis: new role for old drugs. Jadhav, SB; Jain, GK, 2006)	0.33
" The validated method has been successfully used to analyze human plasma samples for application in pharmacokinetic, bioavailability or bioequivalence studies."	( Simultaneous quantification of atorvastatin and active metabolites in human plasma by liquid chromatography-tandem mass spectrometry using rosuvastatin as internal standard. Anjaneyulu, Y; Boosi, R; Kandikere, VN; Maurya, S; Mudigonda, K; Nirogi, RV; Shukla, M, 2006)	0.62
" Oral bioavailability was studied on prepared SMEDDS hard capsules and compared with that of the conventional tablet in Beagle dogs in vivo."	( [Preparation and evaluation of self-microemulsifying drug delivery systems containing atorvastatin]. Li, ZD; Shen, HR; Zhong, MK, 2005)	0.55
" Oral bioavailability of atorvastatin SMEDDS was greater than that of the conventional tablet."	( [Preparation and evaluation of self-microemulsifying drug delivery systems containing atorvastatin]. Li, ZD; Shen, HR; Zhong, MK, 2005)	0.86
" Both hepatic and intestinal metabolism contribute to the low oral bioavailability of ATV in rats."	( Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Benet, LZ; Huang, Y; Lau, YY; Okochi, H, 2006)	0.66
" This might be because concomitant administration of P-glycoprotein substrates, such as statins, and colchicine, which is a P-glycoprotein inhibitor, modifies pharmacokinetics by increasing bioavailability and organ uptake of the substrates, leading to more adverse reactions and toxicities."	( Rhabdomyolysis in a patient treated with colchicine and atorvastatin. Altintas, ND; Cavus, S; Dede, DS; Iskit, AB; Topeli, A; Tufan, A, )	0.38
"Atorvastatin is insoluble in aqueous solution and the bioavailability after oral administration is low."	( Preparation and evaluation of self-microemulsifying drug delivery systems (SMEDDS) containing atorvastatin. Shen, H; Zhong, M, 2006)	2
" These findings suggest that the T-786C polymorphism modulates the effects of atorvastatin on NO bioavailability and oxidative stress."	( eNOS gene T-786C polymorphism modulates atorvastatin-induced increase in blood nitrite. Bem, AF; Metzger, IF; Nagassaki, S; Rocha, JB; Sertório, JT; Tanus-Santos, JE, 2006)	0.83
"The aim of this study was to compare the bioavailability of two atorvastatin formulations (Divator Drogsan Pharmaceuticals, Ankara, Turkey, as the test formulation, and Lipitor, Pfizer Ireland Pharmaceuticals, Dublin, Ireland, as the reference formulation) in 52 healthy volunteers."	( Pharmacokinetic and bioequivalence testing of atorvastatin formulations in healthy male volunteers. Emritte, N; Hajdúch, M; Mendoza, L; Platílová, V; Plausinaitis, R; Svoboda, M, 2006)	0.83
" Consequently, absolute bioavailability values of diltiazem pretreated with atorvastatin (8."	( Effect of atorvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats. Chang, KS; Choi, DH; Choi, JS; Hong, SP, 2007)	0.97
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."	( Hologram QSAR model for the prediction of human oral bioavailability. Andricopulo, AD; Moda, TL; Montanari, CA, 2007)	0.34
"05) increased the bioavailability of verapamil in rats."	( Effect of atorvastatin on the intravenous and oral pharmacokinetics of verapamil in rats. Chang, KS; Choi, DH; Choi, JS; Han, HK; Hong, SP, 2008)	0.75
" Thus, the relative bioavailability increased by the same magnitude with atorvastatin."	( Drug interaction between oral atorvastatin and verapamil in healthy subjects: effects of atorvastatin on the pharmacokinetics of verapamil and norverapamil. Choi, DH; Choi, JS; Shin, WG, 2008)	0.87
" AC, the world's best selling drug is associated with poor oral bioavailability and serious adverse effects like rhabdomyolysis on chronic administration."	( Oral nanoparticulate atorvastatin calcium is more efficient and safe in comparison to Lipicure in treating hyperlipidemia. Ankola, DD; Chandraiah, G; Kumar, MN; Meena, AK; Rao, PR; Ratnam, DV, 2008)	0.66
" In particular, reduced bioavailability of endothelial-dependent nitric oxide production as a result of enhanced oxidative stress represents a common pathological mechanism of cardiovascular risk factors."	( Scientific rationale for combination of a calcium channel antagonist and an HMG-CoA reductase inhibitor: a new approach to risk factor management. Mason, RP, 2008)	0.35
"05) compared with crystalline atorvastatin, suggesting that the enhanced bioavailability was attributed to amorphous nature and particle size reduction."	( Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process. Hwang, SJ; Jin, SJ; Kim, JS; Kim, MS; Lee, S; Park, HJ, 2008)	0.87
" One possible mechanism for this effect is reduced bioavailability of nitric oxide, a key mediator of angiogenesis, secondary to increased oxygen free radicals."	( Atorvastatin increases myocardial indices of oxidative stress in a porcine model of hypercholesterolemia and chronic ischemia. Bianchi, C; Boodhwani, M; Clements, RT; Feng, J; Mieno, S; Ramlawi, B; Sellke, FW; Sodha, NR; Xu, SH, )	1.57
"After 14 days of dosing, the rate and extent of exposure (AUCtau, C(max,ss)) to atorvastatin and its active metabolites were similar with both treatments, indicating that administration of P-OM3 did not affect the steady-state bioavailability of orally administered atorvastatin."	( Effect of omega-3-acid ethyl esters on steady-state plasma pharmacokinetics of atorvastatin in healthy adults. Di Spirito, M; Doyle, RT; Johnson, J; McKenney, J; Morelli, G, 2008)	0.8
" Our results indicate that AMPK phosphorylation of eNOS Ser633 is a functional signaling event for NO bioavailability in ECs."	( AMP-activated protein kinase functionally phosphorylates endothelial nitric oxide synthase Ser633. Chen, Z; DeFea, K; Fu, Y; Hsu, PH; Pan, S; Peng, IC; Shyy, JY; Su, MI; Sun, W; Tsai, MD; Zhu, Y, 2009)	0.35
" Our data support the effects of statins in vivo that have been demonstrated on the endothelium ex vivo, suggesting a beneficial effect by acting on the initial processes that trigger the disease, reducing oxidative stress (increase in the bioavailability of nitric oxide as peroxynitrite levels decrease) and curtailing the inflammatory processes which perpetuate the disease."	( In vivo confirmation of the role of statins in reducing nitric oxide and C-reactive protein levels in peripheral arterial disease. Aguilar, EM; Casariego, CV; García, FA; González, AF; Miralles, Jde H; Moreno, SB, 2009)	0.35
"Maternal protein restriction in rats leads to endothelial dysfunction and decreased NO bioavailability in the offspring."	( Atorvastatin restores endothelial function in offspring of protein-restricted rats in a cholesterol-independent manner. Anthony, FW; Curzen, NP; Hanson, MA; Hopkins, LA; Kelsall, CJ; Torrens, C, 2009)	1.8
" Previous results suggest that vascular dysfunction in OZR is associated with chronic reduction in vascular nitric-oxide (NO) bioavailability and chronic inflammation, both frequently associated with hypercholesterolemia."	( Impact of chronic anticholesterol therapy on development of microvascular rarefaction in the metabolic syndrome. Frisbee, JC; Frisbee, SJ; Goodwill, AG; James, ME; Stapleton, PA, 2009)	0.35
"While the positive impact of chronic statin treatment on vascular outcomes in the metabolic syndrome are independent of changes to total cholesterol, and are more strongly associated with improvements to vascular NO bioavailability and attenuated inflammation, these results provide both a spatial and temporal framework for targeted investigation into mechanistic determinants of vasculopathy in the metabolic syndrome."	( Impact of chronic anticholesterol therapy on development of microvascular rarefaction in the metabolic syndrome. Frisbee, JC; Frisbee, SJ; Goodwill, AG; James, ME; Stapleton, PA, 2009)	0.35
"Induced endothelin-1 (ET-1) production and decreased nitric oxide synthase (NOS) bioavailability have been found in aneurysmal subarachnoid hemorrhage (SAH)."	( Atorvastatin preconditioning attenuates the production of endothelin-1 and prevents experimental vasospasm in rats. Chang, CZ; Howng, SL; Hwang, SL; Kwan, AL; Lin, CL; Wu, SC, 2010)	1.8
" The main pharmacokinetic parameters of atorvastatin acid (mean [relative standard error {RSE}]) for a subject with mean covariate values were the first-order absorption rate constant (3."	( Development of a population pharmacokinetic model for atorvastatin acid and its lactone metabolite. Akhlaghi, F; Asberg, A; Hermann, M; Narwal, R; Rosenbaum, SE, 2010)	0.88
" The in-vitro study showed that solid dispersions increased the solubility and dissolution rate of ATR, and thus may improve its bioavailability compared with plain ATR."	( Microwave induced solubility enhancement of poorly water soluble atorvastatin calcium. Belgamwar, V; Maurya, D; Tekade, A, 2010)	0.6
" In this study, we examined the effect of AMPK phosphorylation on Hcy-induced NO bioavailability impairment and NADPH oxidase 4 (Nox4) derived reactive oxygen species (ROS) accumulation in EPCs."	( AMP-activated protein kinase inhibits homocysteine-induced dysfunction and apoptosis in endothelial progenitor cells. Chen, Z; Jia, F; Lu, G; Wu, C, 2011)	0.37
" The population pharmacokinetic model described differences between the liquid-filled capsule used in phase I and phase IIb and the hot-melt extruded (HME) tablet formulation introduced in phase III, allowing for bridging of the two formulations, and quantified the complex relationship of apparent anacetrapib bioavailability with subject meal intake."	( Model-based development of anacetrapib, a novel cholesteryl ester transfer protein inhibitor. Bergman, AJ; Dockendorf, MF; Dykstra, K; Green, M; Krishna, R; Wagner, JA, 2011)	0.37
" NO bioavailability was assessed using cyclic guanosine monophosphate quantification."	( Atorvastatin worsens left ventricular diastolic dysfunction and endothelial dysfunction of epicardial coronary arteries in normocholesterolemic porcine with left ventricular hypertrophy. Aubin, MC; Carrier, M; Forcillo, J; Maltais, S; Perrault, LP; Shi, YF; Tardif, JC, 2011)	1.81
"We first examined the association of statin treatment with vascular NO bioavailability and arterial superoxide (O(2)(·-)) in 492 patients undergoing coronary artery bypass graft surgery."	( Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling. Antoniades, C; Antonopoulos, AS; Bakogiannis, C; Bendall, J; Casadei, B; Channon, KM; Demosthenous, M; Guzik, TJ; Hale, A; Leeson, P; Marinou, K; Paschalis, A; Psarros, C; Stefanadis, C; Tousoulis, D; Triantafyllou, C; Zhang, MH, 2011)	0.37
" Atorvastatin directly improves vascular NO bioavailability and reduces vascular O(2)(·-) through tetrahydrobiopterin-mediated endothelial NO synthase coupling."	( Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling. Antoniades, C; Antonopoulos, AS; Bakogiannis, C; Bendall, J; Casadei, B; Channon, KM; Demosthenous, M; Guzik, TJ; Hale, A; Leeson, P; Marinou, K; Paschalis, A; Psarros, C; Stefanadis, C; Tousoulis, D; Triantafyllou, C; Zhang, MH, 2011)	1.28
" Since tetrahydrobiopterin (BH(4)) is an essential cofactor for endothelial nitric oxide synthase (NOS3), decreased bioavailability of the substrate l-arginine and/or BH(4) may contribute to decreased NO production with hypercholesterolaemia."	( Acute localized administration of tetrahydrobiopterin and chronic systemic atorvastatin treatment restore cutaneous microvascular function in hypercholesterolaemic humans. Holowatz, LA; Kenney, WL, 2011)	0.6
"The bioavailability of clopidogrel bisulfate (CAS 135046-48-9) form I was compared with that of clopidogrel bisulfate form II in 12 male Sprague-Dawley rats."	( Study on bioavailability difference between clopidogrel bisulfate form I and form II using liquid chromatography/tandem mass spectrometry. Che, WJ; Ou-Yang, PK; Tan, XH; Wei, P; Zhang, ZJ; Zou, QG, 2011)	0.37
"A novel approach to improve the bioavailability and stability of atorvastatin (AT) was developed by constructing a nano-sized polymer-atorvastatin conjugate."	( Enhanced bioavailability of nano-sized chitosan-atorvastatin conjugate after oral administration to rats. Ahmad, FJ; Akhter, S; Anwar, M; Gahoi, S; Jain, GK; Khar, RK; Mallick, N; Talegaonkar, S; Warsi, MH, 2011)	0.86
"Oral bioavailability of atorvastatin calcium (ATC) is very low (only 14%) due to instability and incomplete intestinal absorption and/or extensive gut wall extraction."	( Enhanced bioavailability of atorvastatin calcium from stabilized gastric resident formulation. Dehghan, MH; Khan, FN, 2011)	0.97
"Atorvastatin/metformin ER 10 mg/500 mg FDC has similar bioavailability to the co-administration of separate atorvastatin 10 mg and metformin 500 mg tablets."	( Pharmacokinetics of a fixed-dose combination of atorvastatin and metformin extended release versus concurrent administration of individual formulations: a randomized, open-label, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivale Arora, R; Dey, S; Kandhwal, K; Monif, T; Nazarudheen, S; Rao, S; Reyar, S; Singh, MK; Thudi, NR, 2011)	2.07
"Statins, which improve the bioavailability of endogenous nitric oxide and upregulate endothelial nitric oxide synthase, have been used to prevent cerebral vasospasm after aneurysmal subarachnoid hemorrhage."	( Atorvastatin decreases computed tomography and S100-assessed brain ischemia after subarachnoid aneurysmal hemorrhage: a comparative study. Aout, M; Clarençon, F; Colonne, C; Fonfrede, M; Jean, B; Le Jean, L; Nouet, A; Puybasset, L; Sanchez-Peña, P; Vicaut, E, 2012)	1.82
" This process probably accounts for pitavastatin's increased bioavailability relative to most other statins and contributes to its prolonged duration of action."	( Pitavastatin: an overview. Saito, Y, 2011)	0.37
"The main aim of the present investigation is to develop and characterize the self-nanoemulsifying drug delivery systems (SNEDDS) of atorvastatin calcium (ATV) for improving the dissolution thereby oral bioavailability and to minimize the gastric degradation."	( Development and characterization of self-nanoemulsifying drug delivery systems (SNEDDS) of atorvastatin calcium. Mantri, SK; Murthy, KV; Pashikanti, S, 2012)	0.8
"The aim of this study was to improve the solubility, stability and bioavailability of amorphous atorvastatin calcium (AT) by complexing it with hydroxypropyl-beta-cyclodextrin."	( Preparation, physicochemical characteristics and bioavailability studies of an atorvastatin hydroxypropyl-beta-cyclodextrin complex. Lv, HX; Waddad, AY; Zhang, ZH; Zhou, JP, 2012)	0.82
" The relative bioavailability of AT and o-OAT in test formulation were (105."	( [Pharmacokinetics and bioequivalence of atorvastatin calcium tablets in healthy male Chinese volunteers]. Chen, XY; Guo, LX; Shen, Y; Zhang, YF; Zhong, DF, 2012)	0.65
"The solubility, absorption and distribution of a drug are involved in the basic aspects of oral bioavailability Solubility is an essential characteristic and influences the efficiency of the drug."	( Preparation of candesartan and atorvastatin nanoparticles by solvent evaporation. Dohnal, J; Grunwaldova, V; Jampilek, J; Kral, V; Vaculikova, E, 2012)	0.66
" Atorvastatin has pleiotropic actions, including increasing nitric oxide (NO) bioavailability and reducing inflammation and oxidative damage."	( Atorvastatin protects against deleterious cardiovascular consequences induced by chronic intermittent hypoxia. Baldazza, M; Cachot, S; Faury, G; Fhayli, W; Joyeux-Faure, M; Korichneva, I; Lévy, P; Pépin, JL; Ribuot, C; Totoson, P, 2013)	2.74
"The present study evaluated the bioavailability and bioequivalence of fixed dose combination test formulation (atorvastatin 10 mg and aspirin 150 mg capsule) against marketed reference formulations (Lipitor® tablets 10 mg and Nu-Seals tablets 75 mg)."	( Bioequivalence of fixed dose combination of atorvastatin 10 mg and aspirin 150 mg capsules: a randomized, open-label, single-dose, two-way crossover study in healthy human subjects. Battula, R; Betha, MR; Cheerla, R; Gadiko, C; Khan, SM; Nakkawar, M; Thota, S; Tippabhotla, SK; Vobalaboina, V; Yergude, S, 2013)	0.86
" Knockin of OATP1B1 or OATP1B3 partially restored control clearance, volume, and bioavailability values (24%-142% increase, ≤47% increase, and ≤77% decrease vs."	( Utility of Oatp1a/1b-knockout and OATP1B1/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin, simvastatin, and carboxydichlorofluorescein. Bao, JQ; Fallon, JK; Higgins, JW; Ke, AB; Manro, JR; Smith, PC; Zamek-Gliszczynski, MJ, 2014)	0.6
" The amorphous form of ATC possesses higher solubility, dissolution rate, and bioavailability than its crystalline form."	( Coamorphous atorvastatin calcium to improve its physicochemical and pharmacokinetic properties. Ghavimi, H; Hamishekar, H; Jouyban, A; Shayanfar, A, 2013)	0.77
"Vascular aging is characterized by vascular cell senescence, increased oxidative stress, and endothelial and inducible nitric oxide (NO) synthase (eNOS/iNOS) imbalance, which reduces NO bioavailability and causes endothelial dysfunction."	( Long-term atorvastatin improves age-related endothelial dysfunction by ameliorating oxidative stress and normalizing eNOS/iNOS imbalance in rat aorta. Fu, G; Gong, X; Ma, Y; Ruan, Y; Wu, S, 2014)	0.8
"Serious efforts have been made to overcome the bioavailability problems of ever increasing number of poorly soluble drugs, including atorvastatin (ATO); however, enhancing its gastric solubility has not received much attention."	( Amorphous solid dispersion with increased gastric solubility in tandem with oral disintegrating tablets: a successful approach to improve the bioavailability of atorvastatin. Asghar, S; Lv, H; Salmani, JM; Zhou, J, 2015)	0.82
"To improve the bioavailability of ATO by increasing its gastric solubility in a stable oral disintegration tablet (ODT) formulation."	( Amorphous solid dispersion with increased gastric solubility in tandem with oral disintegrating tablets: a successful approach to improve the bioavailability of atorvastatin. Asghar, S; Lv, H; Salmani, JM; Zhou, J, 2015)	0.61
" In vivo results showed an overall enhancement in the apparent bioavailability (83% and 434% more than Lipitor® and plain amorphous ATO tablets, respectively)."	( Amorphous solid dispersion with increased gastric solubility in tandem with oral disintegrating tablets: a successful approach to improve the bioavailability of atorvastatin. Asghar, S; Lv, H; Salmani, JM; Zhou, J, 2015)	0.61
" The pharmacokinetic study illustrated that the fast absorption and increased oral bioavailability of atorvastatin as well as therapeutic concentration of atenolol in blood were made available through adoption of formulation strategy of bilayer tablets."	( Formulation and evaluation of fixed-dose combination of bilayer gastroretentive matrix tablet containing atorvastatin as fast-release and atenolol as sustained-release. Chattopadhyay, S; Dey, S; Mazumder, B, 2014)	0.83
"The aim of the present study was to investigate the effect of Soluplus® on the solubility of atorvastatin calcium and to develop a solid dispersion formulation that can improve the oral bioavailability of atorvastatin calcium."	( Preparation and evaluation of solid dispersion of atorvastatin calcium with Soluplus® by spray drying technique. Baek, IH; Cho, W; Ha, ES; Hwang, SJ; Kim, MS, 2014)	0.88
" The in vitro drug release and in vivo and ex vivo studies clearly demonstrated the potential of hydrophilic NG in enhancing the solubility, dissolution rate, and bioavailability of ATR."	( Solubility and bioavailability enhancement of poorly aqueous soluble atorvastatin: in vitro, ex vivo, and in vivo studies. Devkar, TB; Divase, GT; Rodde, MS; Tekade, AR, 2014)	0.64
"Oxidative stress [increased bioavailability of reactive oxygen species (ROS)] plays a role in the endothelial dysfunction and vascular inflammation, which underlie vascular damage in diabetes."	( Vascular injury in diabetic db/db mice is ameliorated by atorvastatin: role of Rac1/2-sensitive Nox-dependent pathways. Antunes, TT; Bruder-Nascimento, T; Callera, GE; He, Y; Montezano, AC; Nguyen Dinh Cat, A; Tostes, RC; Touyz, RM, 2015)	0.66
"The objective of this study was to investigate the impact of a novel spray-dried ternary solid dispersion (TSD) on the dissolution rate and bioavailability of a biopharmaceutics classification system (BCS) class II model drug, atorvastatin calcium trihydrate (ATC), and evaluate its in-vitro and in-vivo performance."	( Preparation, in-vitro and in-vivo evaluation of spray-dried ternary solid dispersion of biopharmaceutics classification system class II model drug. Ahuja, BK; Devasari, N; Jena, SK; Paidi, SK; Suresh, S, 2015)	0.6
" It exhibited a fourfold increase in dissolution rate in comparison to ATC, with a considerable enhancement in oral bioavailability (relative bioavailability of 134."	( Preparation, in-vitro and in-vivo evaluation of spray-dried ternary solid dispersion of biopharmaceutics classification system class II model drug. Ahuja, BK; Devasari, N; Jena, SK; Paidi, SK; Suresh, S, 2015)	0.42
"The TSD exhibits a significant increase in dissolution rate, and for this reason should be useful as an efficacious tool to enhance the bioavailability of BCS class II drug molecule, ATC."	( Preparation, in-vitro and in-vivo evaluation of spray-dried ternary solid dispersion of biopharmaceutics classification system class II model drug. Ahuja, BK; Devasari, N; Jena, SK; Paidi, SK; Suresh, S, 2015)	0.42
"7 ng/mL), low endothelial NO bioavailability and high ONOO(-)."	( Atorvastatin enhanced nitric oxide release and reduced blood pressure, nitroxidative stress and rantes levels in hypertensive rats with diabetes. Corbalan, JJ; Dawoud, H; Jacob, RF; Malinski, T; Mason, RP, 2015)	1.86
"The present work was aimed at developing an optimized oral nanostructured lipid carrier (NLC) formulation of poorly soluble atorvastatin Ca (AT Ca) and assessing its in vitro release, oral bioavailability and pharmacodynamic activity."	( Chlorogenic acid stabilized nanostructured lipid carriers (NLC) of atorvastatin: formulation, design and in vivo evaluation. Ali, J; Baboota, S; Khan, S; Narang, JK; Narang, RS, 2016)	0.88
"This study sought to investigate whether the individual cholesterol absorption rate affects atorvastatin's effectiveness to reduce cardiovascular risk in hemodialysis patients."	( Intestinal cholesterol absorption, treatment with atorvastatin, and cardiovascular risk in hemodialysis patients. Baumgartner, I; Drechsler, C; Fauler, G; Genser, B; Grammer, TB; Krane, V; März, W; Ritz, E; Scharnagl, H; Silbernagel, G; Wanner, C, 2015)	0.89
"The concentrations of crospovidone (CP), maltodextrin and microcrystalline cellulose (MCC) have been optimized in the development of self-microemulsified tablets (SMET) to improve the oral bioavailability of an anti-hyperlipidemic drug, atorvastatin, and the in-vivo pharmacokinetic parameters of the optimized SMET were compared with those of a commercial tablet in rabbits."	( Effects of carbohydrate polymers in self-microemulsified tablets on the bioavailability of atorvastatin: In vitro-in vivo study. Biswal, PK; Dixit, PK; Pani, NR, 2015)	0.82
"The present results indicate that the bioavailability of the SMET of atorvastatin is better than the commercial formulation."	( Effects of carbohydrate polymers in self-microemulsified tablets on the bioavailability of atorvastatin: In vitro-in vivo study. Biswal, PK; Dixit, PK; Pani, NR, 2015)	0.87
"Poor water solubility of a drug is a major challenge in drug delivery research and a main cause for limited bioavailability and pharmacokinetic parameters."	( Custom fractional factorial designs to develop atorvastatin self-nanoemulsifying and nanosuspension delivery systems--enhancement of oral bioavailability. Ahmed, OA; Al-Sawahli, MM; Hashem, FM; Nasr, M, 2015)	0.67
"This work focuses on the development of atorvastatin utilizing zein, a natural, safe, and biocompatible polymer, as a nanosized formulation in order to overcome the poor oral bioavailability (12%) of the drug."	( Optimized zein nanospheres for improved oral bioavailability of atorvastatin. Ahmed, OA; Al-Sawahli, MM; Hashem, FM; Nasr, M, 2015)	0.92
" In Wistar albino rats, the bioavailability of atorvastatin from the optimized atorvastatin-zein formulation was 3-fold greater than that from the atorvastatin suspension and the commercially available tablet."	( Optimized zein nanospheres for improved oral bioavailability of atorvastatin. Ahmed, OA; Al-Sawahli, MM; Hashem, FM; Nasr, M, 2015)	0.91
" Quercetin does not alter the oral bioavailability of Atorvastatin Calcium in rats."	( Quercetin does not alter the oral bioavailability of Atorvastatin in rats. Babu, N; Challa, SR; Devi, R; Geddam, LB; Koritala, R; Ragam, SK; Sattenapalli, S; Venkatesh Reddy Challa, VR, 2015)	0.92
" As a result of this, a significant decrease in the intestinal uptake and peroral bioavailability of the P-glycoprotein substrates (verapamil and atorvastatin) was observed along with the progression of diabetes as compared to normal animals."	( Increased intestinal P-glycoprotein expression and activity with progression of diabetes and its modulation by epigallocatechin-3-gallate: Evidence from pharmacokinetic studies. Agarwal, M; Dash, RP; Ellendula, B; Nivsarkar, M, 2015)	0.62
" Pharmacokinetic study in Charles Foster rats showed significant enhancement in oral bioavailability as compared to pure drug suspension."	( Atorvastatin calcium encapsulated eudragit nanoparticles with enhanced oral bioavailability, safety and efficacy profile. Chaurasia, S; Khan, G; Kumar, N; Kumar, V; Mishra, B; Patel, RR, 2017)	1.9
" SEDDS, with their unique solubilization properties, provide the opportunity to deliver lipophilic drugs to the gastrointestinal tract in a solubilized state, avoiding dissolution-a restricting factor in absorption rate of BCS Class 2 drugs, including atorvastatin."	( Development and Evaluation of Liquid and Solid Self-Emulsifying Drug Delivery Systems for Atorvastatin. Amelian, A; Czajkowska-Kośnik, A; Szekalska, M; Szymańska, E; Winnicka, K, 2015)	0.82
"We believed that our findings can help the use of mesoporous silica materials in improving bioavailability of poorly water-soluble drugs."	( Dissolution enhancement of a model poorly water-soluble drug, atorvastatin, with ordered mesoporous silica: comparison of MSF with SBA-15 as drug carriers. Hamidi, M; Maleki, A, 2016)	0.67
"Atorvastatin calcium (AC) is a BCS class II drug which shows poor bioavailability due to inadequate dissolution."	( Dissolution enhancement of atorvastatin calcium by co-grinding technique. Patravale, V; Prabhu, P, 2016)	2.17
" PK results, on the other hand, revealed that the two freeze-dried AC-NPs formulations were of significantly lower bioavailability compared to Lipitor(®)."	( PD-PK evaluation of freeze-dried atorvastatin calcium-loaded poly-ε-caprolactone nanoparticles. Abd-Rabo, MM; Ahmed, IS; El-Hosary, R; Elkhateeb, DG; Nour, S; Shalaby, S, 2016)	0.72
"To improve the dissolution and oral bioavailability (BA) of atorvastatin calcium (ATV), we previously introduced an optimized self-microemulsifying drug delivery system (SMEDDS) using Capmul(®) MCM (oil), Tween(®) 20 (surfactant), and tetraglycol (cosurfactant)."	( Development of a solidified self-microemulsifying drug delivery system (S-SMEDDS) for atorvastatin calcium with improved dissolution and bioavailability. Chae, BR; Choi, YW; Kim, JH; Kim, SR; Lee, SG; Son, HY; Song, SH; Yeom, DW, 2016)	0.9
" Our analysis suggested that patients carrying one variant allele for the rs2622604 polymorphism (ABCG2) show a 55% (95% confidence interval: 16-131%) increase in atorvastatin oral bioavailability relative to the value in individuals without the variant allele."	( Modelling of atorvastatin pharmacokinetics and the identification of the effect of a BCRP polymorphism in the Japanese population. Aarons, L; Galetin, A; Guo, Y; Hall, S; Tsamandouras, N; Wendling, T, 2017)	1.02
"The goal of the present investigation was to improve ATV bioavailability and overcome complications attendant with peroral administration by developing a new nanovesicular system encapsulating ATV for its delivery via the transdermal route."	( Transdermal delivery of atorvastatin calcium from novel nanovesicular systems using polyethylene glycol fatty acid esters: Ameliorated effect without liver toxicity in poloxamer 407-induced hyperlipidemic rats. Aboud, HM; Ali, AA; Hassan, AH; Johnston, TP; Mahmoud, MO, 2017)	0.76
" However, the poor aqueous solubility and low bioavailability hinders the therapeutic potential of it when administrated orally."	( Preparation and characterisation of atorvastatin and curcumin-loaded chitosan nanoformulations for oral delivery in atherosclerosis. J B, VK; Madhusudhan, B; Ramakrishna, S, 2017)	0.73
"This article presents the development of lyophilized orally disintegrating tablets prepared with the dry emulsion technique to enhance the in-vitro dissolution and in-vivo performance of the poorly bioavailable drug atorvastatin calcium (ATV)."	( Experimentally designed lyophilized dry emulsion tablets for enhancing the antihyperlipidemic activity of atorvastatin calcium: Preparation, in-vitro evaluation and in-vivo assessment. Basha, M; El Awdan, S; Salama, AH, 2018)	0.88
" The results revealed that the oral bioavailability of two selected AC-NPs formulations was 235% and 169% relative to Lipitor."	( Efficacy and Safety Profiles of Oral Atorvastatin-Loaded Nanoparticles: Effect of Size Modulation on Biodistribution. Abd-Rabo, MM; Ahmed, IS; El Hosary, R; Haider, M; Hassan, MA, 2018)	0.75
"13-folds increase in the bioavailability as compared to AC suspension."	( In vitro and in vivo evaluation of cyclodextrin-based nanosponges for enhancing oral bioavailability of atorvastatin calcium. Afouna, MI; Ibrahim, EA; Ibrahim, HM; Zidan, MF, 2018)	0.7
" Endothelial dysfunction represents an early but reversible step in atherosclerosis and is characterized by a reduction in the bioavailability of NO."	( Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statin. Dawoud, H; Jacob, RF; Malinski, T; Mason, RP; Sherratt, SCR, 2018)	0.48
"1 mg/mL) and poor oral bioavailability has limited therapeutic application of atorvastatin."	( Atorvastatin-loaded lipid nanoparticles: antitumor activity studies on MCF-7 breast cancer cells. Gambhire, MS; Gambhire, VM; Salunkhe, SM, 2018)	2.15
"Atorvastatin is a lipid lowering agent with poor oral bioavailability (12%) because of poor solubility and extensive first pass hepatic metabolism."	( Systematic approach for the formulation and optimization of atorvastatin loaded solid lipid NANOAPARTICLES using response surface methodology. Jana, U; Manna, PK; Mohanta, GP; Sahoo, J; Sarangi, B, 2018)	2.17
" Augmented bioavailability and reduced lipoprotein levels were key observations."	( Investigation of different types of nano drug delivery systems of atorvastatin for the treatment of hyperlipidemia. Devi Vemula, K; Mathur, M, 2018)	0.72
" However, the low bioavailability of Ato limits its widespread use and clinical effectiveness."	( Synergistic effects of liposomes encapsulating atorvastatin calcium and curcumin and targeting dysfunctional endothelial cells in reducing atherosclerosis. Chen, B; Chen, X; Cheng, D; Li, X; Lin, C; Sun, W; Wang, J; Wu, T; Xiao, H, 2019)	0.77
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
"Atorvastatin, a favored option for hyperlipidemia exhibits the problem of poor gastric solubility and low absolute bioavailability (12%) along with higher pre-systemic clearance (>80%)."	( Surface stabilized atorvastatin nanocrystals with improved bioavailability, safety and antihyperlipidemic potential. Mehta, I; Sharma, M, 2019)	2.29
"A nanoemulsion system was designed for Atorvastatin calcium (ATOR) transdermal delivery to overcome its poor bioavailability of (30%) resulting from the extensive first-pass effect and dissolution rate-limited in vivo absorption."	( Boosting transdermal delivery of atorvastatin calcium via o/w nanoemulsifying system: Two-step optimization, ex vivo and in vivo evaluation. Elhuoni, MA; Ghoneim, AM; Ishak, RAH; Shaker, DS, 2020)	1.11
"Atorvastatin calcium (AT) is an ocular anti-inflammatory with limited bioavailability when taken orally due to its low solubility in low pH and extensive first-pass effect."	( Chitosan-Coated PLGA Nanoparticles for Enhanced Ocular Anti-Inflammatory Efficacy of Atorvastatin Calcium. Arafa, MG; El-Dahan, MS; Girgis, GNS, 2020)	2.22
" Poor bioavailability and blood-aqueous barrier may however limit significant ocular concentration of statins following oral administration."	( Atorvastatin-loaded solid lipid nanoparticles as eye drops: proposed treatment option for age-related macular degeneration (AMD). Giansanti, F; Guzman-Aranguez, A; Kaur, IP; Papucci, L; Perez de Lara, MJ; Schiavone, N; Singh, M; Yadav, M, 2020)	2
"Despite the fact that atrovastatin (At) is being one of the bestselling statins used to prevent complicated cardiovascular diseases, its low oral bioavailability decreases its clinical relevance."	( Enhancement of atorvastatin oral bioavailability via encapsulation in polymeric nanoparticles. Al Thagfan, SS; Elbadawy, HM; Shaker, MA, 2021)	0.97
"Atorvastatin has a significant effect on P-gp mediated intestinal transport of daclatasvir; however, it did not affect the systemic bioavailability of a single oral dose of daclatasvir."	( Effect of Atorvastatin on Single Oral Pharmacokinetics and Safety of Daclatasvir in Rats: Emphasis on P-glycoprotein and Cytochrome P450. El-Demerdash, E; Elbadawy, HA; Wahdan, SA, 2022)	2.57
" Assessment of the individual cholesterol absorption rate to guide initiation of statin treatment is not supported by the findings in the AURORA study."	( High cholesterol absorption is associated with increased cardiovascular risk in haemodialysis patients: insights from the AURORA study. Duarte, K; Fauler, G; Fellström, B; Girerd, N; Jardine, AG; März, W; Massy, ZA; Rossignol, P; Sadiku, S; Scharnagl, H; Schmieder, RE; Silbernagel, G; Zannad, F, 2022)	0.72
" Our study aimed to explore the effect of IBS and IBD on atorvastatin (ATV) pharmacokinetics, enhance ATV oral bioavailability (BCS II drug) using SFT, and analyze drug-disease-formulation interaction using a whole-body physiologically based pharmacokinetic (wbPBPK) model in rat and human."	( Enhancing Atorvastatin In Vivo Oral Bioavailability in the Presence of Inflammatory Bowel Disease and Irritable Bowel Syndrome Using Supercritical Fluid Technology Guided by wbPBPK Modeling in Rat and Human. Abu-Farsakh, NA; Al-Daoud, NM; Alsmadi, MM; Obaidat, RM, 2022)	1.37
" The increase in sofosbuvir bioavailability was more pronounced after atorvastatin intake."	( Statins Increase the Bioavailability of Fixed-Dose Combination of Sofosbuvir/Ledipasvir by Inhibition of P-glycoprotein. Abdelaziz, A; Abdelgaied, MY; Abdelkawy, KS; Belal, F; El-Khodary, NM; Elmekawy, HA, 2022)	0.96
" Like other long-acting GLP-1 analogues, semaglutide reduces gastric emptying and, potentially, alters the rate of absorption of orally co-administered drugs."	( Population pharmacokinetic of paracetamol and atorvastatin with co-administration of semaglutide. Kristensen, K; Langeskov, EK, 2022)	0.98
" Upon successful application of the method to a pharmacokinetic interaction study, the results indicated that NG significantly enhanced the bioavailability of ATV and 2-ATV."	( Development of a UPLC-MS/MS method for the simultaneous determination of atorvastatin, 2-hydroxy atorvastatin, and naringenin in rat plasma and its application to pharmacokinetic interaction studies. Li, W; Li, Y; Wang, S; Xu, X; Zhang, T; Zhang, Y, 2023)	1.14
" In this study, we constructed ATV-loaded nanoemulsions (ATV-NEs) containing multivalent intestinal transporter-targeting lipids to improve the oral bioavailability of ATV."	( Enhancement of the anticancer effect of atorvastatin-loaded nanoemulsions by improving oral absorption via multivalent intestinal transporter-targeting lipids. Byun, Y; Cho, SS; Khadka, B; Kim, KT; Kweon, S; Pandey, P; Park, JW; Shim, JH; Subedi, L, 2022)	0.99
" Although statin therapy can reduce the chances of atherosclerotic plaque formation, they need to be administered in high doses due to low systemic bioavailability and encountered with side effects."	( Enhancing the biopharmaceutical attributes of atorvastatin calcium using polymeric and lipid-polymer hybrid nanoparticles: An approach for atherosclerosis treatment. Gao, T; Jiang, L; Li, F; Li, S; Liu, M; Shi, B, 2023)	1.17
" Co-administration of linagliptin with either carvedilol or atorvastatin can modulate the oral bioavailability of linagliptin."	( Investigation of the effect of concurrently administered carvedilol, atorvastatin and bile salts on intestinal absorption of linagliptin. El Maghraby, GM; Embaby, MA; Osman, MA; Sultan, AA, 2023)	1.39
"Atorvastatin calcium (AC), a cholesterol-lowering medication, has limited oral bioavailability (14 %) and adverse impacts on the gastrointestinal tract (GIT), liver, and muscle."	( Formulation, and optimization of transdermal Atorvastatin Calcium-Loaded Ultra-flexible vesicles; ameliorates poloxamer 407-caused dyslipidemia. Akl, MA; Ibrahim, MF; Kassem, AA; Ryad, S, 2023)	2.61
"Despite significant advances in oral drug delivery technologies, many drugs are prone to limited oral bioavailability due to biological barriers that hinder drug absorption."	( Atorvastatin-loaded pro-nanolipospheres with ameliorated oral bioavailability and antidyslipidemic activity. Gardouh, AR; Ghorab, MM; Khafagy, ES; Motawee, AO, 2023)	2.35

Dosage Studied

Amlodipine besylate (Norvasc) with atorvastatin calcium (Lipitor) marketed as Caduet (Pfizer Ltd) First dual-therapy compound designed to treat hypertension and/or angina and dyslipidemia concurrently with a single daily pill.

Excerpt	Relevance	Reference
" In 4 studies [2-wk rising dose (daily increasing doses for 1 wk; maintenance for 1 wk), 12-wk rising dose (daily dosing with weekly increases in dose), 2-wk toxicity (daily dosing for 2 wk; 3 dose levels), 13-wk toxicity (daily dosing for 13 wk; 3 dose levels)], dogs received up to 400 mg/kg orally."	( Subchronic toxicity of atorvastatin, a hydroxymethylglutaryl-coenzyme A reductase inhibitor, in beagle dogs. Albassam, MA; Clarke, DE; Walsh, KM, )	0.44
"52 mmol/L (400 mg/dl) received once-daily dosing with atorvastatin (Lipitor) 10 mg or simvastatin (Zocor) 10 mg."	( A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Best, J; Black, D; Bracs, P; d'Emden, M; Dart, A; Hamilton-Craig, I; Jerums, G; Nicholson, G; Sullivan, D; Tallis, G; West, M, 1997)	0.77
" The two dosage groups were well matched and had no difference in lipoprotein responses."	( Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia. Bateman, ME; Byrnes, P; Firth, JC; Marais, AD; Martens, C; Mountney, J, 1997)	1.74
" A 52-week interim sacrifice and a reversal group in which dosing was terminated at week 52 and the dogs sacrificed at week 64, was included in the 104-week study."	( Atorvastatin is not cataractogenic in beagle dogs. Robertson, DG; Rothwell, CE; Urda, ER; Walsh, KM, 1997)	1.74
" Thus atorvastatin had no consistent effect on the anticoagulant activity of warfarin and adjustment in warfarin dosing should not be necessary."	( Atorvastatin does not alter the anticoagulant activity of warfarin. Abel, R; Besserer, J; Gibson, GL; Stern, R, 1997)	2.22
" The two drugs exhibited similar IC50's for inhibition of either rat or human reductase, and single oral dosing in rats showed the compounds to be nearly equipotent at inhibiting hepatic cholesterol synthesis."	( Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase: a comparison of atorvastatin and simvastatin. Bergstrom, JD; Bostedor, RG; Chao, YS; Geissler, WM; Rew, DJ; Wright, SD, 1998)	0.52
" In accordance with manufacturers' recommendations, maximum dosage was atorvastatin 80 mg daily or simvastatin 40 mg daily (+cholestyramine 4 g daily in 84% of cases)."	( Comparison of atorvastatin alone versus simvastatin +/- cholestyramine in the management of severe primary hypercholesterolaemia (the six cities study). Simons, LA, 1998)	0.89
" Twenty-seven (N = 27) patients with primary hypertriglyceridemia (TG > 350 mg/dL) were studied before and after 4 weeks on atorvastatin treatment at a dosage of either 20 (n = 16) or 80 (n = 11) mg/d."	( Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin. Bakker-Arkema, R; Black, D; Brown, WV; Innis-Whitehouse, W; Le, NA; Li, X, 2000)	0.72
" LDL cholesterol levels were reduced by 17% at the 40 mg/day and by 28% at the 80 mg/day dosage (P<0."	( Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia. Black, DM; Firth, JC; Heinonen, TM; Illingworth, DR; Kotze, MJ; Marais, AD; Pappu, AS; Pilcher, GJ; Raal, FJ, 2000)	0.58
" Steady-state atorvastatin pharmacokinetic parameters were estimated on the last day of each dosing period."	( Pharmacodynamics and pharmacokinetic-pharmacodynamic relationships of atorvastatin, an HMG-CoA reductase inhibitor. Abel, RB; Hounslow, NJ; MacMahon, M; Olson, SC; Stern, RH; Yang, BB, 2000)	0.9
"6 mmol/l (100 mg/dl) maintained the same dosage regimen until they had completed 16 weeks of treatment."	( Efficacy and safety of atorvastatin in hyperlipidemic, type 2 diabetic patients. A 34-week, multicenter, open-label study. Aguilar-Salinas, CA; Alvarado Vega, A; Angélica Gómez-Díaz, R; Eduardo Romero-Nava, L; Gómez-Pérez, FJ; Guillén, LE; Gulías-Herrero, A; Meaney, E; Mendoza Pérez, E; Moguel, R; Novoa, G; Posadas-Romero, C; Salinas-Orozco, S; Vázquez-Chávez, C, 2000)	0.62
" The calculated average annual maintenance cost was based on the distribution of the final daily dosing regimens and the public drug prices for each regimen."	( Cost-minimization analysis of simvastatin versus atorvastatin for maintenance therapy in patients with coronary or peripheral vascular disease. Allen, SE; Attanasio, E; Russo, P, 2001)	0.57
" Dose-response curves to acetylcholine (10(-9)-10(-4) mol/l) and sodium nitroprusside (10(-9)-10(-4) mol/l) were studied in segmental arteries in the presence or absence of the thromboxane A2/PGH2 receptor antagonist ifetroban (10(-5) mol/l)."	( Atorvastatin prevents glomerulosclerosis and renal endothelial dysfunction in hypercholesterolaemic rabbits. Aragoncillo, P; Cachofeiro, V; Cediel, E; de Las Heras, N; Díaz, C; Hernández, G; Lahera, V; Navarro-Cid, J; Ruilope, LM; Sanz-Rosa, D; Vázquez-Pérez, S, 2001)	1.75
" Dose-response curves of simvastatin for bone formation and resorption differed."	( Effect of statins on bone mineral density and bone histomorphometry in rodents. Conradie, MM; Gopal, R; Hough, S; Hulley, PA; Maritz, FJ, 2001)	0.31
" Six product brands encompassing 20 dosage strengths have been available during the past two years."	( Managed care trends in statin usage. Bazalo, GR, 2001)	0.31
" Trends in market share, mean daily dose, and dosage distribution of the six current statin brands were examined."	( Managed care trends in statin usage. Bazalo, GR, 2001)	0.31
" Nelfinavir increased the steady-state area under the plasma concentration-time curve during one dosing period (AUC(tau)) of atorvastatin 74% and the maximum concentration (C(max)) of atorvastatin 122% and increased the AUC(tau) of simvastatin 505% and the C(max) of simvastatin 517%."	( Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Hsyu, PH; Kerr, BM; Lewis, RH; Lillibridge, JH; Schultz-Smith, MD, 2001)	0.73
" After 5 years of failed therapy with other antihyperlipidemic agents, the patient finally agreed to undergo test dosing to a similar statin agent atorvastatin."	( Using test dose challenges to restore essential therapy in patients with idiopathic anaphylaxis and pharmacophobia: report of a patient with idiopathic anaphylaxis and statin phobia. Davison, R; Harris, KE; Mastrovich, JD; Patterson, R, )	0.33
"The investigation showed that half-tablet dosing was as effective as whole-tablet dosing."	( Effect of tablet splitting on serum cholesterol concentrations. Castle, SS; Duncan, MC; Streetman, DS, 2002)	0.31
"Neural networks have been used in diagnosing and treating many diseases, including the diagnosis of myocardial infarction and insulin dosing in diabetes mellitus."	( A preliminary evaluation of neural network analysis for pharmacodynamic modeling of the dosing of the hydroxymethylglutaryl coenzyme A-reductase inhibitors simvastatin and atorvastatin. Moon, A; Smith, T, 2002)	0.51
"The goal of this study was to develop a preliminary pharmacodynamic model for dosing of the hydroxymethylglutaryl coenzyme A (HMG-CoA)-reductase inhibitors simvastatin and atorvastatin using neural network analysis."	( A preliminary evaluation of neural network analysis for pharmacodynamic modeling of the dosing of the hydroxymethylglutaryl coenzyme A-reductase inhibitors simvastatin and atorvastatin. Moon, A; Smith, T, 2002)	0.7
"A neural network model for the dosing of the HMG-CoA-reductase inhibitors simvastatin and atorvastatin demonstrated an ability to predict appropriate dosing, but inclusion of other factors (eg, age, body weight, sex) and a larger sample size may be necessary for development of a more accurate model."	( A preliminary evaluation of neural network analysis for pharmacodynamic modeling of the dosing of the hydroxymethylglutaryl coenzyme A-reductase inhibitors simvastatin and atorvastatin. Moon, A; Smith, T, 2002)	0.73
" However, atorvastatin had a different dose-response effect from simvastatin on both lipid parameters."	( Dose-response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: a review of five comparative studies. Mikhailidis, DP; Wierzbicki, AS, 2002)	1.02
"The mean dosage of atorvastatin was 24 mg/day."	( Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Athyros, VG; Athyrou, VV; Basayannis, EO; Demitriadis, DS; Kontopoulos, AG; Mercouris, BR; Papageorgiou, AA; Symeonidis, AN, 2002)	1
"The objective of this pilot study was to evaluate the comparative efficacy of alternate-day dosing of atorvastatin compared with the standard once-daily dose based on mean low-density lipoprotein (LDL) reduction from baseline at 6 and 12 weeks of treatment."	( Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day Versus Daily Dosing of Atorvastatin Study (ADDAS). Deedwania, PC; Matalka, MS; Ravnan, MC, 2002)	0.83
" Overall, more patients in the initial rosuvastatin 10-mg group achieved their ATP-II LDL-C goal than those in the initial atorvastatin 10-mg group (98% vs 87%), with 82% of patients treated with rosuvastatin achieving their goal at the 10-mg starting dosage without the need for titration, compared with 59% of patients treated with atorvastatin."	( Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Istad, H; Luurila, O; Olsson, AG; Ose, L; Pears, J; Southworth, H; Stender, S; Tuomilehto, J; Wiklund, O; Wilpshaar, JW, 2002)	0.82
" Policosanol is a cholesterol-lowering drug purified from sugar cane wax with a therapeutic dosage range from 5-20 mg/day."	( Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia. Alvarez, E; Castaño, G; Fernández, L; Illnait, J; Lezcay, M; Mas, R; Mesa, M, 2003)	0.56
" The accumulation of NO2/NO3 in HMEC exposed to increasing concentrations of more intensively oxidized-LDLs showed a nonlinear dose-response curve."	( The effect of lipoproteins on endothelial nitric oxide synthase is modulated by lipoperoxides. Baldi, S; Blandizzi, C; Del Tacca, M; L'Abbate, A; Lubrano, V; Natali, A; Palombo, C; Vassalle, C, 2003)	0.32
" Moreover, the reduction in the cholesterol content of LDL <255 A was directly correlated with the daily dosage of atorvastatin (P=0."	( Effects of atorvastatin on electrophoretic characteristics of LDL particles among subjects with heterozygous familial hypercholesterolemia. Bergeron, J; Couture, P; Gagné, C; Hogue, JC; Lamarche, B; Larivière, M; Pirro, M, 2003)	0.92
" Therefore there is no need to adapt atorvastatin dosage in this particular patient population."	( Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients. Dratwa, M; Lameire, NH; Lins, RL; Matthys, KE; Peeters, PC; Stolear, JC; Verpooten, GA, 2003)	0.92
"Comparing the dose-response of a new drug to that of a previously studied drug can aid in understanding their relative potencies."	( Comparison of the dose-response relationships of 2 lipid-lowering agents: a Bayesian meta-analysis. Berry, DA; Berry, SM; McKellar, J; Pearson, TA, 2003)	0.32
"Combining this study and literature results substantially increased the power to compare the dose-response relationships of rosuvastatin and atorvastatin."	( Comparison of the dose-response relationships of 2 lipid-lowering agents: a Bayesian meta-analysis. Berry, DA; Berry, SM; McKellar, J; Pearson, TA, 2003)	0.52
"Bayesian meta-analysis of results from related studies allows the comparison of the dose-response relationships of 2 drugs, better estimates of a particular dose-response relationship within an individual study, and the expression of relative benefits (of dose and drug) in terms of probabilities."	( Comparison of the dose-response relationships of 2 lipid-lowering agents: a Bayesian meta-analysis. Berry, DA; Berry, SM; McKellar, J; Pearson, TA, 2003)	0.32
"Alternate-day dosing of atorvastatin is an efficacious and safe alternative to daily dosing."	( Efficacy of alternate-day dosing versus daily dosing of atorvastatin. Ahmadi-Kashani, M; Balian, H; Bashir, M; Ebrahimi, R; Jafari, M, 2003)	0.87
" Dosage was increased to 20 mg if LDL cholesterol (LDL-C) levels remained >3."	( Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. Marais, AD; McCrindle, BW; Ose, L, 2003)	0.63
" The mean dose-response relationship has been shown to be log-linear for atorvastatin, but plasma concentrations of atorvastatin acid and its metabolites do not correlate with LDL-cholesterol reduction at a given dose."	( Clinical pharmacokinetics of atorvastatin. Lennernäs, H, 2003)	0.84
" All these parameters were evaluated in patients after 6 and 12 months of treatment with atorvastatin at a dosage of 20 mg/day."	( Long-term hemostatic effects of cholesterol-lowering therapy with atorvastatin. Frisina, N; Gaudio, A; La Rocca, R; Lasco, A; Morini, E; Pizzoleo, MA; Scamardi, R; Trifiletti, A, )	0.59
" Indeed, an interim analysis demonstrated the efficacy of atorvastatin, at a daily dosage of 10 mg as compared to placebo, in the prevention of major cardiovascular events, so that it appeared unethical to continue the study until the end."	( [Clinical study of the month. Premature interruption of ASCOT and CARDS clinical trials of cardiovascular prevention with atorvastatin in patients with arterial hypertension or diabetes mellitus: compromise between ethics and statistics in evidence-based Scheen, AJ, 2003)	0.77
" These results were achieved with atorvastatin 10 mg/day (80 mg/day used in MIRACL), lovastatin 20 to 40 mg/day (caused by dosage titration), pravastatin 40 mg/day, simvastatin 20 to 80 mg/day (caused by dosage titration) or fluvastatin 80 mg/day."	( Atorvastatin: gold standard for prophylaxis of myocardial ischemia and stroke - comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies. Gathof, BS; Gresser, U, 2004)	2.05
"A 67-year-old man receiving a stable maintenance dosage of warfarin experienced an increased international normalized ratio (INR) without bleeding when his atorvastatin therapy was switched to fluvastatin."	( Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature. Andrus, MR, 2004)	0.52
" Combination therapy of amlodipine besylate (Norvasc, Pfizer Ltd) with atorvastatin calcium (Lipitor, Pfizer Ltd), marketed as Caduet (Pfizer Ltd) is the first dual-therapy compound designed to treat hypertension and/or angina and dyslipidemia concurrently with a single daily pill in the full range of dosing combinations."	( Amlodipine/atorvastatin: the first cross risk factor polypill for the prevention and treatment of cardiovascular disease. Frishman, WH; Zuckerman, AL, 2004)	0.95
"5) After a 4-week wash-out period, they were randomized to amlodipine (5 mg) or atorvastatin (20 mg) or their combination at the same oral dosage for 12 weeks in three cross-over periods each separated by a 4-week placebo period (3 by 3 latin square design)."	( Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance. Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Mugellini, A; Rinaldi, A; Zoppi, A, 2004)	0.87
" Instructions for dosage adjustment are seldom provided in the Japanese package inserts."	( A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan. Hasegawa, R; Hirata-Koizumi, M; Miyake, S; Saito, M; Urano, T, 2005)	0.33
"On average, AUC(0-12) [area under the whole blood concentration versus time curve in the dosing interval (0-12 h)] of cyclosporine was 5% (-16, 5) (90% confidence interval) lower upon co-administration with atorvastatin."	( Atorvastatin does not affect the pharmacokinetics of cyclosporine in renal transplant recipients. Asberg, A; Christensen, H; Hartmann, A; Hermann, M; Holdaas, H; Reubsaet, JL, 2005)	1.96
" In addition to recommending lifestyle modifications, eight dosage strengths of amlodipine/atorvastatin single pill (5/10, 5/20, 5/40, 5/80, 10/10, 10/20, 10/40, and 10/80 mg) were electively titrated to improve blood pressure and lipid control."	( Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin gemini study). Blank, R; LaSalle, J; Maroni, J; Reeves, R; Sun, F; Tarasenko, L, 2005)	0.77
" The type and dosage of antihypertensive medications were not altered during statin therapy."	( Statin therapy helps to control blood pressure levels in hypertensive dyslipidemic patients. Akcay, A; Bilgi, M; Bozbas, H; Kanbay, M; Muderrisoglu, H; Ozdemir, FN; Ulus, T; Yildirir, A, 2005)	0.33
" It is advisable to increase the dosage of atorvastatin and preferable to administer it in the evening to guarantee adequate concentrations during the nighttime rapid cholesterol synthesis when rifampin or other potent inducers of cytochrome P450 3A4 are coadministered."	( Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Backman, JT; Luurila, H; Neuvonen, M; Neuvonen, PJ, 2005)	0.82
" Moreover, it is unclear if the cardiovascular disease history length was similar in the two treatment groups as well as the length and dosage of statin treatment of the about 25% of patients taking statins before the enrollment."	( REVERSAL and PROVE-IT: are clinically oriented trials really better than "pure" scientific studies? Cicero, AF; Gaddi, A, 2005)	0.33
" These changes were dependent upon dosage and were directly proportional to dosage rate."	( Histological and ultrastructural changes in cross-striation muscle cells, under the influence of atorvastatin-reductase HMG-CoA inhibitor. Czerny, K; Jedrych, B; Lańcut, M; Lis-Sochocka, M, 2004)	0.54
" Heart weight/body weight ratio and the degree of inflammation were significantly lower in the two dosage statin-treated groups than that in the untreated one."	( Effects of atorvastatin on the Th1/Th2 polarization of ongoing experimental autoimmune myocarditis in Lewis rats. Gao, C; Li, WM; Liu, W; Sun, NL, 2005)	0.72
" Group I-treated with pravastatin, group II--with simvastatin--both drugs in a dosage of 40 mg/kg daily, 5 days/week for a total of 3 weeks."	( Effect of pravastatin, simvastatin and atorvastatin on the phagocytic activity of mouse peritoneal macrophages. Bergman, M; Bessler, H; Djaldetti, M; Salman, H, 2006)	0.6
" Low-density lipoprotein cholesterol is the first priority for treatment, with a statin in adequate dosage as the first choice for pharmacological therapy."	( Reducing cardiovascular risk in diabetes: beyond glycemic and blood pressure control. Hobbs, FD, 2006)	0.33
"Correct execution of prescribed dosing regimen(s) is essential for patients to benefit from lipid lowering treatments."	( Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin. Belmans, A; de Klerk, E; Lesaffre, E; Matthys, K; Vrijens, B, 2006)	0.55
"A supportive pharmaceutical care program consisting of review by patient and pharmacist of each patient's electronically compiled dosing history, plus educational reminders, improves patient adherence to the once-daily atorvastatin dosing regimen, mainly by extending persistence."	( Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin. Belmans, A; de Klerk, E; Lesaffre, E; Matthys, K; Vrijens, B, 2006)	0.73
" Resolution on reduction of dosage or discontinuance and/or change of statin were deemed to constitute confirmation of cause."	( Safety of statins when response is carefully monitored: a study of 336 heart recipients. Aldama-López, G; Campo-Pérez, R; Castro-Beiras, A; Crespo-Leiro, MG; Llinares-García, D; Marzoa-Rivas, R; Muñiz-Garcia, J; Paniagua-Marin, MJ; Piñón-Esteban, P, 2005)	0.33
"We searched Medline, the international medical database, to conduct a systematic review of the literature on the efficacy and tolerability of statins in CKD and renal transplant patients and on specific recommendations for dosage adjustments in this population."	( [Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant]. Deray, G; Isnard-Bagnis, C; Karie, S; Launay-Vacher, V, 2006)	0.33
" Although most statins are not excreted by the kidneys, the dosage of some must be adapted in CKD patients because of pharmacokinetic modifications induced by renal impairment."	( [Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant]. Deray, G; Isnard-Bagnis, C; Karie, S; Launay-Vacher, V, 2006)	0.33
"Statins have been known to reduce progression of atherosclerosis when used in high dosage in patients with elevated cholesterol."	( Prevention of atherosclerosis progression using atorvastatin in normolipidemic coronary artery disease patients--a controlled randomized trial. Goel, PK; Jain, A; Sharma, MK; Shukla, A, )	0.39
" When the dosage of torcetrapib was doubled (at maximum tolerated dose), HDL increased by over 100%."	( Torcetrapib and atorvastatin: a novel combination therapy for dyslipidemia. Zareba, G, 2006)	0.68
" The area under the plasma concentration-time curve (AUC(0-infinity)) for ATV also increased significantly after intravenous dosing of ATV with RIF, but the extent was much less than that observed for oral ATV dosing."	( Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Benet, LZ; Huang, Y; Lau, YY; Okochi, H, 2006)	0.66
"Ezetimibe added to atorvastatin therapy compared with treatment with the most common fixed atorvastatin daily dosage (10 mg) or with common atorvastatin titration strategies (up to 20 mg daily; up to 40 mg daily) resulted in cost per QALY estimates ranging from 25,344 to 44,332 Canadian dollars."	( Cost effectiveness of adding ezetimibe to atorvastatin therapy in patients not at cholesterol treatment goal in Canada. Alemao, E; Attard, C; Bourgault, C; Cook, J; Huse, D; Kohli, M; Lam, A; Marentette, M; Yin, D, 2006)	0.93
" In 3 atorvastatin treated groups mice were fed the same diet as described above except atorvastatin was added to the diet at the dosage of 10 mg/kg per day for the last 8 weeks before euthanasia."	( Atorvastatin has distinct effects on endothelial markers in different mouse models of atherosclerosis. Jamborova, G; Nachtigal, P; Pospechova, K; Pospisilova, N; Semecky, V; Solichova, D; Zdansky, P, 2006)	2.26
"An analysis is made of the effect of alternateday dosing of atorvastatin and standard once-daily dosing, based on mean low-density lipoprotein (LDL) reduction from baseline in type 2 diabetics."	( Alternate-day dosing of atorvastatin: effects in treating type 2 diabetic patients with dyslipidaemia. Ferrer-García, JC; Herrera-Ballester, A; Martínez-Mir, I; Pérez-Silvestre, J, 2006)	0.88
"We sought to test the platelet inhibitory and anti-inflammatory effects of a higher statin dosage compared with combined treatment with ezetimibe plus a low statin dose."	( Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets? Fischer, S; Jaster, M; Martus, P; Morguet, AJ; Piorkowski, M; Rauch, U; Schultheiss, HP; Stellbaum, C, 2007)	0.61
" Statins were replaced with an equal dosage of fluvastatin."	( Fluvastatin as co-medication in heart transplant recipients with elevated creatine-kinase. Delgado, O; Kaczmarek, I; Meiser, B; Reichart, B; Sadoni, S; Schmöckel, M, 2007)	0.34
"A rapid high performance liquid chromatographic method was developed and validated for determination of atorvastatin in pharmaceutical dosage forms, and for evaluation of its stability in the solid phase."	( Validation of HPLC method for determination of atorvastatin in tablets and for monitoring stability in solid phase. Kania, L; Stanisz, B, )	0.6
" Treatment was started with 40 mg, followed by a dosage increase to 80 mg after 4 weeks."	( Effects of short term atorvastatin treatment on cerebral hemodynamics in CADASIL. Dichgans, M; Freilinger, T; Opherk, C; Peters, N; Pfefferkorn, T, 2007)	0.65
" Canadian data on statin dosing were combined with efficacy data from a published meta-analysis to determine the proportion of patients who would be expected to achieve LDL-C targets after treatment with atorvastatin or generic simvastatin."	( A model for assessing the cost-effectiveness of atorvastatin and simvastatin in achieving Canadian low-density lipoprotein cholesterol targets. Lachaine, J; Merikle, E; Montpetit, M; Rinfret, S; Tarride, JE, 2007)	0.78
"Two simple and accurate methods to determine atorvastatin calcium (ATO) and fenofibrate (FEN) in combined dosage forms were developed using second-derivative spectrophotometry and reversed-phase liquid chromatography (LC)."	( Estimation of atorvastatin calcium and fenofibrate in tablets by derivative spectrophotometry and liquid chromatography. Bhatt, HS; Bhatt, KK; Nakarani, NV; Patel, RD, )	0.75
" Application of this flexible first dosing strategy in general practice will, based on available evidence, increase adherence to atorvastatin treatment in patients with high CHD risk."	( Efficacy of atorvastatin after LDL-cholesterol-based dose selection in high risk dyslipidaemic patients: results of the target dose study. Claeys, M; Commers, K; Deforce, J; Ducobu, J; Nachtergaele, H; Van Mieghem, W; Vandenbroucke, M, 2007)	0.92
"To investigate the effects of two different dosage of atorvastatin on endothelium protection in spontaneously hypertensive rats (SHR)."	( [Effects of atorvastatin on endothelium protection in spontaneously hypertensive rats]. Hu, SJ; Sun, J; Zhang, ZJ, 2007)	0.97
" The results suggest that the effect of hydrophobic statins on the engulfing capacity of human peripheral blood phagocytes and apoptosis is dependent on their dosage and physiochemical properties."	( Hydrophobic but not hydrophilic statins enhance phagocytosis and decrease apoptosis of human peripheral blood cells in vitro. Bergman, M; Bessler, H; Djaldetti, M; Salman, H, 2008)	0.35
" The study was performed in a group of stable coronary patients treated for two years with a moderate dosage of atorvastatin (20mg/day)."	( E-selectin and TFPI are associated with carotid intima-media thickness in stable IHD patients: the baseline findings of the MIAMI study. Amato, M; Arquati, M; Baldassarre, D; Brusoni, B; Camera, M; Cortellaro, M; Fiorentini, C; Montorsi, P; Porta, B; Romano, S; Tremoli, E, 2008)	0.56
" In 2 atorvastatin-treated groups, mice were fed the same diets (chow or atherogenic) as described above except atorvastatin was added at the dosage of 10 mg x kg(-1) x day(-1) for the last 8 weeks before euthanasia."	( Endothelial expression of endoglin in normocholesterolemic and hypercholesterolemic C57BL/6J mice before and after atorvastatin treatment. Andrys, C; Jamborova, G; Nachtigal, P; Pospechova, K; Pospisilova, N; Semecky, V; Solichova, D; Zdansky, P, 2007)	1.03
" It is not associated with neurological, cognitive or renal adverse effects and does not require dosage adjustment in patients with renal dysfunction, due to its favourable pharmacokinetic profile, which is unique among the statins."	( Atorvastatin: a safety and tolerability profile. Arca, M, 2007)	1.78
" Estimated GFR improved in both treatment groups but was significantly greater with 80 mg than with 10 mg, suggesting this benefit may be dosage related."	( Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Bittner, V; Breazna, A; Deedwania, P; Dobson, S; Kastelein, JJ; Shepherd, J; Wenger, NK; Wilson, DJ; Zuckerman, A, 2007)	0.61
" Fifty-six patients were randomized to receive optimal dosage of atorvastatin (n = 27) or 200 mg/d micronized fenofibrate (n = 29) for 24 weeks."	( Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia. Antonini, R; Antonini, TM; Arca, M; Fraioli, A; Letizia, C; Luigi, P; Maddaloni, M; Mastrantoni, M; Montali, A; Pigna, G, 2007)	0.94
" Our objective was to explore how differences in prevalences of use, dosing characteristics, choice of statin and continuity of therapy in individual patients adds new information to previous results."	( Aspects of statin prescribing in Norwegian counties with high, average and low statin consumption - an individual-level prescription database study. Eggen, AE; Engeland, A; Furu, K; Hartz, I; Njølstad, I; Sakshaug, S; Skurtveit, S, 2007)	0.34
" Forty one patients remained throughout the study and had their weekly dosage reduced."	( Efficacy of atorvastatin when not administered daily. Ghattas, AE; Pimenta, J, 2007)	0.72
" If the target cholesterol levels has not been achieved 6 weeks after the treatment, then the daily atorvastatin dosage has been increased."	( The effects of atorvastatin therapy on endothelial function in patients with coronary artery disease. Baskurt, M; Cakar, MA; Coskun, U; Guzelsoy, D; Okcun, B; Yildiz, A, 2007)	0.91
" Eight dosage strengths of single-pill amlodipine/atorvastatin were flexibly titrated."	( Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trial. Bruschi, P; Ferdinand, KC; Flack, JM; Jamieson, MJ; Saunders, E; Shi, H; Tarasenko, L; Victor, R; Watson, K, 2008)	0.82
" The proposed method can be useful in the quality control of bulk manufacturing and pharmaceutical dosage forms."	( Stability-indicating reversed-phase liquid chromatographic method for simultaneous determination of atorvastatin and ezetimibe from their combination drug products. Chaudhari, BG; Patel, LJ; Patel, NM; Patel, VP; Shah, PB, )	0.35
" The control group of animals (n=8) was fed with the western type diet (atherogenic diet) and in other two groups atorvastatin was added to the atherogenic diet at the dosage of either 10 mg/kg or 100 mg/kg per day for a period of 2 months."	( Atorvastatin has hypolipidemic and anti-inflammatory effects in apoE/LDL receptor-double-knockout mice. Andrys, C; Jamborova, G; Micuda, S; Nachtigal, P; Pospechova, K; Pospisilova, N; Semecky, V; Solichova, D; Zdansky, P, 2008)	2
"Flexible initial dosing and early aggressive titration of atorvastatin according to LDL-C levels is an efficient and safe strategy for achieving the target level and for improving endothelial dysfunction in hyperlipidemic patients with type 2 diabetes."	( Flexible initial dosing of atorvastatin based upon initial low-density lipoprotein cholesterol levels in type 2 diabetic patients. , 2008)	0.89
" There was also evidence of a dose-response relationship between CRP reductions from baseline and rosuvastatin."	( Models for the analysis of C-reactive protein in statin trials. Dane, A; Southworth, H, )	0.13
"A number of analytical methods were reported for the estimation of atorvastatin and ramipril from their individual dosage forms or in combination with other drugs (Valiyare, 2004; Vachareau and Neirinck, 2000)."	( Simultaneous estimation of atorvastatin and ramipril by RP-HPLC and spectroscopy. George, M; Joseph, L; Rao B, VR, 2008)	0.88
" They were assigned to receive a daily dosage of atorvastatin based on their initial LDL-C levels."	( Efficacy of atorvastatin for achieving cholesterol targets after LDL-cholesterol based dose selection in patients with type 2 diabetes. Albalat-Galera, R; Berzosa-Sanchez, M; Ferrer-García, JC; Herrera-Ballester, A; Sanchez-Ballester, E, 2008)	0.98
" The dose-response effect of atorvastatin on biomarkers of inflammation and oxidative stress has not been investigated in subjects with MS."	( Comparison effect of atorvastatin (10 versus 80 mg) on biomarkers of inflammation and oxidative stress in subjects with metabolic syndrome. Devaraj, S; Jialal, I; Siegel, D; Singh, U, 2008)	0.96
"Eligible patients had a 6-month period of no statin use prior to the initial statin prescription, an initial statin dosage of either 20 or 40 mg of simvastatin or 10 or 20 mg of atorvastatin (the most commonly used doses of both drugs), a 0 to 3-month 'qualifying period' after the first prescription to allow for varying minimum lengths of statin use, and no statin switches."	( Differences in cardiovascular event rates between atorvastatin and simvastatin among new users: managed-care experience. Vogel, RA; Willke, RJ; Zhou, S, 2008)	0.79
" Eight dosage strengths of single-pill amlodipine/atorvastatin (5/10, 10/10, 5/20, 10/20, 5/40, 10/40, 5/80 and 10/80 mg) were titrated to improve blood pressure and lipid control."	( Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study). Aguilar-Salinas, CA; Chaves, H; Chopra, P; Erdine, S; Guindy, R; Howes, LG; Moller, RA; Ro, YM; Schou, IM; Tse, HF, 2009)	0.92
" The results indicated that the bilayer tablets could be a potential dosage form for delivering AT and NA."	( Bilayer tablets of atorvastatin calcium and nicotinic acid: formulation and evaluation. Godwinkumar, S; Muralidharan, S; Nagarajan, M; Nirmal, J; Peddanna, C; Saisivam, S, 2008)	0.67
" To position the PMRP database for large-scale pharmacogenetic association studies in the context of lipid-lowering therapy, we constructed an electronic phenotyping algorithm to quantify exposure and dose-response for atorvastatin, the most commonly prescribed lipid-lowering agent within this population."	( Characterization of low-density lipoprotein cholesterol-lowering efficacy for atorvastatin in a population-based DNA biorepository. Berg, RL; Krauss, RM; Linneman, JG; McCarty, CA; Wilke, RA; Zhao, C, 2008)	0.76
"The impact of the 2 ezetimibe dosing strategies on percent lowering of low-density lipoprotein cholesterol (LDL-C) and achievement of National Cholesterol Education Program Adult Treatment Panel III (ATP III) goals was assessed in all patients prescribed ezetimibe 5 or 10 mg."	( Ezetimibe 5 and 10 mg for lowering LDL-C: potential billion-dollar savings with improved tolerability. Agarwal, S; Baruch, L; Eng, C; Gupta, B; Lieberman-Blum, SS, 2008)	0.35
" Patients were excluded if the dosage of their antidiabetic drugs was changed, if their drug therapy was altered within 3 months before starting statin therapy, or if events occurred that could affect glycemic control such as hospitalization."	( Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. Kadonosono, K; Takano, T; Tanaka, S; Terauchi, Y; Yamakawa, T, 2008)	0.35
"The primary determinants of drug interaction were the ln-transformed area under the plasma concentration versus time curve (AUCtau) and maximum measured steady-state plasma concentration (C(max,ss)) over the final 24 h dosing interval (day 14) for atorvastatin and 2-hydroxyatorvastatin."	( Effect of omega-3-acid ethyl esters on steady-state plasma pharmacokinetics of atorvastatin in healthy adults. Di Spirito, M; Doyle, RT; Johnson, J; McKenney, J; Morelli, G, 2008)	0.75
" The drug was given as monotherapy for 10 days, and after a 6-day run-in period with atorvastatin 80 mg/day, the same dosage of atorvastatin was continued with the respective thienopyridine for 10 days."	( Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects. Brandt, JT; Ernest, CS; Farid, NA; Jakubowski, JA; Konkoy, CS; Li, YG; Payne, CD; Salazar, DE; Small, DS; Winters, KJ, 2008)	0.97
"Blood samples were collected before and at various time points after dosing on days 1 and 11 for determination of plasma concentrations of metabolites and for measurement of platelet aggregation induced by adenosine 5'-diphosphate 20 microM and vasodilator-stimulated phosphoprotein (VASP)."	( Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects. Brandt, JT; Ernest, CS; Farid, NA; Jakubowski, JA; Konkoy, CS; Li, YG; Payne, CD; Salazar, DE; Small, DS; Winters, KJ, 2008)	0.75
" The lack of a clinically meaningful effect of high-dose atorvastatin on the pharmacodynamic response to prasugrel after the loading or maintenance dose indicates that no dosage adjustment should be necessary in patients receiving these drugs concomitantly."	( Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects. Brandt, JT; Ernest, CS; Farid, NA; Jakubowski, JA; Konkoy, CS; Li, YG; Payne, CD; Salazar, DE; Small, DS; Winters, KJ, 2008)	0.99
"Alternate-day dosing of atorvastatin causes a significant lipid-lowering and antiinflammatory effects similar to that of daily administration and yet may provide some cost savings."	( The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and high sensitive C-reactive protein levels. Akar Bayram, N; Aydoğdu, S; Canbay, A; Diker, E; Durmaz, T; Kayhan, T; Keleş, T; Ozdemir, O; Sahin, D, 2008)	0.91
"022) compared with no treatment, and there was an apparent dose-response effect with the lowest levels of total testosterone seen in men treated with >or=20 mg atorvastatin (9."	( Statin therapy is associated with lower total but not bioavailable or free testosterone in men with type 2 diabetes. Channer, KS; Jones, TH; Kapoor, D; Stanworth, RD, 2009)	0.55
" Twenty-two patients (15 without nephropathy and seven with nephropathy) received atorvastatin in individually adjusted oral dosage (range 10-20 mg) once per day for 12 weeks."	( Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy. Abdin, AA; El-Noeman, Sel-D; Hassanien, MA; Ibrahim, EA, )	0.68
"The effects of demographic and clinical covariates on the apparent clearance (CL/F) of orally administered atorvastatin, with chronic dosing in a patient population that included the elderly, were studied in 143 patients (atorvastatin: 34 +/- 26 mg/day, mean +/- SD; men (n = 64), age 64."	( Population analyses of atorvastatin clearance in patients living in the community and in nursing homes. Schwartz, JB; Verotta, D, 2009)	0.88
" A dose of 10 mg of atorvastatin daily to target LDL-C goal was taken as the standard dosage targeting goal (SDTG)."	( [The statin dosage for achieving goal of cholesterol-lowering based on risk stratification in patients with ischemic cerebrovascular diseases]. Fu, YG; Guo, YD; Tan, ZF; Wang, TG; Xu, AD; Yang, WY, 2009)	0.68
" The amplitude of LDL-C lowering was 32% - 35%, 46% - 49%, 51% - 52% and 60% - 65% with corresponding to daily dosage of 10 mg, 20 mg, 40 mg and 80 mg atorvastatin."	( [The statin dosage for achieving goal of cholesterol-lowering based on risk stratification in patients with ischemic cerebrovascular diseases]. Fu, YG; Guo, YD; Tan, ZF; Wang, TG; Xu, AD; Yang, WY, 2009)	0.55
" The dose-response relationship for atorvastatin in elderly patients with unstable angina (UA) during early hospitalization in terms of lowering inflammatory factors, improving vascular endothelium function and safety is unclear."	( Efficacy and safety of atorvastatin during early hospitalization in elderly patients with unstable angina. Ge, ZM; Geng, J; Kang, WQ; Wang, W; Zhang, Y; Zhao, Z, 2009)	0.94
" Moreover, nonsignificant interactions between dosage and duration of therapy were found."	( Pleiotropic effects of atorvastatin on monocytes in atherosclerotic patients. Deng, JT; Hu, XY; Li, L; Liu, XL; Shang, YY; Wang, ZH; Zhang, LP; Zhang, W; Zhang, Y; Zhong, M, 2010)	0.67
" ATN Ca unit dosage form was developed and evaluated for physico-chemical properties, stability, and dissolution rate."	( Solubility and stability enhancement of atorvastatin by cyclodextrin complexation. Palem, CR; Patel, S; Pokharkar, VB, )	0.4
"The CANadians Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (CanACTFAST) trial tested whether an algorithm-based statin dosing approach would enable patients to achieve LDL-C and total cholesterol/high-density lipoprotein cholesterol (TC/HDL-C) ratio targets quickly."	( Achieving cholesterol targets by individualizing starting doses of statin according to baseline low-density lipoprotein cholesterol and coronary artery disease risk category: the CANadians Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titr Calciu, CD; Langer, A; Leiter, LA; Rabkin, SW; Ur, E, 2010)	0.8
"Algorithm-based statin dosing enables patients to achieve LDL-C and TC/HDL-C ratio targets quickly, with either no titration or a single titration."	( Achieving cholesterol targets by individualizing starting doses of statin according to baseline low-density lipoprotein cholesterol and coronary artery disease risk category: the CANadians Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titr Calciu, CD; Langer, A; Leiter, LA; Rabkin, SW; Ur, E, 2010)	0.54
" Patients switched to an equivalent simvastatin dose had lower LDL-C levels and were more likely to achieve LDL-C targets than patients switched to a non-equivalent dose, suggesting physicians must consider dosage equivalence when switching statins, and should measure LDL-C and titrate statins as necessary to achieve LDL-C control."	( LDL-C goal attainment in patients who remain on atorvastatin or switch to equivalent or non-equivalent doses of simvastatin: a retrospective matched cohort study in clinical practice. Burke, JP; Rublee, DA, 2010)	0.62
" In conclusion, commercial ATC samples exhibited diverse solid state behavior that can impact the performance and stability of the dosage forms."	( Solid state characterization of commercial crystalline and amorphous atorvastatin calcium samples. Bansal, AK; Kumar, L; Puri, V; Shete, G, 2010)	0.6
"Fifty-four patients with CAD who had received atorvastatin treatment for at least 8 weeks (mean dosage 30 mg/day) and 54 patients with CAD who had not received atorvastatin therapy were selected from a larger prospective, randomized, double-blind study for inclusion in this post hoc analysis."	( Effect of atorvastatin on haemostasis, fibrinolysis and inflammation in normocholesterolaemic patients with coronary artery disease: a post hoc analysis of data from a prospective, randomized, double-blind study. Borggrefe, M; Dempfle, CE; Hoffmeister, HM; Lang, S; Suselbeck, T; Swoboda, S; Szabo, S; Walter, T, 2010)	1.02
" CsA inhibition ranged from 28 to 77% within a dosing interval, whereas it was less than 1% for Tac, considering free concentrations and assuming competitive inhibition."	( Cyclosporine A, but not tacrolimus, shows relevant inhibition of organic anion-transporting protein 1B1-mediated transport of atorvastatin. Amundsen, R; Asberg, A; Christensen, H; Zabihyan, B, 2010)	0.57
"The existing data suggest that atorvastatin is generally well tolerated across the range of its therapeutic dosage (10 - 80 mg/day)."	( Atorvastatin: safety and tolerability. Athyros, VG; Karagiannis, A; Mikhailidis, DP; Tziomalos, K, 2010)	2.09
" Furthermore, the following trends of interest were calculated for each calendar year: the percentage of statin users prescribed simvastatin or atorvastatin, the median dose of simvastatin and atorvastatin prescribed, and the percentage of simvastatin users prescribed a dosage of 40 mg/day (which is recommended by the Dutch multidisciplinary guideline)."	( Statin prescribing in the elderly in the Netherlands: a pharmacy database time trend study. Geleedst-De Vooght, M; Jansen, P; Maitland-van der Zee, AH; Mantel-Teeuwisse, A; Schalekamp, T, 2010)	0.56
"Two crossover studies were performed in healthy subjects: a two-period study of dalcetrapib 900 mg concurrently with atorvastatin (concurrent dosing study) and a three-period study of dalcetrapib 600 mg (dose chosen for Phase III) with atorvastatin concurrently or serially 4 h after dalcetrapib (interval dosing study)."	( No clinically relevant drug-drug interactions when dalcetrapib is co-administered with atorvastatin. Abt, M; Derks, M; Meneses-Lorente, G; Parr, G; Phelan, M; Young, AM, 2010)	0.79
" In the interval study (n = 52), serial and concurrent co-administration of atorvastatin resulted in similar reductions in dalcetrapib exposure that were comparable to those observed in the concurrent dosing study."	( No clinically relevant drug-drug interactions when dalcetrapib is co-administered with atorvastatin. Abt, M; Derks, M; Meneses-Lorente, G; Parr, G; Phelan, M; Young, AM, 2010)	0.81
"Two spectrophotometric methods are presented for the simultaneous determination of ezetimibe/simvastatin and ezetimibe/atorvastatin binary mixtures in combined pharmaceutical dosage forms without prior separation."	( Enhanced spectrophotometric determination of two antihyperlipidemic mixtures containing ezetimibe in pharmaceutical preparations. Barary, MA; El-Kimary, EI; Hassan, EM; Maher, HM; Youssef, RM, 2011)	0.58
" These data therefore demonstrate that dosing considerations in the current labels for atorvastatin are similar for Asian compared with Caucasian subjects."	( Systemic exposure to atorvastatin between Asian and Caucasian subjects: a combined analysis of 22 studies. Fung, GL; Gandelman, K; Laskey, R; Messig, M, 2012)	0.92
"In this work the effects of Atorvastatin (liptonorm) in a dosage of 10 mg/24h during 12 months concerning the basic indicators of a lipid spectrum of blood in the patients with a metabolic syndrome are estimated."	( [Effect of atorvastatin (liptonorm) on indicators of the lipid spectrum of blood in patients with the metabolic syndrome]. Lakhin, DI; Vasil'eva, LV, 2010)	1.04
"Microwave energy was used to prepare an enhanced release dosage form of the poorly water soluble drug ATR with PEG 6000 as a hydrophilic carrier."	( Microwave induced solubility enhancement of poorly water soluble atorvastatin calcium. Belgamwar, V; Maurya, D; Tekade, A, 2010)	0.6
" The decrease can be prevented by the suggested dosage scheme."	( Use of ultra high performance liquid chromatography-tandem mass spectrometry to demonstrate decreased serum statin levels after extracorporeal LDL-cholesterol elimination. Bláha, M; Bláha, V; Lánská, M; Malý, J; Nováková, L; Solich, P; Solichová, D; Vlcková, H, 2011)	0.37
"To compare the safety and myocardial effects of different atorvastatin loading doses and dosing frequency before PCI in non-ST segment elevation acute coronary syndrome (NSTE-ACS) patients."	( Effect of different loading doses of atorvastatin on percutaneous coronary intervention for acute coronary syndromes. Gao, Y; Pang, X; Qi, G; Sun, Y; Zhang, H; Zhang, Z; Zhao, W, 2010)	0.88
" The reduced liver TG mass induced by a high dosage of atorvastatin may be important for the treatment of patients with fatty liver."	( Effects of high-dose statin on the human hepatic expression of genes involved in carbohydrate and triglyceride metabolism. Eriksson, M; Gustafsson, U; Parini, P; Pramfalk, C; Sahlin, S, 2011)	0.62
"This study was designed to compare the efficacy and tolerability of a generic formulation of atorvastatin 20 mg/d versus a branded formulation at the same dosage in hypercholesterolemic Korean adults at high risk for cardiovascular events."	( Efficacy and tolerability of a generic and a branded formulation of atorvastatin 20 mg/d in hypercholesterolemic Korean adults at high risk for cardiovascular disease: a multicenter, prospective, randomized, double-blind, double-dummy clinical trial. Cho, YS; Hong, SJ; Hyon, MS; Kim, DW; Kim, HS; Kim, SH; Lee, MY; Moon, GW; Park, K; Sung, JD; Yoon, MH, 2010)	0.82
"Two simple and accurate methods to determine atorvastatin calcium and ramipril in capsule dosage forms were developed and validated using HPLC and HPTLC."	( Simultaneous determination of atorvastatin calcium and ramipril in capsule dosage forms by high-performance liquid chromatography and high-performance thin layer chromatography. Panchal, HJ; Suhagia, BN, )	0.68
" As there is neither any consensus nor any guidelines regarding this issue, we aimed to define the optimal statin type and dosage for these patients."	( Optimal statin type and dosage for vascular patients. Mikhailidis, DP; Paraskevas, KI; Veith, FJ, 2011)	0.37
" Atorvastatin and rosuvastatin at the maximum dosage both significantly (p <0."	( Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation. Ai, M; Asztalos, BF; Himbergen, TV; Jones, PH; Nakajima, K; Otokozawa, S; Schaefer, EJ; Stein, E; Thongtang, N, 2011)	1.61
" A linear mixed-effects model was applied to account for the inherent correlation of multiple-plaque measurements from the same patient and to assess dose-response differences to statin therapy."	( In vivo carotid plaque MRI using quantitative T2* measurements with ultrasmall superparamagnetic iron oxide particles: a dose-response study to statin therapy. Gillard, JH; Graves, MJ; Müller, KH; Patterson, AJ; Tang, TY, 2011)	0.37
" At 40 mg dosage from 3rd month to 6th month versus 1st month to 3rd month it was significant decrease, at the end of 1st month and 3rd month it was not significant."	( Short-term therapy with high dose atorvastatin in patients with coronary artery disease can reduce inflammatory process. Abdollahian, F; Nesar Hossein, V; Yosef Nejad, K, )	0.41
"Despite recent advances in solid-state NMR spectroscopy, the structural characterization of amorphous active pharmaceutical ingredients (APIs) in solid dosage forms continues to be a monumental challenge."	( New perspectives of 19F MAS NMR in the characterization of amorphous forms of atorvastatin in dosage formulations. Brus, J; Brusova, H; Sedenkova, I; Urbanova, M, 2011)	0.6
" Serum levels of LDL-C, high-density lipoprotein cholesterol, total cholesterol, triglycerides, and creatinine kinase (CK) were measured before (day 1) and 7, 13, 14, 15, 16, 21, and 28 days after dosing initiation."	( Effect of HMGCR variant alleles on low-density lipoprotein cholesterol-lowering response to atorvastatin in healthy Korean subjects. Cho, SK; Chung, JY; Jang, SB; Lee, DH; Lee, YJ; Lim, LA; Oh, ES; Park, K; Park, MS, 2012)	0.6
"The results of our adverse drug analysis suggest a dose-response relationship."	( Statin-associated rhabdomyolysis: is there a dose-response relationship? Baker, S; Holbrook, A; Ribic, C; Sung, M; Wright, M, )	0.13
" Reduction of atorvastatin dosage when moderate amounts of GFJ are co-ingested does not appear to be necessary."	( Serum concentrations and clinical effects of atorvastatin in patients taking grapefruit juice daily. Browne, K; Derendorf, H; Ellington, D; Greenblatt, DJ; Harmatz, JS; Parent, SJ; Reddy, P; Zdrojewski, I; Zhu, Y, 2011)	0.99
" Serial pharmacokinetic sampling of atorvastatin was conducted on day 7 of atorvastatin dosing and day 70 of lamotrigine + atorvastatin dosing or day 28 of phenytoin + atorvastatin dosing."	( Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers. Alexander, S; Bullman, J; Fleck, R; Messenheimer, J; Miller, J; Nicholls, A; Van Landingham, K; Vuong, A, 2011)	0.88
" Blood samples were collected scheduled intervals for 24 hours after the last dosing to determine plasma concentrations of atorvastatin acid, atorvastatin lactone, 2-hydroxy atorvastatin acid, and 2-hydroxy atorvastatin lactone."	( The effect of the newly developed angiotensin receptor II antagonist fimasartan on the pharmacokinetics of atorvastatin in relation to OATP1B1 in healthy male volunteers. Cho, JY; Jang, IJ; Kim, SE; Kim, TE; Lee, MG; Shin, KH; Shin, SG; Song, IS; Yoon, SH; Yu, KS, 2011)	0.79
" The primary objective of the study was to determine the effect of once-daily dosing of a combination therapy for blood pressure (BP) and dyslipidemia using home BP monitoring on reaching clinical BP and the effect of daily dosing of combination therapy on reaching lipid goals."	( Improving adherence with amlodipine/atorvastatin therapy: IMPACT study. Crabbe, A; Delkhah, Y; Jones, J; Leonard, D; Nesbitt, S; Oliver, S, 2011)	0.64
" The selected excipients such as docusate sodium enhanced the stability and solubility of ATC in gastric media and tablet dosage form."	( Enhanced bioavailability of atorvastatin calcium from stabilized gastric resident formulation. Dehghan, MH; Khan, FN, 2011)	0.66
"Three simple, specific, accurate and precise spectrophotometric methods manipulating ratio spectra are developed for the simultaneous determination of Amlodipine besylate (AM) and Atorvastatin calcium (AT) in tablet dosage forms."	( Three different spectrophotometric methods manipulating ratio spectra for determination of binary mixture of Amlodipine and Atorvastatin. Darwish, HW; El-Zeiny, BA; Hassan, SA; Salem, MY, 2011)	0.77
" However, for a better interpretation of the experimental data as well as to possibly predict cholesterol levels given a certain dosing regimen of statins and phytosterols/-stanols a more theoretically based approach is helpful."	( Modelling approach to simulate reductions in LDL cholesterol levels after combined intake of statins and phytosterols/-stanols in humans. Eussen, SR; Klungel, OH; Rompelberg, CJ; van Eijkeren, JC, 2011)	0.37
" A daily oral dose of atorvastatin calcium treatment for 70 days weakened the long bones of methylprednisolone acetate treated rabbits irrespective of the dosage (2, 10, or 20 mg)."	( Effect of atorvastatin on the cortical bones of corticosteroid treated rabbits. Braitman, LE; Goldstein, DT; Handal, JA; John, TK; Khurana, JS; Saing, M; Samuel, SP, 2012)	1.1
" According to the dosage of preprocedural atorvastatin, the high hs-CRP group was further divided into 10 mg group (n = 49), 20 mg group (n = 66) and 40 mg group (n = 61)."	( [Association between high sensitivity C-reactive protein and contrast induced acute kidney injury in patients with acute coronary syndrome undergoing percutaneous coronary intervention: impact of atorvastatin]. Cai, WQ; Chai, DJ; Chen, GL; Chen, XP; Huang, QY; Su, JZ; Wang, FB; Xue, Y; Zhang, DS, 2011)	0.82
"8) who underwent a primary PCI for a first ST-elevated AMI were randomized for pretreatment with atorvastatin 80 mg (n = 20) or placebo (n = 22) and continued with the same dosage daily for 1 week."	( Early statin treatment prior to primary PCI for acute myocardial infarction: REPERATOR, a randomized placebo-controlled pilot trial. Doevendans, PA; Eefting, FD; Goumans, MJ; Post, MC; Post, S; Rensing, BJ; Stella, PR; van den Branden, BJ; van Es, HW; Wildbergh, TX, 2012)	0.6
"The primary objective of this study was to evaluate the low-density lipoprotein cholesterol (LDL-C)-lowering efficacy of 5 SAR236553/REGN727 (SAR236553) dosing regimens versus placebo at week 12 in patients with LDL-C ≥100 mg/dl on stable atorvastatin therapy."	( Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. Ferrand, AC; Hanotin, C; Kereiakes, DJ; Koren, MJ; McKenney, JM; Stein, EA, 2012)	0.75
"SAR236553 demonstrated a clear dose-response relationship with respect to percentage LDL-C lowering for both Q2W and Q4W administration: 40%, 64%, and 72% with 50, 100, and 150 mg Q2W, respectively, and 43% and 48% with 200 and 300 mg Q4W."	( Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. Ferrand, AC; Hanotin, C; Kereiakes, DJ; Koren, MJ; McKenney, JM; Stein, EA, 2012)	0.57
" These additional reductions are both dose- and dosing frequency-dependent."	( Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. Ferrand, AC; Hanotin, C; Kereiakes, DJ; Koren, MJ; McKenney, JM; Stein, EA, 2012)	0.57
"Evidence suggests that statins reduce cardiovascular complications in patients undergoing noncardiac surgery, although questions remain regarding the mechanism of benefit and the preferred dosing strategy."	( STAR VaS--Short Term Atorvastatin Regime for Vasculopathic Subjects: a randomized placebo-controlled trial evaluating perioperative atorvastatin therapy in noncardiac surgery. Bryson, GL; Neilipovitz, DT; Taljaard, M, 2012)	0.7
"2%, usually atorvastatin), or increasing atorvastatin dosage (59."	( Effectiveness of lipid-lowering therapy with statins for secondary prevention of atherosclerosis--guidelines vs. reality. Bożentowicz-Wikarek, M; Chudek, J; Kocełak, P; Olszanecka-Glinianowicz, M; Smertka, M, 2012)	0.76
"Muscular symptoms associated with average dosage statin therapy are more frequent than in clinical trials and have a greater impact on patients' life than usually thought."	( Discontinuation of statin therapy due to muscular side effects: a survey in real life. Bruckert, E; Dallongeville, J; Rosenbaum, D; Sabouret, P, 2013)	0.39
"The aim of the present study was to combine vibrational spectroscopy and chemometrics for investigating excipient-induced disproportionation of the calcium salt of atorvastatin into the corresponding free acid form in environments relevant to manufacturing and storage of solid dosage formulations."	( Disproportionation of the calcium salt of atorvastatin in the presence of acidic excipients. Christensen, NP; Cornett, C; Rantanen, J; Taylor, LS, 2012)	0.84
"Alternative dosing is often used clinically to address common barriers with statin therapy, such as intolerance and cost."	( The high-dose rosuvastatin once weekly study (the HD-ROWS). Backes, JM; Gibson, CA; Moriarty, PM; Ruisinger, JF, )	0.13
" The type and dosage of concomitant drugs were not changed during the study periods."	( Association of cholesteryl ester transfer protein mass with peripheral leukocyte count following statin therapy: a pilot study. Hirayama, A; Nagao, K; Tani, S, 2012)	0.38
"To compare the therapeutic effects of intensive versus moderate dosage of atorvastatin regimens in new-onset unstable angina with borderline lesions, 100 patients were randomized to receive either 80 mg/d or 20 mg/d atorvastatin for 9 months."	( Intensive-dose atorvastatin regimen halts progression of atherosclerotic plaques in new-onset unstable angina with borderline vulnerable plaque lesions. Gong, P; Lin, J; Liu, S; Lu, J; Lu, X; Qiu, J; Wang, H; Zhang, X, 2013)	0.97
" Log dose-response data revealed linear dose-related effects on blood total cholesterol, low-density lipoprotein (LDL)-cholesterol and triglycerides."	( Lipid lowering efficacy of atorvastatin. Adams, SP; Tsang, M; Wright, JM, 2012)	0.68
" Log dose-response data was linear over the commonly prescribed dose range."	( Lipid lowering efficacy of atorvastatin. Adams, SP; Tsang, M; Wright, JM, 2012)	0.68
"Three simple, specific, accurate and precise spectrophotometric methods depending on the proper selection of two wavelengths are developed for the simultaneous determination of Amlodipine besylate (AML) and Atorvastatin calcium (ATV) in tablet dosage forms."	( Three different methods for determination of binary mixture of Amlodipine and Atorvastatin using dual wavelength spectrophotometry. Darwish, HW; El-Zeany, BA; Hassan, SA; Salem, MY, 2013)	0.81
" Statistically significant increases in the systemic exposure of ortho- and para-hydroxyatorvastatin were also observed upon concomitant dosing with CP-778875."	( Elucidation of the biochemical basis for a clinical drug-drug interaction between atorvastatin and 5-(N-(4-((4-ethylbenzyl)thio)phenyl)sulfamoyl)-2-methyl benzoic acid (CP-778875), a subtype selective agonist of the peroxisome proliferator-activated recep Chen, D; Feng, B; Francone, OL; Frederick, KS; Goosen, TC; Gosset, JR; Kalgutkar, AS; Rotter, CJ; Scialis, RJ; Terra, SG; Varma, MV; Walsky, RL; West, MA, 2013)	0.84
" Subsequently, dogs with CHF (n = 12) were treated with atorvastatin at a dosage of 2 mg/kg q24 h for 8 weeks."	( Short-term effects of atorvastatin in normal dogs and dogs with congestive heart failure due to myxomatous mitral valve disease. Cunningham, SM; Freeman, LM; Rush, JE, )	0.69
" In this cohort, genotypes associated with statin concentration were not differently distributed among dosing groups, implying providers had not yet optimized each patient's risk-benefit ratio."	( Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Choi, YH; DeGorter, MK; Dresser, GK; Hegele, RA; Iwuchukwu, O; Kim, RB; Myers, K; Schwarz, UI; Suskin, N; Tirona, RG; Wei, WQ; Wilke, RA; Zou, G, 2013)	0.64
" Most of the patients on more potent statins were not advised by their cardiologists to change the type or dosage of statin, which was more common in patients on less potent statins."	( Prevalence and types of persistent dyslipidemia in patients treated with statins. Reiner, Ž; Tedeschi-Reiner, E, 2013)	0.39
" The results were better in patients treated with more potent statins and cardiologists advised them much less frequently to change the type and dosage of statin."	( Prevalence and types of persistent dyslipidemia in patients treated with statins. Reiner, Ž; Tedeschi-Reiner, E, 2013)	0.39
"The Biopharmaceutics Drug Disposition Classification System (BDDCS) predicts intestinal transporter effects to be clinically insignificant following oral dosing for highly soluble and highly permeable/metabolized drugs (class 1 drugs)."	( Effect of P-glycoprotein on the rat intestinal permeability and metabolism of the BDDCS class 1 drug verapamil. Benet, LZ; Estudante, M; Maya, M; Morais, JG; Soveral, G, 2013)	0.39
" We leveraged electronic medical records (EMRs) to extract potency (ED50) and efficacy (Emax) of statin dose-response curves and tested them for association with 144 preselected variants."	( Characterization of statin dose response in electronic medical records. Berg, RL; Davis, RL; Denny, JC; Feng, Q; Iwuchukwu, OF; Jiang, L; Jiang, M; Krauss, RM; McCarty, CA; Nickerson, DA; Peissig, PL; Roden, DM; Rotter, JI; Waitara, MS; Wei, WQ; Wilke, RA; Xu, H, 2014)	0.4
" The proposed method can be used for simultaneous estimation of these drugs in marketed dosage forms."	( RP-HPLC method development and validation for simultaneous estimation of atorvastatin calcium and pioglitazone hydrochloride in pharmaceutical dosage form. Ammineni, P; Kondreddy, Vk; Mallikarjuna, S; Peraman, R, 2014)	0.63
" The intrinsic dissolution rate and solubility of ATC-NIC were determined along with plasma concentrations of ATC using HPLC after oral dosing in rats."	( Coamorphous atorvastatin calcium to improve its physicochemical and pharmacokinetic properties. Ghavimi, H; Hamishekar, H; Jouyban, A; Shayanfar, A, 2013)	0.77
" Patients were monitored for 5 years, during which time they received regular visits with the opportunity to increase their dosage if they were above their LDL-C goal."	( Impact of switching treatment from rosuvastatin to atorvastatin on rates of cardiovascular events. Andy Schuetz, C; Folse, H; Gandhi, S; Rengarajan, B; Sternhufvud, C, 2014)	0.65
" Additional studies with multiple dosing of both drugs are needed to further determine the clinical implications of these results."	( Effect of steady-state atorvastatin on the pharmacokinetics of a single dose of colchicine in healthy adults under fasted conditions. Davis, MW; Wason, S, 2014)	0.71
" These data suggest that modeling of dose-response relationships may be useful in predicting clinical equivalence, lowering cost/timelines through effective powering of studies, and predicting the effectiveness of new dosage formulations without the need for additional clinical efficacy trials in regulatory settings."	( Prediction of clinical irrelevance of PK differences in atorvastatin using PK/PD models derived from literature-based meta-analyses. Adewale, A; Behm, MO; Kerbusch, T; Mandema, J; Vargo, R, 2014)	0.65
" The developed methods were applied for simultaneous analysis of aspirin, atorvastatin and clopedogrel in capsule dosage forms and results were in good concordance with alternative liquid chromatography."	( Comparative study of three modified numerical spectrophotometric methods: an application on pharmaceutical ternary mixture of aspirin, atorvastatin and clopedogrel. Hegazy, ND; Issa, MM; Nejem, RM; Shanab, AA; Stefan-van Staden, RI, 2014)	0.84
" The only pharmacologically mediated changes observed during the dosing period were the anticipated changes in circulating cholesterol."	( Combined administration of RG7652, a recombinant human monoclonal antibody against PCSK9, and atorvastatin does not result in reduction of immune function. Baruch, A; Chilton, J; Erwin, R; Forrest, AS; Gelzleichter, TR; Halpern, W; Leabman, M; Peng, K; Satterwhite, CM; Stevens, D, 2014)	0.62
"Atorvastatin has a limited advantage to formulate oral dosage forms."	( Solid self microemulsification of Atorvastatin using hydrophilic carriers: a design. Nanda Kishore, R; Rasheed, A; Sushma, M; Vadlamudi, HC; Vandana, KR; Yalavarthi, PR, 2015)	2.14
" Periodic dosing was negotiated following several patients' refusal of statin therapy because of muscle aches or cost."	( Periodic rosuvastatin or atorvastatin dosing arrays (PRADA): patient-centered practice. Christou, T; Dimitrov, R; Omar, HR, 2014)	0.71
" The primary endpoint was to assess the concentration of low-density lipoprotein cholesterol (LDL-C) and the total cholesterol/high-density lipoprotein cholesterol (TC/HDL-C) ratio with patient-directed dosing intervals."	( Periodic rosuvastatin or atorvastatin dosing arrays (PRADA): patient-centered practice. Christou, T; Dimitrov, R; Omar, HR, 2014)	0.71
"Periodic dosing of rosuvastatin or atorvastatin using a gradual, patient-directed, stepwise approach guided by cholesterol levels is an effective method of lipid lowering and carried a favorable 95."	( Periodic rosuvastatin or atorvastatin dosing arrays (PRADA): patient-centered practice. Christou, T; Dimitrov, R; Omar, HR, 2014)	0.98
" Cultures were treated with a therapeutic dosage of 5 commonly used statins: CEL, ATV + CEL, PGE2, and a selective antagonist of PGE2 receptor 4 (EP4)."	( Statins enhance rotator cuff healing by stimulating the COX2/PGE2/EP4 pathway: an in vivo and in vitro study. Brosh, T; Chechik, O; Dolkart, O; Gabet, Y; Liron, T; Maman, E; Somjen, D, 2014)	0.4
" The flexibility of the alirocumab dosing regimen allows for individualized therapy based on the degree of LDL-C reduction required to achieve the desired LDL-C level."	( Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies Bays, HE; Colhoun, HM; Donahue, S; Du, Y; Hanotin, C; Jones, PH; Robinson, JG, 2014)	0.6
"Opportunity to increase simvastatin dosing through education, prescribing targets and incentives."	( Quality and efficiency of statin prescribing across countries with a special focus on South Africa: findings and future implications. Bishop, I; Campbell, SM; Godman, B; Malmström, RE; Truter, I, 2015)	0.42
"To conduct a cost-effectiveness analysis of three statin dosing schemes in the Brazilian Unified National Health System (SUS) perspective."	( Cost-effectiveness of high, moderate and low-dose statins in the prevention of vascular events in the Brazilian public health system. Duncan, BB; Polanczyk, CA; Restelatto, LM; Ribeiro, RA; Stella, SF; Vieira, JL; Ziegelmann, PK, 2015)	0.42
" Expected differences between FDC and the corresponding co-administered doses were predicted from a dose-response relationship model; sample size was estimated given the expected difference and equivalence margins (±4%)."	( Fixed-dose combination ezetimibe+atorvastatin lowers LDL-C equivalent to co-administered components in randomized trials: use of a dose-response model. Bays, HE; Chen, E; McPeters, G; Polis, AB; Tomassini, JE; Triscari, J, 2015)	0.7
" After the dosage of cyclosporine was increased to 300 mg every day for 8 months, the patient developed body pain and leg weakness, with a serum creatine kinase increase and evidence on magnetic resonance imaging of muscle oedema."	( Increased dosage of cyclosporine induces myopathy with increased seru creatine kinase in an elderly patient on chronic statin therapy. Dong, B; He, J; Huang, X; Mo, L; Yue, Q, 2015)	0.42
" We hypothesized that the pharmacological and pharmacokinetic properties of atorvastatin-induced myopathy are the result of its interaction with high dosage of cyclosporine."	( Increased dosage of cyclosporine induces myopathy with increased seru creatine kinase in an elderly patient on chronic statin therapy. Dong, B; He, J; Huang, X; Mo, L; Yue, Q, 2015)	0.65
" The injection is administered intravenously,with most patients receiving a dosage of 15-20 mL per dose for between 1 and 14 days."	( [Analysis of clinical use of shuxuening injection in treatment of cerebral infarction based on real world]. Luo, YH; Wang, YY; Xie, YM; Yang, W; You, L; Zhuang, Y, 2014)	0.4
"This paper describes a new RP-HPLC method for simultaneous quantification of these compounds in the bulk sample drug as well as in tablet dosage forms."	( New Validated RP-HPLC Analytical Method for Simultaneous Estimation of Atorvastatin and Ezetimibe in Bulk Samples as Well in Tablet Dosage Forms by Using PDA Detector. Debnath, M; Kumar, SA; Seshagiri Rao, JV, 2014)	0.64
" The dosage of atorvastatin will be increased by titration within the usual dose range with a treatment goal of lowering LDL-C below 70 mg/dL based on consecutive measures of LDL-C at follow-up visits."	( Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE-IVUS Trial): Study protocol for a randomized controlled trial. Fujimoto, K; Hokimoto, S; Ishihara, M; Kaikita, K; Koide, S; Komura, N; Matsui, K; Matsumura, T; Matsuyama, K; Morikami, Y; Nakamura, N; Nakamura, S; Nakao, K; Ogawa, H; Oka, H; Ono, T; Oshima, S; Sakaino, N; Sakamoto, K; Shimomura, H; Sugiyama, S; Sumida, H; Tsujita, K; Tsunoda, R; Yamamoto, N; Yamanaga, K; Yamashita, T, 2015)	0.77
" Log dose-response data from both trial designs revealed linear dose-related effects on blood total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides."	( Lipid-lowering efficacy of atorvastatin. Adams, SP; Tsang, M; Wright, JM, 2015)	0.71
" It is a major determinant of half-life and dosing frequency of a drug."	( Volume of Distribution in Drug Design. Beaumont, K; Di, L; Maurer, TS; Smith, DA, 2015)	0.42
"The average daily dosage of atorvastatin was 10, 27, and 40 mg in patients with PHC, FCHL, and FH, respectively; after 12 months of atorvastatin treatment, LDL cholesterol (LDL-C) plasma levels decreased by 44%, 50%, and 53%, respectively (all, P < ."	( Changes in ultracentrifugally separated plasma lipoprotein subfractions in patients with polygenic hypercholesterolemia, familial combined hyperlipoproteinemia, and familial hypercholesterolemia after treatment with atorvastatin. Hayashi, K; Homma, K; Homma, Y; Hori, S; Itoh, H; Ozawa, H; Shiina, Y; Wakino, S; Yoshida, T, )	0.61
" The proposed methods were successfully applied for the determination of the investigated drugs in pure form, dosage form and in synthetic mixtures with good recovery and the results obtained were favorably compared to those obtained with a reference method."	( Application of new spectrofluorometric techniques for determination of atorvastatin and ezetimibe in combined tablet dosage form. Ayad, MF; Magdy, N, 2015)	0.65
"A number of clinical trials have shown that patients with overt atherovascular disease may benefit from more aggressive dosage of statins."	( [In what extend we can reach the current LDL-cholesterol treatment goals in secondary prevention]. Bruthans, J; Mayer, O, 2015)	0.42
"Although the majority of CHD patients are currently being treated with statin, the usual dosage regimen and adherence to the recommended target values were not consistent with current therapeutic standards for secondary prevention of CHD."	( [In what extend we can reach the current LDL-cholesterol treatment goals in secondary prevention]. Bruthans, J; Mayer, O, 2015)	0.42
"25 mg once daily, n = 32) dosing was initiated on days 11 or 8, respectively, with evening (arm 1) or morning (arm 2) dosing; at steady state (days 15 or 22), a single lomitapide dose was administered; CYP3A inhibitor dosing continued for 6 days."	( Evaluation of the effects of the weak CYP3A inhibitors atorvastatin and ethinyl estradiol/norgestimate on lomitapide pharmacokinetics in healthy subjects. Dutta, S; Foulds, P; King, A; Korb, S; Patel, G; Sumeray, M; Wade, JR, 2016)	0.68
" Selection criteria comprised 28 subcriteria under the following main criteria: clinical efficacy, best publish evidence and experience, adverse effects, drug interaction, dosing time, and fixed dose combination availability."	( Statin Selection in Qatar Based on Multi-indication Pharmacotherapeutic Multi-criteria Scoring Model, and Clinician Preference. Al-Badriyeh, D; Al-Khal, A; Alabbadi, I; Fahey, M; Zaidan, M, 2015)	0.42
" Pigs in the CME group received a total dosage of 100,000 microspheres (42 μm) suspended in 10 ml normal saline within 40 min, while animals in the sham group received the same dosage of normal saline."	( Effects of atorvastatin on PDCD4/NF-κB/TNF-α signaling pathway during coronary microembolization of miniature pigs. Li, L; Liu, T; Liu, Y; Su, Q; Wang, J; Zhou, Y, 2015)	0.81
"Two advanced, accurate and precise chemometric methods are developed for the simultaneous determination of amlodipine besylate (AML) and atorvastatin calcium (ATV) in the presence of their acidic degradation products in tablet dosage forms."	( Advanced stability indicating chemometric methods for quantitation of amlodipine and atorvastatin in their quinary mixture with acidic degradation products. Darwish, HW; El-Zeany, BA; Hassan, SA; Salem, MY, 2016)	0.86
" Due to the disadvantages of liquid SEDDS (few choices for dosage forms, low stability and portability during the manufacturing process), attempts were also made to obtain solid SEDDS."	( Development and Evaluation of Liquid and Solid Self-Emulsifying Drug Delivery Systems for Atorvastatin. Amelian, A; Czajkowska-Kośnik, A; Szekalska, M; Szymańska, E; Winnicka, K, 2015)	0.64
" These two mixtures were, therefore, subjected to studies for the evaluation of precompression parameters in order to find their amenability to satisfactory compression into tablet dosage form."	( Stable amorphous binary systems of glipizide and atorvastatin powders with enhanced dissolution profiles: formulation and characterization. Gulati, M; Narang, R; Singh, SK, 2017)	0.71
" Duration and dosage of statin use were obtained from pharmaceutical claims."	( Statin use associated with a reduced risk of pneumonia requiring hospitalization in patients with myocardial infarction: a nested case-control study. Chang, YH; Chien, LN; Chuang, MT; Lin, CF; Liu, JC, 2016)	0.43
" Due to an observational study design, atorvastatin dosage was not intentionally modified for other reasons."	( Effects of Atorvastatin Dose and Concomitant Use of Angiotensin-Converting Enzyme Inhibitors on Renal Function Changes over Time in Patients with Stable Coronary Artery Disease: A Prospective Observational Study. Surdacki, A; Świerszcz, J; Wieczorek-Surdacka, E, 2016)	1.09
" A similar dose-response relationship was observed."	( Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES. Bonilla, H; Butt, AA; Chung, RT; Simon, TG; Yan, P, 2016)	1.88
" Atorvastatin was administered orally to the statin group according to a dosage schedule (80 mg single dose on the evening prior to surgery; 40 mg on the morning of surgery; three further doses of 40 mg on the evenings of postoperative days 0, 1, and 2)."	( Effect of atorvastatin on the incidence of acute kidney injury following valvular heart surgery: a randomized, placebo-controlled trial. Kwak, YL; Park, JH; Shim, JK; Soh, S; Song, JW, 2016)	1.75
" These results suggest that S(M)-SEMDDS offers great potential for the development of solid dosage forms with improved oral absorption of drugs with poor water solubility."	( Development of a solidified self-microemulsifying drug delivery system (S-SMEDDS) for atorvastatin calcium with improved dissolution and bioavailability. Chae, BR; Choi, YW; Kim, JH; Kim, SR; Lee, SG; Son, HY; Song, SH; Yeom, DW, 2016)	0.66
" The dosage of atorvastatin was uptitrated with a treatment goal of lowering low-density lipoprotein cholesterol to below 70 mg/dl in both groups."	( Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: Subanalysis of PRECISE-IVUS trial. Fujimoto, K; Hokimoto, S; Ishihara, M; Kaikita, K; Koide, S; Komura, N; Matsui, K; Matsumura, T; Matsuyama, K; Morikami, Y; Nakamura, N; Nakamura, S; Nakao, K; Ogawa, H; Oka, H; Oshima, S; Sakaino, N; Sakamoto, K; Shimomura, H; Sugiyama, S; Sumida, H; Tsujita, K; Tsunoda, R; Yamamoto, N; Yamanaga, K; Yamashita, T, 2016)	0.79
"Accurate prediction of drug target activity and rational dosing regimen design require knowledge of drug concentrations at the target."	( Intracellular Unbound Atorvastatin Concentrations in the Presence of Metabolism and Transport. Korzekwa, K; Kulkarni, P; Nagar, S, 2016)	0.75
"BACKGROUND Is the timing of dosing for amlodipine and atorvastatin important with regard to therapeutic efficacy? To answer this question, we designed an outpatient, practice-based, case-control study lasting 8 weeks."	( Is Time an Important Problem in Management of Hypertension and Hypercholesterolemia by Using an Amlodipine-Atorvastatin Single Pill Combination? Wang, M; Zeng, R; Zhang, L, 2016)	0.9
" However, regulatory authorities permit the use of in vitro data in establishing similarity between immediate release oral dosage forms containing biopharmaceutical classification system class I and III drugs only."	( PHARMACEUTICAL QUALITY OF GENERIC ATORVASTATIN PRODUCTS COMPARED WITH THE INNOVATOR PRODUCT: A NEED FOR REVISING PRICING POLICY IN PALESTINE. Abed, E; Al-Saghir, R; Hroub, AK; Jibali, S; Shawahna, R; Zaid, AN, )	0.41
" To address this in experimental rats, in the present work, atorvastatin was orally dosed for 1 month to evaluate the outcomes of the subsequent occlusive stroke induced by middle cerebral artery occlusion (MCAO)."	( Association of Long-Term Atorvastatin with Escalated Stroke-Induced Neuroinflammation in Rats. Khodagholi, F; Mehrpour, M; Naderi, N; Nasoohi, S; Simani, L, 2017)	1
" This study is the first to indicate that low doses of atorvastatin and rosuvastatin, the dosing regimen for which has been controversial, could significantly improve diabetes-related metabolic disorders, and could modulate pro-inflammatory cytokines, alleviating inflammation and simultaneously restoring overall humoral and cell-mediated immunity."	( Atorvastatin and rosuvastatin improve physiological parameters and alleviate immune dysfunction in metabolic disorders. An, J; Kim, J; Kim, K; Kong, H; Lee, H; Lee, S; Lee, Y; Song, Y, 2016)	2.12
" The aim of this article was to characterize the relevant classification of drug impurities and to review the methods of impurities determination for atorvastatin (ATV) and duloxetine (DLX) (both in active pharmaceutical ingredients and in different dosage forms)."	( Impurities in Drug Products and Active Pharmaceutical Ingredients. Frankowski, M; Kątny, M, 2017)	0.65
" The model developed may be of clinical importance to guide dosing recommendations tailored specifically for the Japanese."	( Modelling of atorvastatin pharmacokinetics and the identification of the effect of a BCRP polymorphism in the Japanese population. Aarons, L; Galetin, A; Guo, Y; Hall, S; Tsamandouras, N; Wendling, T, 2017)	0.82
" Electronic pharmacy records were used to abstract information on the type, length, and dosage of statin exposures starting in the year prior to diagnosis."	( Influence of Statins and Cholesterol on Mortality Among Patients With Pancreatic Cancer. Chang, JI; Huang, BZ; Li, E; Wu, BU; Xiang, AH, 2017)	0.46
" Vitamin D (25-OHD) dosing was performed by chemiluminescence method through the LIAISON® Vitamin D assay (Diasorin Inc)."	( Impact of high-dose statins on vitamin D levels and platelet function in patients with coronary artery disease. Barbieri, L; Bellomo, G; Daffara, V; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Schaffer, A; Suryapranata, H; Verdoia, M, 2017)	0.46
"To assess whether the protective effect of statins on the risk of glaucoma varies depending on the daily dosage or type of statin taken."	( Association of Daily Dosage and Type of Statin Agent With Risk of Open-Angle Glaucoma. Musch, DC; Stein, JD; Talwar, N, 2017)	0.46
" Using multivariable regression modeling, we assessed the hazard of developing OAG and how it varied by the daily dosage or type of statin and whether any protective effect persists after accounting for baseline low-density lipoprotein level."	( Association of Daily Dosage and Type of Statin Agent With Risk of Open-Angle Glaucoma. Musch, DC; Stein, JD; Talwar, N, 2017)	0.46
" Our study helps inform researchers of a reasonable daily dosage and type of statin to use when designing randomized clinical trials to assess the association between statin use and glaucoma."	( Association of Daily Dosage and Type of Statin Agent With Risk of Open-Angle Glaucoma. Musch, DC; Stein, JD; Talwar, N, 2017)	0.46
" The case for fixed-dose combination (FDC) oral dosage forms and orally disintegrating tablet (ODT) technology to enhance outcomes and compliance is strong."	( Fixed-dose combination orally disintegrating tablets to treat cardiovascular disease: formulation, in vitro characterization and physiologically based pharmacokinetic modeling to assess bioavailability. Badhan, RK; Dennison, TJ; Mohammed, AR; Smith, JC, 2017)	0.46
" Unfortunately, the high dosage used poses side-effects relatively in comparison to other statins."	( Preparation and characterisation of atorvastatin and curcumin-loaded chitosan nanoformulations for oral delivery in atherosclerosis. J B, VK; Madhusudhan, B; Ramakrishna, S, 2017)	0.73
" Patients were randomly assigned to receive daily 20mg atorvastatin for 10days (n=21) or placebo in the same dosage (n=23)."	( Effects of atorvastatin on brain contusion volume and functional outcome of patients with moderate and severe traumatic brain injury; a randomized double-blind placebo-controlled clinical trial. Derakhshan, N; Farzanegan, GR; Ghaffarpasand, F; Khalili, H; Paydar, S, 2017)	1.09
"The relative benefit of higher statin dosing in patients with peripheral artery disease has not been reported previously."	( High-Intensity Statin Therapy Is Associated With Improved Survival in Patients With Peripheral Artery Disease. Amsterdam, EA; Armstrong, EJ; Choy, HK; Foley, TR; Kokkinidis, DG; Laird, JR; Pham, T; Rutledge, JC; Singh, GD; Waldo, SW, 2017)	0.46
"This study explored the impact of intensive daily dosing of atorvastatin on in-hospital N-terminal pro-B-type natriuretic peptide level, left ventricular systolic function and incidence of major adverse cardiac events in non-ST-segment elevation myocardial infarction patients."	( Prognostic impact of intensive statin therapy on N-terminal pro-BNP level in non-ST-segment elevation acute myocardial infarction patients. Dardiri, M; Samir, A; Shehata, M, 2017)	0.7
"Animals dosed with 10 mg/kg presented the worst neurological function and brain damage in the acute phase of stroke injury."	( Coenzyme Q10 supplementation improves acute outcomes of stroke in rats pretreated with atorvastatin. Faizi, M; Khodagholi, F; Naderi, N; Nasoohi, S; Nikseresht, S; Simani, L, 2019)	0.74
"The dosing schedules for hypercholesterolemic subjects randomized in the four phase I studies were (1) ascending, single, intravenous (IV) bococizumab (0."	( The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastati Baum, CM; Billotte, S; Forgues, P; Garzone, PD; Gumbiner, B; Joh, T; Levisetti, M; Liang, H; Pons, J; Shelton, DL; Vana, AM; Wan, H, 2018)	0.48
" The obtained results suggest a promising, easy-to-manufacture and effective dosage form for the treatment of hyperlipidemia."	( Experimentally designed lyophilized dry emulsion tablets for enhancing the antihyperlipidemic activity of atorvastatin calcium: Preparation, in-vitro evaluation and in-vivo assessment. Basha, M; El Awdan, S; Salama, AH, 2018)	0.69
" Their in vivo PK as well as PD measures following oral administration in different dosage regimens in hyperlipidemic rats were evaluated."	( Efficacy and Safety Profiles of Oral Atorvastatin-Loaded Nanoparticles: Effect of Size Modulation on Biodistribution. Abd-Rabo, MM; Ahmed, IS; El Hosary, R; Haider, M; Hassan, MA, 2018)	0.75
"4 years) who received a single oral dose of atorvastatin 20 mg on day 1 (period 1), multiple daily dosing of bazedoxifene 40 mg on days 4-11 (period 2), and coadministration of atorvastatin 20 mg + bazedoxifene 40 mg on day 12 (period 3)."	( A Study of the Potential Interaction Between Bazedoxifene and Atorvastatin in Healthy Postmenopausal Women. Baird-Bellaire, S; Ermer, J; McKeand, W; Patat, A, 2018)	0.98
" In subanalyses, a trend of a dose-response relationship was observed."	( Statin use associated with lower risk of epilepsy after intracranial haemorrhage: A population-based cohort study. Ho, YF; Lin, FJ; Lin, HW, 2018)	0.48
"We determined the proportion of Medicare beneficiaries 66 to 75 years of age taking a low/moderate-intensity statin with (n = 6718) and without (n = 6414) DM who titrated to a high-intensity statin dosage (i."	( Titration to High-Intensity Statin Therapy Following Acute Myocardial Infarction in Patients With and Without Diabetes Mellitus. Brown, TM; Carson, AP; Colantonio, LD; Dai, Y; Farkouh, ME; Giustino, G; Monda, KL; Muntner, P; Rosenson, RS, 2018)	0.48
"The first statin fill following hospital discharge was for a high-intensity dosage among 37."	( Titration to High-Intensity Statin Therapy Following Acute Myocardial Infarction in Patients With and Without Diabetes Mellitus. Brown, TM; Carson, AP; Colantonio, LD; Dai, Y; Farkouh, ME; Giustino, G; Monda, KL; Muntner, P; Rosenson, RS, 2018)	0.48
"Most patients taking a low/moderate-intensity statin were not titrated to a high-intensity dosage following AMI irrespective of their diabetes status, potentially leaving substantial residual risk for recurrent CVD events."	( Titration to High-Intensity Statin Therapy Following Acute Myocardial Infarction in Patients With and Without Diabetes Mellitus. Brown, TM; Carson, AP; Colantonio, LD; Dai, Y; Farkouh, ME; Giustino, G; Monda, KL; Muntner, P; Rosenson, RS, 2018)	0.48
"All patients with age ≤75 years undergoing PCI between January 2011 and May 2016 at an urban, tertiary care center and discharged with available statin dosage data were included."	( Temporal trends, determinants, and impact of high-intensity statin prescriptions after percutaneous coronary intervention: Results from a large single-center prospective registry. Aquino, M; Baber, U; Barman, N; Camaj, A; Chandrasekhar, J; Claessen, B; Dangas, G; Faggioni, M; Farhan, S; Guedeney, P; Kalkman, DN; Kini, A; Kovacic, JC; Mehran, R; Moreno, P; Shah, S; Sharma, S; Sorrentino, S; Sweeny, J; Vijay, P; Vogel, B, 2019)	0.51
"Four new, simple, and reproducible spectrophotometric methods were developed and validated for the simultaneous determination of Amlodipine (AML) and Atorvastatin (AT) in bulk powder and pharmaceutical dosage form."	( Determination of amlodipine and atorvastatin mixture by different spectrophotometric methods with or without regression equations. Fares, NV; Farouk, M; Hemdan, A; Magdy, R, 2019)	1
" Dosing shall continue for 24-mo or until reaching a safety endpoint."	( Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial. Akers, AL; Awad, IA; Cao, Y; Christoforidis, GA; Fam, MD; Flemming, KD; Girard, R; Hanley, DF; Hobson, N; Koenig, JI; Koskimäki, J; Lane, K; Lee, C; Liao, JK; Lyne, SB; McBee, N; Morrison, L; Piedad, K; Polster, SP; Shenkar, R; Sorrentino, M; Stadnik, A; Thompson, RE; Whitehead, KJ; Zeineddine, HA, 2019)	1.96
" RESULTS Ato prevented myocardial fibrosis in spontaneous hypertension rats, especially at the dosage of 50 mg/kg/d."	( Atorvastatin Prevents Myocardial Fibrosis in Spontaneous Hypertension via Interleukin-6 (IL-6)/Signal Transducer and Activator of Transcription 3 (STAT3)/Endothelin-1 (ET-1) Pathway. Fang, T; Guo, B; Wang, L; Xue, L, 2019)	1.96
"5-5 mg atorvastatin daily combined with dexamethasone with stepwise-decreasing dosing for a total of 4 weeks."	( Treatment of Relapsed Chronic Subdural Hematoma in Four Young Children with Atorvastatin and Low-dose Dexamethasone. Dong, J; Gao, C; Huang, J; Jiang, R; Li, L; Quan, W; Sun, J; Tian, Q; Tian, Y; Wang, D; Zhang, J, 2019)	1.2
" Atorvastatin and metabolites' steady-state levels were analyzed before first dosing with bempedoic acid and after 2 weeks of treatment."	( Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: A randomized placebo-controlled trial. Cramer, CT; Hanselman, JC; Lalwani, ND; MacDougall, DE; Sterling, LR, )	1.25
"The aim of this study was to develop a new dosage form as an alternative to the classical tablet forms of atorvastatin calcium (AtrCa)."	( Formulation and In Vitro Evaluation of Self Microemulsifying Drug Delivery System Containing Atorvastatin Calcium. Diril, M; Karasulu, HY; Türkyılmaz, GY, 2019)	0.95
"5%) were adherent to the therapy (PDC ≥ 80%); among them, a small percentage required dosage modification."	( Treatment with Free Triple Combination Therapy of Atorvastatin, Perindopril, Amlodipine in Hypertensive Patients: A Real-World Population Study in Italy. Degli Esposti, L; Gambera, M; Nati, G; Perone, F; Perrone, V; Tagliabue, PF; Veronesi, C; Volpe, M, 2019)	0.77
" More evidence is needed to evaluated of dose-response effects of these drugs before to study in clinical trials."	( Comparison of four pharmacological strategies aimed to prevent the lung inflammation and paraquat-induced alveolar damage. Buendía, JA; Justinico Castro, JA; Sánchez Villamil, JP; Sinisterra, D; Vela, LJT; Zuluaga Salazar, AF, 2019)	0.51
"Increased bococizumab dosage resulted in increased exposure."	( Pharmacokinetics and exploratory efficacy biomarkers of bococizumab, an anti-PCSK9 monoclonal antibody, in hypercholesterolemic Japanese subjects . Li, Y; Matsuoka, N; Suzuki, A; Teramoto, T; Yokote, K, 2019)	0.51
" Furthermore, most preclinical antiepileptogenic studies lack information needed for translation, such as dose-blood level relationship, brain target engagement, and dose-response, and many use treatment parameters that cannot be applied clinically, for example, treatment initiation before or at the time of injury and dosing higher than tolerated human equivalent dosing."	( Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy? Bar-Klein, G; Friedman, A; Hameed, MQ; Jozwiak, S; Kaminski, RM; Klein, P; Klitgaard, H; Koepp, M; Löscher, W; Prince, DA; Rotenberg, A; Twyman, R; Vezzani, A; Wong, M, 2020)	0.56
" Since boosted ARVs double atorvastatin exposure, the initial dosage might be reduced by half, and titrated based on individual clinical targets."	( Influence of Drug-Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV. Alves Saldanha, S; Buclin, T; Cavassini, M; Courlet, P; Csajka, C; Decosterd, LA; Guidi, M; Marzolini, C; Stader, F; Stoeckle, M, 2020)	1.09
" Low-density lipoprotein cholesterol (LDL-C) levels and intensity of statin therapy (based on dosage and type of statin) were assessed from all available hospital records."	( Treatment Patterns of Lipid-Lowering Therapy in Patients with Coronary Artery Disease Aged Above and Below 75 Years: A Retrospective Cross-Sectional Study of 1500 Patients in a Tertiary Care Referral Center in Germany. Al-Rashid, F; Dykun, I; Hendricks, S; Jánosi, RA; Mahabadi, AA; Rassaf, T; Totzeck, M; Wiefhoff, D, 2020)	0.56
"This study aimed to investigate whether the drug-specific and dosage effects of statin use were associated with a lower risk of cancer in adults in South Korea."	( Drug-specific and dosage effects of statins and the risk of cancer: a population-based cohort study in South Korea. Oh, TK; Song, IA, 2021)	0.62
" Log dose-response data over doses of 1 mg to 16 mg revealed strong linear dose-related effects on blood total cholesterol and LDL cholesterol and triglycerides."	( Pitavastatin for lowering lipids. Adams, SP; Alaeiilkhchi, N; Wright, JM, 2020)	0.56
" Cox proportional hazard regression analysis was used to determine the association between the 2 high-intensity atorvastatin dosing regimens and the primary outcome at 1 month and 12 months postdischarge."	( Clinical outcomes of high-intensity doses of atorvastatin in patients with acute coronary syndrome: A retrospective cohort study using real-world data. Al-Shekh, I; Al-Yafei, S; AlAhmad, Y; Aljundi, AH; Alzaeem, H; Arabi, AR; Awaisu, A; Habra, M; Khir, F; Mahfouz, A; Rahhal, A, 2021)	1.09
" It also reduced the dosage of levetiracetam and achieved better control of epilepsy compared to levetiracetam mono-treatment."	( Effects of atorvastatin and aspirin on post-stroke epilepsy and usage of levetiracetam. Ding, Y; Feng, X; Lin, W; Zhao, T; Zhou, C, 2020)	0.95
"Atorvastatin and aspirin co-treatment with levetiracetam can reduce epilepsy in PSE patients and reduce the dosage of levetiracetam required for effective control of PSE."	( Effects of atorvastatin and aspirin on post-stroke epilepsy and usage of levetiracetam. Ding, Y; Feng, X; Lin, W; Zhao, T; Zhou, C, 2020)	2.39
" Doses and dosing intervals were based on previous pharmacokinetic and tolerability studies in mice."	( Systematic evaluation of rationally chosen multitargeted drug combinations: a combination of low doses of levetiracetam, atorvastatin and ceftriaxone exerts antiepileptogenic effects in a mouse model of acquired epilepsy. Bergin, DH; Johne, M; Klein, P; Löscher, W; Schidlitzki, A; Twele, F; Welzel, L, 2021)	0.83
" No consistent differences in plasma exposure of atorvastatin or M1 were observed in mice after single or repeat dosing of atorvastatin with or without mineral oil."	( Effects of mineral oil administration on the pharmacokinetics, metabolism and pharmacodynamics of atorvastatin and pravastatin in mice and dogs. Abrahamsson, B; Agrawal, R; Bergenholm, L; Björkbom, A; Bright, J; Cavallin, A; Gopaul, VS; Hammarberg, M; Hawthorne, G; Hurt-Camejo, E; Jansson-Löfmark, R; Jarke, A; Johansson, MJ; Li, X; Lundborg, E; Pieterman, EJ; Princen, HMG; Svensson, L, 2021)	1.09
" Only rosuvastatin was assessed in a repeated dosing PK study."	( A systematic review on pharmacokinetics, cardiovascular outcomes and safety profiles of statins in cirrhosis. Abraldes, JG; Al-Karaghouli, M; Cabrera Garcia, L; Kalainy, S; Sung, S, 2021)	0.62
" Blood samples were taken over the dosing intervals and drug concentrations quantified by high-performance liquid chromatography-mass spectrometry."	( Mechanistic Considerations About an Unexpected Ramipril Drug-Drug Interaction in the Development of a Triple Fixed-Dose Combination Product Containing Ramipril, Amlodipine, and Atorvastatin. Gundlach, K; Hermann, R; Seiler, D, 2021)	0.81
" Because pharmacodynamic interaction between statins and bempedoic acid is complex, a dose-response model was developed to predict LDL-C pharmacodynamics following administration of statins combined with bempedoic acid."	( Pharmacodynamic effect of bempedoic acid and statin combinations: predictions from a dose-response model. Amore, BM; Barrett, PHR; Catapano, AL; Chapel, S; Crass, RL; Emery, MG; Jadhav, SB; Kerschnitzki, M; Sasiela, WJ; Watts, GF, 2022)	0.72
"Bempedoic acid and statin dosing and LDL-C data were pooled from 14 phase 1-3 clinical studies."	( Pharmacodynamic effect of bempedoic acid and statin combinations: predictions from a dose-response model. Amore, BM; Barrett, PHR; Catapano, AL; Chapel, S; Crass, RL; Emery, MG; Jadhav, SB; Kerschnitzki, M; Sasiela, WJ; Watts, GF, 2022)	0.72
"The study was able to progress through all 4 dosing levels of sorafenib by the accrual of 40 patients."	( Phase I Study Evaluating Dose De-escalation of Sorafenib with Metformin and Atorvastatin in Hepatocellular Carcinoma (SMASH). Ankathi, SK; Banavali, SD; Bhargava, PG; Daddi, A; Goel, M; Gota, V; Jadhav, S; Mandavkar, S; Nashikkar, C; Naughane, D; Ostwal, V; Patkar, S; Ramaswamy, A; Shetty, N; Shriyan, B; Srinivas, S, 2022)	0.95
" We performed an open-label study comparing pharmacokinetics of atorvastatin (OATP1B probe) dosed alone (20 mg single dose) and coadministered with two dose strengths of KHKi (50 and 280 mg once daily) in 12 healthy participants."	( Effect of a Ketohexokinase Inhibitor (PF-06835919) on In Vivo OATP1B Activity: Integrative Risk Assessment Using Endogenous Biomarker and a Probe Drug. Bergman, A; Fonseca, KR; Kimoto, E; King-Ahmad, A; Litchfield, J; Qui, R; Rodrigues, AD; Somayaji, V; Tess, DA; Varma, MVS; Vourvahis, M; Weng, Y, 2022)	0.96
" Peak and trough drug plasma concentrations were collected based on the dosing interval and pharmacokinetics of the drugs and quantified using high performance liquid chromatography."	( Simvastatin, but Not Atorvastatin, Is Associated with Higher Peak Rivaroxaban Serum Levels and Bleeding: an Asian Cohort Study from Singapore. Chan, ECY; Soh, XQ; Tan, DS, 2023)	1.23
" Finally, the established wbPBPK model could describe ATV ADME in the presence of IBS and IBD after oral administration of raw ATV and using the novel SFT formula and can help scale the optimized ATV dosing regimens in the presence of IBS and IBD from rats to humans."	( Enhancing Atorvastatin In Vivo Oral Bioavailability in the Presence of Inflammatory Bowel Disease and Irritable Bowel Syndrome Using Supercritical Fluid Technology Guided by wbPBPK Modeling in Rat and Human. Abu-Farsakh, NA; Al-Daoud, NM; Alsmadi, MM; Obaidat, RM, 2022)	1.12
"After establishing an orthodontic tooth movement model, the left teeth of the retention-stage rats were the maintained side, and the right teeth were the nonmaintained side, which were given physiological saline or atorvastatin dosing at 7d, 14d, and 21d, respectively, by tube feeding, in order to keep the rats as a control group at the beginning of the retention stage."	( The Impact of Atorvastatin on RANKL Expression in Rats during the Retention Stage after Orthodontic Tooth Movement. Gao, Y; Wang, T; Zhao, Y, 2022)	1.27
" In addition, PGx-guided dosing guidelines are now available for multiple CVD drugs, including clopidogrel, warfarin, and statins."	( Pharmacogenomics implementation in cardiovascular disease in a highly diverse population: initial findings and lessons learned from a pilot study in United Arab Emirates. Al-Mahayri, ZN; Al-Maskari, F; Ali, BR; AlKaabi, J; Alqasrawi, MN; Altoum, SM; AlZaabi, A; Badawi, S; George, L; Hamza, D; Jamil, G; Khasawneh, LQ; Ouda, H; Patrinos, GP, 2022)	0.72
" Regarding warfarin, only 20% of the participants exhibited reference alleles at VKORC1-1639G > A, CYP2C9*2, and CYP2C9*3, leaving 80% with alternative genotypes at any of the two genes that can be integrated into the warfarin dosing algorithms and can be used whenever the patient receives a warfarin prescription."	( Pharmacogenomics implementation in cardiovascular disease in a highly diverse population: initial findings and lessons learned from a pilot study in United Arab Emirates. Al-Mahayri, ZN; Al-Maskari, F; Ali, BR; AlKaabi, J; Alqasrawi, MN; Altoum, SM; AlZaabi, A; Badawi, S; George, L; Hamza, D; Jamil, G; Khasawneh, LQ; Ouda, H; Patrinos, GP, 2022)	0.72
" After a 5-week run-in period of treatment with atorvastatin 10 or 20 mg/d (cohorts A and B, respectively), or a bioequivalent dosage of another statin, patients were randomized in a 1:1 ratio within each cohort to receive EZ/AS 10/10 mg FDC (EZ10/AS10) or atorvastatin 20 mg (AS20), once daily (cohort A); or EZ/AS 10/20 mg FDC (EZ10/AS20) or atorvastatin 40 mg (AS40), once daily (cohort B)."	( Efficacy and Tolerability of Ezetimibe/Atorvastatin Fixed-dose Combination Versus Atorvastatin Monotherapy in Hypercholesterolemia: A Phase III, Randomized, Active-controlled Study in Chinese Patients. Chen, J; Ding, C; Ge, J; Li, Z; Liu, Y; Qian, J; Ren, X; Shi, M; Yang, P; Zhang, X, 2022)	1.25
" Logistic regression showed that d, L, different therapeutic agents, and dosage groups were independent risk factors of ISR."	( Treatment effect of metformin combined with atorvastatin in reducing in-stent restenosis after percutaneous coronary intervention in coronary artery disease patients with type 2 diabetic patients. Chen, M; Li, M; Liu, S; Ma, F; Su, B; Wang, C; Yuan, L; Zhang, S; Zhang, Y; Zheng, Q, 2022)	0.98
" Here we present a full PBPK model for atorvastatin and its metabolites able to predict within a 2-fold error their PK after the administration of a solid oral dosage form containing the calcium salt of atorvastatin in single and multiple dosing schedules at 20, 40, and 80 mg and 10 mg dose levels, respectively."	( A physiologically based pharmacokinetic model for open acid and lactone forms of atorvastatin and metabolites to assess the drug-gene interaction with SLCO1B1 polymorphisms. García-Arieta, A; Mangas-Sanjuán, V; Merino-Sanjuan, M; Reig-López, J, 2022)	1.22
" Through a simple and direct technique based on deconvolution and synchronous of the spectrofluorometric spectra, the innovative method enables simultaneous quantification of bisoprolol and atorvastatin as single or co-formulated dosage forms in bulk and plasma."	( Novel Deconvoluted Synchronous Spectrofluorimetric Method For Simultaneous Determination Of Bisoprolol and Atorvastatin As Single or Co-administrated Drugs in Bulk and Plasma; Green Assessment. Abdel-Monem, AH; Abdel-Raoof, AM; Attia, KAM; Eissa, AS, 2023)	1.31
" Furthermore, proCPU concentration and the dosage of atorvastatin were inversely correlated."	( Atorvastatin downregulates plasma procarboxypeptidase U concentrations and improves fibrinolytic potential dose-dependently in hyperlipidemic individuals. Basir, S; Bosmans, J; Bringmans, T; Claesen, K; De Belder, S; De Keulenaer, GW; De Meester, I; Hendriks, D; Sim, Y; Stoffelen, H; van den Keybus, T; Van Edom, G, 2023)	2.6
" In the treat-to-target group (n = 2200), which had 6449 person-years of follow-up, moderate-intensity and high-intensity dosing were used in 43% and 54%, respectively."	( Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease: A Randomized Clinical Trial. Ahn, CM; Choi, D; Hong, BK; Hong, MK; Hong, SJ; Jang, Y; Kang, WC; Kim, BK; Kim, JS; Ko, YG; Lee, JB; Lee, JY; Lee, SJ; Lee, YJ; Yang, TH; Yoon, J, 2023)	0.91
"The results revealed the protective effects of specific types of statins on DLC risk in patients with T2DM and indicated a dose-response relationship."	( Protective effects of statins on the incidence of NAFLD-related decompensated cirrhosis in T2DM. Chen, WM; Chiang, MF; Lee, MC; Lo, HC; Soong, RS; Wu, MS; Wu, SY, 2023)	0.91
"This study aimed to develop atorvastatin-loaded emulgel and nano-emulgel dosage forms and investigate their efficiency on surgical wound healing and reducing post-operative pain."	( Efficacy of topical atorvastatin-loaded emulgel and nano-emulgel 1% on post-laparotomy pain and wound healing: A randomized double-blind placebo-controlled clinical trial. Jafari-Nedooshan, J; Kargar, S; Ramezani, V; Saghafi, F; Sahebnasagh, A; Tabatabaei, SM; Zarekamali, J, 2023)	1.53
" Log dose-response data over the doses of 5 mg to 160 mg revealed strong linear dose-related effects on blood total cholesterol and LDL cholesterol, and a weak linear dose-related effect on blood triglycerides."	( Pravastatin for lowering lipids. Adams, SP; Alaeiilkhchi, N; Tasnim, S; Wright, JM, 2023)	0.91
" There are limited data on effect of dosage of statins and functional outcome in stroke patients."	( Effects of Serum Cholesterol on Severity of Stroke and Dosage of Statins on Functional Outcome in Acute Ischemic Stroke. Chatterjee, A; Gorthi, SP; Nair, R; Prakashini, K; Shridharan, P, )	0.13
" On comparing the mRS values at baseline and on day 90 with the dose of statins, patients who received a higher dosage had a statistically significant fall in mRS (p-0."	( Effects of Serum Cholesterol on Severity of Stroke and Dosage of Statins on Functional Outcome in Acute Ischemic Stroke. Chatterjee, A; Gorthi, SP; Nair, R; Prakashini, K; Shridharan, P, )	0.13
" At the visits, the general condition of patients was evaluated; electrocardiography and echocardiography were performed at rest and during dosed physical exercise (PE); anthropometry was analyzed; and office blood pressure (BP), heart rate (HR) and parameters of systolic and diastolic LV function were recorded."	( [Can a lipophilic statin improve the treatment of heart failure with preserved ejection fraction in patients with hypertension and obesity?] Namazova, GA; Shupenina, EY; Vasyuk, YA; Zavyalova, AI, 2023)	0.91
"Long-term use of the lipophilic statin (atorvastatin) in addition to a standard therapy was associated with regression of clinical manifestations of HFpEF, provided preservation of the systolic function, and some improvement in the LV diastolic function both at rest and during dosed PE."	( [Can a lipophilic statin improve the treatment of heart failure with preserved ejection fraction in patients with hypertension and obesity?] Namazova, GA; Shupenina, EY; Vasyuk, YA; Zavyalova, AI, 2023)	1.18